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Abstract
The aim of the work presented in this thesis was to investigate aspects of canine diabetes 
meilitus in order to improve understanding of the condition and the welfare of dogs 
affected by it. The epidemiology, clinical chemistry and survival data of diabetic dogs 
treated by the author during the period October 1989 to August 1994 were studied. In 
addition, studies on specific insulin and dietary formulations were undertaken. 
Epidemiological studies employing statistical comparisons with a time-matched hospital 
derived control population revealed a complicated relationship between age and gender 
associated with diabetes meilitus, in that females in the older age groups were at greatest 
risk but in the younger age groups they were not. Predisposed breeds were terriers 
(particularly Tibetan, Cairn and Jack Russell), collie crossbreeds and Rottweilers. There 
were differences between the epidemiological characteristics of diabetic dogs of high risk 
breeds and those of normal or low risk breeds suggesting a possible difference in 
pathophysiology.
Investigation of diabetic dogs with associated syndromes revealed differences in age 
distribution between those with hypothyroidism, those with hyperadrenocorticism and 
‘normal* diabetic dogs and that basal plasma insulin analysis prior to ovariohysterectomy 
may be a useful prognostic indicator in metoestrus-associated diabetes meilitus.
‘New* tests, fructosamine and glycated haemoglobin, validated for use with canine 
samples, were determined to be useful in the monitoring of canine diabetes meilitus by 
relative operating characteristic curve analysis. Alkaline phosphatase, alanine 
aminotransferase and aspartate aminotransferase were not useful tests for this purpose.
A highly purified porcine insulin zinc suspension had two reasonably predictable times of 
peak activity following subcutaneous injection at around 4 and 11 hours and an overall 
duration of activity of 14 to 24 hours. The efficacy of the same product, studied during a 
stabilisation and follow-up period in 19 diabetic dogs, was good in both the short and 
long term. Stabilisation was achieved in 10 - 14 days resulting in a final dose of between 
0.8 and 2.0 lU/kg. The rates of bacterial infections and blindness associated with the long 
term use of this product on a single daily basis were 1 per 1.11 and 1 per 2.23 diabetic- 
dog-years, respectively.
The feeding of a commercially produced ‘high fibre* diet reduced mean 24 hour plasma 
glucose concentration and the fluctuation in afternoon post-prandial glycaemia. Feeding 
this diet also improved demeanour and activity scores and plasma concentrations of 
afternoon glucose, fructosamine and alkaline phosphatase. In addition, reductions were 
observed in plasma concentrations of total cholesterol, LDL cholesterol, fi"ee glycerol 
and non-esterified fatty acids. There was an association between feeding this diet and 
weight loss, reduced body condition scores and increased faecal volume score. In the 
very long term (> 4 months) there was a subjectively high prevalence of unexpected 
weight loss, recurrent diarrhoea and small intestinal bacterial overgrowth.
Median survival time for diabetic dogs treated with single daily injections of insulin was 
2.71 years. Median remaining lifetime increased to 3.11 years for those dogs which 
survived the first 5 months of therapy. There was no effect on survival of gender or of 
the type of intermediate duration insulin preparation, but diabetic dogs with 
hyperadrenocorticism had a much poorer prognosis. Survival rates for diabetic dogs 
were close to or greater than those of an age and gender-matched general canine 
population, using a necropsy based modified cohort general life table.
List of contents
Abstract 2
List of contents 3
List of tabies 9
List of figures 12
Acknowledgements 20
Author’s  declaration 21
Chapter 1: General introduction and review 22
Definition 22
History 22
Pathophysiology 22
Aetiology 24
Diagnosis 26
Management 26
Concurrent illness 27
Complications of diabetes meilitus 27
Study objectives 28
Chapter 2: General materials and methods 29
Animals 29
Clinical management 29
Stabilisation 29
Maintenance 31
Computing 31
Hospital system 31
Smart II system 32
Data manipulation and statistics 33
Clinical biochemistry 33
Clinical haematology 34
Chapter 3: The epidemiology of canine diabetes meilitus 40
The control population 41
Introduction 41
Methods 44
Dogs 44
Statistics 44
Results 45
Reasons for referral 45
Age distribution 46
Gender distribution 46
Breed distribution 46
Discussion 46
The diabetic population 47
Methods 47
Statistics 47
Results 48
Age distribution 48
Gender 48
Breed predisposition 51
Seasonality 51
Further observations 51
Discussion 52
Chapter 4: Diabetes meilitus in association with other syndromes 56
Introduction 56
Materials and methods 57
Results 59
Progestagen-associated diabetes meilitus 59
Hyperadrenocorticism-associated diabetes meilitus 60
Concurrent hypothyroidism and diabetes meilitus 63
Metoestrus-associated diabetes meilitus 64
Islet cell hypoplasia 65
Age at diagnosis of diabetes meilitus 67
Gender 68
Initial plasma biochemistry and condition score 68
Dynamic endocrine tests 69
Insulin requirement 70
Discussion 71
Chapter 5: Long-term monitoring of glycaemic control 78
Introduction 78
Materials and methods 85
Fructosamine 85
Glycated haemoglobin 86
Daily variation 88
Monitoring early diabetic therapy 89
Long-term diabetic monitoring 89
Results 92
Fructosamine 92
Glycated haemoglobin 95
Daily variation 99
Monitoring early diabetic therapy 100
Long-term diabetic monitoring 105
Discussion 117
Chapter 6: Pharmacokinetics and efficacy of a mixed insulin zinc
suspension 124
Part I: Pharmacokinetics 124
Introduction 124
Materials and methods 125
Dogs 125
Management 126
Laboratory analyses 126
Derivation of results 127
Results 129
Discussion 133
Part II: Efficacy 135
Objective 135
Materials and methods 135
Dogs 135
Management 135
Analyses 137
Results 138
Hospitalisation 138
Follow-up 140
Discussion 142
Chapter 7: High fibre diet in the management of diabetes meliitus 143
Objective 143
Background 143
Materials and methods 145
Dogs 145
Diet 146
Study design 146
Hospitalisation 147
Serial blood glucose analyses 147
Insulin dose and general health 147
Indicators of glycaemic control 148
Lipid metabolism 148
Missing samples 148
Clinical chemistry and haematology 149
Statistical analyses 149
Results 150
Case summaries 150
Post-prandial glycaemia 150
Twenty-four hour curves 150
Afternoon post-prandial glycaemia 151
Long-term effect on post-prandial glycaemia 152
Insulin dose and general health 158
Insulin dose 158
Bodyweight 158
Body condition 158
Coat condition 159
Activity 159
Demeanour 160
Vision 160
Faecal volume 161
Faecal consistency 161
Routine biochemistry and haematology 162
Indicators of glycaemic control 174
Fructosamine 174
Glycated haemoglobin 174
Alkaline phosphatase 175
Alanine aminotransferase 175
Aspartate aminotransferase 175
Fasting glucose 176
Afternoon (nadir) glucose 176
Lipid metabolism 184
Total cholesterol 184
VLDL cholesterol 184
LDL cholesterol 185
HDL cholesterol 185
Triglycerides 186
Glycerol 186
Non-esterified fatty acids 186
VLDL triglyceride/apolipoprotein B 187
Post heparin hepatic triglyceride lipase 187
Long-term follow-up (> 4 months) 197
Dog 1 197
Dog 3 197
Dog 4 197
Dog 5 198
Dog 6 198
Dog 8 198
Dog 9 198
Dog 10 199
Dog 11 199
Dog 13 199
Discussion 201
Post-prandial glycaemia 201
Insulin dose and general health 205
Indicators of glycaemic control 207
Lipid metabolism 209
Long-term follow-up (> 4 months) 211
Conclusions 212
Chapter 8: Longevity in canine diabetes meilitus 214
Introduction 214
Materials and methods 215
Product-limit estimates 216
General life table 217
Clinical life table 218
Relative survival rates 220
Results 221
Product-limit estimates 221
Gender 221
Insulin treatment 221
Type 221
General life table 221
Clinical life table 225
Relative survival rates 229
Discussion 231
Chapter 9: Conclusions and future study 236
Appendices 240
Glossary 380
Laboratory reference ranges 381
List of references 382
List of tables
Table 1. Classification of diabetes meilitus in humans 25
Table 2. Factors which cause or exacerbate diabetes meliitus in dogs 26
Table 3. File structure of the Animal file 35
Table 4. File structure of the ‘Biochem’ file 36
Table 5. Lists of fields in Smart II database files 37
Table 6. Reagents, principles and instrumentation in routine clinical chemistry 38
Table 7. Breeds over- and under-represented within the diabetic population 51
Table 8. Clinical features of three dogs with progestagen-associated diabetes 
meilitus 60
Table 9. Clinical features of 18 diabetic dogs with hyperadrenocorticism I 62
Table 10. Clinical features of 18 diabetic dogs with hyperadrenocorticism II 63
Table 11. Clinical features of 8 diabetic dogs with hypothyroidism I 64
Table 12. Clinical features of 8 diabetic dogs with hypothyroidism II 64
Table 13. Clinical features of 14 dogs with metoestrus-associated diabetes meilitus 66
Table 14. Mean age at diagnosis of 4 types of diabetes meilitus 68
Table 15. Mean insulin requirements in 4 types of diabetes meilitus 71
Table 16. Calculation of sensitivity and specificity 83
10
Table 17. Calculation of sensitivity, specificity and DPR for fiiictosamine 91
Table 18. Intra-assay coefficients of variation for 4 concentrations of fioictosamine 92
Table 19. Inter-assay coefficients of variation for two concentrations of fiuctosamine
92
Table 20. Plasma fructosamine in 20 non-diabetic dogs 94
Table 21. Intra-assay coefficients of variation for 4 concentrations of glycated
haemoglobin 95
Table 22. Inter-assay coefficients of variation for two concentrations of glycated
haemoglobin 95
Table 23, Glycated haemoglobin concentration in 26 non-diabetic dogs 99
Table 24. Numbers of observations of each clinical chemistry analyte by glycaemic
control group 105
Table 25. Differences between glycaemic control groups for nadir plasma glucose 106
Table 26. Differences between glycaemic control groups for alkaline phophatase 107
Table 27. Differences between glycaemic control groups for aspartate amino­
transferase 108
Table 28. Differences between glycaemic control groups for finctosamine 109
Table 29. Differences between glycaemic control groups for glycated haemoglobin
110
Table 30. Areas under the ROC curves 112
Table 31. Maximum differential positive rates and cut-off values 115
Table 32. Dog details for insulin pharmacokinetic study 126
11
Table 33. Plasma concentrations of insulin after subcutaneous injection of IZS-P 130
Table 34. Insulin dose and pharmacokinetic parameters for IZS-P 130
Table 35. Signalment of diabetic dogs used in IZS-P efficacy study 137
Table 36. Stabilisation details of 19 dogs in the IZS-P efficacy study 139
Table 37. Follow-up details of dogs in the IZS-P efficacy study 141
Table 38. Details of dogs included in the CHF diet study 146
Table 39. Caloric densities of the foods used in the CHF diet study 146
Table 40. High fibre diet study design and missing samples 148
Table 41. Means and standard deviations of values derived fi’om 24 hour glucose
concentrations in 11 dogs before and after changing to CHF 151
Table 42. Means and standard deviations of values derived fi'om afternoon post­
prandial glucose concentrations in 11 dogs before and after changing to 
CHF 152
Table 43. Means and standard deviations of values derived from 24 hour and afternoon
post-prandial glucose concentrations in 5 dogs before, one week and 4 
months after changing to CHF diet 152
Table 44. Further observations: effects of very long term feeding of CHF diet 200
Table 45. Product-limit calculation example 217
Table 46. General life table for female dogs 223
Table 47. General life table for male dogs 224
Table 48. Clinical life table for 86 diabetic dogs 226
12
List of figures
Figure 1. Relationships of files which form the clinical database 32
Figure 2. Distribution of hospital control population 45
Figure 3. Age distributions of referral groups 45
Figure 4. Age distributions of diabetic and time-matched control populations 49
Figure 5. Odds ratios for diabetes meilitus by gender 50
Figure 6. Odds ratios for diabetes meilitus; effect of neutering 50
Figure 7. Odds ratios for diabetes meliitus by age for low and high risk breeds 52
Figure 8. Radiograph of emphysematous cystitis 61
Figure 9. Basal plasma insulin in metoestrus associated diabetes meliitus 67
Figure 10. Age distribution of dogs with 4 types of diabetes meilitus 68
Figure 11. Plasma cortisol responses to intramuscular injection of ACTH 69
Figure 12. Serum thyroxine response to intravenous injection of bovine TSH 70
Figure 13. The glycation reaction 80
Figure 14. Idealised ROC curves 84
Figure 15. Linearity of the fructosamine method 93
Figure 16. Effects of lipaemia on fiuctosamine concentration 93
13
Figure 17. Effects of storage of whole blood on fructosamine concentration 94
Figure 18, Inter-assay CV and effect of storage on glycated haemoglobin 96
Figure 19. Effect of haemolysis and storage on glycated haemoglobin 96
Figure 20. Mean percentage change in glycated haemoglobin concentration
following incubation with glucose 97
Figure 21. Comparison of affinity and ion-exchange chromatography for glycated
haemoglobin measurement 97
Figure 22. Comparison of affinity chromatography and gel electrophoresis for glycated 
haemoglobin measurement 98
Figure 23. Effect of anticoagulant on glycated haemoglobin measurement 99
Figure 24. Serial concentrations of alkaline phosphatase, alanine aminotransferase,
fructosamine and glucose in three diabetic dogs over 24 hours 100
Figure 25. Mean plasma glucose concentration during early diabetic therapy 101
Figure 26. Mean plasma fructosamine concentration during early diabetic
therapy 102
Figure 27. Mean glycated haemoglobin concentration during early diabetic
therapy 102
Figure 28. Mean change in alanine aminotransferase concentration during early diabetic 
therapy 103
Figure 29. Mean change in alkaline phosphatase concentration during early diabetic
therapy 103
Figure 30. Pre-treatment fructosamine concentration versus duration of polydipsia 104
Figure 31. Nadir glucose concentrations for 7 groups of glycaemic control 106
14
Figure 32. Alkaline phosphatase concentrations for 7 groups of glycaemic control 107
Figure 33. Aspartate aminotransferase concentrations for 7 groups of glycaemic
control 108
Figure 34. Fructosamine concentrations for 7 groups of glycaemic control 109
Figure 35. Glycated haemoglobin concentrations for 7 groups of glycaemic
control 110
Figure 36. Alanine aminotransferase concentrations for 7 groups of glycaemic
control 111
Figure 37. ROC curve for nadir plasma glucose 112
Figure 38. ROC curve for plasma alkaline phosphatase 113
Figure 39. ROC curve for plasma alanine aminotransferase 113
Figure 40. ROC curve for plasma aspartate aminotransferase 114
Figure 41. ROC curve for plasma fructosamine 114
Figure 42. ROC curve for glycated haemoglobin 115
Figure 43. DPR curve for nadir plasma glucose 116
Figure 44. DPR curve for plasma fructosamine 116
Figure 45. DPR curve for glycated haemoglobin 117
Figure 46. Plain plot of percentage IZS-P remaining to be absorbed 128
Figure 47. Semilogarithmic plot of percentage IZS-P remaining to be absorbed 128
Figure 48. Individual 24 hour plots of insulin and glucose concentration in 10 dogs
131
15
Figure 49. Mean percentage of maximum insulin concentration 132
Figure 50. Mean percentage of maximum plasma glucose concentration 132
Figure 51. Absolute 24 hour plasma glucose in 11 dogs on original diet 153
Figure 52. Absolute 24 hour plasma glucose in 11 dogs on CHF diet 153
Figure 53. Afternoon post-prandial glycaemia in 11 dogs on original diet 154
Figure 54. Afternoon post-prandial glycaemia in 11 dogs on CHF diet 154
Figure 55. Absolute 24 hour plasma glucose in 5 dogs on original diet 155
Figure 56. Absolute 24 hour plasma glucose in 5 dogs after one week on CHF diet 155 
Figure 57. Absolute 24 hour plasma glucose in 5 dogs after 4 months on CHF diet 156 
Figure 58. Afternoon post-prandial glycaemia in 5 dogs on original diet 156
Figure 59. Afternoon post-prandial glycaemia in 5 dogs on CHF diet (one week) 157 
Figure 60. Afternoon post-prandial glycaemia in 5 dogs on CHF diet (4 months) 157 
Figure 61. Absolute insulin dose 163
Figure 62. Percentage change in insulin dose 163
Figure 63. Absolute bodyweight 164
Figure 64. Percentage change in bodyweight 164
Figure 65. Absolute body condition score 165
Figure 66. Percentage change in body condition score 165
Figure 67. Absolute coat condition score 166
16
Figure 68. Percentage change in coat condition score 166
Figure 69. Absolute activity score 167
Figure 70. Percentage change in activity score 167
Figure 71. Absolute owner observed demeanour score 168
Figure 72. Percentage change in owner observed demeanour score 168
Figure 73. Absolute vet observed demeanour score 169
Figure 74. Percentage change in vet observed demeanour score 169
Figure 75. Absolute owner observed vision score 170
Figure 76. Percentage change in owner observed vision score 170
Figure 77. Absolute vet observed vision score 171
Figure 78. Percentage change in vet observed vision score 171
Figure 79. Absolute faecal volume score 172
Figure 80. Percentage change in faecal volume score 172
Figure 81. Absolute faecal consistency score 173
Figure 82. Percentage change in faecal consistency score 173
Figure 83. Absolute plasma fructosamine concentrations 177
Figure 84. Percentage change in plasma fructosamine concentrations 177
Figure 85. Absolute glycated haemoglobin concentrations 178
Figure 86. Percentage change in glycated haemoglobin concentrations 178
17
Figure 87. Absolute plasma alkaline phosphatase concentrations 179
Figure 88. Percentage change in plasma alkaline phosphatase concentrations 179
Figure 89. Absolute plasma alanine aminotransferase concentrations 180
Figure 90. Percentage change in plasma alanine aminotransferase concentrations 180 
Figure 91. Absolute aspartate aminotransferase concentrations 181
Figure 92. Percentage change in aspartate aminotransferase concentrations 181
Figure 93. Absolute fasting plasma glucose concentrations 182
Figure 94. Percentage change in fasting plasma glucose concentrations 182
Figure 95. Absolute afternoon (nadir) plasma glucose concentrations 183
Figure 96. Percentage change in afternoon (nadir) plasma glucose concentrations 183 
Figure 97. Absolute total plasma cholesterol concentrations 188
Figure 98. Percentage change in total plasma cholesterol concentrations 188
Figure 99. Absolute plasma VLDL cholesterol concentrations 189
Figure 100. Percentage change in plasma VLDL cholesterol concentrations 189
Figure 101. Absolute plasma LDL cholesterol concentrations 190
Figure 102. Percentage change in plasma LDL cholesterol concentrations 190
Figure 103. Absolute plasma HDL cholesterol concentrations 191
Figure 104. Percentage change in plasma HDL cholesterol concentrations 191
Figure 105. Absolute plasma triglyceride concentrations 192
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
18
06. Percentage change in plasma triglyceride concentrations 192
07. Absolute plasma free glycerol concentrations 193
08. Percentage change in plasma free glycerol concentrations 193
09. Absolute plasma non-esterified fatty acids concentrations 194
10. Percentage change in plasma non-esterified fatty acids concentrations 194
11. Absolute VLDL triglyceride/apolipoprotein B ratios 195
12. Percentage change in VLDL triglyceride/apolipoprotein B ratios 195
13. Absolute post heparin hepatic triglyceride lipase activities 196
14. Percentage change in post heparin hepatic triglyceride lipase activities 196
15. Insulin doses in 11 dogs before and after one week on CHF diet 204
16. Insulin doses in 5 dogs before, one week after and 4 months after changing 
to CHF diet 204
17. Product-limit survivorship function by gender 222
18. Product-limit survivorship function by insulin type 222
19. Product-limit survivorship function by concurrent endocrinopathy 223
20. Probability of death curves 224
21. Clinical life table survivorship function for 86 diabetic dogs 227
22. Probability density function for 86 diabetic dogs 227
23. Hazard function for 86 diabetic dogs 228
19
Figure 124. Hazard function for all 86 diabetic dogs and those without hyperadreno­
corticism 228
Figure 125. Median remaining life time for 86 diabetic dogs 230
Figure 126. Relative survival rates by gender 230
Figure 127. Relative survival rates by insulin type 231
Figure 128. Relative survival rates for all 86 diabetic dogs and those without hyper­
adrenocorticism 231
20
Acknowledgements
Financial support for this work was provided by the University of Glasgow, Waltham 
Centre for Pet Nutrition and Intervet UK Ltd. and I am grateful to Professor Norman 
Wright, Mr Peter Markwell, Dr Ian Maskell, Mr John Watson and Dr Aart Coert for 
their support in obtaining this funding.
This thesis would certainly not exist if it had not been for the guidance of Professor 
Andrew Nash and his efforts in my supervision but particularly since he was responsible 
for initiating my interest in canine diabetes meilitus. The support of Professor Max 
Murray, in whose department this work was performed, has been unfailing and the 
existence of this thesis also owes much to Mr Brian Wright and his ‘magic wand* for 
ensuring that I had the necessary equipment and supplies to complete my work.
Technical assistance was gratefully received from Ronnie Barron and Kenny Williamson 
who performed the haematological analyses; Anne Galbraith who performed the insulin 
analyses and Christine Marshall, Chris McComb, Jim Harvey, David Moffat and David 
French who performed routine clinical chemistry analyses. June Downs conducted the 
plasma glycerol measurements and, along with Kathryn McBride, some of the glycated 
haemoglobin analyses. John Armstrong, Linda Forrest, Arlene Macrae, June and Kathryn 
all contributed to my ‘laboratory education* ensuring that I quickly learned one end of an 
air displacement pipette from the other and the meaning of the word microlitre.
Drs. Tim Watson, Joan Barrie and Roger Clampitt kindly helped me through the 
complexities of clinical lipidology and biochemistry and Joan also provided me with the 
know how for performing quantitative analysis of canine lipoproteins.
I received advice on statistical methods from Professor George Gettinby and Dr Stuart 
Reid but could not have performed the analyses or ventured into the hospital computer 
network without patient tutoring from David Irvine.
Expert nursing care for the dogs featured in this thesis was provided by Pamela Gillan, 
Mairi Austin, Susan Fitzpatrick, Carole Anderson and Janice Moffat all of whom along 
with Chris McComb, Callum Blair, Kathryn McBride and Andrew Nash ensured there 
was someone to help me obtain blood glucose samples after normal working hours.
I have benefited much from association with clinical colleagues including Drs Carmel 
Mooney, Sean Callanan, Chris Little, Ms Jo Dukes McEwan and houseofficers past and 
present and I owe them many thanks. The assistance of staff in radiography, clinical 
records, photography and veterinary pathology in the pursuance of my clinical work 
must also be acknowledged.
Combinations of firiendship, support, encouragement and advice were provided during 
the completion of this work by: my family; Drs Sandy Love, Richard McCulloch, 
Heather Spence, Chris Hunter, Jo Burke and Lubna Nasir; Jean Rodgers, Tom Irwin, 
Carl Mills, Chris Rawlinson, Ian Scott, Tim Harvey, David Murphy, Janice Lloyd, 
Michael Wilkinson, and Juan Escala in addition to that by many of those already 
mentioned.
21
Author’s declaration
The work presented in this thesis was performed solely by the author except where the 
assistance of others has been acknowledged.
The details of diabetic dogs presented in this thesis relate to cases treated by the author 
in the Department of Veterinary Medicine, University of Glasgow during the period 
October 1989 to August 1994.
PETER A. GRAHAM, May 1995
Some of the work in this thesis has been the subject of the following publications or 
presentations:
Graham PA. Maskell IE and Nash AS (1994) (Zanned high fiber diet and postprandial glycemia in dogs 
with naturally occurring diabetes meilitus. Journal o f Nutrition 124: 2712S -2715S
Graham PA. McKellar QA and Nash AS (1995) The pharmacokinetics of a highly purified porcine 
insulin zinc suspension (IZS-P) in dogs with naturally occurring diabetes meliitus. Journal o f Small 
Animal Practice (Submitted for publication. May 1994).
Graham PA and Nash AS (1995) How long will my diabetic dog live? British Small Animal Veterinary 
Association Annual Congress Proceedings p 217.
Graham PA The Modem Management of Canine Diabetes Meilitus, Proceedings o f the 1st Congress o f 
the Federation o f European Companion Animal Veterinary Associations PanSy November 1994. p599
Graham PA Maskell BE, Markwell PJ and Nash AS (1994). The long term effects of feeding a 
conunercially produced high-fibre diet to dogs with naturally-occurring diabetes meilitus. Association of 
Veterinary Teachers and Research Workers Annual Scientific Meeting, Scarborough.
Graham PA Maskell IE and Nash AS (1993) The effects of feeding a conunercially produced high fibre 
diet on post prandial glycaemia in naturally-occurring diabetic dogs. Waltham Symposium on the 
Nutrition of Companion Animals at 15th International Congress of Nutrition, Adelaide, Australia.
Graham PA Maskell BE and Nash AS (1993) The effects of feeding a commercially produced high fibre 
diet on post prandial glycaemia in naturally-occurring diabetic dogs. British Small Animal Veterinary 
Association Annual Congress Proceedings p 195
Graham PA and Nash AS (1992) The long-term use of a highly purified porcine insulin zinc suspension 
(IZS-P) in dogs with naturally-occurring diabetes meliitus. British Small Animal Veterinary Association 
Annual Congress Proceedings p 230
Graham PA. McKellar QA and Nash AS (1992) The pharmacokinetics of a highly purified porcine 
insulin zinc suspension (IZS-P) in dogs with naturally-occurring diabetes meilitus. British Small Animal 
Veterinary Association Annual Congress Proceedings p 167
CHAPTER 1 22
Chapter 1: 
General Introduction and review
This chapter is a brief review of the background, pathophysiology, diagnosis and 
management of canine diabetes meliitus and an outline of the objectives of the thesis as a 
whole. More detailed reviews of certain specific aspects of canine diabetes meilitus are 
presented within relevant chapters.
Definition
Diabetes meliitus is not a single disease but is a clinically and aetiologically 
heterogeneous group of hyperglycaemic diseases and conditions (Harris and Zimmet, 
1992; Unger and Foster, 1985). Hyperglycaemia results fi'om an absolute or relative 
deficiency of insulin combined with an absolute or relative excess of glucagon.
History
Diabetes meilitus has been recognised in man and animals for many centuries. The 
earliest reports of the condition in man are fi'om Egypt (cl 500 BC), India (c600 BC) and 
Greece (300 BC) (Tunbridge and Home, 1991; Wilkinson 1957; Harris and Zimmet, 
1992) and although diabetic urine had been described as ‘sweet* for many centuries it 
was not until 1674 that an English physician Willis proposed that sweet urine was likely 
to be secondary to a sweetness of blood. This theory was proven in the late 1700's and 
some years later glucose was discovered to be the relevant sugar. In veterinary literature 
the first mention of sugar in the urine of a polyuric animal appeared in Blaine's 
Veterinary Art of 1802 (Wilkinson, 1957) with a description of diabetes meilitus in the 
horse and the suggestion was that it was not an infrequent disease. Reports of cases of 
spontaneous canine diabetes meilitus did not appear until the very late 19th and early 
20th century (Foster, 1975) but an identical condition was experimentally induced in 
dogs following pancreatectomy by Von Mehring and Minkowski in 1889 (\^lkinson, 
1957), a discovery which paved the way for the elucidation of the underlying 
mechanisms of the disease in the early 20th century.
Pathophysiology
The hormone insulin is produced by P-cells of the pancreatic islets of Langerhans and is 
secreted into the blood in response to a rise in the plasma concentration of glucose or
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amino acids (Chastain and Ganjam, 1986a). Its principal action is to facilitate the 
transport of glucose, potassium and phosphate into cells (Chastain and Ganjam, 1986a). 
Insulin is antagonised by the hormone glucagon which is secreted by the a-cells of the 
pancreatic islets in response to an increase in plasma concentrations of amino acids such 
that its role may be to protect against hypoglycaemia during protein stimulation of insulin 
secretion (Chastain and Ganjam, 1986a). Insulin normally suppresses glucagon driven 
glycogenolysis and mobilisation of peripheral fat and protein and their subsequent 
conversion to glucose (gluconeogenesis) whilst promoting the storage o f fat, protein and 
carbohydrate (Chastain and Ganjam, 1986a). When there is insufficient insulin to 
suppress the effects of glucagon these processes proceed uncontrolled and raise blood 
glucose concentrations (Chastain and Ganjam, 1986b). This situation is further 
aggravated because insulin is also required to transport glucose into cells from plasma. 
When plasma glucose concentration is greater than 10-12mmol/l, the renal threshold is 
exceeded resulting in glycosuria and an osmotic diuresis occurs (Feldman and Nelson, 
1987), with compensatory polydipsia. Bodyweight is reduced because of the mobilisation 
and metabolism of fat and protein stores (Chastain and Ganjam, 1986b).
The energy deficit created in peripheral tissues by the reduced uptake of glucose is met 
by the mobilisation of fat stores and their metabolism in the liver to produce ketones 
which can be used as an alternative energy source (Chastain and Ganjam, 1986b). 
Ketogenesis is suppressed by insulin in the normal animal. In addition, insulin normally 
has an inhibitory action on hormone sensitive lipase in adipose tissue (Allen, 1987) but 
when this inhibition is lost there is increased lipolysis and movement of fatty acids from 
fat stores to the liver and other tissues. Concentrations of circulating triglycerides are 
increased in diabetes meilitus because lipoprotein lipase (LPL) - dependent clearance is 
reduced, insulin being permissive for the efficient synthesis and activity of lipoprotein 
lipase. Hepatic synthesis of triglyceride is also increased as a result of the increased 
concentration, and therefore, uptake of non-esterified fatty acids (Nikkila, 1984). As a 
result, many diabetics have raised circulating concentrations of triglyceride, non- 
esterified fatty acids and cholesterol. The structure and composition of the lipoproteins, 
particularly very low density lipoprotein (VLDL), is also seriously altered in diabetes 
meliitus (Abbate and Brunzell, 1990). The consequence of the mobilisation of peripheral 
fat and hepatic triglyceride synthesis is fatty infiltration of the liver (hepatic lipidosis) 
which in turn induces elevations in plasma concentrations of alanine aminotransferase 
(ALT), alkaline phosphatase (ALKP) (Nelson, 1989a; Allen, 1987) and occasionally 
gamma-glutamyl transferase (GGT). Plasma concentrations of aspartate aminotransferase 
may be elevated in unstable canine diabetics because of the catabolism of protein stores 
(muscle) for gluconeogenesis. Prolonged elevations of plasma glucose concentrations 
increase the degree of non-enzymatic glycation of plasma proteins and haemoglobin. The
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concentrations of glycated plasma proteins (fructosamine) and glycated haemoglobin, 
therefore reflect the mean concentration of plasma glucose which has prevailed in the 
preceding weeks or months (Dolhofer and Weiland, 1979; Wood and Smith, 1980; Bunn, 
1981; Mahaffrey and Cornelius, 1982; Higgins et al  ^ 1982; Reusch et al, 1993).
When insulin deficiency is absolute or when glucagon excess is very large, diabetic 
animals are prone to become ketoacidotic. There is no negative feedback mechanism for 
ketogenesis and so ketone production, which is regulated by the insulin:glucagon ratio, 
can exceed requirements (Unger and Foster, 1985: Chastain and Ganjam, 1986b). When 
overproduction of ketones exceeds the body’s buffering capacity, ketoacidosis results 
(Chastain and Ganjam, 1986b).
Aetiology
In human medicine, diabetes mellitus has been broadly classified as being idiopathic or 
secondary in origin (Table 1). Idiopathic diabetes mellitus includes insulin dependent 
diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) (World 
Health Organisation 1985). Secondary diabetes mellitus can result fi"om a number of 
causes such as generalised pancreatic disease or injury, effects of antagonistic hormones 
or drug toxicities. The aetiopathologically descriptive terms Type I and Type II have 
been used synonymously with the clinically descriptive terms IDDM and NIDDM, 
respectively, by many in human medicine (Unger and Foster, 1985). However, some 
authors restrict the use of the term Type I diabetes mellitus to refer solely to diabetes 
mellitus resulting from immune-mediated islet cell cytotoxicity and the term Type II 
diabetes mellitus to refer to those diabetics who do not have immune-mediated islet cell 
toxicity nor any other known cause of diabetes mellitus (Unger and Foster, 1985). This 
has led to confusion in applying classifications of human diabetes mellitus to the 
veterinary field and some veterinary diabetologists have exacerbated this confusion by 
classifying canine diabetes mellitus into Type I, Type II and Type m  based on plasma 
concentrations of insulin and glucose without regard for aetiopathogenesis (Kaneko et 
al  ^ 1978). Nearly all canine diabetics require insulin therapy and are therefore insulin 
dependent. However, it does not appear that all diabetic dogs fit the human classification 
of IDDM/Type I because most canine diabetes mellitus appears to be secondary in origin 
(zW insulin dependent (Chastain and Ganjam, 1986b; Eigenmann 1989).
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Idiopathic
Secondary
IDDM
NIDDM
Generalised pancreatic disease 
Hormonal antagonism 
Drug toxicity
Insulin receptor abnormality
Gestational
Impaired glucose tolerance
Malnutrition associated
Previous or potential abnormality of glucose tolerance 
Table 1. Classification of diabetes mellitus in humans
Canine diabetes mellitus can be caused (or exacerbated) by any factors which interfere 
with insulin production, transport or activity in target tissues (Table 2). For example, 
failure of insulin production could be the result of immune-mediated islet cell destruction 
(Sai et al 1984) or chronic pancreatitis (Dixon and Sanford, 1962). Peripheral insulin 
insensitivity can result from obesity, hypercortisolaemia of hyperadrenocorticism or other 
hormonal antagonism. Failure of insulin transport e.g. by the formation of insulin 
antibodies is possible but rarely occurs as a recognisable clinical syndrome in dogs 
(Feldman et al, 1983; Feldman and Nelson, 1987; Ihle and Nelson, 1991). Dogs which 
are, or are about to become, diabetic primarily as a result of insulin insensitivity initially 
exhibit compensatory elevations in insulin production (Kaneko et al, 1978; Mattheeuws 
et al, 1984a; Mattheeuws et al, 1984b; Eigenmann, 1989). However, after a sustained 
period of increased output, which may last months, insulin secreting p-cells may become 
exhausted (Kaneko et al, 1978; Mattheeuws et al, 1984a; Mattheeuws et al, 1984b; 
Eigenmann 1989), leaving a diabetic which has a combination of failed insulin production 
and target tissue insensitivity. In such cases, if the primary cause of insulin resistance can 
be identified and eliminated early, the dog need not be diabetic for the rest of its life 
(Campbell and Latimer, 1984; Eigenmann, 1989; Blaxter, 1990). The most common 
example of a ‘cured’ diabetic dog is the bitch with metoestrous diabetes, associated with 
progesterone excess and consequent induction of elevated concentrations of growth 
hormone which is spayed before P-cell exhaustion occurs (Eigenmann, 1989; Blaxter, 
1990).
The relative prevalence of canine diabetes mellitus resulting from each of the known 
causes is difficult to ascertain. Dixon and Sanford (1962) found as many as 4 out of 8 
diabetic dogs to have evidence of pancreatic inflammation at post-mortem examination. 
It has since been suggested (Chastain and Ganjam, 1986b) that pancreatitis is a relatively 
unimportant cause of canine diabetes mellitus. Hormonal antagonism, especially by
CHAPTER 1 26
progesterone induced growth hormone secretion, progestagens or cortisol, is thought to 
be a much more common aetiology (Nelson and Feldman, 1987; Eigenman, 1989). Islet 
auto-immunity has also been recorded in some diabetic dogs (Sai et al, 1984; Haines and 
Penhale, 1985) and a condition resembling human Type II diabetes has been reported in 
about 10% of diabetic dogs, but in which insulin replacement therapy was necessary 
(Mattheeuws et al, 1984b). It is likely that autoimmunity, pancreatic inflammation, 
hormonal antagonism and Type II disease all have a role in the development of canine 
diabetes mellitus. However, there are no reported studies which accurately define their 
relative importance.
Failure of:
Insulin production Insulin transit Target tissue sensitivity
autoimnmnity 
pancreatitis 
islet cell hypoplasia 
chemical toxicity 
pancreatic neoplasia 
pancreatectomy 
senile degeneration
insulin antibodies obesity
hormonal antagonism 
glucagon 
growth hormone 
progesterone/agens 
glucocorticoids 
catecholamines 
autoimmunity?
Table 2. Factors which cause or exacerbate diabetes mellitus in dogs
Diagnosis
Diagnosis of canine diabetes mellitus is based on the documentation of a persistent 
fasting hyperglycaemia (blood glucose > 12-14mmol/l) with glucosuria.
Management
The management of canine diabetes mellitus is based on insulin replacement therapy and 
dietary manipulation (Chastain and Ganjam, 1986b; Feldman and Nelson, 1987). Only 
rarely can diabetic dogs be managed without insulin replacement. In these instances, oral 
hypoglycaemic or antihyperglycaemic agents (sulphonylureas and biguanides) can be 
used to control hyperglycaemia. These agents depend on the presence of functional P- 
cells for their action (Hermann and Melander, 1992; Lebovitz and Melander, 1992). 
They are therefore unlikely to be useful where there is little or no reserve insulin 
production capacity. In the long-term, sulphonylureas may even reduce insulin 
production capacity (Lebovitz and Melander, 1992). Insulin replacement therapy is by 
once or twice daily injection of intermediate or long duration insulin preparations (see 
Chapter 6). Dietary management is by provision of consistency of composition, quantity 
and times of meals from day to day. In addition, modifying the composition of the diet 
can improve the degree of glycaemic control (see Chapter 7). Generally, a period of
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‘stabilisation’ is required during which an ideal treatment regime is sought and this is 
followed by a maintenance period. Therapeutic success is monitored during the 
stabilisation period by measurement of blood glucose concentrations and in the 
maintenance period by measurement of plasma concentrations of ‘hepatic’ enzymes in 
addition to nadir blood glucose concentrations.
Concurrent illness
When diabetes mellitus coexists with other disease, insulin requirements are frequently 
increased because of insulin insensitivity. Bacteraemia and uraemia in man and 
experimental animals are known to promote insulin insensitivity via an increase in 
glucagon levels such that sick and dehydrated diabetics are at greater risk of becoming 
unstable on treatment and of becoming ketoacidotic (Ihle and Nelson, 1991). Similarly 
dogs with concurrent hyperadrenocorticism (Peterson et al, 1981), acromegaly or 
phaeochromocytoma (Ihle and Nelson, 1991) and entire bitches in metoestrus 
(Eigenmann, 1981) can have marked insulin insensitivity because of hormonal insulin 
antagonism. Recently, hypothyroidism has been associated with insulin insensitivity but 
the underlying mechanisms are less clear (Ford et al, 1993).
Complications of diabetes mellitus
Longstanding canine diabetes mellitus, is associated with relatively few complications. 
The most common of these is the formation of ocular cataracts and loss of vision. 
Cataracts are believed to form because of the osmotic effects of intralenticular polyols 
which result from high blood sugar concentrations and increased activity of aldose 
reductase in the sorbitol pathway (Wyman et al, 1988). Terminal hepatic failure and 
cirrhosis are also possible sequelae to diabetes mellitus which arise as a result of chronic 
hepatic fatty infiltration common in poorly controlled diabetics (Nelson, 1989a). In 
human diabetic medicine, microvascular and neuropathic complications are of great 
concern (Borch-Johnsen and Deckert, 1992) and although neuropathy has been recorded 
in canine diabetes mellitus (Katherman and Braund, 1983; Anderson et al, 1986; 
Misselbrook, 1987; Haining, 1993), microvascular complications including retinopathy 
and nephropathy are rare (Nelson, 1989). Macrovascular complications, principally 
atherosclerosis, common in diabetic humans (Borch-Johnsen and Deckert, 1992; 
Uusitupa et al, 1992) are reported only rarely in canine diabetics (Hargis et al, 1981). 
Pancreatitis can occur in dogs as a consequence as well as a cause of diabetes mellitus 
and in man an increased risk of pancreatitis has been associated with elevated 
concentrations of circulating triglycerides (European Atherosclerosis Society, 1988) such 
as those common in poorly controlled diabetics.
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Study objectives
The ultimate aim of the work presented in this thesis is to improve the welfare of dogs 
with spontaneously occurring diabetes mellitus. Principally the potential for improvement 
in canine diabetic management has been explored through studies on specific dietary and 
insulin preparations and through the appraisal of the most useful tools for long-term 
monitoring. In addition, epidemiological techniques have been applied to a large group of 
diabetic dogs to identify any changes in the nature or pattern of the disease and to 
generate useful indicators of therapeutic success and longevity for use in future studies. 
This study has required a multidisciplinary approach including the application of clinical 
veterinary medicine, endocrinology, pharmacokinetics, nutrition, gastroenterology and 
numerous facets of biochemistry, medical computing and biostatistics but it has permitted 
the cultivation of a more comprehensive understanding of canine diabetes mellitus and 
provided the opportunity to develop many skills applicable to the study of animal disease.
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Chapter 2: 
General materials and methods
Additional specific materials & methods are presented within each relevant chapter 
Animals
All dogs described within this thesis were referred to the Department of Veterinary 
Medicine, University of Glasgow by veterinary surgeons in general practice (general 
veterinary practitioners) between 1989 and 1994. Most referrals came from West Central 
Scotland but there were some from as far as the Western Isles, Cumbria and Co Durham. 
The reasons for referral were varied. Most were referred immediately following diagnosis 
for initial diabetic stabilisation; some for futher investigation of their apparently 
complicated condition and some before a diagnosis had been made.
Clinical management 
Stabilisation
Following referral, untreated and previously treated but unstable cases underwent a 
stabilisation period for which they were hospitalised. During this period a suitable insulin 
dose was determined. Prior to stabilisation the diagnostic work up included a thorough 
clinical examination and a full routine plasma biochemical and haematological analysis. 
Other diagnostic procedures such as radiography, urinalysis and dynamic endocrine 
testing were only performed when there was a strong clinical indication.
Non-ketotic dogs were immediately begun on a single daily insulin injection and tvdce 
daily feeding stabilisation regimen following laboratory confirmation of diagnosis. The 
insulin preparations used in this regimen were of the intermediate duration type and were 
either isophane (Evan's Isophane, Hypurin Isophane) or mixed insulin zinc suspension 
(lente) (Insuvet Lente, Hypurin Lente, Lentard MC, Caninsulin). Daily insulin injections 
were administered with 1/3 to 1/2 of the dogs’ daily dietary ration and the second 
portion of the ration was offered at 6 hours post-injection. Diets consisted of commercial 
canned dog foods (Chappie or Pedigree Chum; Pedigree Petfoods) fed alone or in
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combination with bread or commercial mixer biscuit (Mixer, Pedigree Petfoods; Winalot, 
Spillers). The ration was fed at a rate of 40-80kcal/kg based on a subjective assessment 
of body size and condition.
The initial dose of insulin administered to an untreated case was between 0.5 and 1.0 
lU/kg and subsequent adjustments to dose were made on a daily basis according to the 
plasma glucose concentration in a blood sample taken just before the second meal on the 
previous afternoon. It was assumed that the plasma concentration of glucose just before 
the second meal was likely to be the lowest concentration (nadir) in the day. Adjustments 
to insulin dose were made until nadir concentrations of plasma glucose were consistently 
in the range 3.5-7.5 mmol/1. The size of increments or decrements in insulin dose from 
day to day depended both on the size of the dog and on the concentration of plasma 
glucose the previous afternoon such that very small dogs may have had their doses 
adjusted by only 1-2 lU/day but in very large dogs this adjustment may have been 4-6 
lU/day. Afternoon plasma glucose concentrations >20 mmol/1 would have meant larger 
increases in dose than plasma glucose concentrations between 7 and 10 mmol/1. Urine 
samples for glucose estimation were not taken routinely.
Once diabetic stability had been acheived, ovariohysterectomy was performed on entire 
bitches subject to owner consent. However, bitches which had metoestrus-associated 
diabetes were, if possible, spayed after only a brief period of insulin replacement therapy 
and before stability had been achieved.
Ketoacidotic dogs which had reasonable appetite and were not vomiting were treated in 
a similar way to non-ketotic dogs but they were treated much more intensely if their 
appetite began to wane. The treatment protocol for those ketoacidotic dogs which were 
anorexic or vomiting included the administration of intravenous fluid therapy 
supplemented with potassium chloride and soluble insulin therapy. Initially the 
intravenous fluid would have been physiological saline but this would have been replaced 
by 4% dextrose saline once blood glucose began to fall. Potassium supplementation was 
by the addition of approximately 10 mmol potassium chloride to each litre of intravenous 
fluids and soluble insulin therapy was administered at a rate equivalent to 0.1 lU/kg/hr 
either by continuous infusion or regular bolus. When there was difficulty in providing 
overnight care, a low dose of approximately 0.25 lU/kg isophane insulin was 
administered subcutaneously last thing at night to provide insulin until the morning. Once
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appetite returned and vomiting ceased, the standard stabilistation protocol outlined for 
non-ketotic dogs was followed.
Maintenance
Once stabilisation had been achieved, dogs were discharged from the hospital to be 
managed by their owners at home following a prolonged consultation during which the 
owners were instructed in the administration of insulin and the recognition and 
importance of insulin-induced hypoglycaemia.
Owners were requested to return with their dogs at one and three weeks after they were 
discharged from the hospital. Thereafter, a one to two month interval was recommended 
between follow-up visits. At each visit, blood samples were taken for routine plasma 
biochemical and haematological analyses (outlined below) and a general clinical 
examination was performed. A brief distant direct ophthalmological examination was 
carried out on most of these occasions to record the development of cataracts and a 
‘glycaemic control score’ (1 to 7; see chapter 5) was allocated to each dog on each visit 
based on the owner’s description of their dog’s demeanour, clinical condition and an 
afternoon plasma glucose concentration. A body condition score (1 to 6) was also 
allocated at each visit.
Computing 
Hospital system
The hospital computing system operated by the Departments of Veterinary Medicine and 
Pathology at University of Glasgow was used to record animal details and the results of 
biochemical analyses of all the diabetic dogs in this study and to provide details of a 
control group of dogs referred to the hospital over the period of the study. This hospital 
system uses multiuser, relational database software (Dataflex, Data Access Corporation, 
Miami, USA) and a CP/M operating system which runs on a Jarogate Sprite 386 
(Jarogate, UK) as the central or host processer. There are terminals for data entry 
situated within the case reception office and the results of biochemical analyses are 
imported from a separate IBM-PC compatible processer which is linked to an automated 
analyser (Cobas Mira, Roche) and is situated within the Department o f Veterinary 
Medicine Clinical Biochemistry Laboratory. In addition, network connections east with 
a processor within the Department of Veterinary Pathology which allows access to files 
concerning necropsy, biopsy and bacteriological examinations performed within that
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department. Data generated by interrogation of the hospital computer system can be 
transferred from the Jarogate Sprite in the form of a textfile via a 5V4 inch floppy disk 
drive.
The animal file is the central file to many others but it contains only limited information 
on each animal. Only hospital number, animal name, gender, date of birth and date first 
seen are directly recorded in this file but it contains numeric references to other files 
which contain data relating to species, breed, owner, staff member and referring 
veterinary surgeon. In addition there are ‘counter’ fields within the animal file which 
record the number of biochemistry, bacteriology, biopsy, necropsy (maximum one) and 
clinical summary reports generated for each animal. Figure 1 summarises the relationship 
of files within the hospital system and Tables 3 and 4 list the fields in the animal and main 
biochemistry files.
Referring Vet Clinician Species & BreedOwner
Invoice
Central Animal File
Via Network 
Link to Vet. 
Pathology
Case Summary Biochemistry
BacteriologyNecropsy Biopsy
Figure 1. Relationships of files which form the clinical database within the Departments of 
Veterinary Medicine and Pathology, University of Glasgow.
Smart II system
To enable the further manipulation of the data relating to diabetic dogs and the addition 
of data not recorded on the hospital system a separate set of database files were created
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on an IBM-PC compatible computer. Database files were designed using a commercial 
software package (Smart II; Informix Software, Lenexa, Kansas, USA). Four mmn files 
were created and these contained animal details (ANIMAL), biochemistry results 
(BIOCHEM), glycated haemoglobin results (GLYTEK) and fiaictosamine results 
(FRUCT). Each diabetic animal had only one ANIMAL record but had many records in 
the BIOCHEM, GLYTEK and FRUCT data files. Records in the ANIMAL file and the 
other three files were related by unique hospital numbers and records in the BIOCHEM, 
GLYTEK and FRUCT data files were related using an ‘OLAP’ field which contained a 
number generated from a combination of the animal’s case number and the date of the 
sample. In this way biochemistry data could be matched up with glycated haemoglobin 
and fiiictosamine data for any particular animal on any particular day. The BIOCHEM 
file contained additional information obtained at follow up examinations such as body 
weight, insulin dose and clinical comments. A numeric scoring system for glycaemic 
control and the progression of cataracts was employed and fields to contain this 
information were included in the BIOCHEM file. The structure and relationships of the 
Smart II data files are represented in Table 5.
Data manipulation and statistics
Data manipulation and presentation was facilitated by use of a number of computer 
software packages including: Word for Windows 2.0 (Microsoft Corporation, USA), 
Excel 4.0 (Microsoft Corporation, USA), Lotus 123 for Windows (Lotus Development 
Corporation, Cambridge, MA, USA) and Harvard Graphics for Windows 2.0 (Software 
Publishing Corporation, Santa Clara, CA, USA). Statistical analyses were performed 
using MINITAB release 8, MINITAB for Windows release 9 (Minitab Incorporated, 
State College, PA, USA), Epilnfo 5.01b (Centers for Disease Control and World Health 
Organisation), Stata release 3.1 (Stata Corporation, College Station, Texas) and Excel 
4.0 (Microsoft Corporation, USA). Statistical methods were based on those descibed in 
the MINITAB Handbook (Ryan et al, 1985), MINITAB Software Reference Manuals 
(Minitab Incorporated, State College, PA, USA), Principles o f Biostatistics (Pagano and 
Gauvreau, 1992) and Statistical Methods fo r Survival Data Analysis (Lee, 1992) and 
those taught in the short course Statistics fo r Bioscientists, University of Strathclyde.
Clinical biochemistry
Clinical biochemistry analyses were performed in the Department of Veterinary Medicine 
Clinical Biochemistry Laboratory with the exception of glycated haemoglobin and
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glycerol measurements, which were performed in the Department of Veterinary Medicine 
Research Laboratory. The following analytes were measured in what will be referred to 
as a routine biochemical profile: urea, sodium, potassium, chloride, phosphate, calcium, 
bilirubin, cholesterol, glucose, creatinine, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, total protein, albumin and globulin. Table 6 lists the common 
clinical chemistry methodologies used. Additional methodologies which were used as 
part of specific studies are described within relevant chapters.
Plasma and blood glucose analyses were also carried out at times when laboratory 
facilities were not available using either the Glucometer and Glucostix System (Ames) or 
the Vettest analyser (IDDEX Laboratories). Some clinical chemistry analyses relevant to 
this thesis were performed outwith the University of Glasgow. These included plasma 
determinations of trypsin-like immunoreactivity, folate and cobalamin which were 
performed in the Department of Veterinary Pathology, University of Liverpool, some 
insulin and some thyroxine estimations which were performed at Serono Clinical 
Laboratories, Cambridge and a growth hormone analysis performed in the Faculty of 
Veterinary Medicine, Utrecht University.
Clinical haematology
A routine haematological profile was generally generated on the same occasions as 
routine biochemical profiles and included a white blood cell count (WBCC), red blood 
cell count (RBCC), mean red cell volume (MCV), haematocrit, mean corpuscular 
haemoglobin (MCH), mean cell haemoglobin concentration (MCHC), platelet count and 
differential white cell count. This was performed in the Department of Veterinary 
Pathology, University of Glasgow using an ABX Minos Vet automated cell counter 
(Roche).
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Field Referenced File Comment
HOSP_NO
NAME
OLAPl
SPECIES
BREED1
BREED2
DOB
SEX
ALIVE
SAMPLE_ONLY
VET_REF
STAFF1_REF
DATE_FIRST_SEEN
DATE_LAST_SEEN
VISITS
SPARES
LAST_SIGN
LAST_HAEM
LAST_BIOP
LAST_NECRO
LAST_BIOCH
LAST_DIAG
LAST_SUMMARY
LAST BACT
Species & Breed 
Species & Breed 
Species & Breed
Referring Vet 
Clinician
used for indexing purposes 
species code
e.g. retriever, terrier, etc 
e.g. golden, cairn, etc 
date of birth
not used 
not used
number of hospital visits 
not used 
not used 
not used
not used
Table 3. File structure of the Animal file on the Jarogate hospital computer system
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Field Comment
OLAPl REFl and REF2 combined
REFl hospital number
REF2 number of records for this animal
LAB NO laboratory number
DATE_COLL date collected
DATE_RECV date received
DATE_REPORT date analysed
SAMPLE sample type (plasma/urine/CSF etc)
HOSP NO hospital number
DAYS age
WEEKS age
MONTHS age
YEARS age
ALIVE not used
BIOCHEMIST not used
COST cost of analysis
CHARGE not used
STATUS not used
UREA
SODIUM
POTAS potassium
CHLOR chloride
CAL calcium
MAGNES magnesium
PHOS phosphate
SUGAR glucose
CHOL cholesterol
CREAT creatinine
BIL bilirubin
S ALK PHOS alkaline phosphatase
AST aspartate aminotransferase
ALT alanine aminotransferase
TOT PROT total protein
ALB albumin
GLOB globulin
CPK creatine phosphokinase
GGT gamma-glutamyl transferase
LDH lactate dehydrogenase
AMY amylase
COMMENT
Table 4. File structure of the *Biochem’ file on the Jarogate hospital computer system
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ANIMAL BIOCHEM GLYTEK FRUCT
1 Hospital number Hospital number Hospital number Hospital number |
Owner name Date collected Date collected Date collected
Animal name 1 OLAP OLAP OLAP 1
Species Urea Species Species
Date of Birth Sodium Date assay Date assay
Original gender Potassium Optical density 1 Fructosamine
Present gender Chloride Optical density 2 Diagnosis
Date neutered Calcium Glycated HE (%)
Breed 1 Phosphate Diagnosis
Breed 2 Glucose
Alive/Dead Cholesterol
Date first diagnosed Creatinine
Date first presented Bilimbin
Date died Alkaline phosphatase
Weeks of polydipsia AST
Other disease 1 ALT
Date diagnosed 1 Total protein
Other disease 2 Albumin
Date diagnosed 2 Globulin
Other disease 3 GGT
Date diagnosed 3 Amylase
Current insulin type Triglyceride
Current insulin since Plasma insulin
Injection frequency Cortisol
Previous insulin type Cortisol post-ACTHl
Previous insulin since Cortisol post-ACTH2
Meal/Injection time 1 Thyroxin
Meal 1 content Thyroxin post TSH
Meal/Injection time 2 Fasting/post prandial
Meal 2 content Glycaemic control score
Meal/Injection time 3 Clinical comment
Meal 3 content Insulin dose (TU)
Meal/Injection time 4 Bodyweight
Meal 4 content Obesity score 
Cataract score (right) 
Cataract score (left)
Table S. Lists of fields in Smart II database files ANIMAL, BIOCHEM, GLYTEK and FRUCT. 
Double bordered boxes signify reference fields between data files.
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Analyte Reagent/Kit Manufacturer Principle Instrumentation
Urea UREA Roche urease and glutamate 
dehydrogenase
Roche Cobas Mira
Sodium Instrumentation
Laboratories
flame photometry Flame Photometer 
543
Potassium Instrumentation
Laboratories
flame photometry Flame Photometer 
543
Chloride Coming coulometric analysis Choride Analyser 
925
Calcium Instrumentation
Laboratories
atomic absorption Atomic absorption 
spectrophotometer 
257
Cholesterol CHOL Roche cholesterol esterase, 
cholesterol oxidase and 
peroxidase
Roche Cobas Mira
Glucose GLUC-PAP Roche glucose oxidase and 
peroxidase
Roche Cobas Mira
Glucose GLUCOSE Roche glucose hexokinase and
glucose-6-phosphate
dehydrogenase
Roche Cobas Mira
Creatinine Creatinine
Reagent
Bayer
(Technicon
Series)
Jaffe method. Picric acid 
and sodium hydroxide
Roche Cobas Mira
Inorganic
phosphoms
PHOS Roche ammonium molybdate to 
phosphomolybdate
Roche Cobas Mira
Bilirubin Bilirubin
Test
Roche Cafieine accelerator 
(Jendrassik/Grof 
reaction, 1938)
Roche Cobas Mira
Alkaline
phosphatase
ALP-DGKC Roche 4-nitrophenyl phosphate 
substrate in 
diethanolamine buffer
Roche Cobas Mira
Aspartate
aminotransferase
AST Roche L-aspartate, 2- 
oxoglutarate, malate and 
lactate dehydrogenase 
(IFCC)
Roche Cobas Mira
Alanine
aminotransferase
ALT Roche L-alanine, 2- 
oxoglutarate, lactate 
dehydrogenase (IFCC) 
(pyridoxal phosphate 
activated)
Roche (Zobas Mira
Total protein TP Roche biuret method Roche Cobas Mira
Albumin On-site bromocresol green 
binding in succinate 
buffer
Roche Cobas Mira
Globulin Arithmetic subtraction 
(total protein - albumin)
Gamma-glutamyl
transferase
GGT plus Roche carbojty-GLUPA
substrate
Roche Cobas Mira
Table 6. Reagents, principles and instrumentation used in tbe commonly measured clinical 
chemistry analytes
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Analyte Reagent/Kit Manufacturer Principle
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Instrumentation
Triglycerides TRIG Roche lipase, glycerol kinase, 
glycerol phosphate 
oxidase and peroxidase
Roche Cobas Mira
Non-esterified NEFA-C Wako acyl-CoA synthetase, Roche Cobas Mira
fatty acids (ACS-
ACOD)
distributed 
through Alpha 
Laboratories
acyl-CoA oxidase, 
peroxidase, 3-methyl-N- 
ethyl-N-(p- 
hydroxyethyl)-aniline 
and 4-aminoantipyrine
Glycerol Glycerol Randox
laboratories
quinoneimine 
chromogen system 
utilising glycerol kinase, 
glycerol phosphate 
oxidase and peroxidase
Manual and 
Beckman DU65 
Spectrophotometer
Amylase AMYL Boehringer
Mannheim
p-nitrophenyl-a,D- 
malto-heptaoside 
substrate with a- 
gluccsidase
Roche Cobas Mira
Lipase LIPASE IDDEX
laboratories
Vettest analyser
Ammonia NH4+ IDDEX
laboratories
Vettest analyser
Fructosamine FRUC Roche nitroblue tétrazolium Roche Cobas Mira
Glycated GLYCO-Tek Helena affinity chromatography Manual &
haemoglobin Affinity
Columns
Laboratories using dihyroxyboiyl 
column and magnesium 
chloride and sorbitol 
eluents
Beckman DU65 
Spectrophotometer
Cortisol Magic
Cortisol
Ciba Coming radioimmunoassay using 
magnetic separation and 
1311 tracer
Canberra Packard 
Cobra II gamma 
counter
Insulin Coat-a Diagnostic solid phase radio­ Canberra Packard
Count Products immunoassay with 1311 Cobra n gamma
Insulin Corporation tracer counter
Thyroxin Magic T4 Ciba Coming radioimmunoassay using 
magnetic separation, 8- 
anilino-l-naphthalene- 
sulfonic acid and 13 H 
tracer.
Canberra Packard 
Cobra n gamma 
counter
Table 6 (cont). Reagents, principles and instrumentation used in the commonly measured clinical 
chemistry analytes.
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Chapter 3: 
The epidemiology of canine diabetes mellitus
The accurate description of the pattern of a disease within a population is essential to the 
understanding of that disease. Principally, such a description can help identify factors 
which may be associated with predisposition to or initiation of the disease under study 
and in special circumstances may result in the identification of a single ‘cause*. 
Knowledge of predisposing factors for a given disease also allows for the identification 
of ‘high-risk* groups which can be selected for further, more detailed, investigation of 
the disease and which may act as ‘models* for the disease in a different species.
The epidemiological features of canine diabetes mellitus which have been previously 
reported are based on a number of large case series. In the United Kingdom, the largest 
of such reports are by Wilkinson (1960) who reported on 56 cases fi"om The Royal 
Veterinary College London and Lauder (1972) who reported 97 cases fi"om the 
University of Glasgow. Neither of these reports made use of control populations for 
comparison with the diabetic population. Foster (1975) reported on case details fi'om 
103 diabetic dogs collected by questionnaire survey of 47 veterinary practices in Kent 
and generated a non-diabetic ‘control* population fi’om cases seen at a single veterinary 
practice. Foster was able to demonstrate differences between diabetic and control 
populations but did not apply statistical methods to determine their significance. Only 
one British report of 43 diabetic dogs from the Royal (Dick) School of Veterinary 
Studies, Edinburgh (Doxey et al, 1985) has used statistical methods for comparison with 
a referral hospital population. There have also been large case series published fi'om 
abroad; Marmor et al (1982) reported on 1,468 cases fi'om 14 universities in United 
States of America and Canada, Ling et al (1977) reported on 75 cases fi'om California 
and Krook et al (1960) reported on 167 cases in a post-mortem survey in Sweden. These 
reports generally agree that elderly, entire bitches are most likely to be affected and each 
report provides a list of ‘high-risk* breeds.
The epidemiology of canine diabetes mellitus in the West of Scotland was last reported 
more than 20 years ago (Lauder, 1972) and it would be incorrect to assume that the 
pattern of canine diabetes mellitus has remained the same or that it is the same elsewhere 
in the world. Indeed, medical journals dedicated to the subject of diabetes mellitus
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frequently contain papers indicating that the epidemiological patterns of human diabetes 
mellitus in many different countries and localities throughout the world are not uniform 
or constant.
The aim of this part of the study was to determine whether any of breed, age or gender 
were important factors predisposing to the development of canine diabetes mellitus based 
on a group of 89 diabetic dogs referred to the University of Glasgow and whether any 
predisposing factors identified agreed with those reported previously for the condition. 
To facilitate this aim it was necessary to generate a time-matched control population 
from non-diabetic dogs referred to the University of Glasgow with which comparisons 
could be made. There were, therefore, two distinct components to this investigation. 
Firstly, because the control population was derived from a referred hospital population 
and not from a normal or healthy population it was necessary to characterise its structure 
in terms of age, gender and breed and to assess its suitability as a control population 
from which to draw accurate conclusions about the structure of the diabetic population. 
The second part of the study was to identify differences between the structure of the 
control and diabetic populations so that predisposing factors for canine diabetes mellitus 
could be determined.
The control population 
Introduction
It is most unlikely that the structure of the population of dogs referred to a specialist 
centre such as the University of Glasgow Veterinary School will be exactly the same as 
the general or healthy dog population, however that may be defined, and therefore a 
control population drawn from such a hospital population might not be suitable for the 
purposes of investigating the epidemiology of a particular disease. In order to assess the 
suitability of a hospital derived control population for epidemiological purposes it is 
necessary to consider the individual factors which determine its structure.
There are three broad levels or categories of factors which determine the structure of a 
canine referred hospital population in Western society:
• The source population. The structure of the overall local canine population will be 
determined by the sociology, psychology and economics of the local society which 
will affect the size, breeds and life expectancy of dogs within that locale. In addition, 
the local genetic pool will affect the nature of the cross-bred component of the 
population.
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• The reasons for referral. The rationale behind the decision made by general 
veterinary practitioners and owners to refer a particular animal is similarly heavily 
based on local psychology and socio-economics. For example, it is a commonly 
suggested but unsupported comment that young pedigree dogs are more likely to be 
referred to a specialist centre than old or cross bred dogs.
• The referral clinician and disease effects. The specific disease interests of 
clinicians working within a referral centre will influence the kinds of dogs which they 
see because many canine diseases are age, gender and breed related. If the number of 
referrals seen within any particular clinical speciality is large this will ultimately affect 
the overall referral population.
In attempting to determine the validity of a hospital derived control population for 
epidemiological purposes, the contribution of each of the three points above should be 
considered. It could be suggested that in order to be valid, a control population must 
accurately reflect the local general canine population. Such a requirement would not only 
be difficult to test but also might be irrelevant. If conclusions about a disease based on a 
control population are to be comparable with those generated at other referral centres, 
then the use of a referral population instead of a local general population as the control 
would be more correct.
The likelihood of referral based on ‘the reasons for referral* should be similar for the 
disease under study and the remainder of the hospital population, so that using a referral 
control population rather than a source control population will provide a more relevant 
comparison. In terms of ‘reasons for referral*, animals within the disease and control 
groups will have experienced a similar chance of selection to be part of the hospital 
population.
Consequently, for the valid comparison of epidemiological data among referral centres, it 
is less important that a hospital control population is an accurate reflection of the local 
general population and more important that it reflects its source population to the same 
degree as other referral centres reflect theirs. Again such a requirement is difficult to test 
without a large scale multi-centre census study. Ideally, the factors affecting ‘the reasons 
for referral* would be uniform between referral centres but it would be naive to believe 
that they were. However, differences in factors affecting ‘the reasons for referral* 
between localities are more likely to result in a difference in the total number of referrals 
(referrals per capita) than in the degree to which the structure of the referral population 
reflects that of its source population, since the relative likelihood of referral for a young.
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pedigree or valuable dog compared with an old, cross-bred or inexpensive one is likely to 
be roughly uniform between centres in Western society.
In consideration of ‘clinician and disease effects* it is possible that these may cause 
considerable bias in the structure of the hospital population and alter the degree to which 
it reflects its source population. One way to account for such bias would be to make 
repeat epidemiological analyses of a disease group following exclusion of individual 
referral groups from the control population which are known to heavily bias its structure. 
In that way a more rounded appreciation of the factors important in the disease under 
study can be developed free from the bias of particular referral groups or clinicians and 
which is more likely to be based on a population determined by the factors which 
influence ‘the source population* and ‘the reasons for referral* above.
It was accepted that in developing a control population at the University of Glasgow for 
the present study it would not be possible to test how closely the hospital population 
reflected the source population or whether it reflected its source to the same degree as 
other referral centres. However, it was possible to investigate ‘the clinician and disease 
effects*. This was done with the aim of determining if the control population was uniform 
across referral groups or whether referral groups were sources of bias in the control 
population which would have to be accounted for when using the control population for 
comparison with the diabetic population. Dogs were grouped according to likely reasons 
for referral and each group was investigated for differences in age, breed and gender 
distribution from the remainder of the control group
There were two possible approaches to investigating potential bias from referral groups. 
The one used was a comparison of each referral group with the remainder of the referral 
groups. There were disadvantages to this approach. Mainly, any referral groups which 
caused bias would be present in the ‘control* group when another referral group was 
being tested and potentially disrupt the conclusions drawn about the group under study. 
However, if there were sufficient groups the pooling approach should have diluted any 
such disruption. An alternative approach would have been to compare each referral 
group to a ‘benchmark* group. This method would not have suffered the disadvantages 
of the former but the question as to the most suitable group to be the ‘benchmark* could 
not be resolved.
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Methods
Dogs
All diabetic dogs referred to the hospital between January 1989 and April 1994 for which 
there was a complete set of information regarding date of birth, breed, gender and date 
of first referral were used as the study group (n=89)(Appendix 2). A time-matched 
control population was generated by selecting the subsequent 10 dogs which presented 
to the hospital for the first time following each diabetic dog. Dogs with incomplete 
records were excluded and these were replaced by the first dog after the group of 10 
which did have a complete record. This generated a time matched control population of 
890 dogs which represented approximately 10% (890 of 8831) of all non-diabetic dogs 
referred to the hospital for the first time between January 1989 and April 1994. The dogs 
in the control population were allocated a most likely reason for referral based on the 
veterinary surgeon to whom the dog had been referred. The categories were General 
Medicine, General Surgery, Orthopaedics, Ophthalmology, Neurology and 
Reproduction. A summary of the age, breed and gender distribution of dogs among 
referral groups is given in Appendices 3 and 4.
Statistics
Chi-square tables (r x c contingency tables) were used to determine differences in age, 
gender and breed distributions between each referral group and the remainder of the 
control population. Where there was a statistically significant higher or lower proportion 
of a particular age, gender or breed category within a test group compared to that 
expected based on a control group, that category was referred to as being over- or 
under-represented as appropriate. Gender was categorised as entire female, neutered 
female, entire male and neutered male and 4 x 2  contingency tables used. Age was
divided into biennial categories (0-2, 2-4, 4 -6 .......14-16 years) and an 8 x 2 table used.
To test for differences in breed distribution the 10 most commonly represented breeds 
within each referral group were tested for over-representation when compared to the 
remainder of the control population. This method was used to give an impression of the 
differences of breed distributions between the referral groups without exhaustive testing 
of all breeds in all groups. It was acknowledged that this approach to estimating breed 
differences could not provide information on the under-represented breeds.
All calculations were performed using computer software^ Differences between 
distributions were tested for statistical significance using the Chi-square method or the
 ^ Epi Info, Version 5.01b (1991); Centers for Disease Control, Epidemiology Program 
Office, Atlanta, Georgia and World Health Organisation, Geneva, Switzerland
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two-tailed Fisher’s exact test when appropriate. Significance levels (p values) of less than 
5% were considered statistically significant.
Results
Reasons for referral
The distributions of the referral groups are represented in Figure 1. The majority of non­
diabetic canine referrals was for surgical reasons and within the surgical disciplines, 
general surgery and orthopaedics were the most common. The largest, and therefore 
most important referral groups were General Medicine in which there were 254 cases 
representing 29% of the control population; General Surgery which consisted of 253 
cases and represented 28.4% and Orthopaedics in which there were 215 cases and which 
represented 24.1%.
Medicine 
(n=254, 29%)
Surgery 
(n=636, 71%)
Repro (n=11, 2%) 
General (n=253, 40%)
Neuro (n=83, 13%) 
Ortho (n=215, 34%) 
Ophthal (n=74, 12%)
Figure 2. Distribution of hospital control population according to reason for referral
Proportion of dogs
HiGen Surg mOrth —Total
Ï1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Age (years)
Figure 3. Age distributions of referral groups General Surgery (Gen Surg) and Orthopaedics 
(Orth) and the age distribution of the entire control population of dogs.
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Age distribution
The General Surgery, Orthopaedic and Ophthalmology referral groups had highly 
significant differences in age distribution fi'om the remainder of the referral groups (p 
<0.005). In the General Surgery group, there was a high proportion of adult dogs, 
whereas in the Orthopaedic group there was a high proportion of very young dogs. The 
Ophthalmology group had an unusually large number of both very young and middle 
aged dogs. The age distributions of the General Surgery and Orthopaedic groups are 
represented in Figure 3 along with the age distribution of the total control population.
Gender distribution
Only the Neurology referral group had a significantly different gender distribution fi'om 
the remainder of the control population (p = 0.020).
Breed distribution
It is known that certain breeds are prone to the development of particular diseases. To 
test whether this was reflected in the breed distribution of the referral groups the 10 most 
commonly represented breeds within each referral group were tested for over­
representation when compared to the remainder of the control population. In the 
Medicine group, there were high numbers of Golden retrievers. Soft Coated Wheaten 
terriers and Bull terriers. In General Surgery, there were high numbers of German 
shepherd dogs and collie cross dogs but unusually few Golden retrievers. Yorkshire 
terriers were in high numbers in the Neurology group and there were high numbers of 
Cocker spaniels. Jack Russell terriers, Wiemaraners and Miniature Poodles in the 
Ophthalmology group. The Orthopaedic group contained significantly higher proportions 
of Labrador retrievers. Rottweilers and Greyhounds than the remainder of the control 
population.
Discussion
There were three large referral groups: General Medicine, General Surgery and 
Orthopaedics. These were the groups most likely to bias the control population. 
However, because the General Medicine and General Surgery groups were, by definition, 
very broad clinical categories it is unlikely that these groups contributed greatly to any 
bias away from a general or normal referral population. Of greater concern was the 
Orthopaedic referral group, which although large, represented a narrow clinical 
discipline. There are breed predispositions to orthopaedic conditions, particularly racing 
injuries, osteochondrosis and hip dysplasia and younger dogs are more likely to suffer 
developmental skeletal diseases or be involved in traumatic incidents. These observations 
are supported by the findings of a significantly different age distribution of the
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Orthopaedic referral group and that 3 of the 10 most commonly represented breeds 
within the Orthopaedic referral group were over-represented when compared to the 
remainder of the control population. The potential for bias in the age and breed 
distributions of the control population is increased by the inclusion of the Orthopaedic 
referral group. However, the age distribution of the General Surgery referral group goes 
some way to compensate for the bias in the control population age distribution arising 
from the Orthopaedic group.
The gender distribution of the Neurology referral group was different from the remainder 
of the control population but because of the low numbers of dogs in this group it was 
unlikely that the gender distribution of the total control group was biased by the inclusion 
of this referral group.
In conclusion, the structure of a time-matched control population generated for analysis 
of the epidemiology of a group of diabetic dogs was affected by the specialist interests of 
hospital clinicians and the age, gender and breed predilection of the diseases that they 
treat. This was particularly because of the large proportion of dogs referred to the 
University of Glasgow for orthopaedic reasons. It was therefore reasonable to investigate 
the group of diabetic dogs for predisposing factors using both the total time-matched 
control population and also control populations from which individual referral groups 
which are sources of bias have been removed.
The diabetic popuiation 
Methods
All 89 diabetic dogs were included in the epidemiology study and diabetes mellitus was 
treated as a single disease. Special consideration is given to diabetes mellitus in 
association with other syndromes in Chapter 4.
Statistics
Statistical testing for association between the presence of a factor (e.g. being female) and 
the presence of the disease was performed using the chi-square test. Crude odds ratios 
(OR’s) were calculated to measure the strength of any association (Cornfield, 1951 cited 
by Lee, 1992) and 95% confidence intervals (CL’s) were calculated (Lee, 1992). Fisher's 
exact test was used where numbers or expected numbers in one or more cells were less 
than 5 in which case 95% exact confidence limits were calculated (Mehta et al 1985). 
When testing for the effect of gender, the data were stratified into 2 year age groups (0-
2, 2-4, 4 -6 ......14-16 years) and a Mantel-Haenzel weighted odds ratio calculated if odds
ratios across all 8 tables were uniform (Pagano and Gauvreau, 1992). A two sample t~
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test was used to test for differences in age between diabetic and control groups and an 
odds ratio ‘profile* was generated for the diabetics according to age using the 8-10 year 
age group as the reference group. This was repeated after dividing the diabetic dogs 
according to whether or not their breed was considered to be at ‘high-risk*. The effect of 
breed was tested using a 2 x 2 Chi-squared table whereby the proportion of a particular 
breed within the diabetic group was compared with the proportion of that breed within 
the control population. Those breeds which were over-represented in the diabetic 
population were classified as ‘high-risk* breeds.
An alternative method to assess the effect of breed would have been to make 
comparisons for individual breeds with the risk of being diabetic associated with a 
particular ‘benchmark* breed e.g. Labrador retrievers. This method was rejected, despite 
some of its advantages, because it would prevent simple comparison with breed 
dispositions at other referral centres (particularly on an international level) and because 
of the difficulties in selecting a suitable breed as the ‘benchmark*.
Results 
Age distribution
Diabetic dogs were older than the dogs in the time-matched control population 
(p=0.0000). The mean age of the diabetic dogs was 8.7 years (SD 2.72) and that of the 
control population was 5.17 years (SD 3.65). Following exclusion of the Orthopaedic 
referral group from the control population because of its bias towards young dogs, 
diabetic dogs were older than the new control population (p=0.0000). The mean age of 
the control population without the Orthopaedic group was 5.72 years (SD 3,63). The 
age distributions of diabetic and control populations are represented in Figure 4.
Gender
Odds ratios for the presence of diabetes mellitus by gender stratified for age are 
represented in Figure 5 for male versus female and in Figure 6 for entire female versus 
neutered female. There was a statistically significant odds ratio of 3.47 (p = 0.010, 95% 
CLs 1.19<OR<10.38) in favour of females when compared to males within the 10-12 
years age group. The odds ratios for the other age groups were not statistically 
significant. A test for homogeneity of odds ratios across 8 tables for female versus male 
indicated that they were uniform enough for a summary odds ratio to be valid. The 
summary odds ratio gave a close to statistically significant value (p = 0.075) of 1.54 
(95% CLs 0.96<OR<2.55). This can be interpreted as females being at 1.5 times greater 
risk of developing canine diabetes mellitus than males. Closer inspection of the age 
stratified tables suggests that the association between gender and diabetes mellitus was
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age dependent. Indeed, if the diabetic population is divided into those under 7 years of 
age and those over, there was an odds ratio in the under 7 years group of 0.41 (p = 0.09) 
which if it was statistically significant would indicate that males were at 2.5 times greater 
risk than females. In the over 7 years group, females were at greater risk (p=0.002, OR = 
2.25, 95% CLs 1.28<OR<3.96).
There was no overall effect of neutering within the female group. The summary odds 
ratio across 8 contingency tables was not statistically significant. However, within the 8- 
10 year age group entire females were at a much greater risk of developing diabetes 
mellitus than the neutered females (p = 0.032, Odds ratio = 3.60, 95% CLs 0.93 < OR < 
15.24).
Proportion of dogs in respective group
0.18
■  D iabetic  
□ C o n tr o l
0.16
0.14
0.12
0.1
0.08
0.06
0.04
0.02
<1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Age (years)
Figure 4. The age distributions of diabetic and time matched control populations (diabetic n=89, 
control n=890).
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Odds Ratio
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Figure 5. Odds ratios for the presence of canine diabetes mellitus by gender (female versus male) 
stratified by age. Odds ratio (OR) >1 means females ‘at greater risk’ than males, * p=0.075, **p = 
0.010.
Odds Ratio
n=14
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n=1 n=1 n=3
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I
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Figure 6. Odds ratios for the presence of diabetes mellitus according to effect of neutering (entire 
female versus neutered female) stratified by age. Odds ratio >1 means entire females ‘at greater 
risk* than neuters, * p = 0.032.
CHAPTER 3 51
Breed predisposition
A list of breeds which were significantly over- or under-represented within the group of 
diabetic dogs when compared to the control population is given in Table 7. Because of 
the known influence of the breed distribution of the control population by some referral 
groups, analyses were repeated following the exclusion of individual referral groups.
Additionally, Mniature Smooth-haired Dachshunds, Whippets, Border terriers, and 
Australian terriers were over-represented but not to a statistically significant degree. 
English Springer spaniels were similarly under-represented.
Seasonality
There was no apparent seasonal pattern to the number of referrals o f diabetic dogs. 
However, this could not be tested statistically because a time-matched control population 
had been generated.
Breed Odds Ratio Significance (p) Exact 95% 
Confidence 
Limits
Over-renresented breeds
Miniature Poodle 6.2 0.029 0.94 - 32
English setter 20.4 0.023 1.05 - 1206
Cairn terrier 10.8 0.000 3.40 - 34
Jack Russell terrier 3.7 0.013 1.16-10
Tibetan terrier 20.0 0.023 1.04 - 1206
All terriers 3.2 0.000* 1.87-5
Underrenresented breeds
German shepherd dog 0.3 0.015* 0.05-0.81
Golden retriever 0.0 0.017 0.00 - 0.79
Over-renresented breeds followine exclusion of sinele referral erouns
Collie Xt 3.7 0.048 0.80 - 14
Rottweiler* 4.0 0.022 1.03 - 13
Table 7. Breeds over and under-represented witbin the diabetic population. *p value for Chi 
statistic, all others refer to Fisher’s exact test, t  following exclusion of the General Surgery 
referral group, t  following exclusion of the Orthopaedic referral group.
Further observations
Following analyses of breed dispositions to the development of diabetes mellitus, the 
diabetic dogs were classified into two groups: those belonging to high-risk breeds (all 
terriers, English setters, Rottweilers, collie crosses and Miniature Poodles) and those 
belonging to normal or low risk breeds. The age distribution of dogs was different
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between the two risk categories ( 8 x 2  Chi-square, p = 0.012). To further examine this 
difference and to help determine if the relationship between the development of diabetes 
mellitus and age differed according to risk category, odds ratios by 2 year age group 
profiles were generated for the two risk categories and for the overall diabetic population 
by using the 8-10 year age group (the largest 2 year age group) as the reference age 
group (0R=1) within each category. Odds ratio profiles for the two risk categories and 
the overall diabetic population are represented in Figure 7.
Analyses for differences in gender distribution between the two risk categories were also 
performed. There was a close to statistically significant difference between the gender 
distribution of the two categories ( 4 x 2  Chi-square, p = 0.066), no difference between 
male versus female, but a statistically significant difference in entire female versus 
neutered female ( 2 x 2  Chi-square, p = 0.029, OR = 3.56, Exact 95% confidence limits 
0.98 - 13.22). There was a higher proportion of entire females in the low or normal-risk 
category than in the high-risk category.
Odds Ratio
5
I  Exact/limits 
— All diabetics 
Low risk 
High risk
4
3
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1
0
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10-12 12-14 14-16
Figure 7. Odds ratio profiles for the development of diabetes mellitus by age compared to the 
referent age group 8-10 years for all diabetics and following subdivision into low and high risk 
categories. Odds ratios > 1 mean *at greater risk* dogs than those in the referent age group. Exact 
limits are for all diabetics. Low risk n = 46; High risk n = 43.
Discussion
Based on 89 cases of canine diabetes mellitus seen at the University of Glasgow 
Veterinary School, the condition affected all ages of dogs but middle aged and aged dogs
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were most prone. Gender had a complicated association with the occurrence of diabetes 
mellitus, in that, young males were at equal or greater risk of developing the condition 
compared to young females but in the older age groups, females were at greater risk. 
Neutering history did not seem to be an important risk factor for diabetes within females 
except in the 8-10 year age group where it was associated with a greatly increased risk 
for entire females. Some breeds of dog were predisposed to diabetes mellitus (Miniature 
Poodles, English setters, terriers, especially. Cairn, Tibetan and Jack Russell, collie cross 
breeds and Rottweilers) and some were unlikely to be diabetic (German shepherd dogs 
and Golden retrievers). The age and gender distribution of diabetes mellitus in the dogs 
belonging to the high-risk breed category was different fi'om that in those whose breed 
was associated with a normal or low-risk. In the high-risk category, the odds ratios for 
the presence of diabetes mellitus for both young and very old dogs were greater than 
would be expected from a population of diabetic dogs of normal or low risk breeds and 
there were fewer entire females in the high-risk category.
Previous case series of canine diabetes mellitus in Britain which did not feature statistical 
comparisons with control populations (Wilkinson, 1960; Lauder, 1972 and Foster 1975) 
reported that the disease affects dogs between 3 and 14 years old, is most common in 8- 
12 year olds and that between 66 and 75% of cases are female. The breeds of dog which 
they considered predisposed were principally Dachshunds and Poodles but also included 
Samoyeds, King Charles spaniels, mongrels and Cairn terriers. Doxey et al (1985) 
reported an age range for diabetic dogs of 2.33 to 14 years (mean 9.83 ± SD 2.25 years) 
and after statistical comparison with a referral hospital group concluded that there were 
significantly more entire females and significantly less entire males in the diabetic group 
and that cross-bred terriers. Cairn terries and Poodles were significantly over­
represented.
Case series of canine diabetes from the United States of America (Ling et al, 1977 and 
Marmor et al, 1982) reported that the condition can occur in any age of dog but agreed 
that dogs older than 7 years were most at risk. Females were at greater risk than males 
except, according to Marmor et al (1982), in the very young age groups where males 
were at equivalent or greater risk than females. Dachshunds and Poodles were reported 
as the predisposed breeds in the USA, along with Cairn terriers and a short list of breeds 
which are unpopular in Britain. Breeds identified by Marmor et al (1982) as resistant to 
diabetes mellitus included German shepherd dogs, collies, Pekingese, Boxers and Cocker 
spaniels.
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In Sweden (Krook et al, 1960), there was a similar picture; the mean age of diabetic 
dogs was 8 years (± SD 0.19) and females were more commonly affected than males. 
Predisposed breeds included Rottweilers, Dachsbraches, Cocker spaniels, Swedish 
hounds and mongrels and the resistant breeds were German shepherd dogs and Boxers.
In the present study of diabetic dogs referred to the University of Glasgow there is some 
agreement with the findings of previous reports of the condition. The age at which 
diabetes mellitus is most likely to occur does appear to be within the age range of 8-12 
years and this is in accord with the findings of the other large case series. However, to 
quote this age range is misleading and disguises the fact that approximately 20% of 
diabetic dogs in this study were less than 7 years of age. It is difficult to ascertain 
whether there has been a change in the age distribution of canine diabetes mellitus in 
Britain because of the methods of reporting age in the previous British case series but in 
the USA (Ling et al, 1977 and Marmor et al, 1982) up to 30% of diabetic dogs fell into 
this younger age group.
This study shows that in Scotland the association between gender and the development 
of canine diabetes mellitus is not as simple as ‘females are at greater risk’ (Wilkinson, 
1960; Krook et al, 1960; Lauder, 1972; Foster, 1975; Ling et al, 1977; Doxey et al, 
1985) but that, as described by Marmor et al (1982) in California, gender-associated risk 
is age-dependent. The effect of neutering on the development of canine diabetes mellitus 
is also age-dependent. The explanation for increased risk for entire females in the 8-10 
age group probably lies in the diabetogenic effects of progesterone and growth hormone. 
These hormones are found in increased concentrations during metoestrus in the bitch 
(Eigenmann and Venker-van Haagen, 1981; Eigenmann, 1981, Eigenmann, 1989) and 
are believed to promote the exhaustion of the pancreatic islets by their antagonistic 
effects on insulin. It is likely that the degree of metoestrus-associated islet cell exhaustion 
which results in clinical diabetes mellitus (either on its own or in combination with other 
processes) will take many oestrus cycles to develop and result in a late middle age onset 
of the disease. Neoplastic mammary tissue may be responsible for even greater 
production of growth hormone (a powerful insulin antagonist) during metoestrus than is 
normal (Selman et al, 1994c) such that the epidemiology of diabetes mellitus in this 
group of dogs may to some extent be a reflection of the epidemiology of canine 
mammary neoplasia, a condition which is less likely to occur in young or neutered 
bitches.
It is interesting to note that there are some similarities in the predisposed and resistant 
breeds reported in this study and those in previous reports. Poodles, Caim terriers,
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collies and Rottweilers which are over-represented in this study have been mentioned by 
others (Wilkinson, 1960; Krook et al, 1960; Foster, 1975; Ling et al, 1977; Marmor et 
al, 1982; Doxey et al, 1985). This report also agrees with the findings of Krook et al 
(1960) and Marmor et al (1982) that German shepherd dogs are at an unusually low risk 
of diabetes mellitus. There are some differences in the list of high-risk and resistant 
breeds in this report fi'om those in previous ones. This is to be expected after 
consideration of the likelihood that the genetic makeup of the dog population will be the 
same in many countries or indeed that it will be static. The list of predisposed breeds 
reported by Lauder (1972) also fi'om the University of Glasgow does not contain any 
breeds considered at increased risk by the present study (with the exception of the 
statistically insignificant over-representation of Miniature Smooth haired Dachshunds). 
This difference between the two reports highlights the potentially dynamic nature of the 
epidemiology of canine diabetes mellitus.
Further analyses of the characteristics of diabetics belonging to high-risk breeds have not 
previously been reported. It seems that dogs in the high-risk category have an increased 
risk of diabetes mellitus both when they are young and when they are very old. In 
addition, being an entire female is less important in the development of the disease in this 
group than in the normal or low-risk category. The genetic or family basis of 
predispostion to canine diabetes mellitus has been highlighted by familial cases reported 
by Gepts and Toussaint (1960) and Eigenman et al (1984).
In conclusion, all of age, gender and breed are important predisposing factors in the 
development of canine diabetes mellitus based on a group of 89 diabetic dogs referred to 
the University of Glasgow when compared to a time-matched referred population. There 
is general agreement between the present study and previously published case series on 
the ages, gender and some of the breeds most commonly affected. However, this report 
highlights some aspects which have not been previously emphasised, namely: the large 
proportion of young dogs affected; the relationship between age and gender-associated 
risks; the dynamic nature of the epidemiological characteristics of the condition and the 
possible differences in epidemiological characteristics (and therefore perhaps 
pathophysiology) between the disease in high-risk breeds and that in normal or low-risk 
breeds.
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Chapter 4: 
Diabetes mellitus in association with other syndromes 
introduction
Diabetes mellitus is a group of disorders and syndromes within which chronic 
hyperglycaemia features. Factors which interfere with the production of insulin, its 
transport to, or action in, target tissues can cause or exacerbate diabetes mellitus (Unger 
and Foster, 1985; Stogdale, 1986). A number of syndromes have been associated with 
the presence of diabetes mellitus in dogs, including autoimmune islet cell destruction (Sai 
et al, 1984; Haines and Penhale, 1985); hormonal antagonism, particularly by 
endogenous or exogenous progestagens (Eigenmann, 1981; Eigenmann and Venker-van 
Haagen, 1981; Eigenmann, 1989) or endogenous or exogenous glucocorticoids 
(Peterson et al, 1981; Blaxter and Gmfîydd-Jones, 1990; Walker, 1962; Campbell and 
Latimer, 1984); pancreatic inflammation (Dixon and Sanford, 1961) and a syndrome 
resembling Type II human diabetes mellitus (Mattheeuws et al, 1984b). In addition, there 
are less common hormonal antagonisms associated with canine diabetes mellitus such as 
spontaneous acromegaly (Eigenmann, 1981), phaeochromocytoma and glucagonoma 
(Chastain and Ganjam, 1986b). The association of progestagens or metoestrus and 
diabetes mellitus in dogs is mediated through the production of growth hormone which is 
a powerful insulin antagonist (Eigenmann, 1981). Using a reverse transcriptase 
polymerase chain reaction and other techniques the source of this growth hormone 
production has been identified as the mammary glands, particularly in the presence of 
mammary neoplasia (A. Rijnberk, Faculty of Veterinary Medicine, Utrecht University, 
personal communication; Selman etal, 1994c).
In addition, the occurrence of diabetes mellitus in association with other endocrine 
dysfunction has also been recognised in dogs (Milne and Hayes, 1981; Hargis et al, 
1981; Eigenmann et al, 1984; Chastain, 1992; Kintzer, 1992; Ford et al, 1993) and in 
humans (Carpenter et al, 1964; Ganz and Kozak, 1974; Mouradian and Abourizk, 1983). 
In humans, such multiple endocrine failure syndromes are considered to have an 
autoimmune basis (Eisenbarth, 1985) and this may also be the case in dogs (Kintzer, 
1992). In the dog, the most common co-existent endocrine failures are 
hypoadrenocorticism and hypothyroidism (Schmidt* syndrome) (Bowen et al, 1986; 
Kintzer, 1992).
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Islet cell hypoplasia has been recognised in dogs (Anderson et al, 1986, Atkins et al, 
1988) and in man (Dodge and Lawrence, 1977). Such a condition has, however, not 
been reported in a British dog. In this condition there are either no recognisable islets of 
Langerhans or they are shrunken, low in number or contain degenerate vacuolated cells 
(Atkins e/a/, 1988).
The aims of this part of the study were to identify those diabetic dogs in which a 
syndrome associated with their diabetic condition could be found and to investigate the 
clinical features of these dogs for evidence of differences in clinical presentation from 
those dogs in which no other identifiable syndromes were present.
Materials and methods
The clinical records and laboratory findings of 94 diabetic dogs were reviewed. Fifty 
dogs had no identifiable associated syndrome and this group formed the control group. 
Of the remaining 44 dogs, three had received progestagen therapy shortly before 
developing diabetes mellitus, 18 had concurrent hyperadrenocorticism, 8 were 
hypothyroid, 14 had an onset of diabetes mellitus during or shortly after a metoestrous 
phase of the reproductive cycle and one dog had islet cell hypoplasia. The low numbers 
in the progestagen related and islet cell hypoplasia categories meant that these cases 
could not be included in statistical analyses as separate groups.
The diagnosis of hyperadrenocorticism was based on the combination of clinical signs 
and the results of an adrenocorticotrophic hormone (ACTH) stimulation test. Plasma 
cortisol concentrations were measured before, and 45 or 60 minutes after, an 
intramuscular injection of 250pg of an ACTH analogue (tetracosactrin, Synacthen; 
Ciba). In those dogs in which a 45 minute sample was taken a further sample was taken 
at 90 minutes. A post-ACTH plasma cortisol concentration of close to or greater than 
600 nmol/1 in association with a consistent clinical presentation was considered to 
indicate the presence of hyperadrenocorticism.
The diagnosis of hypothyroidism was based on either an extremely low basal total serum 
thyroxine concentration or the results of a thyrotropin stimulation test. Serum 
concentration of thyroxine were measured before and 6 hours after an intravenous 
injection of bovine thyroid stimulating hormone (TSH; Sigma). Dogs which failed to 
increase serum thyroxine concentration by 150% or to exceed a post TSH cut-off point 
of 26 nmol/1 were diagnosed hypothyroid.
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Following a diagnosis of hyperadrenocorticism a course of adrenocorticolytic therapy 
was instituted if the owners agreed. The protocol used was a low dose mitotane (o,p- 
DDD, Lysodren; Kingston Animal Health) regimen of 25mg/kg for an initial loading 
period of 10 days with glucocorticoid supplementation at 0.4mg/kg of prednisolone. 
Following this initial period, weekly doses of mitotane were continued at 25 or 50 mg/kg 
and the frequency of these doses were further adjusted according to response.
Dogs which were diagnosed hypothyroid began thyroid replacement therapy using L- 
thyroxine (Soloxine, Vet-2-Vet Marketing) at 10 pg/kg once or, if necessary, twice 
daily.
Bitches with metoestrus-associated diabetes mellitus underwent ovariohysterectomy as 
soon as was reasonably possible. Anaesthesia was by low dose intravenous induction 
(thiopentone or propofol) and maintenance by inhalational anaesthesia (halothane, 
nitrous oxide and oxygen). Fine diabetic stabilisation was not attempted in these dogs 
until after ovariohysterectomy unless it was going to be some time before surgery could 
be performed. Sufficient insulin therapy was, however, administered to allow the 
documentation of a glycaemic response.
The clinical features, breed, age, gender and relevant laboratory test results for dogs with 
each associated syndrome were reviewed, tabulated and subjectively evaluated.
To investigate the possibility of certain plasma biochemical characteristics being useful 
for the differentiation of the types of diabetes mellitus, one-way analysis of variance was 
used to test for differences in the mean initial concentrations of plasma glucose, 
cholesterol, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase 
and basal insulin between the groups (concurrent hyperadrenocorticism, (HAC); 
concurrent hypothyroidism (HypoT4); metoestrus-associated (Meto) and no identified 
associated syndrome (Norm)). The same technique was used to attempt to identify 
differences in the pre-treatment body condition score between groups. Body conditon 
was scored as follows: 1 - very thin; 2 - thin; 3 - good; 4 - overweight; 5 - veiy 
overweight and 6 - grossly obese.
For those dogs in which an ACTH stimulation test was performed, one-way analysis of 
variance was used to test for differences between the groups with respect to mean 
cortisol concentrations before, 45/60 minutes and 90 minutes after the administration of 
ACTH. A two-sample r-test was used to compare pre- and post TSH concentrations of 
thyroxine between the hypothyroid group and the ‘normal’ group.
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One-way analysis of variance was used to test for differences among groups in the mean 
insulin dose (lU/kg) required to treat ‘normal’ diabetic dogs and that required by dogs 
with concurrent hypothyroidism or hyperadrenocorticism before therapy with thyroxine 
or mitotane was begun.
Differences in the mean age of dog in each group were tested using one-way analyses of 
variance and differences between an associated syndrome and the ‘normal’ group were 
further investigated by means of a Chi-square 2x2 analysis and relative risk calculation 
using statistical software (Epi Info 5.01b). Differences in gender distribution between the 
disease groups were also investigated using the Chi-square technique (except for 
metoestrus-associated diabetes mellitus).
Relative risk = (number diseased/number exposed to risk factor)/
(number diseased/ number unexposed to risk factor)
Where one-way analysis of variance revealed a difference in means between groups, 
Tukey’s pairwise comparison method (MINITAB 9) was used to elucidate which groups 
were different from which.
Results
Progestagen-associated diabetes mellitus
It was not possible to determine in these cases whether the administration of progestagen 
(proligestone) by injection was directly connected with the presence of diabetes mellitus 
but the known association of these products and diabetes mellitus prevented the inclusion 
of these dogs in any other analysis group. A summary of the clinical features of these 
dogs is presented in Table 8. All three dogs had received proligestone by repeated 
injection for a number of years and all three required continuous insulin therapy 
following diagnosis of diabetes mellitus. One dog, no. 122551, required high doses of 
insulin which suggested the presence of insulin resistance. However, this dog also had 
histologically confirmed cirrhosis and a low growth hormone concentration indicating 
that proligestone was unlikely to be directly responsible for the insulin resistance at that 
time.
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Hospital Breed Age Gender last progestagen Insulin 
number before diabetes required
112598 Samoyed 9.0 F 3.6 continuous
115131 Jack Russell 8.0 F 4.4 continuous
terrier
122551 Labrador 7.0 F 9.4 continuous
retriever and -13.2
Hospital Mean Minimum Maximum Comments
number insulin dose insulin insulin
(lU/kg) dose dose
112598 0.76 0.70 0.83 pyometra 63 weeks after
diabetes diagnosis
115131 1.16 0.93 1.34 mammary neoplasia
122551 2.67 1.58 3.45 cirrhosis
Table 8. Clinical features of three diabetic dogs which received long acting progestagen by 
injection shortly before developing overt diabetes mellitus.
Hyperadrenocorticism-associated diabetes mellitus
The clinical features of 18 dogs with concurrent hyperadrenocorticism and diabetes 
mellitus are presented in Tables 9 and 10. There was no apparent gender predisposition 
(8 male, 9 neutered female and 1 entire female) and a wide variety of breeds were 
affected. Subjectively, Poodles and terriers were most commonly affected. Two dogs had 
received therapy for previously diagnosed hyperadrenocorticism for some time prior to 
developing diabetes mellitus and in the others the diagnosis of hyperadrenocorticism was 
made either at the time of diabetes diagnosis or up to 2.6 years afterwards. The time 
between the diagnosis of diabetes mellitus and that of hyperadrenocorticism was related 
to the mean insulin dose pre-mitotane therapy in those dogs in which the diagnosis of 
diabetes mellitus came first (simple regression, p = 0.023, r = 0.58, mean insulin = 2.17 + 
0.016 X weeks diabetic, n = 15). Basal insulin concentration was measured in 8 dogs and 
varied from 3.6 to 41 plU/ml. There was no apparent relationship between basal insulin 
and prognosis in this small group of dogs. In 9 dogs, the institution of mitotane therapy 
resulted in a substantial decrease in insulin dose and in two cases this was to less than 0.5 
lU/kg. In two dogs, nos. 113936 and 116318, the post-ACTH cortisol concentration did 
not exceed 600 nmol/1. However, there were strong clinical signs present in these dogs, 
which along with the presence of high insulin requirements (> 2 lU/kg) supported the 
diagnosis of hyperadrenocorticism. In one other dog, no. 118626, the diagnosis of 
hyperadrenocorticism was made on the basis of clinical and necropsy findings.
There were a number of unusual clinical presentations in the dogs with concurrent 
hyperadrenocorticism and diabetes (Table 10). The most significant of these were
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neuropathies, displayed by three dogs, and emphysematous cystitis in two others. 
Neuropathies were rarely seen in the ‘normal’ diabetic group and emphysematous cystitis 
was not seen in any of the other groups. Figure 8 shows the radiographic appearance of 
emphysematous cystitis in dog no. 122026.
The survival data for dogs with concurrent hyperadrenocorticism and diabetes mellitus 
are analysed statistically in Chapter 8.
Figure 8. Lateral radiograph of the caudal abdomen of caae no. 122026. There is extensive gas 
lying within the wall of the bladder consistent with a diagnosis of emphysematous cystitis.
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Hospital
number
Unusual presentations Comments Alive/
Dead/
lost
survival
(years)
109434 superficial pyoderma euthanased for age Dead 0.30
109826 colitis euthanased for age Dead 1.66
113105 ketoacidotic on presentation therapy failed Dead 0.02
113498 Homer's syndrome both eyes at separate 
times, ? gastric neuropathy
euthanased for persistent 
vomiting
Dead 3.86
113936 chronic gingivitis, colitis Dead 1.89
114895 KCS died during hypoglycaemia Dead 0.36
116315 euthanased for aggression Dead 0.24
116318 Homer's syndrome one eye Alive 3.75
116744 normal ACTH results at 0 days Lost 0.84
117369 facial nerve paralysis, resistant E coli 
cystitis and haematuria
Dead 0.31
117705 hepatocutaneous syndrome lost to follow up Lost 0.31
118388 osteopenia on radiography Dead 0.39
118626 hyperosmolar syndrome treatment ineffective 
euthanased at 24 hours
Dead 0.00
119010 lost to follow up Dead 3.17
122026 resistant E coli emphysematous cystitis Alive 1.60
122150 euthanased because of acute 
pancreatitis
Dead 2.77
122970 Alive 1.00
122973 owner unwilling to continue 
therapy
Dead 0.10
Table 10. Clinical features of 18 dogs with concurrent diabetes mellitus and hyperadrenocorticism 
n : unusual presentations, comments, outcome and survival times. KCS- keratoconjuctivitis sicca
Concurrent hypothyroidism and diabetes mellitus
The clinical features of 8 dogs with concurrent hypothyroidism and diabetes mellitus are 
presented in Tables 11 and 12. In all cases the diagnosis of hypothyroidism was made at 
the time of or after the diagnosis of diabetes mellitus. There were two Tibetan terriers 
and two English setters in this group suggesting a breed predisposition. Unfortunately, 
pedigrees were not available for these dogs for analysis. There were more males (5) than 
females (3) affected but this was not significant (Chi-square analysis). Four of the 6 dogs 
which were stabilised on insulin therapy prior to treatment with thyroxine had a high 
insulin requirement (> 2 lU/kg) which was reduced by thyroxine therapy. There was no 
relationship between the number of weeks of diabetes prior to the diagnosis of 
hypothyroidism and the mean pre-thyroxine insulin requirement. Basal insulin analysis 
was performed in three dogs and ranged from 4.8 to 11.5 nmol/1. No association could 
be made with these results to any other parameters because of their low number. 
Neuropathies, pyodermas and pancreatitis were among the unusual presentations in the 
hypothyroid dogs. None of these presentations were commonly seen in the ‘normal*
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diabetic group. Seven of the 8 dogs underwent ACTH stimulation testing (Appendix 5) 
and none had hypoadrenocorticism. The survival data of these dogs are evaluated in 
detail in Chapter 8.
Hospital Breed 
number
Age
(years)
Gender Number of Basal Post-TSH 
weeks diabetic thyroxine thyroxine 
before HypoT4 nmol/1 at 6 hrs
Basal
plasma
insulin
plU/ml
Thyroxine
therapy
107303 Collie cross 5.7 M 107 2.0 * Yes
112714 Tibetan terrier 4.0 FN 14 20.4 19.6 * Yes
113648 Scottish terrier 5.0 M 123 9.4 7.9 5.0 Yes
116146 English setter 6.0 M 54 5.6 2.0 * Yes
119136 English setter 5.4 M 0 1.0 1.0 4.8 Yes
120811 Tibetan terrier 6.9 FN 6 8.0 11.0 * Yes
120931 Caim terrier 2.5 M 109 8.8 23.8 * No
124684 Cross breed 8.0 FN 0 5.8 8.7 11.5 Yes
Table 11. Clinical features of 8 dogs with concurrent diabetes mellitus and hypothyroidism L * 
not done.
Hospital Mean Minimum Maximum Unusual presentations Comments Alive/ survival
number insulin 
dose pre­
thyroxine 
(lU/kg)
insulin
dose
insulin
dose
Dead/
Lost
(years)
107303 1.72 1.52 1.72 Alopecia, superficial 
pyoderma
Euthanased because 
of age
Dead 7.73
112714 2.51 1.6 3.18 Extreme hyper-
cholesterolaemia,
Tpancreatitis
Alive 4.90
113648 2.32 1.45 3.04 KCS, pyoderma Alive 4.57
116146 0.76 0.4 0.76 RHL neuropathy Euthanased because 
of aggression
Dead 2.17
119136 * 0.516 1.32 RHL neuropathy Alive 2.68
120811 2.73 2.14 4.00 Euthanased because 
of pancreatitis
Dead 0.57
120931 3.24 * * ? pancreatitis Lost 2.13
124684 * 0.862 1.65 Alive 0.32
Table 12. Clinical features of 8 dogs with concurrent diabetes mellitus and hypothyroidism II: 
unusual presentations, comments, outcome and survival times. * - not done or not applicable, KCS 
- keratoconjunctivitis sicca, RHL - right hindlimb.
Metoestrus-associated diabetes mellitus
The clinical features of 14 dogs with metoestrus associated diabetes mellitus are 
presented in Table 13. A variety of breeds of dog were represented and all had been in 
oestrus recently (mean 6.28 weeks ± SD 1.90). Ovariohysterectomy was performed 
within a few weeks of the diagnosis of diabetes mellitus except in two dogs (nos. 112324 
and 121143) which had been managed in practice prior to referral to the University
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clinic, in one dog (no. 111353) which the owners had been reluctant to spay until the dog 
experienced fluctuating insulin requirements and one dog (no. 114460) which was 
included on a surgical waiting list in order that cervical spondylopathy investigation and 
ovariohysterectomy could be performed under one general anaesthetic. Five dogs 
required continuous insulin therapy after diagnosis, 4 dogs experienced temporary 
remission of insulin requirement (in two dogs this was prior to ovariohysterectomy) and 
4 dogs had no requirement for insulin therapy after ovariohysterectomy although in one 
of these, insulin therapy was necessary for a few weeks following surgery. One dog 
failed to recover from ovariohysterectomy and was not made available for necropsy. 
Basal plasma insulin analysis was performed in 10 dogs and the results of 9 of these are 
represented graphically in Figure 9 according to whether insulin requirement was 
continuous or whether there was temporary or indefinite remission. The numbers of 
observations in each group make statistical analyses inappropriate, but all three ‘cured* 
dogs had basal insulin concentrations greater than 40 |iIU/ml and all those with 
continuing insulin requirement or temporary remission had basal insulin concentrations of 
less than 20 plU/ml.
Although insulin resistance is a feature of metoestrus-associated diabetes mellitus 
(Eigenmann, 1981), mean insulin dose pre-ovariohysterectomy was not calculated since 
it was unlikely to reflect the true insulin requirement because therapeutic policy in the 
case of these dogs was to arrange for ovariohysterectomy before attempting to achieve 
fine glycaemic control. Only one dog had classical clinical signs of canine acromegaly 
including soft tissue swelling of the head (Eigenmann, 1981) and even in this dog it was 
only a very temporary feature. In 4 dogs, there was mammary neoplasia and two suffered 
pseudopregnancy. The survival data of these dogs are included in Chapter 8 among the 
‘normal* group but not for those dogs which had remission of insulin requirement.
Islet cel! hypoplasia
One female Caim terrier was presented with islet cell hypoplasia at 5 months of age. This 
dog was stunted and had been polydipsic for 2-3 weeks. An intravenous glucose 
tolerance test confirmed that this dog had no insulin response. Plasma insulin 
concentrations remained < 2.5pIU/ml for 2 hours following an intravenous glucose load 
of Ig/kg. Pancreatic biopsy was performed within one month of diagnosis and 
histopathological examination revealed no normal islets with only a few small foci of 
degenerate, vacuolated cells and connective tissue. The exocrine pancreas was normal 
The dog was managed on single daily injections of isophane insulin at doses r a n ^ g  from 
0.89 to 2.08 lU/kg (mean 1.42) and was still alive at the end of the study period (3.14 
years).
bO
I
I
I
I
I
I
| o |
ill
II II
00
vo
00
[Jh
00 \o
vo
vo
00
b b
I
00
b
I
I
ov
b
i
I
b
o
r-
o
vo
ov<s
■I
vo
vo
<s
vo
ov
ov
Ov
8
I
r*v
CS
§
I
I
•I
S'
I
ë
I
CHAPTER 4 67
1000
100
Basal plasma insulin concentration (ulU/ml)
10
0.1
continuous
insulin
requirement
temporary
remission
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Figure 9. Basal plasma insulin concentration plU/ml (logarithmic scale) in bitches with 
metoestrus-associated diabetes mellitus categorised according to duration of insulin requirement.
Age at diagnosis of diabetes mellitus
The age at diagnosis of diabetes mellitus was significantly different between the groups 
(p = 0.000). Dogs with concurrent hyperadrenocorticism were significantly older than 
those with hypothyroidism and the ‘normal’ group. The dogs with concurrent 
hypothyroidism were significantly younger than those with metoestrus-associated 
diabetes mellitus and the ‘normal’ group. There was no statistically significant difference 
between the mean ages in the metoestrus-associated group and those in the 
hyperadrenocorticism or ‘normal’ groups. The mean (± standard deviation) ages for each 
group are presented in Table 14 and Figure 10 represents the age distribution of the 4 
groups.
Further analysis of the age distribution of dogs with concurrent hyperadrenocorticism by 
the Chi-square 2 x 2  method revealed that dogs which were 8 years of age or older when 
diagnosed diabetic were approximately 5 times more likely to have concurrent 
hyperadrenocorticism than those diagnosed at less than 8 years of age (relative risk = 
4.65, Taylor series 95% confidence limits 1.16 and 18.58, p = 0.009). In the case of 
hypothyroidism, dogs diagnosed diabetic at less than 7 years of age were approximately
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15 times more likely to develop concurrent hypothyroidism than those which did not 
become diabetic until 7 years of age or older (relative risk = 15.56, Taylor series 95% 
confidence limits 2.06 and 117.28, p = 0.000).
Number of dogs
HypoT4
□HAC
Norm
0< 2  2 < 4  4 < 6  6 < 8  8 < 1 0 1 0 < 1 21 2< 1 41 4< 1 6
Age group (years)
Figure 10. Age distributions of dogs with diabetes mellitus categorised according to disease type.
Group Number of dogs Mean age (years) Standard deviation
H>^eradrenocorticism
Hypothyroidism
Metoestrus
‘Normal’
18
8
14
50
10.61
5.43
9.82
8.14
2.41
1.68
1.61
2.40
Table 14. Mean ages of dogs at diagnosis of 4 types of diabetes mellitus.
Gender
There were no significant differences in gender distribution among the groups of diabetic 
dogs tested (HAC, HypoT4 and Norm).
Initial plasma biochemistry and condition score
The initial results of plasma biochemical analyses and body condition scores for those 
dogs presented to the University of Glasgow clinic before insulin therapy had begun are 
presented in Appendix 6. There were no statistically significant differences in initial 
plasma glucose, cholesterol alkaline phosphatase, alanine aminotransferase, aspartate
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aminotransferase, basal insulin or body condition score between the four groups of 
diabetic type.
Dynamic endocrine tests
The results of 15 ACTH stimulation tests and 13 thyroid investigations in ‘normal’ 
diabetic dogs are presented in Appendix 7 and those from 7 ACTH stimulation tests in 
diabetic dogs with hypothyroidism are presented in Appendix 5. Dynamic endocrine tests 
were not performed in metoestrus-associated diabetes mellitus. There was a significant 
difference between the groups (HAC, HypoT4 and Norm) in basal cortisol concentration 
(p = 0.017). Basal cortisol was significantly higher in the HAC group than in the HypoT4 
or Norm groups. There was no difference in basal cortisol between the HypoT4 and 
Norm groups. This pattern was repeated for the 45/60 minute post-ACTH cortisol 
results (p = 0.000) and the 90 minute results (p = 0.002). These results are summarised 
in Figure 11. A two-sample /-test revealed a significant difference in basal thyroxine 
concentration between the hypothyroid and ‘normal’ groups (p = 0.000) and this 
difference was also evident in the 6 hours post-TSH thyroxine concentration (p = 0.000). 
These results are summarised in Figure 12.
Plasma cortisol nmol/l
1000
800
600
400
200
Figure 11. Plasma cortisol responses (mean ± SEM) to intramuscular injections of a synthetic 
ACTH in diabetic dogs with concurrent hyperadrenocorticism (HAC) or hypothyroidism 
(HypoT4) or no concurrent illness (Norm). * - significantly different from the Norm group.
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100
80
60
40
20
Plasma total thyroxin nmol/l
I  +/ -SD
HypoT4
Norm
Cir-
Figure 12. Serum thyroxine concentration responses to intravenous bovine TSH in diabetic dogs 
with hypothyroidism (HypoT4) and those with no other illness (Norm).
Insulin requirement
One-way analyses of variance of mean insulin doses administered to diabetic dogs 
(excluding those during mitotane or thyroxine therapy and those for ‘cured’ metoestrus- 
associated diabetes mellitus) revealed a significant difference between the groups HAC, 
HypoT4, Meto and Norm (p = 0.000). The data used for this analysis are presented in 
Appendix 8. Tukey’s paired comparisons revealed the mean insulin requirement of the 
HAC group to be higher than the Meto and Norm groups. The mean insulin requirements 
of the HypoT4 and Norm groups were also higher than those in the Meto group. Mean 
insulin doses (and standard deviations) are presented for each group in Table 15. Further 
analyses were also performed, including doses administered during mitotane or thyroxine 
therapy, and the same pattern emerged (p = 0.001) with the exception of the lack of 
significant difference between the HAC and Norm groups. This analysis was principally 
included so that the mean range in insulin doses for each group could be tested as a 
measure of fluctuating requirement and, by inference, of difficulty in management. There 
was no significant difference in the range of insulin doses administered to each group (p 
= 0.36).
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Group Number of dogs Mean insulin Standard deviation
requirement
(lU/kg)
Hyperadrenocorticism 15 2.58 1.13
Hypothyroidism 6 2.21 0.87
Metoestrus 11 0.86 0.32
'Normal'________________________ 45______________L58_____________ 069________
Table IS. Mean insulin requirement in 4 types of canine diabetes mellitus (excluding doses 
administered during mitotane or thyroxine therapy).
Discussion
The clinical features and laboratory test results of dogs with diabetes mellitus in the 
presence of associated syndromes were investigated. Of a referred population of 94 
diabetic dogs, 3.2% developed diabetes mellitus following a recent injection of long 
acting progestagen (proligestone), 19.1% had hyperadrenocorticism, 8.5% had 
concurrent hypothyroidism, 14.9% developed diabetes mellitus following a recent 
oestrus and 1.1% had islet cell hypoplasia. The remaining 50 dogs had no identifiable 
diabetes associated syndromes.
Based on only a small sample, diabetes mellitus associated with proligestone 
administration was not transient but required continuous insulin therapy. Insulin 
insensitivity (high insulin requirement) was not a consistent feature of this condition.
In the case of concurrent hyperadrenocorticism and diabetes mellitus, small breeds 
appeared to be more commonly affected and the degree of insulin insensitivity (insulin 
requirement) was related to the time between the diagnosis of diabetes mellitus and that 
of hyperadrenocorticism. In 89% of cases the diagnosis of diabetes mellitus preceded the 
diagnosis of hyperadrenocorticism and the association between insulin insensitivity and 
glucocorticoid excess was exemplified by the amelioration of insulin requirement 
following subsequent adrenocorticolytic therapy.
In all cases of concurrent hypothyroidism and diabetes mellitus, the diagnosis of 
hypothyroidism was made following the diagnosis of diabetes mellitus. There was 
unusual breed representation within this group with two each of Tibetan terriers and 
English setters - breeds of dog not represented in any other diabetic dog group. Insulin 
insensitivity (high insulin requirement) was an important feature of this condition and 
there was a subjectively high prevalence of co-existing neuropathy, pyoderma and 
pancreatitis. The condition observed in these dogs did not fit the classical description of 
Schmidt’s syndrome in man because of the absence of hypoadrenocorticism.
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Metoestrus-associated diabetes mellitus was diagnosed approximately 6 weeks post­
oestrus on average and varying degrees of reduced insulin requirement were observed 
along with the requirement for continued insulin therapy. Basal plasma insulin analyses at 
the time of diagnosis may be a useful prognostic indicator. Classical signs of canine 
acromegaly were a rare finding present in only one of these dogs.
The distribution of age at diagnosis of diabetes mellitus was different between the groups 
of diabetic dogs. In general, hypothyroid dogs were younger, and dogs with 
hyperadrenocorticism were older, than ‘normal* diabetic dogs. However, there was no 
difference in gender distribution between the groups (with the exception of the 
metoestrus-associated group). There was no difference in initial concentration of plasma 
biochemical analytes, nor in body condition score between the groups but there was a 
difference in insulin requirement.
In no previously reported large case series of diabetic dogs has there been an attempt to 
estimate the relative frequency of different types of diabetes mellitus within the study 
population (Lauder, 1972; Foster, 1975; Ling etal, 1977; Marmor et al, 1982; Doxey et 
al, 1985), However, Lauder (1972) recorded one case of hyperadrenalism in a group of 
diabetic dogs which underwent post-mortem examination and suggested that 40% of 
diabetic dogs were entire bitches which developed the condition shortly after oestrus. In 
addition, Foster (1975) recorded three cases of diabetes mellitus and concurrent 
(unspecified) endocrine disease and observed that 29% of diabetic dogs were entire 
bitches which developed diabetes mellitus within 10 weeks of the last oestrus. There 
have been reports of the proportion of dogs with hyperadrenocorticism which have co­
existent diabetes mellitus (22% - Peterson et al, 1981) and the proportion of dogs with 
hypothyroidism that have concurrent diabetes mellitus (1.2% - Milne and Hayes, 1981) 
but not of the proportion of diabetic dogs with either of these two conditions.
The subject of progestagen (proligestone)-associated diabetes mellitus was a topic of 
great debate in the veterinary literature during the late 1980*s (Milne, 1987; Milne, 1988; 
Evans and Sutton, 1988a; Rutteman etal, 1988; Evans and Sutton, 1988b) as a result of 
suggestions by the distributors that proligestone was not diabetogenic and could be 
safely used in diabetic bitches for prevention of oestrus. Rutteman et al (1988) saw an 
unspecified number of dogs which developed diabetes mellitus while under proligestone 
therapy. Evans and Sutton (1988) claimed that no such cases had been reported to the 
manufacturers or the Veterinary Medicines Directorate in the UK during the period 
1978-1988. It has since become apparent that proligestone can induce growth hormone
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secretion and that it can therefore be considered to be diabetogenic (Selman et al, 1994c) 
and as a consequence is contraindicated in dogs with diabetes mellitus.
A similar breed predisposition for concurrent diabetes mellitus and hyperadrenocorticism 
to that observed in the present study was reported by Peterson et al (1981). Vrithin their 
group of 30 dogs, 56% were Poodles and 13% terriers. Of the group of 8 dogs with 
concurrent hyperadrenocorticism and diabetes mellitus reported by Blaxter and 
Grufifydd-Jones (1990), 37% were poodles and 12% terriers. A greater proportion of the 
cases reported by Peterson et al (1981) had hyperadrenocorticism diagnosed before 
diabetes mellitus (23%) than in the present study but in the group of dogs reported by 
Blaxter and Grufiydd-Jones (1990), all diagnoses of hyperadrenocorticism were made 
after the diagnosis of diabetes mellitus.
Previously published basal plasma insulin analysis in three dogs with concurrent 
hyperadrenocorticism and diabetes mellitus (Blaxter and Grufiydd-Jones, 1990) revealed 
very high concentrations, contrary to the findings of the present study of normal to low 
concentrations (Serono Clinical Laboratories, Cambridge canine insulin reference range 
5-40 jilU/ml). The low basal insulin concentrations observed may be indicative of P-cell 
exhaustion due to chronic stimulation by glucocorticoid induced insulin insensitivity and 
may explain the requirement for continuous insulin replacement therapy despite 
adrenocorticolytic therapy seen in the present study and in that of Peterson et al (1981). 
Blaxter and Gruffydd-Jones (1990) noted a reduction in insulin insensitivity associated 
with a more aggressive adrenocorticolytic therapy regimen (mitotane at 50mg/kg/day) 
than that used in the present study but which resulted in the requirement for intensive 
therapy for hypoglycaemia in 3/8 cases. Hypoglycaemia occurred in only one dog in the 
present study but unfortunately this episode was fatal. Peterson et al (1981) recorded 
reduced (but not abolished) insulin requirement within 3 weeks of adrenocorticolytic 
therapy. There have been no previous reports relating the duration of diabetes mellitus 
prior to a diagnosis of hyperadrenocorticism and the level of insulin requirement before 
adrenocorticolytic therapy. However, the finding in the present study of a direct 
correlation emphasises the dynamic nature of these concurrent illnesses. It may be that 
early in the course of concurrent diabetes mellitus and perhaps unrecognised or sub- 
clinical hyperadrenocorticism there may be considerable P-cell function but which is 
insufficient to overcome the insulin insensitivity induced by glucocorticoid excess, 
meaning that only a low dose of exogenous insulin is required to make up the shortfall 
Later in the course of the condition, P-cell function may wane, and glucocorticoid 
induced insulin insensitivity may increase, necessitating higher doses of exogenous insulin 
to achieve glycaemic control. Interestingly, both the present study and that of Blaxter
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and Gruffydd-Jones (1990) include a single case of bilateral keratoconjunctivitis sicca 
(KGS). It may be that this represents a rare complication of the two conditions when 
they occur in combination.
None of the cases of diabetes mellitus in the present study were induced by exogenous 
glucocorticoid administration.
Five dogs in the USA with concurrent hypothyroidism and diabetes mellitus have been 
the subject of detailed reports (Eigenmann et al  ^ 1984; Ford et al, 1993) and less 
extensive reports have stated the occurrence of the condition in a further 48 dogs (Milne 
and Hayes, 1981, Hargis et al, 1981). Ford et al, (1993) noted insulin insensitivity in the 
form of high insulin requirement in the three dogs featured in their report, consistent with 
that observed in 4/8 dogs in the present study. In man (Ganz and Kozak, 1974) and some 
dogs (Eigenmann et al, 1984), however, the combination of hypothyroidism and diabetes 
mellitus leads to a reduced insulin requirement. The familial or genetic basis of the 
condition is highlighted by the two breed clusters in the present study, the occurrence of 
the syndrome in two littermates (Eigenmann et al, 1984) and its occurrence in a colony 
of beagles (Hargis et al, 1981) in which there was clustering of the syndrome within 
litters.
In all cases of concurrent hypothyroidism and diabetes mellitus reported by Hargis et al 
(1981), hypothyroidism was diagnosed prior to the development of diabetes mellitus, 
contrary to the findings of the present study. All necropsy reports of concurrent 
hypothyroidism and diabetes mellitus have revealed islet vacuolation without 
inflammatory infiltration (Hargis e/ a / 1981; Eigenmann et al, 1984). Unfortunately, the 
one diabetic dog with hypothyroidism made available for post-mortem examination in the 
present study was suffering from active pancreatitis at the time of euthanasia. A case 
series of 66 hypothyroid dogs (Panciera, 1994) recorded 19 with neurological 
abnormalities including peripheral neuropathy so the finding of peripheral neuropathies in 
2/8 dogs in the present study is not surprising. However, it is interesting that the two 
English setters had very similar neuropathies affecting the same limb.
Polyendocrine failures in man have been associated with autoimmune syndromes 
(Eisenbarth, 1985; Ganz and Kozak, 1974) and a similar association has been suggested 
in dogs (Bowen et al, 1986; Kintzer, 1992). Future studies will be directed at 
discovering what, if any, autoimmune processes underlie concurrent hypothyroidism and 
diabetes mellitus in dogs.
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The association between metoestrus and diabetes mellitus has been established for a 
number of years (Lauder, 1972; Foster, 1975; Eigenmann, 1981; Eigenmann and 
Venker-van Haagen, 1981). The lower prevalence of metoestrus-associated diabetes 
mellitus in the present study than that of Lauder, (1972) and Foster (1975) may be a 
reflection of improved veterinary education and a reduced number of this kind of referral 
or reflection of an increase in elective ovariohysterectomy in dogs over the last 20 or so 
years.
In previously published reports, metoestrus-associated diabetes mellitus has been 
completely ‘cured’ by ovariohysterectomy (Eigenmann, 1981; Eigenmann, 1989, Reusch 
et al, 1993) or has required continued insulin replacement therapy despite 
ovariohysterectomy (Eigenmann, 1981). There are no previous reports of temporary 
remission of diabetes mellitus nor of the use of basal plasma insulin concentration as a 
prognostic indicator. Based on the small number of cases in the present study, a cut-off 
value for basal plasma insulin concentration in the range 20 to 40 plU/ml might be very 
useful in determining which dogs are likely to be completely ‘cured’ by 
ovariohysterectomy. Based on the experience of the present study, classical findings of 
canine acromegaly (Eigenmann and Venker-van Haagen, 1981) are not a common 
feature of this condition.
Islet cell hypoplasia in the dog has not been previously reported in Britain and the 
presentation of the one dog in this study was consistent with those reported in the USA 
(Anderson etal, 1986; Atkins et al, 1988). It is noteworthy that Cairn terriers are among 
those breeds identified in Chapter 3 of this thesis as being at high risk for the 
development of diabetes mellitus.
The difference in age at diagnosis of diabetes mellitus between the 4 groups studied is an 
interesting finding which has not been previously reported in other case series. The 
younger age of the hypothyroid dogs suggests a genetic (Milne and Hayes, 1981) or 
immunological disease process. The older age of dogs with concurrent 
hyperadrenocorticism is consistent with the age distribution of canine 
hyperadrenocorticism (Chastain and Ganjam, 1986c) and agrees with the finding of 
Peterson et a/ (1981), of 87% of cases being 8 years of age or more at diagnosis (88% in 
the present study).
With the exception of minimum and maximum values for alkaline phosphatase 
concentration from a group of 43 ‘normal’ diabetic dogs for comparison with results 
fi-om 8 diabetic dogs with hyperadrenocorticism (Blaxter and Grufiyyd-Jones, 1990),
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comparisons of initial biochemical results between different types o f diabetic dog have 
not been previously reported. The lack of difference between the groups in 
concentrations of alkaline phosphatase and cholesterol suggests that, in diabetic dogs, 
these analytes, which are traditionally used as an aid to diagnosis of 
hyperadrenocorticism and hypothyroidism, respectively are likely to be o f little value in 
identifying these endocrinopathies.
Although a difference in basal insulin concentration might have been expected between 
those conditions associated with insulin insensitivity and those which are not, the fact 
that there was no difference highlights the dynamic nature of these conditions, the 
possibility of P-cell exhaustion and the presence of (perhaps obesity-related) insulin 
insensitivity in a group of ‘normal* diabetic dogs. By the time some diabetic dogs, even 
those with insulin insensitivity as the primary mechanism for their diabetes mellitus were 
sampled, some degree of P-cell exhaustion may have occurred.
The present study confirms that ACTH and TSH stimulation tests were valid methods of 
diagnosis of concurrent endocrinopathy in diabetic dogs. Close examination of cortisol 
results in normal and hypothyroid dogs (Appendices 5 and 7) revealed certain cases 
where there are post-ACTH cortisol concentrations close to those in the 
hyperadrenocorticism group. The ACTH stimulation test results were interpreted 
cautiously and always with regard to signalment and clinical presentation, as is necessary 
when this test is used in non-diabetic dogs.
The analysis of insulin requirement confirmed that concurrent hyperadrenocorticism and 
diabetes mellitus was associated with a high insulin requirement consistent with the 
findings of Peterson e/ a/ (1981) and Blaxter and Grufifyyd-Jones (1990) and suggested 
that dogs with metoestrus-associated diabetes mellitus remaining on insulin therapy 
following ovariohysterectomy have unusually low requirements.
In conclusion, the relative occurrence of recognisable types of canine diabetes mellitus in 
a referred population of dogs has been documented. Some of the findings of previous 
reports of diabetes mellitus in association with other syndromes were confirmed, such as 
the predisposition of Poodles and terriers to hyperadrenocorticism-associated diabetes 
mellitus, the reduction of insulin requirements in affected dogs by adrenocorticolytic 
therapy, the occurrence of keratoconjunctivitis and neuropathies in diabetic dogs with 
concurrent endocrinopathies, the possibility of insulin insensitivity in concurrent 
hypothyroidism and the clinical and histopathological presentation of canine islet cell 
hypoplasia. Original observations included: normal or low basal plasma insulin
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concentrations in diabetic dogs with hyperadrenocorticism; a relationship between 
duration of diabetes mellitus and degree of insulin requirement in dogs with 
hyperadrenocorticism; a difference in the average ages of ‘normal* diabetic dogs and 
those with hypothyroidism or hyperadrenocorticism; ovariohysterectomy in dogs with 
metoestrus-associated diabetes mellitus may result in temporary remission of insulin 
requirement and that basal insulin analyses may be a useful prognostic tool in these dogs.
In summary, there are distinct presentations of canine diabetes mellitus and knowledge of 
these can only improve their recognition and therefore the accuracy of prognoses 
offered.
Future studies will be directed at elucidating the underlying immunologic or genetic basis 
of concurrent hypothyroidism and diabetes mellitus and the validation of the basal insulin 
observations in metoestrus-associated diabetes mellitus by accumulation of additional 
cases.
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Chapter 5:
Long-term monitoring of glycaemic control
introduction
The ultimate aim in diabetic management is to restore euglycaemia by utilising 
therapeutic measures to compensate for the dysfunction of mechanisms responsible for 
glucose homeostasis. In the design, implementation and adjustment of therapeutic 
protocols, the ability to determine the degree of success in achieving this aim is 
imperative.
The ideal system for monitoring glycaemic control in treated diabetic people or animals 
would be continuous blood glucose monitoring. Experimentally, this has been acheived 
in human diabetic patients in the form of an ‘artificial pancreas* which took 
measurements of blood glucose concentration every minute (1440 samples per day) to 
enable adjustments in insulin infusion rate (Albisser et al, 1974). Unfortunately, technical 
problems of miniaturisation of such systems and of reliability of glucose sensors has 
meant that they have not become a viable option. Currently, in human diabetic medicine 
the most common practical alternative to continuous monitoring is repeated thumb-prick 
capillary blood glucose testing, often performed between 5 and 10 times daily (Albisser, 
1992) using a dedicated portable glucometer and reagent strips. In the veterinary 
situation, however, this degree of blood glucose monitoring is impractical and 
prohibitively costly. A less invasive and expensive method than repeated serial blood 
glucose analyses is required for the assessment of glycaemic control in diabetic dogs. 
Ideally, such a method would be based on the inexpensive measurement of a single 
analyte on a single sample obtained at any time of day to gain an accurate assessment of 
glycaemic control achieved by a particular therapeutic regimen or insulin dose.
There are a number of candidate blood biochemical analytes which could be considered 
to fulfil this role in the dog, namely: blood concentrations of nadir glucose, alkaline 
phosphatase, alanine aminotransferase, asparatate aminotransferase, fiiictosamine and 
glycated haemoglobin.
Nadir blood glucose concentrations can be used to give an accurate assessment of 
glycaemic control at only a very specific and ephemeral point in the day and therefore
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can be thought to have little value as indicators of overall glycaemic control. However, if 
used for the purposes of monitoring patients in which the daily effective duration of the 
regimen has already been assessed by the creation of a 24 hour serial glucose curve then 
single daily nadir blood glucose concentrations may have a place.
The next most likely candidate analytes are the so-called ‘liver enzymes* (alkaline 
phosphatase, alanine aminotransferase and aspartate aminotransferase) since their 
measurement is inexpensive and already features as part of the general or routine 
biochemical health screen. Their potential value as indicators of glycaemic control lies in 
the fact that the plasma concentrations of these analytes are ofren grossly elevated in 
untreated and unstable diabetic dogs (Nelson, 1989a). It is possible that treated and 
stable diabetic dogs would have normal or near normal plasma concentrations.
Alkaline phosphatase is an enzyme which has a number of iso-forms originating from 
bone, intestine and liver including a specific steroid-induced form of hepatic origin. 
Conditions associated with cholestasis induce increased production of hepatic alkaline 
phosphatase (by enhanced RNA transcription) and its consequent release into the 
circulation (Cornelius, 1989). Alanine aminotransferase is an enzyme whose elevation in 
plasma of small animals is associated with conditions of hepatocellular necrosis 
(Cornelius, 1989). In uncontrolled diabetic animals there is generally hepatomegaly 
consequent upon the mobilisation of lipid stores. This hepatic fatty infiltration leads to 
hepatocellular death and to increased intrahepatic pressure on the biliary tree, and 
therefore cholestasis, resulting in elevated plasma concentrations of these enzymes. 
Aspartate aminotransferase is much less ‘liver specific* in dogs than alanine 
aminotransferase and raised plasma concentrations are more often associated with 
damage to many other soft tissues, particularly muscle (Kramer, 1989). Concentrations 
of plasma aspartate aminotransferase are elevated in unstable diabetics probably because 
of protein (muscle) catabolism for gluconeogenesis in addition to the contribution made 
by hepatic aspartate aminotransferase.
In human diabetic medicine, the measurement of glycated proteins, including 
haemoglobin, has been used to assess glycaemic control. The non-enzymatic chemical 
combination of sugars and proteins to form stable ketoamine products has been known 
of for many years. Emil Fischer synthesised isoglucosamine (fiuctosamine) in 1886 
(Kruse-Jarres et al, 1989), and in 1912, Maillard described the reaction responsible and 
noted its potential importance to medical pathology (Dominiczak, 1991). Food 
technologists have exploited the Maillard reaction for many years because the products 
are brown in colour and it is for this reason that the process is commonly referred to as
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the ‘browning reaction*. The first stage in the Maillard reaction is the condensation of the 
fi-ee aldehyde group of a sugar with the amino group of the protein. This results in an 
unstable Schiff-base compound (aldimine) which can fi’eely dissociate back into sugar 
and protein and whose concentration is dependent on prevailing glucose concentration. 
Alternatively, such compounds can undergo molecular transformation by Amadori 
rearrangement into much more stable ketoamines (Dominiczak, 1991) (Figure 13).
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Figure 13. The glycatlon reaction.
Glycosylated haemoglobin, or more correctly, glycated haemoglobin (Roth, 1983), was 
the first glycation product to be used by medical diabetologists to monitor diabetic 
control. The minor components of human haemoglobin were discovered by cation 
exchange chromatography in 1958 and termed HbAla, HbAlb and HbAlc. Collectively 
these haemoglobin variants accounted for less than 10% of total haemoglobin (Allen et 
al, 1958). The association between elevated concentrations of particularly HbAlc and 
the presence of diabetes mellitus in humans was recognised by the early 1970’s but not 
understood until 1976 when it was discovered that HbAlc could be generated by 
incubation of haemoglobin or whole blood with glucose (Fluckiger and ^^terhalter, 
1976). Human HbAlc is haemoglobin (HbA) modified by glucose at the amino terminus 
of the p chain. This modification generates a negative charge on the new molecule and 
this is the basis for the separation and measurement of HbAlc by ion exchange
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chromatography, isoelectric focusing, high performance/pressure liquid chromatography 
and agarose gel electrophoresis. HbAlc is the principal human glycated haemoglobin 
fraction but glycation occurs at a number of loci along both the a  and P chains of the 
haemoglobin molecule (principally at lysine sites). The measurement of all glycated 
haemoglobin, and not just that which is responsible for large alterations in charge can be 
achieved using affinity chromatography. The basis for this separation technique is the 
affinity of boronic acid for cw-diol groups. Boronate immobilised on a gel matrix retains 
glycated haemoglobins and the non-glycated component passes through. The adsorbed 
glycated products can then be displaced by a high concentration of a competing ligand 
such as sorbitol. It is likely that affinity choromatography methods would be more 
applicable to the measurement of glycated haemoglobin in domestic animals where the 
structural forms of glycated haemoglobin and their ionic properties are not known. 
Glycated haemoglobin concentrations have been used routinely in human diabetic 
monitoring since the early 1980*s and they are believed to reflect integrated blood 
glucose concentrations over the preceding 7-8 weeks (approximately the average half-life 
of human red blood cells). The measurement of glycated haemoglobin in dogs has been 
reported by Wood and Smith (1980) using macro-column ion-exchange chromatography, 
by Mahaffey and Cornelius (1982) using a mini-column ion-exchange method and by 
Smith et al, (1982) using a colorimetric assay as an alternative to column methods. 
Higgins et al, (1982) compared the concentrations of glycated haemoglobin in a number 
of species commonly used in diabetes research, including dogs, using cation exchange 
chromatography, agarose gel electrophoresis and affinity chromatography. One of the 
conclusions of this work was that despite the similar red cell life span between dogs and 
humans (120 days), glycated haemglobin concentrations in dogs were likely to be lower 
than in humans because the permeability to glucose of canine red cells is approximately 
half that of human red blood cells.
Shortly after the introduction of glycated haemoglobin measurement in human diabetes 
clinics, attention shifted to the possibility of using other glycation products such as serum 
albumin and other proteins. The first reports of glycated albumin synthesis in vitro and its 
isolation from human serum were published in 1979 (Dolhofer and Wieland, 1979; Day 
et al, 1979) and these used chromatographic techniques and a colorimetric thiobarbituric 
acid method which measured 5-hydroxymethylfurfural (5-HMF) released by acid 
hydrolysis of ketoamine-protein complexes. A very much more convenient simple 
colorimetric test for glycated proteins in serum was described by Johnson et cd (1982) 
and was termed the finctosamine test. This test was further modified to limit interference 
from sample matrix and lipaemia and included a new glycated polylysine standard 
(Kruse-Jarres et al, 1989), and became available in a simple-to-automate kit form. The
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main drawback of the fructosamine assay is that about 90% of fructosamine activity 
measured in human serum is glycated albumin (Kennedy, 1992). This makes the test 
sensitive to fluctuations in serum albumin concentration and a number of workers have 
advocated the use of albumin or protein corrected values (McCance et al, 1987) whilst 
others have suggested that they are unneccessary except in severely protein deficient 
states (Kruse-Jarres et al 1989; Rowe and Dominiczak, 1989). The measurement of 
fioictosamine in humans has now been reported and critically reviewed in many 
publications. The use of the assay in veterinary medicine has also started to receive 
attention not only as an indicator of diabetic control in dogs and cats (Reusch et al, 
1993; Kawamoto et al, 1992; Jensen, 1992; Jensen and Aaes, 1992; Jensen 1993) but 
also as an indicator of protein turnover (Heath and Connan, 1991) and malnutrition 
(Cantley et al, 1991) in sheep.
When using a laboratory test in the diagnosis or monitoring of a disease condition it is 
essential to regard such a test as an aid. The confidence with which decisions regarding 
diagnosis or prognosis can be made when based on laboratory tests depends greatly on 
the quality of the performance characteristics of such tests.
There are a number of components to the assessment of the quality of a new laboratory 
test or of an old test used for a new purpose. The initial stage in the evaluation of a 
laboratory test is to define the performance characteristics of the test within the analytical 
laboratory. Important factors such as consistency of results, smallest concentration of 
analyte detectable and whether the test measures the analyte for which it is designed are 
normally assessed by the performance characteristics: intra and inter-assay coefficients of 
variation, sensitivity (limit of detection) and accuracy. For the test to be useful when 
applied to the clinical setting, there must be a difference between the results generated 
fi-om the healthy and diseased populations on which a reference range can be based and 
the test must be able to distinguish between healthy and diseased animals within a target 
population of animals suspected of being diseased.
To assess the usefulness of a laboratory test based on the last criterion of distinguishing 
between healthy and diseased animals in a target population, indices have been developed 
based on the rate (ratio) at which a laboratory test gives true (as opposed to false) 
positive and true negative predictions of the presence of a disease. These indices have 
been termed the sensitivity (true postive ratio) and specificity (true negative ratio) of the 
assay (Youden, 1950; Ryan, 1991; Jensen and Poulsen, 1992) and are calculated 
according to Table 16. Normally such indices would be developed on a ‘test* target
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population in which the diagnosis of the presence of disease could be determined by a 
different and independent means.
Diseased Healthy
Test Postive A B
Test Negative___________________ C____________________ D
Sensitivity (true positive ratio) = A/(A+C)
Specificity (true negative ratio) = D/(B+D)
Table 16. Calculation of sensitivity and specificity of a laboratory test
The ideal laboratory test would give no false positives or false negatives and so 
sensitivity and specficity would both equal 1. Certainly, to be useful, a laboratory test 
must give more true positive than false positive results and more true negative than false 
negative ones. In effect, this means that the sensitivity and specificity must both be 
greater than 0.5 to make the test more useful than tossing a coin. Youden (1950) 
proposed the creation of a performance index (J = Sensitivity + Specificity - 1) such that 
a perfect test would have a performance index, 1 = 1  and that a worthless test would 
have a performance index, J = 0.
The use of the method outlined above to assess laboratory test performance depends on 
a dichotomous test result. This works well for some tests, particularly serological and 
parasitological tests in which the antibodies or parasites are detectable or they are not. 
However, many biochemical and haematological test methods give rise to a continuous 
scale of possible results and a dichotomous outcome has to be artifically created. This is 
achieved by selecting a cut-off point above or below which a disease can be said to be 
present. For example, anaemia is usually deemed to be present when a packed cell 
volume result is below an arbitrary cut-off value. Commonly cut-off values are selected 
fi-om the limits of the traditional reference range (mean ± 2SD’s or 5 and 95 percentiles 
of results obtained from a reference population) and sensitivity and specificity indices 
calculated on that basis. However, the selection of a different cut-off point will alter the 
ratio of true positives and true negatives and therefore the sensitivity and specificity, 
particularly if the ranges of results generated from diseased and healthy animals overlap 
greatly.
As a general rule, the specificity of a laboratory test will increase, but sensitivity 
decreases, as the cut-off value is shifted towards the affected animals and sensitivity will 
increase, but specificity decreases as the cut-off value migrates towards non-affected
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animals. This means that as the cut-off value is varied across a continuous range of test 
results an associated range of pairs of sensitivity and specificity values is created. This 
range of sensitivity and specificity pairs form the basis of the relative (or receiver) 
operating characteristic (ROC) curve. The generation of an ROC curve means that the 
usefulness of a laboratory test can be assessed across the whole range of possible results 
and in a way which is independent of a particular cut-off value. ROC curves have been 
used in human laboratory medicine since the late 1970’s but in veterinary laboratory 
medicine only recently and rarely (Jensen, 1994). The ROC curve is created by plotting 
sensitivity (true positive ratio) on the ordinate (y-axis) against the false positive ratio (1- 
specificity) on the abscissa (x-axis) for each of a range of cut-off values. In an ideal 
laboratory test which could perfectly distinguish between healthy and diseased 
individuals the ROC curve would be drawn from the origin (0,0) to (0,1), the top left 
hand comer and then horizontally across to (1,1), the top right hand comer of the plot. A 
test which has no value and produces true and false positive results at an equal rate will 
have an ROC curve which is the diagonal (0,0) to (1,1). Therefore, the more useful the 
laboratory test, the more the ROC curve will extend into the top left hand comer of the 
plot. This can be measured more accurately in terms of the area under the ROC curve. A 
perfect test will have an area under the ROC curve of 1 and a useless test an area under 
the curve of 0.5 (Hanley and McNeil, 1982). Thus it is possible to have a single value 
(the area under the ROC curve) with which to determine the usefulness of a laboratory 
test for a particular purpose, independent of cut-off values, and with which direct 
comparisons can be made with other candidate laboratory tests designed for that same 
clinical purpose. Statistical methods have also been developed to determine the 
significance of a difference between the area under an ROC curve and 0.5 with which the 
assessment of the laboratory test can be supported (Hanley and McNeil, 1982).
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Figure 14. Idealised ROC curves for (a) a perfect laboratory test and (b) a useless laboratory test
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Once a laboratory test has been determined to be useful for a particular purpose by the 
ROC curve method, the next stage is to determine what the cut-off value needs to be to 
make the test the most ‘efficient*. This can be achieved by an alternative representation 
of the data included in the ROC curve. The differential positive rate (DPR) can be 
calculated fi-om the pairs of sensitivity and specificity values generated across a range of 
cut-off values for creation of the ROC curve and it is the difference between the true 
positive and false positive ratios (sensitivity - (1 - specificity)) (Ward, 1986). The optimal 
cut-off value is that at which this difference (DPR) is greatest. DPR is a linear 
transformation of Youden* s performance index (J = sensitivity + specificity - 1) and so 
the same result can be achieved by calculating a series of Youden’s indices across the 
range of cut-off values (Jensen, 1994). The maximum DPR value can be used in a similar 
way to the area under the ROC curve when comparing laboratory tests designed for the 
same purpose. A maximum DPR value of 1 would indicate a perfect test and of 0 a 
worthless test.
The aims of this chapter were to validate the use of two new laboratory tests 
(fiuctosamine and glycated haemoglobin) in the University of Glasgow Veterinary 
School and to assess the usefulness of measuring plasma concentrations of alkaline 
phosphatase, alanine aminotransferase, aspartate aminotransferase, fiuctosamine and the 
concentration of glycated haemoglobin in the short and long term monitoring of canine 
diabetes mellitus using advanced techniques of laboratory test evaluation.
Materials and methods 
Fructosamine
Plasma fiuctosamine concentrations were measured using a commercial colorimetric test 
kit based on the ability of keto-amines to reduce nitroblue tétrazolium (NET) in alkaline 
conditions (Unimate Fructosamine, Roche). The production of formazan forms of NBT 
is proportional to the concentration of fiuctosamine and was measured photometrically 
using an autoanalyser. The autoanalyser protocol was supplied by the kit manufacturers. 
The reaction pH and the time course ensure negligible interference from other reducing 
substances such as glucose and creatinine (Johnson et al, 1982). Using this method 
fiuctosamine measurements are made against a calibrator solution based on glycated 
polylysine supplied by the kit manufacturer (Fructosamine Calibrator, Roche). To 
confirm the correct function of this test in canine plasma samples a number of validation 
procedures were performed. Assay precision was assessed on the basis of intra- and 
inter-assay coefficients of variation. Intra-assay coefficient of variation was estimated at 
4 different concentrations of fiuctosamine using pooled plasma on three occasions and 
plasma from an individual animal on the fourth (Case no. 122739). Inter-assay
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coefficients of variation were estimated at two concentrations of fructosamine over 8 
occasions.
CK%=
Mean
The sensitivity, or limit of detection, of the assay kit was estimated by analysis of 20 
replicates of physiological saline for fructosamine concentration. Linearity of the method 
was assessed by measurement of fructosamine concentrations in serial dilutions of a 
plasma pool of high fructosamine concentration as follows: 1 in 1.5, 1 in 2, 1 in 3, 1 in 4, 
1 in 6 and 1 in 8. The effect of lipaemia on fructosamine results was studied because 
plasma taken from diabetic dogs is frequently lipaemic. This was performed by adding 
15|il of varying concentrations of a commercial lipid based enteral nutrition product 
(Intralipid - soya bean oil and glycerol emulsion, Kabi Pharmaceuticals) to 200pl aliquots 
of plasma pools containing high and low concentrations of fructosamine, thus creating a 
range of samples from no visible lipaemia through to gross lipaemia similar to that seen 
in some diabetic plasma samples.
Samples of whole blood from 4 dogs (nos. 97218, 115678, 115980, 120899) were 
stored on a laboratory bench for 48 hours and aliquots removed at 24 hour intervals for 
analysis of plasma fructosamine concentration to simulate delayed transport to the 
analytical laboratory.
A conventional reference range for non-diabetic dogs was created by the analysis of 
fructosamine concentration in 20 samples of surplus dog plasma submitted for routine 
clinical chemistry analysis.
Glycated haemoglobin
Glycated haemoglobin concentrations were measured using a commercially available mini 
affinity column chromatography kit (GLYCO-Tek Affinity Columns; Helena 
Laboratories). This method separates all glycated haemoglobins from non-glycated 
haemoglobin in lysed red blood cells based on the the affinity of dihydroxyboryl groups 
(bound to a celluose resin) for cw-diol groups present in simple sugars (including 
glucose) incorporated in glycated haemoglobin. A basic eluent removes all non-glycated 
haemoglobin, labile glycated haemoglobin and carbamylated haemoglobin from the 
chromatography column but leaves the glycated forms which are eluted using a sorbitol 
buffer. A comparison of the concentrations of the glycated and non-glycated 
haemoglobins is made using photometric determination of haemoglobin concentration at
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415 nm and a percentage concentration of glycated haemoglobin calculated using the 
following formula:
GlycHBVo = ------------------------------------------------------^
Abs.GlycHB+i5xAbs.NonGfycHB)
Volume ofNon-Glycated haemoglobin eluent = 15ml 
Volume of Glycated haemoglobin eluent = 3 ml
To assess the precision of this method, intra-assay coefficients of variation were 
calculated for 4 samples of canine blood: three diabetic and one non-diabetic. Inter-assay 
coefficients of variation were calculated for 8 replicate analyses of glycated haemoglobin 
in two blood samples (one diabetic and one non-diabetic) over a period of three weeks. 
This information was also used to assess the long term effects of refrigerated storage of 
samples intended for glycated haemoglobin analysis. The effects of sample quality and 
sample storage conditions were examined by repeated analyses of 5 aliquots of a single 
canine sample stored in a refrigerator over two weeks or stored at room temperature for 
one week. Two aliquots were haemolysed by repeated passage through a fine (23 gauge) 
hypodermic needle at the beginning of the study.
To verify that glycated haemoglobin was being measured, an incubation experiment was 
conducted. A solution containing 4% dextrose saline solution was added to three whole 
blood samples with initial glycated haemoglobin concentrations of 2.2, 3.3 and 2.1%, in 
the proportions 9 parts whole blood to 1 part dextrose saline. This gave an approximate 
final concentration of glucose in each sample of approximately 27 mmol/1 which is close 
to the physiological maximum plasma glucose concentrations seen in diabetic patients 
with good renal perfusion and function.
Comparison with two other methods of analysis of glycated haemoglobin were made. 
The first was with a commercially available cation exchange kit (Glycohaemoglobin 
HbAl Test; Bio-Stat Diagnostics). This kit binds non-glycated haemoglobin to a weak 
binding cation exchange resin and allows photometric determination of glycated 
haemoglobin in the supernatant. The concentration of glycated haemoglobin is then 
calculated from the absorbances of total and glycated haemoglobin in the sample and 
those of a standard glycated haemoglobin solution. This kit measures HbAlc which is the 
principal component of human glycated haemoglobin and consists of haemoglobin with 
glucose bound at the terminal valine sites of the two p chains. Glucose attached at this 
site alters the isoelectric point of the haemoglobin molecule and allows for separation
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from non-glycated haemoglobin by cation exchange chromatography. Ten whole blood 
samples from 7 diabetic dogs were used to make the comparison between the cation 
exchange and affinity column methods over two analysis days. Simple scatter plot and 
linear regression were used to assess the relationship between results obtained by the two 
methods.
The second method of analysis for comparison with affinity colunm chromatography was 
agarose gel electrophoresis. A commercial agarose gel kit (Diatrac, Beckman) and 
scanning densitometer (Appraise, Beckman) were used to analyse 16 whole blood 
samples from 15 diabetic dogs and one dog with a functional P-cell tumour over two 
analysis days. This kit measures HbAlc based on the difference in charge, and therefore 
electrophoretic mobility, between non-glycated haemoglobin and HbAlc.
To assess the effect of anticoagulant on the assay, 9 whole blood samples from 8 diabetic 
dogs and one non-diabetic dog were analysed over three analysis days. Simple regression 
analysis was used to determine the relationship between the results of both types of 
samples and a paired /-test was used to test for differences between the methods.
A conventional reference range for non-diabetic dogs was created by analysis of glycated 
haemoglobin concentration in 26 samples of surplus canine whole blood submitted for 
routine haematological analysis.
Daily variation
The measurement of plasma glucose is useful in monitoring diabetic therapy. However, 
in a diabetic therapy regime using only single daily injections of an intermediate acting 
insulin preparation there can be wide variations in glucose concentration over a 24 hour 
period, severely restricting the time of day at which a useful determination can be made. 
Before assessing the usefulness of alkaline phosphatase, alanine aminotransferase and 
fructosamine for diabetic monitoring, it was important to determine whether these 
analytes were subject to fluctuations during the day in a manner similar to plasma 
glucose concentrations. Because of the manual and expensive nature of glycated 
haemoglobin analyses, an equivalent study of this parameter was not performed. The 
serial analysis of aspartate aminotransferase was also not performed. Three dogs were 
bled at regular intervals over 24 hours as part of a study of the effects o f diet on 
glycaemic control (Chapter 7) and plasma concentrations of alkaline phosphatase, alanine 
aminotransferase and fructosamine were determined in surplus plasma. Plasma 
concentrations of alkaline phosphatase, alanine aminotransferase and fructosamine were 
transformed to percentage changes from basal for graphing purposes and general linear
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model analysis (two way analysis of variance using the model: analyte = dog time) was 
used to test for the effect of sampling time on plasma concentrations of these analytes.
Monitoring early diabetic therapy
To compare the usefulness of measuring the plasma concentrations of afternoon glucose, 
alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, fiuctosamine 
and the concentration of glycated haemoglobin for monitoring the early response to 
diabetic therapy, three early sampling periods were chosen. These sampling periods were 
0-7 days (Period A), 8-21 days (Period B) and 22-42 days after the start of treatment 
(Period C) and they were chosen to include samples obtained before treatment and those 
obtained at the first two follow up examinations post-stabilisation. After the first 6 week 
period owners did not always return with their pets with sufficient regularity to continue 
this type of monitoring. Only the biochemical results of 20 dogs which had fiuctosamine 
concentrations measured within at least two of the early sampling periods were used for 
analysis in order to reduce the number of missing results, to improve the reliability of the 
statistical analyses and to allow for a valid comparison between the parameters. Only 15 
of these dogs had glycated haemoglobin measurements performed. Statistical analysis 
was performed using general linear model analysis (two way-analysis of variance model) 
to determine whether there was a significant change in the concentration of the 
parameter. For those parameters in which there was a significant change, a Newman- 
Keuls multiple range test (‘macro* for MINITAB by DR Irvine) was performed to 
determine how the sampling periods differed.
The effect of the duration of diabetes mellitus prior to treatment (based on the number of 
weeks of polydipsia) on pre-treatment concentrations of alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, fiuctosamine and glycated haemoglobin 
concentration was investigated using simple regression analysis.
Long-term diabetic monitoring
To assess the usefulness of alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, fiuctosamine and glycated haemoglobin concentrations as aids to 
monitoring long-term diabetic control, the results of many hundreds of follow-up 
examinations were coded according to the degree of glycaemic control which was 
believed to prevail at that time. This was achieved according to afternoon blood glucose 
concentrations and clinical information provided by the owner or discovered on clinical 
examination. The group codings were defined as follows:
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Group 1 untreated diabetics;
Group 2 very poor control (high afternoon blood glucose
concentrations and clinical signs such as polyuria/dipsia);
Group 3 poor control (high afternoon blood glucose concentrations but
without clinical signs of diabetic instability or good afternoon
blood glucose concentrations but recent history of significant 
clinical signs of instability);
Group 4 fair control (moderately elevated afternoon blood glucose
concentrations and no history of clinical signs of instability or 
good afternoon blood glucose concentrations but with very 
occasional signs of moderate instability);
Group 5 good control (good afternoon plasma glucose concentrations
and no clinical signs of diabetic instability);
Group 6 excellent control (afternoon blood glucoses in the range 3 - 5
mmol/1 and serial blood glucose evidence of good 24 hour 
diabetic control);
Group 7 excessive insulin dose (generally, afternoon blood glucose
concentrations below 3 mmol/1 and/or clinical signs of 
hypoglycaemia)
Group 8 non-diabetic dogs for fiuctosamine (n = 20) and glycated
haemoglobin (n = 26) only
One way analysis of variance was used to determine the presence of statistically 
significant differences between the means of these groups for concentrations of afternoon 
plasma glucose, alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, fiuctosamine and glycated haemoglobin and Tukey’s family error rate 
method of multiple comparisons (MINITAB 9) was used to determine how the groups 
differed.
In order to get a mathematical assessment of the usefulness of alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, fiuctosamine and glycated 
haemoglobin concentrations in determining the degree of glycaemic control achieved in a 
diabetic dog, a dichotomous outcome of the test results was necessary. The ability of 
these biochemical tests to differentiate between poorly controlled diabetic dogs (follow- 
up examinations in glycaemic control Groups 2 and 3) and fair to well controlled dogs 
(follow-up examinations in glycaemic control Groups 4, 5 and 6) was assessed using 
ROC curves generated for each parameter including afternoon plasma glucose. For those 
tests determined by the ROC curves to be useful, differential positive rate (DPR) curves
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were created to determine the optimum cut-off value between the poorly controlled dogs 
and those with some degree of control.
The methods used to generate ROC curves and differential positive rates were those 
recommended by Jensen and Poulsen (1992) based on those of Hanley and McNeil 
(1982). For demonstration purposes, details of the first and last 10 sensitivity, specificity 
and DPR values used in the evaluation of the fiuctosamine assay are recorded in Table 
17. The methods used to calculate the area under the ROC curve and determine its 
statistical difference from 0.5 are also those recommended by Jensen and Poulsen (1992) 
based on Hanley and McNeil (1982) and these are detailed by example in Appendix 9.
Value Cut-off 
number value
Number observations in each Sensitivity Specificity 1 - DPR 
glycaemic control group specificity
2 3 4 5 6
1 190 0 0 0 1 0 1.000 0.000 1.000 0.000
2 193 0 0 0 1 0 1.000 0.004 0.996 0.004
3 195 0 0 0 1 0 1.000 0.008 0.992 0.008
4 200 0 0 0 0 0 1.000 0.013 0.987 0.013
5 208 0 0 0 0 0 1.000 0.013 0.987 0.013
6 223 0 0 0 1 0 1.000 0.013 0.987 0.013
7 228 1 0 0 0 0 1.000 0.017 0.983 0.017
8 229 0 0 0 0 0 0.989 0.017 0.983 0.006
9 232 0 0 1 1 0 0.989 0.017 0.983 0.006
10 236 0 0 1 1 0 0.989 0.025 0.975 0.015
208 633 0 1 0 0 0 0.096 0.996 0.004 0.092
209 636 0 0 1 0 0 0.085 0.996 0.004 0.081
210 639 0 1 0 0 0 0.085 1.000 0.000 0.085
211 648 0 1 0 0 0 0.074 1.000 0.000 0.074
212 676 1 0 0 0 0 0.064 1.000 0.000 0.064
213 692 0 1 0 0 0 0.053 1.000 0.000 0.053
214 711 1 0 0 0 0 0.043 1.000 0.000 0.043
215 713 1 0 0 0 0 0.032 1.000 0.000 0.032
216 771 1 0 0 0 0 0.021 1.000 0.000 0.021
217 781 1 0 0 0 0 0.011 1.000 0.000 0.011
- Sensitivity: the proportion of dogs with poor control (glycaemic control groups 2 and 3) with 
fiuctosamine concentrations at or above the cut-off value
- Specificity: the proportion of dogs with fair to good control (glycaemic control groups 4,5 and 6) with 
fiuctosamine concentrations below the cut-off value
- DPR = Sensitivity - (1 - Specificity)
Table 17. The calculation of sensitivity, specificity and differential positive rate for the first and 
last 10 cut-off values for fructosamine concentrations used in distinguishing between poorly and 
fair to well controlled diabetic dogs.
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Results
Fructosamine
Intra-assay coefficients of variation ranged from 0.83 to 2.26 % across the 4 levels of 
fiuctosamine concentration tested (Table 18) making the mean intra-assay CV 1.38 %. 
The inter-assay C’s of V assessed at two levels of fiuctosamine concentration were 3.11 
and 3.23 % (mean 3.17 %) and are given in Table 19.
low pool high pool 1 122739 high pool 2
Replicates 10 10 10 10
Mean 260.0 331.7 408.1 643.7
SD 3.77 7.50 4.12 5.31
CV%_________________ L45____________ 226_____________ IM _____________ 0.83
Table 18. Intra-assay coefficients of variation for 4 concentrations of fructosamine.
low pool high pool 1
Replicates 8 8
Mean 248.5 341.7
SD 8.0 10.6
CV%_________________ 323_____________3.11
Table 19. Inter-assay coefficients of variation for two concentrations of fructosamine.
The analyses of 20 samples of physiological saline yielded results with a mean of 2.85 
pmol/l and a standard deviation of 1.31 which, according to the recommendations of 
Buttner et al (1980) (mean + 2.6SD), creates a limit of detection for the fiuctosamine 
assay of 6.26 pmol/l.
The linearity of the method was excellent across the range 100 to 640 pmol/l with no 
obvious deviation even at the highest dilution of 1 in 8 (Figure 15).
There were no obvious trends in measured fiuctosamine concentration upwards or 
downwards as a result of progressive lipaemia at two levels of fiuctosamine 
concentration (Figure 16).
The maximum deviation from basal concentrations of fiuctosamine over 48 hours of 
storage of whole blood at room temperature was ± 3% (Figure 17).
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Fructosamine concentration umol/i
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Figure 15. Linearity of fructosamine method at 6 dilutions of a plasma pool of high fructosamine 
concentration.
Fructosamine concentration umol/1
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Figure 16. Effects of lipaemia on fructosamine concentration following the addition of Intralipid to 
two plasma pools.
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Percentage change in plasma fructosamine concentration
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Figure 17. Effects of short term storage of 4 samples of whole blood at room temperature on 
plasma fructosamine concentration (percentage change).
The reference range for plasma fructosamine concentration in non-diabetic dogs (mean ± 
2SD) was 162 to 310 pmol/1 (Table 20) based on results from 20 non-diabetic dogs.
Fructosamine concentration pmcl/l
278 219
303 180
259 212
285 172
225 196
213 260
287 216
233 256
200 267
223 243
Mean 236.4
SD 37.0
Mean + 2 SD 310.3
Mean - 2 SD 162.4
Table 20. Plasma fructosamine concentrations in 20 non-diabetic dogs.
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Glycated haemoglobin
The intra-assay coefficient of variation for glycated haemoglobin over the 4 levels tested 
ranged from 3.5 to 4.5 % (mean 3.84%) (Table 21). The mean inter-assay CV was 
7.31% and details of the two levels tested are given in Table 22.
___________________ non diabetic________ 115131___________122739__________ 113648
Replicates 10 5 10 5
Mean 3 4.4 6.42 9.11
SD 0.10 0.159 0.293 0.34
CV%__________________3 J_____________ 16______________4^ 5_____________ 3.76
Table 21. Intra-assay coefficients of variation for 4 concentrations of glycated haemoglobin.
non-diabetic 121228
Replicates 8 8
Mean 3.11 5.97
SD 0.25 0.38
CV%_________________ i n _____________ 6.49
Table 22. Inter-assay coefficients of variation for two concentrations of glycated haemoglobin.
There was no obvious trend in glycated haemoglobin concentration over three weeks of 
refrigerated storage of whole blood. At the higher initial concentration there was an 
apparent initial rise over the first week (Figure 18). The significance of this rise is 
difficult to ascertain.
The effects of sample haemolysis and storage at room temperature caused large 
fluctuations in measured glycated haemoglobin concentration. Only the concentration of 
glycated haemoglobin stored without haemolysis in a refrigerator remained stable over 
the two week study period (Figure 19).
The incubation of whole blood with high concentrations of glucose caused an increase in 
glycated haemoglobin concentration over a one week study period and this increase was 
greatest in those samples stored at 37 °C (Figure 20).
There was no significant correlation (p = 0.438) between concentrations of glycated 
haemoglobin measured by affinity chromatography and cation exchange chromatography 
(Figure 21) but there was good correlation between the affinity column and agarose gel 
electrophoresis methods (p = 0.005, r = 0.666, n = 16, Affinity = 1.77 + 0.588 
Electrophoresis) (Figure 22).
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Glycated haemoglobin concentration (%)
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Figure 18. Interassay CV and effects of 3 weeks refrigerated storage of whole blood samples on 
glycated haemoglobin concentration.
Glycated haemoglobin concentration
11
Nonhaem-F -^H aem -F ♦N onhaem -B  ~^Haem-B
10
9
8
7
6
5
10 126 a 14 160 2 4
Days
Figure 19. Changes in glycated haemoglobin concentration due to haemolysis and storage 
conditions (Haem - haemolysed, B - stored on laboratory bench, F - stored in a refrigerator).
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Percentage change in glycated haemoglobin concentration (%)
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Figure 20. Mean percentage change in glycated haemoglobin concentration in three samples 
incubated with an initial glucose concentration of approximately 27 mmol/1 and stored at either 
room temperature or 37°C.
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Figure 21. Comparison of glycated haemoglobin concentrations obtained using affinity column or 
cation exchange chromatography techniques.
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Figure 22. Comparison of glycated haemoglobin concentrations obtained using affinity column 
chromatography or agarose gel electrophoresis.
The choice of anticoagulant did not affect the assay. There was excellent correlation 
between results from lithium heparin and those from EDTA samples (p = 0.000, r = 
0.979, n = 9, EDTA = - 0.077 + 1.01 LH) and no significant difference between the 
results obtained (p = O.SS) (Figure 23).
The reference range for glycated haemoglobin concentration in non-diabetic dogs based 
on samples from 26 animals (mean ± 2SD) was 1.7 to 4.9% (Table 23).
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Glycated haemoglobin concentration (%)
3.48 3.88 2.91 3.39
3.39 4.26 3.99 3.37
3.69 5.09 2.71 3.61
3.11 2.85 2.88 5.48
3.23 1.75 3.12 2.18
3.18 3.24 2.33 2.83
3.02 3.13
Mean 3.31
SD 0.80
Mean + 2 SD 4.9
Mean - 2 SD 1.7
Table 23. Glycated haemoglobin concentrations in 26 non-diabetic dogs.
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Figure 23. Comparison of glycated haemoglobin concentrations by affinity column 
chromatography measured in samples containing EDTA or lithium heparin anticoagulant
Daily variation
The results of 24 hour profiles for plasma concentrations of alkaline phosphatase, alanine 
aminotransferase, glucose and fhictosamine in three dogs are presented in Appendix 10 
and represented in Figure 24 as mean percentage changes from basal concentrations. 
Sampling time had no significant effect on the plasma concentrations of alkaline 
phosphatase, alanine aminotransferase or fhictosamine but there was a significant effect
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of sampling time on plasma glucose concentrations (p = 0.039). As expected there were 
significant inter-dog differences in the concentrations of all of these analytes (p = 0.000).
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Figure 24. Mean percentage change from basal concentrations plasma concentrations of alkaline 
phosphatase, alanine aminotransferase, fructosamine and glucose in three diabetic dogs over 24 
hours.
Monitoring early diabetic therapy
There was a significant change in afternoon plasma glucose concentrations over the three 
early sampling periods (p = 0.000). Since the aim in diabetic stabilisation is to reduce this 
parameter into the ‘normal’ range this is not surprising. Newman-Keuls multiple range 
test revealed significant differences between Period A and Period B, and between Period 
A and Period C but not between Period B and C. The statistical picture was the same for 
fhictosamine (p = 0.000) and glycated haemoglobin (p = 0.000). There were no 
significant changes in alkaline phosphatase concentration (p = 0.134) nor in aspartate 
aminotransferase (p = 0.373). There was a significant change in alanine aminotransferase 
concentration (p = 0.028) by general linear model analysis but Newman-Keuls Multiple 
range testing revealed only close to significant differences between Periods A and B and 
between Periods B and C. The principal trend in the concentrations of afternoon glucose, 
fructosamine and glycated haemoglobin was downwards and this is represented 
graphically in Figures 25 to 27. However, the concentrations of alanine aminotransferase 
and (although not significantly) alkaline phosphatase appeared to rise in the early post
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stabilisation period. This is apparent in Figures 28 and 29 in which the concentrations of 
these analytes have been represented by percentages of their pretreatment concentrations 
because of their wide variation between dogs.
There was no significant correlation between the duration of polydipsia prior to diagnosis 
and the pre-treatment concentrations of any of alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase or glycated haemoglobin. However, there 
was a significant correlation for fructosamine concentration (p = 0.022, r = 0.43, n = 28, 
fiuc = 375 + 36.4 weeks) which is represented in Figure 30.
Afternoon plasma glucose concentration mmol/I
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Figure 25. Mean afternoon plasma glucose concentration (± SEM) in 20 dogs during sampling 
periods A, B and C.
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Plasma fructosamine concentration umol/l
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Figure 26. Mean fructosamine concentration (± SEM) in 20 dogs during sampling periods A, B and 
C.
Glycated haemoglobin concentration %
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Figure 27. Mean glycated haemoglobin concentration (± SEM) in 15 dogs during sampling periods 
A, B and C.
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Percentage of pretreatment plasma alanine aminotransferase concentration
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Figure 28. Mean percentage (± SEM) of pretreatment plasma alanine aminotransferase 
concentration in 20 dogs during sampling periods A, B and C.
Percentage of pretreatment plasma alkaline phosphatase concentration
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Figure 29. Mean percentage (± SEM) of pretreatment plasma alkaline phosphatase concentration 
in 20 dogs during sampling periods A, B and C.
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Plasma fructosamine concentration umol/l
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Figure 30. Pretreatment plasma fructosamine concentration versus duration of pretreatment 
polydipsia (shaded area is reference range 162 to 310 umol/l).
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Long-term diabetic monitoring
The results of many hundreds of follow-up examinations were coded according to the 
degree of glycaemic control believed to prevail at the time. The distribution of these 
observations for each analyte among the 7 glycaemic control groups along with the 
numbers of dogs from which these samples originated are detailed in Table 24.
There were significant differences between the 7 glycaemic control groups in the mean 
concentrations of nadir (afternoon) plasma glucose (p = 0.000), plasma alkaline 
phosphatase (0.005), plasma aspartate aminotransferase (p = 0.000) and between the 8 
groups in plasma fructosamine (p = 0.000) and glycated haemoglobin (p = 0.000). There 
were no significant differences in mean plasma alanine aminotransferase concentration 
between the glycaemic control groups. Results of Tukey’s family error rate multiple 
comparisons for nadir plasma glucose, alkaline phosphatase, aspartate aminotransferase, 
fructosamine and glycated haemoglobin are summarised in Tables 25 to 29.
Glycaemic control group
Aftemoon plasma glucose 74 53 163 193 261 8 18
(68) (34) (59) (64) (65) (4) (13)
Alkaline phosphatase 73 52 162 190 258 7 17
(66) (35) (59) (64) (65) (4) (13)
Alanine aminotransferase 74 52 153 180 253 7 17
(67) (35) (55) _ (63) (65) (4) _ (13)
Asparate aminotransferase 73 51 143 178 254 7 17
(67) (35) (54) (63) (64) (4)_ . (13)
Fructosamine 28 23 71 105 130 2 9
(27) (18) (33) (42) (37) (1) (7)
Glycated haemoglobin 18 21 66 92 124 2 8
(17) (17) (31) (38) (37) (1) (7)
Table 24. Numbers of observations of eacb analyte in eacb glycaemic control group with the 
number of dogs sampled in brackets.
There were significant differences in mean nadir glucose concentration between the 
untreated, very poorly and poorly controlled groups and all of the others except between 
the untreated and very poorly controlled groups. There were also differences between 
the fairly controlled group and the good and overdosed groups. There were no 
differences between the good control group and the excellent and overdose control 
groups. Figure 31 represents the plasma glucose concentrations in each of the glycaemic 
control groups.
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Glycaemic
control group
Table 25. Statistically significant (p < 0.05) differences between glycaemic control groups for nadir 
plasma glucose concentration (+ = significantly different between groups).
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Figure 31. Nadir plasma glucose concentrations (mmol/l) for 7 groups of glycaemic control (Group 
1 - untreated. Group 2 - very poor. Group 3 - poor. Group 4 - fair. Group 5 - good. Group 6 - 
excellent and Group 7 - insulin overdosage).
In the case of alkaline phosphatase concentrations, the untreated diabetic group had 
significantly higher mean concentration than those under poor, fair or good control but 
not those under excellent or excessive control. There were no differences between any of 
the treated diabetic groups. The wide variation in alkaline phosphatase concentrations is 
demonstrated graphically in Figure 32 in which the data have been plotted on a 
logarithmic scale and with means and standard error of the mean (SEM), rather than 
standard deviations (SD), because this variation was so extreme.
CHAPTERS 107
Glycaemic
control group
Table 26. Statistically significant (p < 0.05) differences between glycaemic control groups for 
plasma alkaline phosphatase concentration (+ = significantly different between groups).
Alkaline phosphatase U/l
100,000
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1,000
100
7 85 640 1 2 3
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Figure 32. Plasma alkaline phosphatase concentrations (U/l - logarithmic scale) for 7 groups of 
glycaemic control (Group 1 - untreated, Group 2 - very poor. Group 3 - poor. Group 4 - fair. 
Group S - good. Group 6 - excellent and Group 7 - insulin overdosage).
Mean aspartate aminotransferase concentrations were significantly higher for the 
untreated and very poorly controlled groups than for the poor, fair and good glycaemic 
control groups. There were no differences between the untreated and very poor control 
groups nor between any of the poor through to excessive control groups. The aspartate 
aminotranferase concentrations of all 7 glycaemic control groups are represented in 
Figure 33 along with the mean and SEM using a logarithmic scale because of the wide 
variation in concentration within groups.
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Glycaemic
control group
Table 27. Statistically significant (p < 0.05) differences between glycaemic control groups for 
aspartate aminotransferase concentration (+ = significantly different between groups).
Aspartate aminotransferase U/l
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Figure 33. Plasma aspartate aminotransferase concentrations (U/l - logarithmic scale) for 7 groups 
of glycaemic control (Group 1 - untreated, Group 2 - very poor, Group 3 - poor. Group 4 - fair, 
Group 5 - good. Group 6 - excellent and Group 7 - insulin overdosage).
Mean fhictosamine concentrations were significantly higher for the untreated and very 
poorly controlled groups than for the fair, good, excessive control and non-diabetic 
groups but there were no differences between the untreated, very poor and poor control 
groups. The mean fructosamine concentration was also greater for the poorly controlled 
group than for the fair, good, excessive control and non-diabetic groups and for the fair 
control group than for the good, excessive control and non-diabetic groups. The good 
glycaemic control group had a significantly greater mean fhictosamine concentration 
than the non-diabetic group but there was no difference between the non-diabetic groups 
and those results from those dogs under excessive diabetic control. There were no 
significant differences between the excellent glycaemic control group and any of the
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others because of the small number of observations. The fructosamine concentrations for 
the 7 glycaemic control groups are represented in Figure 34.
Glycaemic 1 2 3 4 5 6 7
control group 
2
3 - -
4
5
6 
7
(non-diabetic) 8
Table 28. Statistically significant (p < 0.05) differences between glycaemic control groups for 
plasma fructosamine concentration (+ = significantly different between groups).
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Figure 34. Plasma fructosamine concentrations (pmol/l) for 7 groups of glycaemic control; shaded 
area is reference range 162 to 310 pmol/l (Group 1 - untreated. Group 2 - very poor, Group 3 - 
poor, Group 4 - fair. Group 5 - good. Group 6 - excellent and Group 7 - insulin overdosage).
Mean glycated haemoglobin concentrations were greater for the untreated and very 
poorly controlled groups than for the fair, good, excessive control and non-diabetic 
groups. Additionally, in the untreated group mean glycated haemoglobin was greater 
than in the poorly controlled group. There were also significant differences in mean 
glycated haemoglobin concentration between the poorly and fairly controlled groups and 
the good, excessive control and non-diabetic groups. The good glycaemic control group
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had a higher mean glycated haemoglobin concentration than the non-diabetic group but 
there were no differences between good control and excessive control groups or between 
the excessive control and non-diabetic groups. There were no significant differences 
between the excellent control group and any of the others because of the small number of 
observations in this group. Glycated haemoglobin concentrations for all 7 groups are 
represented in Figure 35.
Glycaemic 
control group
1 2 3 4 5 6 7
2 -
3 4- -
4 + + -
5 + + +
o
7 + + + +
(non-diabetic) 8 + + + + + - -
Table 29. Statistically significant (p < O.OS) differences between glycaemic control groups for 
glycated haemoglobin concentration (+ = significantly different between groups).
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Figure 35. Glycated haemoglobin concentrations (%) for 7 groups of glycaemic control; shaded 
area is reference range 1.7 to 4.9% (Group 1 - untreated, Group 2 - very poor, Group 3 - poor. 
Group 4 - fair. Group 5 - good. Group 6 - excellent and Group 7 - insulin overdosage).
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There were no significant differences in mean alanine aminotransferase concentrations 
between the 7 glycaemic control groups. This is demonstrated in Figure 36.
Alanine aminotransferase U/l
10,000
□  + / - SEM ■& Mean ♦ Data
1,000
100
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1
82 3 4 6 70 1 5
Group
Figure 36. Plasma alanine aminotransferase concentrations (U/l - logarithmic scale) for 7 groups of 
glycaemic control (Group 1 - untreated, Group 2 - very poor, Group 3 - poor, Group 4 - fair, 
Group 5 - good. Group 6 - excellent and Group 7 - insulin overdosage).
The areas under the ROC curves (W) for nadir plasma glucose, plasma finctosamine and 
glycated haemoglobin concentrations were all significantly greater than 0.5, meaning that 
they were all useful tests for distinguishing between samples fi*om animals with very poor 
or poor glycaemic control and those from animals with fair, good or excellent control 
(Table 30). The nadir plasma glucose concentration test was superior to fiuctosamine 
and glycated haemoglobin concentrations, based on a higher area under the ROC curve. 
The areas under the ROC curves for alkaline phosphatase, alanine aminotransferase and 
alanine aminotransferase were not significantly different fi’om 0.5 (Table 30), meaning 
that these tests could not distinguish between the two groups of glycaemic control and 
were therefore worthless in this context. The ROC curves of nadir glucose, alkaline 
phosphatase, alanine aminotransferase, aspartate aminotransferase, finctosamine and 
glycated haemoglobin are represented in Figures 37 to 42, demonstrating the relative 
merits of these tests.
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Number of Number of Area under the p value
Analyte cut-off observations ROC curve (probability that
values (W) ± SE(W) W = 0.5)
Nadir glucose 230 678 0.956 ± 0.009 0.000*
Alkaline phosphatase 545 669 0.538 ±0.024 0.053
Alanine aminotransferase 236 645 0.512 ±0.025 0.319
Aspartate aminotransferase 102 633 0.508 ± 0.026 0.382
Fructosamine 217 331 0.780 ± 0.028 0.000*
Glycated haemoglobin 295 304 0.705 ± 0.032 0.000*
Table 30. Areas under the ROC curve for nadir glucose, alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, fructosamine and glycated haemoglobin including 
numbers of cut-off values and observations used.
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Figure 37. ROC curve for nadir glucose concentration in distinguishing between very poor or poor 
glycaemic control and fair, good or excellent glycaemic control.
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Figure 38. ROC curve for plasma alkaline phosphatase concentration in distinguishing between 
very poor or poor glycaemic control and fair, good or excellent glycaemic control
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Figure 39. ROC curve for plasma alanine aminotransferase concentration in distinguishing 
between very poor or poor glycaemic control and fair, good or excellent glycaemic control
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Figure 40. ROC curve for plasma aspartate aminotransferase concentration in distinguishing 
between very poor or poor glycaemic control and fair, good or excellent glycaemic control
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Figure 41. ROC curve for plasma fructosamine concentration in distinguishing between very poor 
or poor glycaemic control and fair, good or excellent glycaemic control
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Figure 42. ROC curve for glycated haemoglobin concentration in distinguishing between very poor 
or poor glycaemic control and fair, good or excellent glycaemic control
Differential positive rates were calculated for nadir plasma glucose, fructosamine and 
glycated haemoglobin because these were the tests determined by the ROC curves to be 
the most useful. The optimal cut-off values for deciding between very poor or poor 
glycaemic control and fair, good or excellent glycaemic control were 11.0 mmol/l, 
435 pmol/1 and 6.13%, respectively, for nadir glucose, fructosamine and glycated 
haemoglobin. These values along with the associated DPR’s are given in Table 31. The 
DPR curves for each of the three useful analytes are represented in Figures 43 to 45.
Analyte
Nadir glucose 
Fructosamine 
Glycated haemoglobin
Maximum DPR
0.853
0.470
0.352
Cut-off value
11.0 mmol/l 
435 (jmol/1 
6.13%
Table 31. Maximum differential positive rates (DPR) and associated cut-off values for nadir 
glucose, fructosamine and glycated haemoglobin when used for distinguishing between very poor 
or poor glycaemic control and fair, good or excellent glycaemic control
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Differential positive rate
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Figure 43. DifTerential positive rate curve for nadir plasma glucose when used for distinguishing 
between very poor or poor and fair, good or excellent glycaemic control (maximum DPR is 0.853 at 
11.0 mmol/l).
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Figure 44. Differential positive rate curve for fructosamine concentration when used for 
distinguishing between very poor or poor and fair, good or excellent glycaemic control (maximum 
DPR is 0.470 at 435 pmol/1).
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Differential positive rate
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Figure 45. Differential positive rate curve for glycated haemoglobin when used for distinguishing 
between very poor or poor and fair, good or excellent glycaemic control (maximum DPR is 0.352 at 
6.13 %).
Discussion
The validity of laboratory methods for the measurement of finctosamine and glycated 
haemoglobin in canine samples was studied along with the potential use of plasma 
concentrations of afternoon glucose, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, finctosamine and concentrations of glycated haemoglobin as 
indicators of glycaemic control, including the early effects of diabetic stabilisation on the 
concentration of these analytes.
The fhictosamine assay was accurate (as assessed by linearity), precise (mean intra and 
inter-assay CV’s 1.38 and 3.17 respectively) and sensitive (limit of detection 6.26 
|4mol/l) when applied to canine plasma samples. The performance of the assay was not 
affected by significant lipaemia and fhictosamine was stable in whole blood at room 
temperature for at least 48 hours.
The glycated haemoglobin assay was less precise than the fructosamine assay (mean intra 
and inter-assay CV’s 3.84 and 7.31 respectively) in keeping with the manual nature of 
the test. Glycated haemoglobin was stable in whole blood at 4 °C for at least three weeks 
but storage of haemolysed samples or samples at room temperature greatly affected test
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results. Incubation of whole blood with high concentrations of glucose at 37 ®C resulted 
in a dramatic increase in glycated haemoglobin within one week. When the affinity 
chromatography method was compared to others it was discovered that cation exchange 
chromatography appeared to be an inappropriate test for canine glycated haemoglobin 
but that agarose gel electrophoresis might be an acceptable alternative. The choice of 
anticoagulant between lithium heparin and EDTA had no effect on the results of the test.
The concentrations of alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase and fructosamine did not vary over 24 hours in contrast to marked 
fluctuations in plasma glucose over the same time period in insulin treated diabetic dogs. 
During the early post-stabilisation period, concentrations of afternoon glucose, 
fructosamine and glycated haemoglobin were reduced by therapy but the plasma 
concentrations of alkaline phosphatase and alanine aminotransferase increased. The 
duration of clinical signs of diabetes prior to presentation for treatment was not related 
to the severity of abnormality in the pre-treatment concentrations of glucose, alkaline 
phosphatase, alanine aminotransferase, aspartate aminotransferase or glycated 
haemoglobin but was related to the pre-treatment concentration of fructosamine.
Afternoon plasma glucose, fiuctosamine and glycated haemoglobin were determined to 
be useful tests in the long term monitoring of canine diabetes mellitus both by 
comparison of mean concentrations between glycaemic control groups and ROC curve 
analysis. However, alkaline phosphatase, alanine aminotransferase and aspartate 
aminotransferase were shown to be worthless tests for long term diabetic monitoring 
although there was a significantly higher mean concentration of alkaline phosphatase in 
samples from untreated diabetic dogs than in samples from diabetic dogs under poor to 
good glycaemic control and significantly higher mean concentrations of aspartate 
aminotransferase in samples from untreated and very poorly controlled diabetic dogs 
than in those from dogs under poor to good control. These statistically significant 
differences would be irrelevant clinically because of the wide range of alkaline 
phosphatase and aspartate aminotransferase concentrations within each glycaemic 
control group.
The results of this study show that fhictosamine and glycated haemoglobin assays are 
valid and useful tests in the monitoring of canine diabetes mellitus and that the ‘liver 
enzymes’ - alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase 
- have no role in this context.
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The results of this study compare very favourably with previously published reports of 
the precision of the fructosamine assay used for both human and animal samples. Kruse- 
Jarres et al (1989) reported the range of C’sV obtained by 12 analytical laboratories 
using three human serum pools across a range of fructosamine concentrations (200 to 
500 pmol/l) as 0.5 to 3.0 and 0.9 to 4.8 for intra and inter-assay C’sV respectively. Sobel 
and Abbassi (1991) reported intra and inter-assay C’sV of 3.1 and 4.5 % when the assay 
was used on a similar analyser to the present study to measure fructosamine in diabetic 
children. In dogs, Kawamoto et al (1992) reported mean intra and inter-assay C’sV of 
5.6 and 5.7 using a manual adaptation of the method. Jensen (1992), using a similar 
autoanalyser method to the one in the present study was only able to achieve a mean 
intra assay CV of 3.5% despite analysing 30 replicates. The mean inter-assay CV 
achieved by his method was better than in the present study at 3 %. Reusch et al (1993) 
reported intra and inter-assay C’sV of 2.4 and 3.4 %, respectively, using an autoanalyser 
method and these are also very similar to the results of the present study. The present 
study was also in agreement with Kruse-Jarres et al (1989) findings in human serum of 
no interference by lipaemia (up to triglyceride concentrations of at least 25 mmol/), that 
the method was linear (up to 1000 pmoI/1 in their study) and that the limit of detection of 
the assay was 7 pmol/l). Only Jensen (1992) has previously reported the linearity and 
limit of detection of the fiuctosamine assay in dog samples and he suggested that there 
were some problems with linearity in his laboratory and that the limit of detection was 
9.11 |imol/l. There are no previous reports of the effect of lipaemia on fructosamine 
measurement in canine samples. In the present study the fiuctosamine assay performed 
well and was improved upon when compared with previously published reports of its use 
for canine samples.
Jensen (1992) and Reusch et al (1993) demonstrated that fiuctosamine was stable in 
serum at 4 and 25°C for 5 days, and the present study shows that it is stable in whole 
blood at room temperature for sufficient time to transport samples to the laboratory even 
by post. The canine reference range for fiuctosamine of this study is similar to that 
published by Kawamoto et al (1992) of 170 to 338 jimol/l but slightly lower than that 
published by Jensen and Aaes (1992) of 258 to 343pmol/l and that of Reusch et al 
(1993) o f249 to 374 ^mol/l using 29 and 48 dogs, respectively.
There are no previous reports of the use of mini affinity chromatography columns for the 
measurement of glycated haemoglobin in dog samples with which to compare the 
performance of the assay used in this study. The manufacturers of the assay used suggest 
that a mean intra-assay CV of 2.4 % can be obtained in human samples using their Idt 
and independent reports cited by Kennedy (1992) agree that C’Vs of between 2.0 and
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2.6% have been achieved in human samples using affinity chromatography methods. The 
Idt manufacturer also claims a mean inter-assay CV of 2.9% but this is based on very 
large numbers of replicate samples (n = 14 to 45) and it is unwise to make a comparison 
with a precision study using only 8 replicate analyses. Kggins et al (1982), using a 
different affinity chromatography method for canine samples, reported the results of only 
two analyses and precision was not investigated. The assay used in the present study was 
clearly more precise than the colorimetric method of Smith et al (1982), when used in 
canine samples, which had a mean intra assay CV of 9.9%. The precision of the cation 
exchange methods used by Wood and Smith (1980) and Mahafifrey and Cornelius (1982) 
were not reported.
The importance of a long-term storage study for glycated haemoglobin was greater than 
for fructosamine because the manual nature of the glycated haemoglobin method meant 
that it was most suited to batch analysis. The findings of this study concur with the 
recommendations of the kit manufacturer, that accurate test results can be obtained from 
refrigerated human blood samples for up to 15 days after collection and that storage of 
samples at room temperature for more than 12 hours can cause erratic results. Again, 
there are no previous detailed reports of affinity chromatography methods applied to 
canine samples with which to compare this data. The study in which whole blood was 
incubated at a high glucose concentration confirmed that glycated haemoglobin was the 
product being measured by the affinity chromatography method and that the production 
of glycated haemoglobin is temperature dependent as reported by Dolhofer, Stadele and 
Wieland (1977) (cited by Kennedy, 1992). In addition, this part of the study suggested 
that an increase in glycated haemoglobin concentration could be expected within one 
week of clinical hyperglycaemia although the change in vivo would be less dramatic 
because of the contribution of new haemoglobin constantly being introduced to the 
circulating pool.
The use of cation exchange chromatography for glycated haemoglobin measurement in 
canine samples was inappropriate, based on the trial of one commercially available kit. 
This is not surprising since the structure and ionic properties of the principal glycated 
haemoglobins of the dog are not known. To improve separation of the glycated and non­
glycated components with this kind of methodology would involve adjusting buffer pH 
on a trial and error basis to discover that most suited to canine haemoglobin. It seems 
imprudent to make in-house modifications to a relatively expensive commercial assay 
when there are more appropriate and less expensive methods available. Higgins et al 
(1982) utilised three different pH buffers for a cation exchange method in 6 species but 
interestingly, in the light of the findings in the present study, the same pH for human and
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canine samples was chosen. Agarose gel electrophoresis gave comparable results to the 
affinity column method but each gel has 10 tracks, making the requirement to batch 
samples greater for cost effectiveness. This approach is, however, compromised by the 
much shorter stability of samples destined for this type of analysis. In addition, the 
accurate measurement of very small concentrations of glycated haemoglobin in normal 
dogs was difficult even at 500% magnification of the densitometric scan.
The excellent correlation between lithium heparin and EDTA samples means that a single 
whole blood sample can be submitted to the analytical laboratory for analyses of both 
fiuctosamine and glycated haemoglobin along with the ‘routine’ plasma biochemical 
analyses.
The use of an affinity chromatography method for canine glycated haemoglobin seems 
more appropriate than the other methods investigated in this study. Kennedy (1992) 
proposed that this method will become the most popular for the measurement of human 
glycated haemoglobin because of its high degree of specificity and reproducibility. Even 
as long ago as 1982, Higgins et al were very impressed by the power and versatility of 
this technique, particularly in relation to the measurement of glycated haemoglobin in 
animal samples.
Although it has been recognised that the ‘liver’ - enzymes alkaline phosphatase, alanine 
aminotransferase and aspartate aminotransferase - are elevated in untreated and unstable 
diabetic dogs (Chastain and Ganjam, 1986b; Nelson 1989a), reports of the effects of 
stabilisation on the 24 hour profile of these enzymes are extremely difficult to find. The 
finding of increased alanine aminotransferase and possibly alkaline phosphatase activity in 
the early post-stabilisation period is unexpected. It suggests that stabilisation itself is a 
form of hepatic insult. Such an insult may be a consequence of the sudden turnaround in 
hepatic metabolism which must occur following the institution of insulin therapy in 
previously untreated diabetic dogs. Certainly, this study has shown that the measurement 
of plasma concentrations of alanine aminotransferase or alkaline phosphatase in the early 
post-stabilisation period should not be used to make judgements concerning the progress 
of therapy. Reductions in fiuctosamine and glycated haemoglobin concentrations in a 
manner mirroring glucose concentrations following diabetic stabilisation or improved 
control have been reported in human medicine (Dolhofer and Weiland, 1980; Ce&lu et 
a/, 1988; Sobel and Abbassi, 1991) and similar reduction in fiuctosamine has previously 
been reported in diabetic dogs by Reusch et al (1993), but there are no reports on the 
effect of stabilisation on canine glycated haemoglobin concentrations.
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The fact that fructosamine concentration can be within the reference range in untreated 
diabetic dogs was also noted by Reusch et al (1993) who cited the example of two dogs 
with short duration of clinical signs. This is not a surprising finding considering the rate 
of the glycation reaction and the half life of plasma proteins. There was a similar but not 
statistically significant trend in the relationship between glycated haemoglobin and 
duration of clinical signs. One dog, presented after one week of overt clinical signs, had a 
glycated haemoglobin result which fell within the reference range but all dogs presenting 
after two weeks of clinical signs had glycated haemoglobin concentrations outwith that 
range. Plasma concentrations of glucose, alkaline phosphatase, alanine aminotransferase 
and aspartate aminotransferase in untreated diabetics cannot be used to assess the 
duration or severity of the condition based on the results of this study.
A comparison between the biochemical characteristics of different groups of glycaemic 
control in diabetic dogs has not previously been reported (except by Reusch et al (1993) 
for fiuctosamine). Such a comparison highlights the potential benefits of fiuctosamine 
and glycated haemoglobin analyses in canine diabetic monitoring and was usefiil as a 
preliminary investigation prior to embarking on more sophisticated evaluative techniques.
The use of ROC curves to determine the usefulness of a laboratory test have only rarely 
been used in veterinary medicine (White et a/, 1986; McNab et a/, 1991; Jensen and 
Poulsen 1992; Jensen, 1993). In this study the ‘near perfect test result’ of the ROC curve 
analysis of afternoon (nadir) plasma glucose concentration in the differentiation of poor 
and fair to excellent control must be interpreted with caution because the allocation of 
observations to glycaemic control groups was not independent of this result. However, 
even although the contribution of the afternoon glucose concentration to the estimation 
of glycaemic control was great, it still allowed the creation of a benchmark (if not 
perfect) test by which the usefulness of the other analytes could be compared to one 
another. It is likely that fiuctosamine is a much more accurate test in determining the 
degree of glycaemic control than a single estimate of blood glucose (Kennedy, 1992; 
Reusch et al, 1993) and that fiuctosamine concentrations would have been a much more 
representative classification method for glycaemic control. However, in assessing the 
performance of the ‘new’ tests (fiuctosamine and glycated haemoglobin) it was 
important to have a method of classification independent of those tests and the choice of 
afternoon plasma glucose as the benchmark test was not expected to affect the 
comparison between them. The ideal cut-off point for afternoon glucose concentration of 
11.0 mmol/l fits well with clinical practice and is not surprising considering the 
contribution of this value in the classification system used. Jensen (1993) used an ROC 
curve method to determine that the upper limit of his reference range was an ideal cut-off
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value for fructosamine concentration when used as in the diagnosis of canine diabetes 
mellitus. Also, using an ROC curve method, that study suggested that there was no 
advantage to making protein or albumin-corrected fiuctosamine concentrations for 
diagnostic purposes. Reusch et al (1993) grouped observations of fiuctosamine 
concentration from treated diabetic dogs into those with fully satisfactory glycaemic 
control, moderately satisfactory glycaemic control and poor glycaemic control, based on 
fasting blood glucose concentrations, and suggested a cut-off value of 400 timol/1 to 
differentiate between dogs with satisfactory control and those under insufficient control. 
Interestingly, this value is not dissimilar to the cut-off value of 435 ^unol/l suggested by 
the present study for differentiation of poor control and those with some degree of 
glycaemic control. There are no previous reports of a suggested cut-off value for 
glycated haemoglobin in the differentiation of poor and good glycaemic control in treated 
diabetic dogs.
In conclusion, the ‘new’ tests fiuctosamine and glycated haemoglobin are valid \^ e n  
applied to canine samples within the University of Glasgow Veterinary School and are 
useful tests in monitoring diabetes mellitus in dogs. Alkaline phosphatase, alanine 
aminotransferase and aspartate aminotransferase have no role in monitoring therapy in 
diabetic dogs despite the common finding of elevated concentrations of these en^mes in 
the plasma of untreated and unstable diabetic dogs.
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Chapter 6: 
Pharmacokinetics and efficacy of a mixed 
insuiin zinc suspension 
Part I: Pharmacokinetics 
Introduction
Insulin is a large peptide with a molecular weight of around 5800 which consists of an a  
and a P chain connected by two disulphide bridges. It is formed by the removal of a 
connecting peptide (C-peptide) from between the two chains of its precursor molecule 
pro-insulin. Peptides are digested in the intestinal tract, so insulin cannot be administered 
orally and the large size of insulin prevents trans-mucosal administration, leaving 
injection as the only feasible insulin delivery route. However, unmodified insulin has only 
a very short half life (Laurence and Bennett, 1987) and many repeated injections or 
continuous infusion would be necessary for therapeutic effect. Since the discovery of 
insulin and its subsequent purification for use as a therapeutic product, many attempts 
have been made to prolong the duration of action of insulin preparations (Home and 
Alberti, 1992). This has resulted in three main types of prolonged action insulin 
preparations: isophane (NPH), lente (insulin zinc suspension) and protamine zinc insulin 
(PZI).
Protamine zinc and isophane insulin preparations have a longer duration of activity when 
administered subcutaneously because insulin has been combined with the basic protein 
protamine. Protamine is found in large quantities in fish sperm nuclei and it has a smooth 
sheet like structure which is poorly immunogenic. Insulin-protaminate complexes are 
acted upon by tissue proteinases causing insulin to be released slowly. Protamine zinc 
insulin contains a greater proportion of protamine than isophane to slow absorption 
further and zinc which may inhibit the action of tissue proteinases (Home and Alberti,
1992).
Insulin zinc suspensions have prolonged activity because of the reduced solubility of 
insulin in the presence of large concentrations of zinc (Home and Alberti, 1992). By 
altering the pH at which insulin zinc precipitates are formed, insulin preparations with 
differing properties can be generated. Ultralente insulin is a crystalline form which is first
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generated at a pH of 5.5 and is then adjusted to a pH of 7.4. This process alters the 
crystalline structure of the zinc-insulin and creates a preparation which is absorbed very 
slowly from subcutaneous sites. Semilente insulin is an amorphous zinc-insulin 
precipitate formed between insulin and excess zinc at a pH of 7.4 when there is no initial 
crystallisation stage. Semilente insulin is much more rapidly absorbed from subcutaneous 
sites and 'lente' insulin preparations are a mixture of 30% amorphous semilente and 70% 
crystalline ultralente and are therefore mixed insulin zinc suspensions (Feldman and 
Nelson, 1987; Home and Alberti, 1992).
In human diabetic medicine there is a noticeable difference in duration of modified insulin 
preparations which is dependent on the species of origin of the insulitL Bovine insulin is 
more slowly absorbed and is more immunogenic than either porcine or genetically 
engineered human insulins which differ from one another by only one amino-acid residue 
at the end of the P chain (B30) (Home and Alberti, 1992).
The intermediate duration types, isophane (NPH) and mixed insulin zinc suspenâon 
(lente) are the most commonly used in the management of canine diabetes mellitus. Data 
are available on the absorption kinetics of isophane insulin in the normal dog (Goeders et 
al 1987) but not for the lente group. Previous studies of the peak and duration of activity 
of porcine mixed insulin zinc suspension (IZS-P) were based solely on plasma glucose 
responses (Church 1981).
The aim of this study was to determine the times of peak and duration of activity for an 
IZS-P (Caninsulin; Intervet UK) in dogs with naturally-occurring diabetes mellitus by 
serial measurement of plasma insulin concentrations following injection.
Materials and methods 
Dogs
Ten dogs of varying breed with naturally-occurring diabetes mellitus, referred for 
diabetic stabilisation, were included in the study. Individual animal details are 
summarised in Table 32. Three of the 5 females and two of the 5 males had been 
neutered. The average age was 8.6 years (SD 2.7; range 5-12 years) and average body 
weight was 16.25 kg (SD 11.9; range 5.5-41.5). For the purposes of this study and the 
subsequent efBcacy study, dogs were assigned a trial number in addition to their hospital 
number. Dogs are referred to by their trial number throughout this chapter.
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Dog
No.
Hospital
number
Breed Bweight
(kg)
Age
(years)
Sex
03 113648 Scottish terrier 10.0 5 M
04 109126 West Ihghland White terrier 10.5 12 MN
05 111513 Labrador X 14.0 12 FN
06 114460 Dobermann 31.0 7 F
07 114653 Spaniel X 24.0 11 F
08 114695 Terrier X 10.5 9 FN
09 115009 Dachshund 5.5 10 FN
014 115678 Rottweiler 41.5 5 M
018 116594 Oaim terrier 10.3 6 M
019 116744 Miniature Poodle 6.3 9 MN
126
Table 32. Details of dogs included in the insulin pharmacokinetic study (M: male, F: female, N: 
neutered).
Management
During stabilisation of their diabetic state, all animals received a diet consisting of 
commercial canned food and bread or biscuit divided evenly into two meals. One meal 
was fed at the time of a single daily insulin injection and the other 7.5 to 8 hours later. 
The diet fed was based on 40-80 kcal/kg depending on a subjective assessment of size 
and body condition. Insulin dosages were adjusted according to the previous afternoon 
plasma glucose concentrations.
On the morning of the pharmacokinetic study, each dog received a subcutaneous 
injection of IZS-P at a dose according to individual expected requirement and was 
offered the morning meal. The afternoon meal was fed 7.5 hours later. Immediately prior 
to the insulin injection and at two hourly intervals over the following 24 hour period 
blood samples were obtained by jugular venepuncture and aliquots transferred into 
fluoride/oxalate and lithium heparin coated containers (Sarstedt). All samples were 
centrifuged immediately and plasma drawn into plastic containers. The fluoride/oxalate 
plasma samples were stored at 4°C until analysis at the end of the 24 hour study period 
and the lithium heparin plasma samples were stored at -20^C.
The clinical condition of each animal was carefully monitored and particular attention 
was paid to any changes in attitude or demeanour suggestive of hypoglycaemia or 
adverse reaction.
Laboratory analyses
Plasma glucose analyses were carried out using a glucose hexokinase method (Roche) 
with a Cobas Mira analyser (mean intra-assay coefficient of variation 3.4 per cent).
CHAPTER 6 127
Plasma insulin analyses were performed using a commercial solid phase 
radioimmunoassay kit (Coat-a-Count® Insulin; Diagnostic Products Corporation). The 
mean intra-assay coefficient of variation for the insulin assay was 6.8 per cent. Recovery 
of known amounts of porcine insulin (Velosulin; Novo Nordisk) added to a plasma pool 
of low insulin concentration was between 90 and 120 per cent. Dilutional parallelism of 
this kit was also good.
Derivation of results
Plasma insulin versus time curves were examined visually to identify times of peak insulin 
concentration.
Persistence, i.e., the time taken for plasma insulin concentration to return to its pre- 
injection level was estimated as the sample time preceding the first one at which plasma 
insulin concentration was within 15% of the preinjection concentration or lowest assay 
standard. Persistence greater than 24 hours (dogs C3 and C l4) was arbitrarily designated 
a value of 24 hours.
Plasma insulin concentrations were converted to incremental values by subtraction of the 
lowest plasma insulin concentration for each dog and areas under the plasma 
concentration versus time curves (AUC) for insulin were calculated using the trapezoidal 
rule. Mean residence times (MRT) calculated fi'om the area under the moment curves 
(AUMC or AUC x /) are commonly used measures of the persistence of a drug within 
the body when that drug is administered as a bolus and its disposition is by first order 
kinetics. When the absorption of a drug follows first order kinetics, the rate of its 
absorption is proportional to its concentration and its fi-actional absorption rate is 
constant. These processes can be described using a half life value which will be constant 
at all concentrations of the drug. In zero order or rate limited processes the rate of 
absorption is constant regardless of the concentration of the drug. In absorption kinetics, 
if the percentage of dose of a drug remaining to be absorbed is plotted against time on a 
plain (Cartesian) graph, zero order absorption is represented by a straight line and first 
order absorption by a progressively decreasing gradient with time. On a semilogarithmic 
plot, first order absorption processes are represented by a straight line and zero order by 
a progressively increasing gradient (Rowland and Tozer, 1989).
In a first order process, the MRT (AUMC/AUC) is equivalent to the time taken to 
eliminate 63.2 per cent of a given dose and in zero order processes it is the time taken to 
eliminate 50 per cent. Examination of the percentage remaining to be absorbed versus
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time curves generated from the AUC data showed that the absorption and elimination of 
IZS-P did not follow first or zero order kinetics (Figures 46 and 47) and so MRT was 
not calculated.
Percentage remaining to be absorbed
100
12
Hours
16 20 24
Figure 46. Plain (Cartesian) plot of percentage of IZS-P remaining to be absorbed versus time 
(based on area under the mean percentage of maximum plasma insulin concentration curve).
Percentage remaining to be absorbed
100
0 244 8 12 16 20
Hours
Figure 47. Semilogarithmic plot of percentage of IZS-P remaining to be absorbed versus time 
(based on area under the mean percentage of maximum plasma insulin concentration curve).
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For the purposes of comparison with other preparations an equivalent residence time 
(RT63.2, i e., approximate time taken for absorption of 63.2 per cent of dose) was 
calculated from the percentage remaining to be absorbed versus time curves. Because of 
the short half life of insulin, residence time would have been mostly dependent on 
absorption time.
To allow the graphical representation of the mean insulin absorption curve, the variation 
in dose administered was compensated for by transforming plasma insulin concentrations 
into percentages of the maximum plasma insulin concentration reached in each dog. 
Plasma glucose concentrations were manipulated in the same way to allow a mean 
glucose response curve to be generated.
R e s u l t s
Plasma insulin concentrations following injection are given in Table 33 and represented 
in Figure 48. In all dogs there was an initial peak in plasma insulin concentration between 
2 and 6 hours (mean 4.3 +/- SD 1.3) post-injection (Table 34). As expected, peak plasma 
concentration of insulin varied between dogs (mean 150pIU/ml +/- SD 64.5; range 85- 
288) because each dog received a different dose (Table 34). In dogs nos. C3, C14, C18 
and C l9, the plasma concentration of plasma insulin peaked again after the second meal, 
in another (no. C4), there were two further peaks of plasma insulin at 8 hours and at 
around 12 hours. In dogs nos. C14, C18 and C19 the second peak was the greater of the 
two. In three dogs (nos. C6, C7 and C8) the rate of reduction in plasma insulin 
concentration appeared less around the time of and for up to three hours after the second 
meal, forming a * shoulder* to the plasma insulin curve. When present, the second peak or 
‘shoulder* in insulin concentration occurred at 11 hours (mean 11 +/- SD 1.85; range 8- 
14) post-injection (Table 34). Values for Persistence, AUC and RT63.2 are given in 
Table 34. Persistence ranged between 14 hours and 24 hours (mean 17.4 +/- SD 3.65) 
(Table 34).
The mean insulin absorption curve, based on plasma insulin concentrations transformed 
into percentages of maximum concentration is represented graphically in Figure 49.
There were statistically significant correlations (Pearson*s r, p < 0.05) between the time 
of the second peak and AUC and R T 6 3 .2 ; between AUC and Persistence and R T 6 3 .2  
and between Persistence and R T 63 .2 - There were no statistically significant correlations 
between insulin dose (lU/kg) and any of AUC, Persistence or R T 63 .2 -
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Hours post- 
mjection
Dog
C3 C4 C5 C6 C7 C8 C9 C14 C18 C19
0 5 44 3 11 45 14 7 27 9 23
2 154 109 70 43 137 170 65 81 85 85
4 155 288 85 91 183 171 71 148 77 98
6 91 81 57 51 148 187 92 122 35 100
8 79 126 41 49 131 107 44 127 41 97
10 99 83 37 34 117 99 25 102 35 80
12 88 180 29 31 62 41 17 115 100 130
14 80 110 16 20 60 27 9 194 22 96
16 54 82 9 15 65 18 5 111 16 21
18 25 54 3 11 47 16 7 109 7 5
20 16 38 3 6 57 17 4 80 6 0
22 15 25 0 8 50 16 7 86 0 3
24 9 15 0 8 53 13 6 91 8 0
Table 33. Plasma concentrations of insulin (plU/ml) following subcutaneous injection of IZS-P in 
10 dogs with naturally-occurring diabetes mellitus.
Dog
No.
Dose
OU/kg)
1st Peak 
(hours)
2nd Peak 
(hours)
AU.C.
(lUhr/ml)
Persistence
(hours)
RT63.2
(hours)
C3 2.80 3 10 1606 24 10.03
C4 2.47 4 12 2051 18 10.95
C5 1.35 4 - 703 16 7.51
C6 1.16 4 8S 593 16 7.83
C7 2.41 4 10® 1132 16 7.61
C8 1.61 6 lOS 1453 16 6.84
C9 2.10 6 - 609 14 6.59
C14 1.01 4 14 2020 24 14.34
C18 1.56 2 12 865 16 10.39
C19 2.56 6 12 1453 14 10.52
Table 34. Insulin dose, times of peak concentration, area under plasma insulin versus time curve 
(AUQ, persistence and residence time of 63.2 per cent of dose (R T g j^  in 10 dogs with naturally- 
occurring diabetes mellitus following subcutaneous injection of IZS-P.
* Denotes 'shoulder* rather than distinct peak
The plasma glucose responses to injection of IZS-P are represented in Figure 48. Plasma 
glucose concentration were reduced in all animals following injection of IZS-P. In 5 dogs 
(nos. C3, C6-C9), this decrease continued only to the feeding of the second meal, after 
which plasma glucose concentration continued to rise to preinjection concentrations or 
higher. In two dogs (nos. C5, C l8), plasma glucose was dramatically reduced following 
injection and remained at a low level (<5mmol/l) between 4 and 18 hours despite the 
feeding of a second meal. In another dog (no. 04), plasma glucose was also low 
(<5mmol/l) between 4 and 24 hours post-injection with only a transient increase in 
response to the second meal. In dog no. 019, plasma glucose concentration fell after an 
initial post prandial peak and remained at an acceptable level until 18 hours post 
injection. A similar effect was seen in dog no. 014 but with a further post prandial peak 
after the second meal. The mean glucose response curve is represented in Figure 50.
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Percentage of maximum plasma insulin concentration
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Figure 49. Mean percentage of maximum plasma insulin concentration reached following 
subcutaneous injection of IZS-P in 10 dogs (±SEM).
Percent of maximum plasma glucose concentration
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Figure SO. Mean percentage of maximum plasma glucose concentration reached following 
subcutaneous injection of IZS-P in 10 dogs (±SEM).
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Discussion
In this study, porcine insulin zinc suspension had two peaks of activity following 
subcutaneous administration (the first at around 4 hours and the second at around 11 
hours) and a duration of activity of between 14 and 24 hours.
The secondary peaks in plasma insulin concentration seen in dogs nos. C3, C14, CIS and 
C19 and the * shoulders' created by the slower rate of decrease of plasma insulin in dogs 
nos. C6, C7 and C8 are likely to represent the absorption of the crystalline component of 
the zinc insulin suspension. Alternatively, they could represent endogenous insulin 
release in response to feeding (as would be seen in normal dogs under the same feeding 
schedule). However, the presence of exogenous insulin and some degree of 
hypoglycaemia might be expected to suppress endogenous insulin release, thus rendering 
this explanation less likely.
The area under the plasma insulin versus time curve results did not correlate directly with 
insulin dose (lU/kg) administered. This is likely to be the result of the variation between 
dogs with regard to age, sex, breed, body condition, endogenous insulin production and 
endogenous insulin response to feeding since it is known, or can be assumed, that these 
were not constant between dogs. It is, however, apparent that IZS-P is well absorbed 
following subcutaneous injection in naturally-occurring diabetic dogs.
It could be argued that, all dogs should have received the same dose of insulin or perhaps 
have been starved. However, it was considered of greater practical value to assess the 
effects of IZS-P under the conditions for which it was designed, i.e., in naturally- 
occurring diabetic dogs receiving the particular dose of insulin required and a calculated 
ration of food at the recommended times post-injection. Moreover, this study was 
performed during the normal clinical management of these dogs and was designed so as 
not to interfere with the progress of their treatment.
In the 10 dogs studied, the time of the initial peak plasma insulin concentration and the 
time of the second peak (when present) have a much narrower distribution than that 
previously reported for peak activities of lente insulins in dogs. Feldman and Nelson 
(1987) suggested a wide range of peak activity of lente and IZS-P of 2-10 hours, but 
these values were based on plasma glucose concentrations and not insulin 
concentrations. The wide range was probably due to the fact that mixed insulin zinc 
suspensions should have two peaks of activity and that these were regarded as one.
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Church (1981) reported a range of 4-8 hours for peak activity of IZS-P in diabetic dogs, 
also based on plasma glucose concentrations. Contrary to the impression given 
previously, the narrow distribution of times of peak plasma insulin concentration in the 
present study indicates that the timings of peak activities for IZS-P are reasonably 
predictable. There are obvious clinical benefits of this feature of the pharmacokinetics of 
IZS-P.
The relatively wide range in duration of activity of 14 to 24 hours is similar to the 8-20 
hours reported by Church (1981) and suggests that in some dogs this insulin preparation 
would be most useful when administered twice daily.
The choice of a porcine insulin preparation for use in dogs may have some benefits 
principally because it is antigenically identical to canine insulin (Smith, 1966). In the dog, 
exogenous insulin therapy using purified porcine insulin preparations has induced less 
immunological response than using insulins of bovine or mixed origin (Feldman et cd 
1983), reducing the chances of immunological interference or of unpredictable release of 
insulin fi*om insulin/antibody complexes (Bolli et al 1984). However, the presence of 
antibodies to exogenous insulin could be advantageous because they may prolong the 
duration of action of the preparation and prevent sudden fluctuations in plasma insulin 
concentrations by the creation of an 'insulin reservoir’ (Bolli et a/, 1984; Feldman and 
Nelson, 1987). This absence of antibodies to porcine insulin preparations may explain the 
clinical impression of a more rapid onset and shorter duration of action of porcine 
insulin preparations than those of bovine or mixed origin (Feldman and Nelson, 1987).
This study has shown that IZS-P is well absorbed following subcutaneous injection and is 
capable of lowering plasma glucose concentration in dogs with naturally-occurring 
diabetes mellitus. It has an intermediate duration of action and reasonably predictable 
times of peak activity. A single daily injection regimen and 7.5 hour feeding schedule 
works well in many dogs but twice daily injection would be necessary in some to achieve 
optimal glycaemic control.
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Part II: Efficacy 
Objective
The purpose of this study was to monitor the effects of a mixed porcine insulin zinc 
suspension (IZS-P, Caninsulin; Intervet UK) on plasma and urine glucose and clinical 
condition when used in dogs with naturally occurring diabetes mellitus over an initial 
'stabilisation* period. The effects of long-term use of this product were also studied.
Materials and methods 
Dogs
Nineteen diabetic dogs were used in this study. Three of these had been stabilised and 
maintained using an isophane insulin (Evans or Hypurin) before being changed to IZS-P 
for the purposes of this study. The remaining dogs received only IZS-P except dog C15 
which was given regular insulin (Hypurin Neutral) as part of the management of an initial 
ketoacidosis.
Ten of these dogs were included in a study of the pharmacokinetics of IZS-P (Chapter 6, 
Part I).
There were 12 female and 7 male dogs. Five females were speyed prior to first 
presentation and 6 were speyed as part of stabilisation management or soon after 
stabilisation. One of the males had been castrated before first presentation and one other 
was castrated during treatment on suspicion of testicular neoplasia. A variety of breeds 
were represented in the study group. Nine were terrier types, three mongrels, one 
Rottweiler, one Dobermann, one Poodle, one Dachshund, one Beagle, one Labrador 
retriever and one Samoyed. The average age was 8.72 years ± 2.75 SD, range 4 - 1 5  
years.
Management
Each dog was given a single daily injection of IZS-P and received a diet of commercial 
canned dog food mixed with bread or mixer, divided evenly into two meals. One meal 
was fed at the time of the insulin injection at 9.30am and the other 7.5 hrs later. Owners 
were advised to continue this regimen when the dog returned home.
The diet fed was based on 40-80 kcal/kg bodyweight depending on a subjective 
assessment of size and body condition. Details of animals used and diets fed are 
summarised in Table 35.
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AU Caninsulin used in this study was from batch number 9405, expiry date October 1991 
refrigerated at 4°C following receipt from Intervet UK Ltd. Caninsulin supplied to 
owners after June 1991 was from batch 13, expiry date March 1993.
Dog nos. C4, C5 and CIO had been previously stabilised on an isophane insulin at 
University of Glasgow Veterinary School. Dog C8 had been partiaUy stabilised on 
isophane insulin by the owner and C9 had undergone a degree of stabilisation by the 
referring veterinary surgeon using Lentard MC (Novo-Nordisk Pharmaceutical Ltd). 
Both were restabilised on IZS-P when they were returned to the hospital for boarding 
and they were not subjected to thorough re-investigation prior to conversion to IZS-P. 
The other 15 dogs were all assessed on initial presentation for suitability for inclusion in 
the study. Diabetes mellitus was confirmed by plasma glucose analysis and routine 
haematological and plasma biochemical analyses were performed. Lateral thoracic and 
abdominal radiographs were taken and suspected concurrent endocrinopathies or other 
diseases were investigated.
On admission to the study, each dog received a starting daily dose of IZS-P according to 
their expected requirement. Each morning thereafter, a 1 ml blood sample was taken into 
a fluoride oxalate collection tube prior to insulin injection and feeding. At this time each 
dog was also taken for a short walk to enable collection of a voluntarily voided urine 
sample. If this was unsuccessful, urine was not collected, as collection by catheterisation 
or cystocentesis were considered to be unnecessarily invasive. Blood and urine sampling 
were repeated 12 hours after the insulin injection. A further 1 ml blood sample was taken 
prior to the second meal. The results of glucose analyses on these samples were used to 
calculate the following day*s dose. However, technical difficulties occasionally meant 
that these results were not available in time to be included in this decision. All blood 
samples were taken from the jugular veins using 20 or 21 gauge hypodermic needles and 
2ml syringes (Terumo).
During the stabilisation period most dogs (depending on owner consent) were sampled 
for plasma glucose at frequent intervals over a 24 hour period to generate a plasma 
glucose curve.
Careful monitoring of the clinical condition of each dog was carried out each day whilst 
hospitalised. Particular attention was paid to changes in attitude, demeanour and 
willingness to exercise which might have suggested hypoglycaemia or adverse reaction. 
Dogs were weighed regularly.
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Generally speaking, when a consistent and acceptable afternoon plasma glucose 
concentration was achieved using a specific dose of IZS-P, the dog was discharged fi*om 
the hospital and the owners were instructed concerning insulin dose, diet and exercise. 
On occasion, dogs were discharged before this 'ideal* stabilisation because of holiday 
periods (C l5 especially). Owners of dogs in which this 'steady state* had been difficult 
or impossible to achieve were supplied with urine testing sticks (Keto-diastix, Ames) and 
instruction was given in adjusting insulin dose according to urine glucose concentrations.
Owners were requested to return with their animals for follow-up checks approximately 
7 and 14 days after discharge and for once monthly checks thereafter. Unfortunately, 
only a few owners were able to return this frequently but the others were encouraged to 
allow follow-up checks as often as possible. At each follow-up visit a clinical 
examination was performed and blood samples were taken for routine biochemical and 
haematological analyses.
Dog
no.
Hospital
Number
Previously
Stabilised
Age
(years)
Gender Body-
w ei^t
Breed kcal/kg
C3 113648 NO 5 M 10.0 Scottish terrier 75
04 109126 YES 12 MN 10.5 WHW terrier 70
05 111353 YES 12 FN 14.0 Labrador X 85
06 114460 NO 7 F 31.0 Dobermann 50
07 114653 NO 11 F 24.5 Spaniel X 50
08 114695 NO 9 FN 10.5 Terrier X 75
09 115009 NO 10 FN 5.5 Dachshund 90
010 112598 YES 8 F 29.0 Samqyed 45
O il 115131 NO 8 F 5.8 Jack Russell terrier 65
012 115164 NO 4 FN 8.5 Caim terrier 70
013 107674 NO 7 F 11.5 Beagle 70
014 115678 NO 5 M 40.0 Rottweiler 60
015 115980 NO 8 F 30.0 Labrador 55
016 116315 NO 15 FN 12.0 WHW terrier 70
017 116334 NO 11 M 19.0 Collie cros^red 60
018 116594 NO 6 M 12.0 Caim terrier 60
019 116744 NO 9 MN 6.0 Miniature Poodle 80
020 116825 NO 8 M 8.7 Australian terrier 75
021 117056 NO 11 F 6.3 Jack Russell terrier 70
Table 35. Signalment of diabetic dogs used in IZS^P study, including initial bodyweight and daily 
caloric intake.
Analyses
Plasma glucose analysis was carried out in the Department of Veterinary Medicine 
Clinical Biochemistry Laboratory as detailed in Chapter 6, Part I. Occasionally at 
weekends, plasma glucose concentrations were measured using a Vettest 8008 dry 
chemistry autoanalyser (IDDEX).
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Urinanalysis was carried out in the Department of Veterinary Medicine Research 
Laboratoiy using Labstix urine reagent stips (Ames) and Clinitest reagent tablets (Ames) 
in accordance with manufacturer's instructions. The maximum possible urine glucose 
concentration measurable using these methods, was 2% (2g/100mls) although urine 
glucose concentrations were often much higher.
Results
Detailed case reports of the stabilisation of 19 diabetic dogs included in the study are 
contained within Appendix 11.
Hospitalisation
Dogs which were bright and lively on admission to the hospital remained so throughout 
the hospitalisation period, except for C9 and C13 which became diarrhoeic and dull for a 
few days. Dogs which were ill on admission (C3, C14, C16 and C20) became bright and 
alert within a few days of starting IZS-P therapy and continued to be so for the 
remainder of the hospitalisation period. Dogs C6, 7 and 21 had recently been in oestrus 
prior to joining the study and were believed to be suffering from metoestrus-assodated 
diabetes mellitus.
Nine dogs were ketonuric at the start of stabilisation and in all cases but one this 
resolved within 6 days. One dog still had 'trace* or 'small* quantities of ketones until 11 
days after the start of stabilisation.
Dogs were considered to be 'stable*, in terms of their plasma glucose response to IZS-P 
injection, when afternoon (5pm) plasma glucose concentrations fell within the range 3 - 
8.5 mmol/1. All dogs, except C5 and C l5, achieved this target afternoon plasma glucose 
concentration by 2 or 3 days prior to discharge. Dog 05 was discharged with relatively 
high afternoon plasma glucose concentrations because increases in insulin dose had to be 
made cautiously in the light of previously exaggerated responses to lower insulin doses 
and an episode of clinical hypoglycaemia. Dog C l5 was discharged early for owner 
convenience.
Dogs C3, C5, C7, C12, C14, C16 and C18-21 were polydipsic (water intake 
>50ml/kg/day) at the beginning of treatment with IZS-P. Of these dogs, C5 (for reasons 
explained above) and C16 were polydipsic at discharge. Nevertheless, the daily water 
consumption of dog C l6 was approximately halved by IZS-P therapy. Dog C4 was also 
polydipsic at discharge although plasma glucose concentrations in this dog appeared to 
be controlled.
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Dog Hospital
Number
Days
Hospitalised
Initial Dose 
OU/kg)
Final Dose 
(lU/kg)
Change in Body­
weight (% of initial)
C3 113648 12 0.45 2.36 0.00
C4 109126 15 2.20 1.57 -2.54
C5 111353 20 1.21 1.25 -14.29
C6 114460 23 0.53 1.68 -19.71
07 114653 24 1.14 0.00 -7.35
08 114695 13 1.43 1.33 0.00
09 115009 14 2.50 2.09 -4.17
OlO 112598 6 0.83 0.83 0.00
O il 115131 16 1.21 1.23 12.07
012 115164 10 1.29 1.70 3.53
013 107674 13 1.13 1.04 8.70
014 115678 14 1.00 1.20 2.50
015 115980 12 0.83 1.45 10.00
016 116315 10 1.00 1.17 0.00
017 116334 11 1.00 1.47 0.00
018 116594 1 1.00 1.58 0.00
019 116744 10 1.00 2.67 0.00
020 116825 11 1.15 0.92 0.00
021 117056 17 0.95 0.00 4.76
Table 36. Stabilisation details of 19 dogs treated with IZS-P including initial and final Insulin doses 
and change in body weight.
Fourteen dogs (73.6%) maintained or gained weight whilst hospitalised (Table 36). 
Significant weight loss (>5%) was seen in C l and considerable weight loss (>10%) was 
seen in dogs C5 and C6. This can be explained by resistance to insulin and, therefore, 
therapy associated with metoestrus, seen in dogs C6 and C7, and by a steatorrhoeic and 
hypoglycaemic episode seen in dog C5.
Starting doses of IZS-P varied between 0.45 lU/kg and 2.50 lU/kg (Table 36). The high 
starting doses in dogs C4 (2.20 lU/kg) and C9 (2.50 lU/kg) were based on previous 
responses to insulin therapy. Dogs C3 (0.45IU/kg) and C6 (0.53IU/kg) started at a low 
dose. The remainder of the starting doses of IZS-P fell within the range 0.80 to 1.50 
lU/kg. Final insulin doses were mostly between 1 and 2 lU/kg but zero in dogs C7 and 
C21 (Table 36). Dogs C3 and C19 were discharged on relatively high doses (>2IU/kg). 
These two dogs were later discovered to have been suffering fi’om hypothyroidism and 
hyperadrenocorticism, respectively. Clinical signs of hypothyroidism had not been 
apparent in dog C3 at the beginning of the study and so a TSH stimulation test was not 
carried out and in dog C l9 the results of initial ACTH stimulation tests did not indicate 
the presence of hyperadrenocorticism.
The duration of the hospitalisation period depended not only on the dogs’ responses to 
IZS-P but was very strongly dependent on the choice of increment/decrement in insulin
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dose made from day to day. The size of the increment/decrement used was subjective in 
all cases and was not consistently based on any particular protocol. The duration of 
hospitalisation varied between 6 days (CIO) and 24 days (C7) (Table 36). The mean 
duration of hospitalisation for all dogs was 13.95 days (± SD 4.54 days). The 
exceptionally long hospitalisation times seen in dogs C6 and C7 were because of the time 
taken to overcome insulin resistance, i.e., for levels of antagonistic hormones to 611 
sufficiently for their effects to be overcome by IZS-P (dog C6) or to allow resolution of 
the problem (dog C7). In dog C5 the prolonged hospitalisation period was due to a 
steatorrhoeic and hypoglycaemic episode and the short hospitalisation time in CIO was 
because of previous stabilisation. The mean duration of hospitalisation for new cases, not 
previously stabilised and which did not have metoestrus associated diabetes mellitus, was 
12.31 days ± SD 1.89 days (n=13).
Follow-up
The following results are based on follow-up information obtained during the study 
period March 1990 to September 1991. No comparisons with other insulin preparations 
were made in this study.
Of the 19 dogs which started IZS-P therapy, 12 continued, one was withdrawn by its 
owner, two no longer required insulin therapy and 4 died. Of those which died, C4 was 
euthanased upon diagnosis of a cerebral tumour, C9 was euthanased 33 days after the 
start of treatment when showing signs of hepatic encephalopathy, C16 was euthanased 
for aggression and C l7 was euthanased for domestic reasons.
Those dogs which were alive and continuing on IZS-P therapy at the end of the study 
period were monitored for between 125 and 448 days after the start of treatment with 
IZS-P (Table 37).
During the follow-up period the dogs which remained alive at the end of the study period 
and 3 of the dogs euthanased later (C4, C16 and C17) were generally healthy. Dog C14 
returned at day 47 when its condition became unstable. Bacterial infections were the 
most common subsidiary problems encountered in these dogs. Infected interdigital 
cysts/abcesses occurred in dogs C6 (day 337), C8 (day 254) and twice in C14 (days 92, 
114). Dog C5 developed cystitis around day 88, C8 suffered bronchiectasis around day 
17, C l8 had conjunctivitis at day 62 and C12 suffered an undiagnosed but probable 
bacterial infection at day 11. Dog C l7 had small intestinal bacterial overgrowth from day 
34. These diagnoses represent a rate of illness associated with bacterial infection in this
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group of diabetic dogs of 1 incident per 1.1 diabetic-dog-years (i.e. 9 incidents in 9.96 
years of risk).
Dog Hospital
Number
Duration of 
follow-up 
(days)
Status at end 
of stucfy 
period
Change in dose 
required to 
maintain stability 
(% of maximum)
C3 113648 349 Alive 0.0
C4 109126 146 Dead 0.0
C5 111353 224 Alive 18.8
C6 114460 448 Alive 33.3
07 114653 24 Oured
08 114695 431 Alive 6.7
09 115009 33 Dead 14.3
OlO 112598 30 Withdrawn
Oil 115131 280 Alive 0.0
012 115164 176 Alive 25.0
013 107674 213 Alive 53.3
014 115678 271 Alive 34.5
015 115980 242 Alive 40.0
016 116315 85 Dead 0.0
017 116334 158 Dead 28.6
018 116594 166 Alive 19.0
019 116744 127 Alive 25.0
020 116825 125 Alive 42.9
021 117056 22 Cured
Table 37. Follow up details of 19 dogs treated with IZS-P including duration of follow-up, status at 
end of study period and range of insulin dose adjustment required to maintain stability ('cured* 
refers to dogs which had indefinite remission of insulin requirement).
Ocular cataracts, a common complication of canine diabetes mellitus, were present in 
both eyes of dogs C5 and Cl 6 and in one eye of dog CIS before starting treatment with 
IZS-P. Cataracts sufficiently severe to significantly affect vision developed in 4 other 
dogs, C3, C13, C15 and in the other eye of CIS at days 99, 187, 220, and 62 
respectively, representing a blindness rate of 1 per 2.23 diabetic-dog-years (4 in 9.11 
years of risk). Significant cataracts were observed in dog C ll at day 131 but there was 
no noticeable visual impairment by the end of the study period.
Adjustments in insulin dose were necessary to maintain glycaemic stability in those dogs 
which continued on IZS-P therapy (Table 37). The size of these adjustments varied 
greatly between dogs. The average range of insulin doses each dog received was 21% of 
their maximum dose (± SD 17%). In 7 dogs less than 20% adjustment was necessary and 
in 4 others, no adjustment in insulin dose was required to maintain stability. Dogs C l3, 
C14 and CIS were notable exceptions as they required large adjustments in dose. In dog
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C14, this was mainly because of changes in diet but the increased requirements could not 
be explained in dogs C13 and CIS.
Discussion
There are no previous comprehensive reports of the stabilisation of naturally occurring 
diabetic dogs with exogenous insulin. This study has shown that stabilisation of diabetic 
dogs with a mixed insulin zinc suspension can be achieved in 10 to 14 days of insulin 
dose adjustment to a final insulin dose of between 0.80 and 2.0 lU/kg. In the majority of 
cases, weight loss can be arrested or reversed and polydipsa controlled by a single daily 
insulin injection regimen. Ketonuria can also be controlled by this protocol. In the long­
term, diabetic dogs can be managed with single daily injections of mixed insulin zinc 
suspension and twice daily feeding for periods greater than 4 months.
Many veterinary textbooks and articles outline a stabilisation protocol but do not indicate 
the expected duration of stabilisation nor the expected short term response to insulin 
treatment. Such guidance is even difficult to find within medical literature. In addition, 
there are veiy few previously published reports on the long-term management of canine 
diabetics with which to compare the findings of the present efficacy study using a mixed 
insulin zinc suspension. However, one report (Marmor et a/, 1977) details the 
complications encountered in 39 diabetic dogs managed with single daily injections of 
isophane (NPH) insulin. In that report 94% of dogs which did not have visual impairment 
following stabilisation subsequently developed cataracts and 33% of dogs suffered 
bacterial infections of the urinary tract or skin. Unfortunately, Marmor et a! did not 
provide information on the duration of monitoring applied to these animals. A direct 
comparison with rates of blindness and bacterial infection reported in the present study 
cannot therefore be made.
This study provides unique information of use to veterinary surgeons when advising 
owners of diabetic dogs on the expectations of treatment, duration of hospitalisation for 
stabilisation and long-term prognosis and chances of blindness when a single daily insulin 
injection regimen using a mixed insulin zinc suspension is proposed. Furthermore, the 
results of the stabilisation and follow-up of 19 diabetic dogs suggest that IZS-P used 
once daily In conjunction with a twice daily feeding schedule is effective in the 
management of canine diabetes mellitus in the long term (>4months).
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Chapter 7: 
High fibre diet in the management of diabetes meiiitus 
Objective
The aim of this study was to evaluate the short and long-term effects of feeding a specific 
high fibre diet (Pedigree Canine High Fibre Diet® (CHF)) to dogs with naturally 
occurring diabetes mellitus.
Background
Alterations to diet are of major importance in the management of diabetes mellitus. In the 
obese cat and the Type II diabetic human, dietary control can be the primary therapeutic 
approach, obviating the requirement for insulin or oral hypoglycaemic therapy (Mann and 
Lewis-Bamed, 1992). Dietary manipulation is also important in the management of 
canine diabetes mellitus and is often employed. Consistency of meal times, content and 
size are the primary dietary recommendations for insulin treated diabetic dogs. In the 
past, recommendations centred on feeding diets low in easily digested carbohydrate. 
More recently, however, there has been a shift in emphasis, following changes in human 
diabetic management, towards increased complex carbohydrate intake including dietary 
fibre. Increasing dietary fibre reduces post prandial hyperglycaemia, improves lipid 
profiles and possibly has a direct effect on modifying insulin receptor activity (Anderson, 
1979; I^ollund et a/, 1983; Nelson, 1988; Nelson, 1989b; Fuessel et o/, 1987; Simpson 
et al, 1981; British Diabetic Association, 1982). Since most human diabetics suffer fi’om 
type n  diabetes mellitus which is best managed by reduction in calorie intake and weight 
control, many dietary recommendations for human diabetics include calorie restriction. 
Weight control is also important in Type I diabetics as obesity leads to decreased tissue 
sensitivity to insulin. The mechanisms by which increased dietary fibre and complex 
caibohydrates might reduce post-prandial hyperglycaemia include: delayed gastric 
emptying, slowed starch hydrolysis, mechanical interference with glucose absorption and 
altered intestinal transit time. The mechanisms by which plasma cholesterol and 
triglyceride might be reduced after feeding diets high in fibre and complex carbohydrates 
may be similar to those which reduce post-prandial hyperglycaemia. However, the ways 
in which dietary fibre might alter the fi'actionation of plasma cholesterol between the 
lipoprotein classes is less clearly understood.
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There is much scope for study of dietary aspects of the management of canine diabetes 
as, currently, most recommendations are based on human data. There are only two 
published studies on the effects of diets containing increased amounts of complex 
carbohydrates including fibre in diabetic dogs. Nelson et al (1991) studied the effect of 
canned diets high in soluble and insoluble fibre in 6 experimentally induced diabetic dogs. 
In that study, the mean concentration and fluctuation of plasma glucose, urinary glucose 
excretion and glycated haemoglobin concentrations were reduced after feeding the high 
fibre diets. The effects of these diets were not tested in dogs with naturally occurring 
diabetes mellitus, which differs fi'om the experimentally induced disease in terms of 
pathophysiology and possibly digestive function i^ in the former, there is co-existent 
chronic pancreatitis or gastrointestinal neuropathy. Blaxter et al (1990) studied the short 
term effects of dietary fibre by an acute change of diet in 4 dogs with naturally occurring 
diabetes mellitus but used home-made diets in which the fibre sources were sprinkled on 
to standard caimed pet food. No statistically significant differences were observed in 
post-prandial glycaemia in these diabetic dogs following the change in diet although 
differences were observed in a control group of 6 normal beagles. Although these 
previously published preliminary studies have been directed at application in the 
naturally-occurring disease, there are no reports of the effects of canned high fibre diets 
in dogs with naturally occurring diabetes mellitus.
Diabetes mellitus is invariably associated with elevations in plasma concentrations of 
cholesterol, triglyceride, non-esterified fatty acids, alanine aminotransferase, alkaline 
phosphatase and aspartate aminotransferase (Nelson, 1989a). These elevations have been 
reduced following improved management in diabetic dogs and/or humans (Nelson, 
1989a; Nikkila, 1984), although Chapter 5 of this thesis suggests that alanine 
aminotransferase, alkaline phosphatase and aspartate aminotransferase are of limited 
value in diabetic monitoring. Similarly, the concentrations of mean 24 hour plasma 
glucose, glycated haemoglobin (Wood and Smith, 1980; Bunn, 1981; Dolhofer et al, 
1981; Mahaffiey and Cornelius, 1982;) and glycated plasma proteins (fiuctosamine) 
(Dolhofer and Weiland, 1979; Dolhofer et al, 1981; Mahaffiey et al, 1984; Reusch et al,
1993) have also been reduced. Lipoprotein lipase activity (Nikkila, 1984; Nelson, 
1989a), lipoprotein profiles (Kissebah and Schectman, 1987) and VLDL 
triglyceride/apolipoprotein B ratios (Abbate and Brunzell, 1990) also tend to normalise 
following improved diabetic management. Any study assessing effectiveness of a diabetic 
management change designed to improve diabetic control should include monitoring of 
all the above parameters.
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In addition to those parameters already mentioned, plasma glucose concentrations 
obtained at particular times in the day can be used as indicators of glycaemic control. In 
treated diabetic dogs, the plasma concentration of glucose in a sample taken just before 
the morning injection of insulin (fasting glucose) is often the highest that will occur in a 
24 hour period. Fasting plasma glucose is often elevated well above normal ranges in 
treated diabetic dogs receiving a single daily injection of intermediate acting insulin. This 
is because intermediate duration insulins are seldom effective for as long as 24 hours in 
dogs. Fasting plasma glucose is usually the highest concentration of plasma glucose 
during the day, so it gives an indication of the worst degree of glycaemic control 
achieved by the treatment protocol. This information is generally used in conjunction 
with the afternoon (nadir) plasma glucose concentration which gives an indication of the 
best degree of glycaemic control achieved.
Plasma glucose concentration usually reaches its nadir just before the second meal o f the 
day in diabetic dogs treated according to the protocol used in this study. Measuring 
plasma glucose concentration at this time gives an indication of the maximum degree of 
glycaemic control achieved by the treatment protocol and insulin dose administered. A 
well controlled, stable diabetic dog should have nadir plasma glucose concentrations of 
between 3.5 and 7.5mmol/l.
Materials and methods 
Dogs
Thirteen privately-owned dogs with naturally occurring diabetes mellitus were recruited 
from diabetic dogs referred to the University of Glasgow Veterinary School over the 
period 1990 to 1992. To be included in the study each dog had to have been ‘stable’ for 
at least 4 months. With the exception of one dog which was diagnosed as hypothyroid 
after inclusion in the study, dogs with concomitant endocrinopathies were excluded. Two 
of the recruited dogs had to be excluded early in the study. Dog 7 was withdrawn by its 
owners and dog 12 died. Neither dog had received the CHF diet. The remaining 11 dogs 
were maintained on a once daily injection of an intermediate acting insulin Qsophane, or 
IZS-P) and fed two evenly divided meals 6-8 hours apart, with the first meal fed at the 
time of the insulin injection. All dogs were insulin dependent. This did not mean, 
however, that they were all hypoinsulinaemic. To prove hypoinsulinaemia, an insulin 
response test by administration of an insulin secretagogue is required and this was not 
carried out routinely. Pre-treatment basal insulin concentrations in the 7 dogs in which it 
could be measured were at the low end of the reference range (SCL Bioscience 5-40p 
lU/ml). There was wide variation in age and breed as would be expected in a study of 
this type and duration. Each dog was allocated a trial number in addition to their hospital
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number for the puposes of this study. Details of dogs involved in the study are listed in 
Table 38.
Diet
Canned Pedigree Canine High Fibre Diet ® (CHF) was supplied by Waltham Centre for 
Pet Nutrition and stored indoors until use. This diet contains guar and pea fibre at a level 
which results in a total dietary fibre (DF) content of approximately 5.7g/100kcal. The 
study design required the dogs to be fed an amount of CHF diet which was iso-caloric 
with their previous diets. The caloric densities of common petfoods which were used to 
calculate the volume of CHF diet to be fed are given in Table 39.
No. Case Number Age (years) Sex Breed
1 115678 6.5 M Rottweiler
2 119147 7.4 FN Large cross-breed
3 115131 8.9 FN Jack Russell terrier
4 115980 9.0 FN Labrador
5 117222 11.1 FN Whippet
6 113648 7.3 M Scottish terrier
8 97218 8.5 FN Labrador
9 117898 11.5 FN Caim terrier
10 121228 9.2 MN Labrador
11 121252 3.2 FN Rottweiler
13 120899 8.8 FN Yorkshire terrier
Table 38. Details of diabetic dogs included in the dietary management study.
Caloric density (kcal/lOOg)
Pedigree Canine High Fibre Diet® 
Pedigree Chum®
Chappie®
Whiskas®
Bread/Biscuit
95
77
82
65
200
Table 39. Caloric densities of the foods used by the owners of 11 diabetic dogs prior to changing to 
CHF diet
Study design
Because of the limited number of recruitable diabetic dogs, it was not possible to 
conduct this study with separate matched control and treatment groups. After a minimum 
period of 4 months of ‘normal’ diabetic management, each dog was monitored for a 
period of one month without change, then changed to CHF diet and monitored monthly 
for a further 4 months. Dogs started in the study in batches of up to three animal» to 
reduce the influence of external time dependent factors, such as analytical methods, on 
the results of the study.
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Hospitalisation
To facilitate conversion to CHF feeding, the dogs were hospitalised for approximately 10 
days. During this time, afternoon blood glucose analyses were carried out so that any 
necessary adjustments in insulin dose could be made. The change to an iso-caloric 
quantity of CHF was made via an intermediate day when the dogs were fed meals made 
up of equal quantities of CHF and their previous diet. Clinical examination was 
performed on a daily basis and faecal quality was monitored.
Serial blood glucose analvses
At the beginning (-10 days) and end (0 days) of the hospitalisation period a 24 hour 
blood glucose curve was generated for each dog by taking blood samples for glucose 
estimation at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20 and 24 hours post insulin injectioa The 
second curve was made after 6-7 days of being fed CHF alone. Additionally, samples 
were taken at 6.16, 6.32, 6.5, 7, 7.5 and 9 hours post injection so that the effects of CHF 
on afternoon post-prandial glycaemia (APPG) could be more closely observed. The 
second meal of the day (fed at 6 hours post injection) was chosen for further study 
because the effects of exogenous insulin on blood glucose concentrations would be less 
dynamic at that time. In 5 of the dogs it was possible to generate a third 24 hour blood 
glucose curve after 4 months of being fed CHF diet.
Insulin dose and general health
Insulin dose (lU/kg) was recorded carefully so that any decrease in insulin requirement 
could be noted and increases in insulin dose could be considered in the explanation of 
any improvement in glycaemic control.
The following plasma biochemical and haematological parameters were measured, so 
that the effects of any unrelated illnesses could be accounted for and any adverse effects 
of feeding CHF identified; urea, creatinine, phosphate, sodium, potassium, chloride, 
calcium, bilirubin, gamma glutamyl transferase, amylase, total protein, albumin, white 
blood cell count, neutrophil count, lymphocyte count, eosinophil count, red blood cell 
count, packed cell volume, mean corpuscular volume and platelet count.
At clinical examination, bodyweight was recorded, and a visual analogue method was 
used to record coat condition, body condition, faecal volume, faecal consistency, activity 
and both owner and veterinary observations of demeanour and quality of vision.
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Indicators of glvcaemic control
The following biochemical parameters were monitored because of their known value as 
indicators of glycaemic control in diabetics: fiuctosamine (glycated plasma proteins), 
glycated haemoglobin, alkaline phosphatase, alanine aminotransferase and aspartate 
aminotransferase. Direct measurements of plasma glucose concentration were also taken 
in the morning and afternoon when possible.
Although, daily water intake (ml/kg/day) is also a useful indicator of diabetic control it 
proved too difficult for owners to measure reliably at home and its monitoring was 
abandoned.
Lipid metabolism
To assess the effect of feeding CHF on lipid metabolism, plasma concentrations of 
cholesterol, triglyceride, non-esterified fatty acids and glycerol were measured. Changes 
in total plasma cholesterol concentration were studied further by quantitative analyses of 
the cholesterol concentration in each of the lipoprotein classes: VLDL, LDL and HDL. 
Post-heparin lipoprotein lipase activity and VLDL triglyceride:apolipoprotein B were 
also monitored. The analyses of these parameters require fasting blood samples and so 
they were only measured at -1 month, -10 days, 0 days, +2 months and +4 months.
Missing samples
Unfortunately, not all dogs were available for examination at every sampling time. Dog 
no. 2 was withdrawn by its owner after 2 months on CHF diet and dog no. 13 was not 
available at the +2 and +3 months sample times. Table 40 summarises the study design 
and the missing values.
Day -1 mth -10 days Odays +1 mth +2 mth +3 mth +4 mth
Visit Whole Hospitalisation Afternoon Whole Afternoon Whole
day sample day sample day
Diet Original Original CHF CHF CHF CHF CHF
Dog 1 + + + + + + +
2 + + + + + * •
3 + + + + + + +
4 + + + + + + +
5 + + + + + + +
6 + + + + + + +
8 + + + + + + +
9 + + + + + + +
10 + + + + + + +
11 + + + + + + +
13 + + + + * * +
Table 40. Study design and missing samples. * denotes data missing for all parameters
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Clinical chemistry and haematology
Routine clinical chemistry and haematology analyses were performed as described in 
Chapter 2. Additional methods were employed for the quantative analysis of plasma 
lipoproteins, lipoprotein lipase (LPL), hepatic triglyceride lipase (H-TGL) and VLDL 
apolipoprotein B concentrations and these are outlined in Appendices 12 - 14.
Statistical analyses
Statistical analyses were performed using a proprietary statistical software package 
(MINITAB, Minitab Incorporated). Comparison between two times, e.g. before and one 
week after changing to CHF diet, was performed using a paired /-test. When more than 
one group was to be analysed, e.g., mean afternoon post-prandial plasma glucose 
concentrations in 5 dogs on three separate occasions, an analysis of variance (randomised 
block) method was used and the data blocked by dog. When there was missing data, e.g., 
plasma fiuctosamine concentrations in 11 dogs for the 7 sampling days over the 4 
months of the study, a general linear model (GLM) analysis was used to determine the 
effects of dog and sample day (two-way analysis of variance). If GLM analysis revealed 
statistically significant differences then the data was grouped by sample day and re- 
interrogated using the Neuman-Keuls multiple range testk A level of probability of 5% 
(p<0.05) was chosen as the cut-off for the presence of statistical significance in all of the 
above analyses.
Because of the wide inter-dog variation for certain parameters e.g. alkaline phosphatase, 
body condition etc., results were also analysed as a percentage change. The mean of the 
-1 month and -10 days results was taken as the baseline value.
Throughout this chapter a simple system of graphical representation of results has been 
employed. This was because of the number of animals in the study and the presence of 
marked inter-dog variation (resulting fi-om: age, breed, sex, duration of diabetes, insulin 
type, etc.). In this system, the interquartile range (25th to 75th percentile) was plotted as 
a box, the median as a line, the mean as an asterisk and the data as individual dots. This 
system appeared to give an accurate and honest representation of the data. Wide 
discrepancies between the median and mean for any given set of data generally indicate 
that the data are not evenly distributed.
1‘Macro’ for MINITAB written by D R. Irvine, Department of Veterinary Medicine, 
University of Glasgow.
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Results 
Case summaries
Comments relating to the health and treatment of the dogs involved in the CHF diet 
study are contained in Appendix 15. An outline of the contents of the case reports is 
given below. More detailed information on certain aspects of their health and treatment 
(e.g. insulin dose, body weight, body condition, etc.) are included in relevant sections.
A variety of breeds and ages of dogs were included in the study and a variety of diets fed 
before the change to CHF diet. Two dogs were fed Chappie (Pedigree Petfoods) alone, 
two were fed Chappie and bread, two were fed Chum (Pedigree Petfoods) and bread, 4 
were fed Chum and biscuit mixer and one was fed Whiskas (Pedigree Petfoods) and 
bread. Two different types of intermediate insulin preparations were used; 4 dogs 
received Caninsulin (porcine insulin zinc suspension (lente); Intervet) and 7 dogs 
received Hypurin Isophane (Fisons).
With the exception of dog no. 2, the dogs remained generally well throughout the study 
period. According to their owners, 6 of the dogs improved noticeably in terms of their 
general health and liveliness and with the exception of two dogs (no. 5 and no. 13) all 
maintained a good appetite throughout the period of the study. Three dogs suffered 
diarrhoea which required treatment following the change to CHF and in two this was 
attributed to the presence of small intestinal bacterial overgrowth. Two dogs (including 
one which had diarrhoea (no. 2)) suffered colitis after changing to CHF but in dog no. 9 
this was only for a few days immediately following the change. One dog became 
constipated and was given vegetable oil supplements by its owner in an attempt to 
alleviate the problem. Three dogs (nos. 1, 2 and 8) had hypoglycaemic episodes during 
the period of the study and in two (nos. 2 and 8) this was whilst being fed CHF diet. The 
incidence of hypoglycaemic episodes in diabetic dogs fed standard diets managed under 
the regimen used is not known and so no comparison can be made. The visual ability of 
two dogs (nos. 8 and 10) deteriorated noticeably during the period of the study.
Post-prandial glycaemia 
Twentv-four hour curves
Blood samples were taken at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20 and 24 hours post injection 
from 11 dogs both before and one week after changing to CHF. The results are detailed 
in Appendix 16 and displayed graphically in Figures 51 and 52. These results were 
analysed both as absolute values and as incremental values by subtracting the nadir 
glucose concentration. The following parameters were analysed for statistical difference 
between original and CHF diets by the paired /-test method: mean absolute glucose
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concentration (ABSMEAN), mean incremental glucose concentration (INCMEAN) and 
area under the incremental glucose concentration versus time curve (INCAUC).
The standard deviations of absolute glucose concentrations (ABSSD) were calculated as 
indicators of the fluctuation in plasma glucose over the sample period. Unfortunately, 
statistical analysis of the difference in fluctuation in plasma glucose between the two 
diets was not possible because of the complexity of the statistical method required and 
the means of these values are given for illustration only. The mean absolute and 
incremental glucose concentration were less (p = 0.0087 and p = 0.034 respectively) on 
the CHF day than on the original diet. There was a reduction in INCAUC which was 
close to statistically significant (Table 41).
Original (mean ± sd) CHF (mean ± sd)
ABSMEAN t  13.00 ±5.68 6.0912.41
ABSSD 4.49 3.24
INCMEAN tt  6.08 ± 2.57 4.95 ± 1.17
INCAUC m _____________ 8363 ±3494______________ 722011673________
Table 41. Means and standard deviations of values derived from 24 hour glucose concentrations In 
11 dogs before and after changing to CHF (Statistically different between diets t (p^.0087), tt 
(p=0.034)).tttp« 0.056.
Afternoon post-prandial elvcaemia
Blood samples were taken at 6, 6.16, 6.32, 6.5, 7, 7.5, 8, 9, 10, 12 and 14 hours post 
injection from 11 dogs both before and one week after changing to CHF. The results are 
included in Appendix 16 and displayed graphically in Figures 53 and 54. The results were 
standardised by subtracting the glucose concentration at 6 hours. The following 
parameters were derived from these results: mean afternoon post-prandial glucose 
concentration (APPGMEAN), standard deviation of afternoon post-prandial glucose 
concentrations (APPGSD) and area under the afternoon post-prandial glucose 
concentration versus time curve (APPGAUC). Adjusted means, standard deviations and 
areas under the curve were also calculated based on only the 6, 7, 8, 9, 10, 12 and 14 
hour results (ADJMEAN, ADJSD and ADJAUC). Although there are striking trends 
towards reductions in APPGSD and ADJSD these are not mathematically sound 
measurements of plasma glucose fluctuation and appropriate statistical analysis could not 
be performed because of its complex nature. However, the means of APPGSD and 
ADJSD are given for illustration. The remaining derived values were analysed for 
statistically significant differences between the original and CHF diet using a paired /-test 
method. There were reductions in these 4 parameters which were not statistically 
significant (Table 42).
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Original (mean ± SD) CHF (mean ± SD)
APPGMEAN 1.57 ±2.76 0.88 ± 1.27
APPGSD 2.18 111
APPGAUC 1180 ±1696 583 ±723
ADJMEAN 2.08 ± 3.01 1.11 ±1.33
ADJSD 1189 581
ADJAUC 2.21 ±1.17 1.16 ±0.60
Table 42. Means and standard deviations of values derived from afternoon post prandial glucose 
concentrations in 11 dogs before and after changing to CHF.
Long-term effect on-post-prandial glvcaemia
In 5 dogs, 24 hour and afternoon post-prandial plasma glucose curves were generated 
after 4 months on CHF (Appendix 16) as well as before and one week after changing to 
CHF. These results are displayed graphically in Figures 55 - 60. The following 
parameters were statistically analysed using the an analysis of variance method: mean 
absolute glucose concentration (ABSMEAN), mean incremental glucose concentration 
(INCMEAN), area under the incremental glucose concentration versus time curve 
(INCAUC), mean afternoon post-prandial glucose concentration (APPGMEAN), and 
area under the afternoon post-prandial glucose concentration versus time curve 
(APPGAUC). Adjusted means and areas under the curve were also calculated based on 
only the 6, 7, 8, 9, 10, 12 and 14 hour results (ADJMEAN and ADJAUC). There were 
no statistically significant differences (p<0.05) in any of these parameters, although there 
were striking trends (Table 43). Previous comments relating to parameters derived firom 
standard deviations apply to ABSSD, APPGSD and ADJSD (Table 43) and so statistical 
analyses were not performed.
Original
mean±SD
CHF 1 week 
mean ± SD
CHF 4 months 
mean ± SD
ABSMEAN 13.00 ± 5.68 6.09 ±2.41 7.71 ±2.21
ABSSD 4.49 3.24 5.39
INCMEAN 5.24 ±2.49 5.13 ± 1.25 4.95 ±1.16
INCAUC 7415 ±3549 7580 ±1691 7220 ±1673
APPGMEAN 0.59 ±1.35 0.42 ±1.38 0.04 ±0.57
APPGSD 1.85 1.26 0.61
APPGAUC. 741 ±933 309 ± 830 35 ±320
ADJMEAN 1.34 ± 1.75 0.72 ±1.55 0.12 ±0.63
ADJAUC 786 ±953 323 ±796 45 ±309
ADJSD 1.57 1.31 0.65
Table 43. Means and standard deviations of values derived from 24 hour and afternoon post­
prandial glucose concentrations in 5 dogs before, 1 week and 4 months after changing to CHF diet
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^Q1-Q3 ^Median
Hours
Figure 51. Absolute 24 bour glucose concentrations in 11 dogs on original diet fed in evenly divided 
meals at 0 and 6 hours (median and interquartile range).
CSJQ1-Q3 ^Median
Hours
Figure 52. Absolute 24 hour glucose concentrations in 11 dogs on CHF diet fed in evenly divided
meals at 0 and 6 hours (median and interquartile range).
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Figure 53. Afternoon post-prandial glycaemia in 11 dogs on original diet (median and interquartile 
range).
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Figure 54. Afternoon post prandial glycaemia in 11 dogs on CHF diet (median and interquartile
range).
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Figure SS. Absolute 24 bour glucose concentrations in S dogs on original diet fed in evenly divided 
meals at 0 and 6 hours (median and interquartile range).
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Figure 56. Absolute 24 bour glucose concentrations in 5 dogs after one week on CHF diet fed in 
evenly divided meals at 0 and 6 hours (median and interquartile range).
CHAPTER? 156
i
£
C01
Ia>
E
«
Q.
# 0 1 -0 3  ^m edian
0 2 4  6 8 10 12 14 16 18 2 0  2 2  2 4
Hours p o st injection
Figure 57. Absolute 24 bour glucose concentrations in 5 dogs after 4 months on CHF diet fed in 
evenly divided meals at 0 and 6 hours (median and interquartile range).
01-03 ^Median
.
i
£
C0
1
I 
8
I
O)
I
CL
-4
6 8 10
H ours p o st injection  
Afternoon meal fed at 6 hours post-injection
Figure 58. Afternoon post-prandial glycaemia in 5 dogs on original diet (median and interquartile 
range).
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Figure 59. Afternoon post-prandial glycaemia in 5 dogs after one week on CHF diet (median and 
interquartile range).
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Figure 60. Afternoon post prandial glycaemia in 5 dogs after 4 months on CHF diet (median and 
interquartile range).
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Insulin dose and general health
Insulin dose
Insulin dosc was recorded on an international units per kilogram basis because of the 
variation in size of the dogs included in the study. Absolute insulin doses for 11 dogs 
over the period of the study are given in Appendix 17, represented graphically in Figure 
61 and as percentage change from basal values in Figure 62. There were no statistically 
significant changes in insulin dose over the period of the study and other than a slight 
increase in median dose at +4 months there were no apparent trends towards a change in 
insulin dose.
Bodvweight
Bodyweight was recorded at each visit by means of electronic scales. Absolute 
bodyweights (kg) are given in Appendix 17 and represented graphically in Figure 63 and 
as percentage change from basal values in Figure 64.
General linear model analysis revealed a statistically significant change in bodyweight 
(p=0.0000). Multiple range analysis indicated statistically significant differences between 
-1 month and +2 months; -1 month and +4 months; -10 days and +2 months and between 
-10 days and +4 months. There were also statistically significant differences between +2 
months and all the other CHF diet days (bodyweight at +2 months was higher than on all 
the other days) and between +4 months and all the other CHF diet days (bodyweight at 
4-4 months was lower than all the other days).
Analysis of bodyweight as a percentage of the mean of the two original diet days 
revealed a significant reduction over the period of the study (p=0.0001). Multiple range 
analysis indicated that there were statistically significant reductions in bodyweight from 
basal at 4-1 month, 4-2 months, 4-3 months and 4-4 months. The difference between basal 
and 0 days was close to statistically significant. There was also a statistically significant 
decrease in bodyweight between 0 days and 4-4 months.
Bodv condition
Body condition was assessed using a linear visual analogue scale 10 cm in length. A mark 
was made at a position which represented the dog’s body condition and the distance of 
the mark from the zero end of the scale measured in millimetres. The zero end of the 
scale represented emaciation and the 10 cm end gross obesity. Dogs with a healthy, 
normal body condition generally received a body condition score o f45 - 55mm. Absolute 
body condition scores are given in Appendix 17, represented graphically in Figure 65 and 
as percentage change from the mean of the -1 month and -10 days results in Figure 66.
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General linear model analysis revealed a statistically significant reduction in body 
condition (p=0.0000). Multiple range testing indicated that there were statistically 
significant differences between -1 month and both +3 months and +4 months and 
between -10 days and both +3 and +4 months. There were also statistically significant 
differences between +3 months and both 0 days and +1 month and between +4 months 
and all of the CHF days. There was also a statistically significant decrease in body 
condition when analysed on a percentage change basis (p=0.0003). On multiple range 
testing, there was a statistically significant difference between basal and +4 months. 
There were also statistically significant differences within the CHF days between 0 days 
and +3 months and between +4 months and all of 0 days, +1 month and +2 months.
Coat condition
Coat condition was given a score at each visit by means of a visual analogue scale. On 
this 10 cm scale the zero end represented very dull and the 10 cm end very glossy. 
Scores were converted to millimetres fi*om the zero end for statistical analysis. The 
absolute coat condition scores are given in Appendix 17, represented graphically in 
Figure 67 and as percentage change fi*om the mean of the original diet days values in 
Figure 68.
There were no statistically significant changes in coat condition nor any apparent trends. 
Activitv
An activity score was allocated to each dog on each visit based both on the owner’s 
comments and veterinary observation by means of a visual analogue scale. The zero end 
of the 10 cm line represented lethargic and the 10 cm end active. These results were 
converted to millimetres for statistical analyses.
Absolute activity scores are given in Appendix 17, represented graphically in Figure 69 
and as percentage change fi*om the mean of the -1 month and -10 days results in Figure 
70.
General linear model analysis revealed a statistically significant increase in activity score 
(p=0.0000). Multiple range testing indicated that there were statistically significant 
differences between -1 month and all of the CHF diet days and between -10 days and all 
o f+1, +2,4-3 and 4-4 months. There was also a statistically significant increase in activity 
score when considered on a percentage change basis (p=0.0022). Multiple range testing 
indicated statistically significant differences between basal (mean of -1 month and -10 
days) and all of the CHF diet days.
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Demeanour 
Owner observed
Owner observations of demeanour were recorded on a 10 cm visual analogue scale. The 
zero end of this scale represented dull and the 10 cm end bright. Owners were asked to 
mark the scale *blind’ but then given an opportunity to amend their mark after seeing 
their judgement at the previous visit.
Owner observed demeanour scores are given in Appendix 17, represented graphically in 
Figure 71 and as a percentage change for the mean of the original diet days scores in 
Figure 72.
There were no statistically significant changes in owner observed demeanour over the 
course of the study. Graphically there was a slight upward trend.
Vet observed
Demeanour was also scored on a visual analogue scale by the veterinary surgeon. This 
score was based both on the owner’s description of the dog’s behaviour between visits 
and on direct observation.
Demeanour scores from veterinary observation are given in ^pendix  17, represented 
graphically in Figure 73 and as percentage change fi’om the mean of the original diet days 
scores in Figure 74.
There was a statistically significant improvement in veterinary observed demeanour by 
general linear model analysis (p=0.0012) and multiple range testing revealed statistically 
significant differences between -1 month and +3 and +4 months and between -10 days 
and +3 and +4 months. The differences between both -1 month and -10 days and +2 
months were close to statistically significant. There were also statistically significant 
differences between 0 days and +3 and +4 months and a statistically significant 
improvement in veterinary observed demeanour when the results were considered on a 
percentage change basis (p=0.0073). Multiple range analysis revealed statistically 
significant differences between basal (mean of -1 month and -10 days) and +2, +3 and +4 
months.
Vision
Owner and Vet observed
Msion was assessed both by the veterinary surgeon and the owner using a 10cm visual 
analogue scale which represented blind at the zero end and pre-diagnosis vision at the
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10cm end. Owners marked their observation on the scale and were given an opportunity 
to amend their mark after seeing their assessment from their previous visit.
Owner and vet observed vision scores are given in Appendix 17, represented graphically 
in Figures 75 and 77 and as a percentage change from basal in Figures 76 and 78.
There were no statistically significant differences in owner observed or vet observed 
vision when considered as either absolute score or as percentage change in score. 
Positive percentage changes in vision score are more likely to be artefactual results of the 
scoring system, because genuine improvements in vision are not likely to be biologically 
feasible.
Faecal volume
Faecal volume score was recorded on a 10 cm visual analogue scale based on the 
veterinary surgeon's interpretation of owners comments.
Faecal volume scores are given in Appendix 17, represented graphically in Figure 79 and 
as a percentage change form the mean of the original diet days scores in Figure 80.
General linear model analysis revealed a statistically significant increase in faecal volume 
score (p=0.0000). Multiple range testing indicated that there were statistically significant 
differences between -1 month and all of the CHF diet days and between -10 days and all 
of the CHF diet days. There was also a statistically significant increase in faecal volume 
when considered on a percentage change basis (p=0.0003). Multiple range testing 
indicated statistically significant differences between basal (mean of -1 month and -10 
days) and all of the CHF diet days.
Faecal consistencv
Faecal consistency score was recorded on a 10 cm visual analogue scale. The zero end of 
the scale represented *loose’ which was interpreted as * watery’ and the 10 cm end of the 
scale represented 'hard’. Scores were allocated by veterinary interpretation of owner 
comments.
Faecal consistency scores are given in Appendix 17, represented graphically in Figure 81 
and as a percentage of the mean of the original diet days scores in Figure 82.
There were no statistically significant changes in frecal consistency score when 
considered either as absolute scores or as percentage change in score from basal.
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Routine biochemistry and haematology
Routine biochemical and haematological analyses were performed on blood samples 
taken at -1 month, -10 days, 0 days, +1 month, +2 months, +3 months and +4 months. 
The results of these analyses are given in Appendix 17. Very few of the results were 
outwith the reference ranges and there were no apparent trends in any of the parameters. 
Detailed statistical analyses were, therefore, not carried out.
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Figure 61. Absolute insulin dose (IU/kg) in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 62. Percentage change in insulin dose in 11 dogs from one month before to 4 months after
changing to CHF diet (median, mean and interquartile ranges).
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Figure 63. Absolute bodyweight (kg) in 11 dogs from one month before to 4 months after changing 
to CHF diet (median, mean and interquartile ranges).
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Figure 64. Percentage change in bodyweight in 11 dogs from one month before to 4 months after
changing to CHF diet (median, mean and interquartile ranges).
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Figure 65. Absolute body condition score in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 66. Percentage change in body condition score in 11 dogs from one month before to 4
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 67. Absolute coat condition score in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 68. Percentage change in coat condition score in 11 dogs from one month before to 4 months
after changing to CHF diet (median, mean and interquartile ranges).
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Activity score (mm)
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Figure 69. Absolute activity score in 11 dogs from one month before to 4 months after changing to 
CHF diet (median, mean and interquartile ranges).
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Figure 70. Percentage change in activity score in 11 dogs from one month before to 4 months after
changing to CHF diet (median, mean and interquartile ranges).
CHAPTER? 168
Demeanour score - owner observation (mm)
0 = dull, 100 = bright
100
□q3/q1 — median * mean • data
2 2 3 4 51 0 1
Months
Figure 71. Absolute owner observed demeanour score in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 72. Percentage change in owner observed demeanour score in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 73. Absolute vet observed demeanour score in 11 dogs from one month before to 4 mcmths 
after changing to CHF diet (median, mean and interquartile ranges).
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Figure 74. Percentage change in vet observed demeanour score in 11 dogs from one month before
to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 75. Absolute owner observed vision score in 11 dogs from one month before to 4 months 
after changing to CHF diet (median, mean and interquartile ranges).
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Figure 76. Percentage change in owner observed vision score in 11 dogs from one month before to
4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 77. Absolute vet observed vision score in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 78. Percentage change in vet observed vision score in 11 dogs from one month before to 4
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 79. Absolute faecal volume score in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 80. Percentage change in faecal volume score in 11 dogs from one month before to 4 months
after changing to CHF diet (median, mean and interquartile ranges).
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Figure 81. Absolute faecal consistency score in 11 dogs from one month before to 4 months after 
changing to CHF diet (median, mean and interquartile ranges).
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Figure 82. Percentage change in faecal consistency score in 11 dogs from one month before to 4
months after changing to CHF diet (median, mean and interquartile ranges).
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Indicators of glycaemic control 
Fructosamine
The results of plasma fructosamine analyses from 11 dogs sampled at -1 month, -10 
days, 0 days, +1 month, +2 months +3 months and +4 months after changing to CHF are 
given in Appendix 18. Figure 83 displays these results graphically and Figure 84 shows 
these results expressed as a percentage change from the mean of the -1 month and -10 
days values.
General linear model analysis revealed a statistically significant reduction in absolute 
plasma fiiictosamine concentration (p = 0.01). Further analysis by Newman-Keuls 
multiple range test revealed the only significant difference to be -1 month versus +2 
months. Differences between -10 days and +2 months and between -1 month and 0 days 
were close to statistically significant. General linear model analysis of percentage change 
in plasma fiiictosamine concentration revealed a statistically significant reduction (p= 
0.036). Again, the only significant difference on multiple range analysis was between the 
basal (mean of -1 month and -10 days) and +2 months. Differences between basal and 0 
days, basal and +3 months and basal and +4 months were close to statistically significant. 
Graphically, there is an apparent trend towards reduced plasma fiiictosamine on the CHF 
diet days.
Glvcated haemoglobin
The results of glycated haemoglobin analyses from 11 dogs sampled at -1 month, -10 
days, 0 days, +1 month, +2 months +3 months and +4 months after changing to CHF are 
given in Appendix 18. Figure 85 displays these results graphically and Figure 86 shows 
these results expressed as a percentage change from the mean of the -1 month and -10 
days values.
General linear model analysis revealed a statistically significant reduction in absolute 
glycated haemoglobin concentration (p < 0.002). Further analysis by Newman-Keuls 
multiple range test revealed statistically significant differences between -10 days and +1 
month, +2 months, +3 months and +4 months. Differences between -1 month and +1 
month, +2 months, +3 months and +4 months were close to statistically significant. 
General linear model analysis of percentage change in glycated haemoglobin 
concentration revealed a statistically significant reduction (p= 0.048). Multiple range 
analysis failed to identify any significant differences. Differences between basal (mean of 
-1 month and -10 days) and +1 month, +2 months, +3 months and +4 months were very 
close to statistically significant. Graphically, there is a strong trend towards reduced 
glycated haemoglobin on the CHF diet days.
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Alkaline phosphatase
The results of plasma alkaline phosphatase analyses from 11 dogs sampled at -1 month, - 
10 days, 0 days, +1 month, +2 months +3 months and +4 months after changing to CHF 
diet are given in Appendix 18. Figure 8? displays these results graphically and Figure 88 
shows these results expressed as a percentage change from the mean of the -1 month and 
-10 days values.
General linear model analysis revealed a statistically significant decrease in plasma 
alkaline phosphatase concentrations (p = 0.023). Newman-Keuls multiple range test 
failed to identify any statistically significant differences but the differences between -10 
days and 0 days, +1 month, +2 months and +4 months were close to statistically 
significant. There were no statistically significant differences in percentage change in 
plasma concentration of alkaline phosphatase by general linear model analysis. Following 
re-examination of the percentage change data it was apparent that dog 13's results may 
have been having a large influence on the statistical analyses.
Alanine aminotransferase
The results of plasma alanine aminotransferase analyses from 11 dogs sampled at -1 
month, -10 days, 0 days, +1 month, +2 months +3 months and +4 months after changing 
to CHF diet are given in Appendix 18. Figure 89 displays these results graphically and 
Figure 90 shows these results expressed as a percentage change from the mean of the -1 
month and -10 days values.
General linear model analysis found no statistically significant reductions in absolute or 
percentage change in plasma alanine aminotransferase concentrations. Figure 90 shows a 
moderate trend towards decreased alanine aminotransferase concentrations.
Aspartate aminotransferase
The results of plasma aspartate aminotransferase analyses from 11 dogs sampled at -1 
month, -10 days, 0 days, +1 month, +2 months +3 months and +4 months after changing 
to CHF diet are given in Appendix 18. Figure 91 displays these results graphically and 
Figure 92 shows these results expressed as a percentage change from the mean of the -1 
month and -10 days values.
There were no statistically significant differences in either the absolute or percentage 
change in plasma aspartate aminotransferase concentration but there is an apparent trend 
visible in Figure 92 in which most of the percentage change results are negative.
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Fasting glucose
The results of fasting plasma glucose concentrations from 11 dogs sampled at -1 month, 
-10 days, 0 days, +2 months and +4 months after changing to CHF diet are given in 
Appendix 18. Figure 93 displays these results graphically and Figure 94 shows these 
results expressed as a percentage change from the mean of the -1 month and -10 days 
values.
There were no statistically significant differences in the absolute or percentage change in 
fasting plasma glucose concentrations but there was a trend towards a reduction in 
absolute fasting plasma glucose concentration at the 0 days and +2 months sample points 
(Figure 93).
Afternoon (nadir) glucose
The results of afternoon plasma glucose concentrations from 11 dogs sampled at -1 
month, -10 days, 0 days, +1 month, +2 months, +3 months and +4 months after changing 
to CHF diet are given in Appendix 18. Figure 95 displays these results graphically and 
Figure 96 shows these results expressed as a percentage change from the mean of the -1 
month and -10 days values.
General linear model analysis revealed statistically significant reductions in afternoon 
plasma glucose concentration (p<0.03). Multiple range testing identified differences 
between -1 month and 0 days, -10 days and 0 days and between -1 month and +2 
months. The difference between -10 days and +2 months was close to statistically 
significant. There was also a significant difference from basal in the percentage change 
data (p<0.02) and multiple range testing identified the differences between basal and 0 
days and between basal and +2 months as statistically significant. The trend, apparent 
graphically, is towards a reduced afternoon plasma glucose concentration after changing 
to CHF diet (Figures 95 and 96).
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Figure 83. Absolute plasma fructosamine concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 84. Percentage change in plasma fructosamine concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 85. Absolute glycated haemoglobin concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 86. Percentage change in glycated haemoglobin concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 87. Absolute plasma alkaline phosphatase concentrations in 11 dogs from one month before 
to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 88. Percentage change in plasma alkaline phosphatase concentrations in 11 dogs from one
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 89. Absolute plasma alanine aminotransferase concentrations in 11 dogs from one month 
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 90. Percentage change in plasma alanine aminotransferase concentrations in 11 dogs from
one month before to 4 months after changing to CHF diet (median, mean and interquartile
ranges).
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Figure 91. Absolute aspartate aminotransferase concentrations in 11 dogs from one month before 
to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 92. Percentage change in aspartate aminotransferase concentrations in 11 dogs from one
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 93. Absolute fasting plasma glucose concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 94. Percentage change in fasting plasma glucose concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 95. Absolute afternoon (nadir) plasma glucose concentrations in 11 dogs from one month 
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 96. Percentage change in afternoon (nadir) plasma glucose concentrations in 11 dogs from
one month before to 4 months after changing to CHF diet (median, mean and interquartile
ranges).
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Lipid metabolism
Total cholesterol
Samples for cholesterol analyses were taken from fasted dogs to minimise the effects of 
post-prandial hypercholesterolaemia. The results of plasma cholesterol analyses from 11 
dogs sampled at -1 month, -10 days, 0 days, +2 months and +4 months after changing to 
CHF are given in Appendix 19 and represented in Figure 97. Figure 98 represents the 
results expressed as a percentage change from the mean of the -1 month and -10 days 
results.
General linear model analysis revealed a statistically significant reduction in total fasting 
plasma cholesterol concentration (p = 0.0023). Multiple range testing indicated that there 
were statistically significant differences between -1 month and 0 days and between -10 
days and 0 days. The differences between +2 months and both -1 month and -10 days 
were close to statistically significant. There was a highly statistically significant reduction 
in the percentage change data after changing to CHF diet (p=0.0000) and further analysis 
by multiple range testing indicated that there were statistically significant differences 
between all the CHF diet days and the mean of the two original diet days. There were 
also statistically significant differences between 0 days and both +2 months and +4 
months.
Graphically, the reductions in absolute and percentage change data are striking. 
However, there is an apparent upward trend after 0 days.
VLDL cholesterol
The concentration of plasma cholesterol associated with very low density lipoproteins 
was measured after preparative ultracentrifugation. Technical difficulties were 
encountered in measuring this cholesterol fraction directly because of the veiy low 
concentrations of cholesterol involved and the difficulties in recovering the whole 
fraction intact after tube splitting. For the purposes of this study, a calculated VLDL 
cholesterol concentration was used (VLDL cholesterol = Total cholesterol - ‘bottom 
fraction* cholesterol, i.e., VLDL cholesterol = Total cholesterol - (LDL cholesterol + 
HDL cholesterol)). VLDL cholesterol was measured in fasting plasma samples. The 
reference range for this method was 0.4? ± 0.?0 (mean ± SD, n=33) (Barrie et al, 1993).
The results of VLDL cholesterol estimations are given in Appendix 19 and displayed 
graphically in Figure 99. Figure 100 represents these results expressed a percentage 
change from the mean of the -1 month and -10 days results.
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General linear model analysis did not reveal any statistically significant changes in VLDL 
cholesterol concentration. However, there is a slight trend towards reduced VLDL 
cholesterol evident graphically at the 0 days and +2 months sample points.
LDL cholesterol
The plasma concentration of cholesterol associated with low density lipoprotein was 
calculated after preparative ultracentrifugation fi*om the difference in concentration of 
cholesterol in the infranatant before and after precipitation of the LDL by heparin- 
manganese chloride. The reference range for this method was 1.72 ± 1.88 (mean ± SD, 
n=33) (Barrie etal, 1993).
The results of LDL cholesterol estimations are given in Appendix 19 and displayed 
graphically in Figure 101. Figure 102 represents these results expressed a percentage 
change fi'om the mean of the -1 month and -10 days results.
General linear model analysis revealed a statistically significant reduction in LDL 
cholesterol concentration (p= 0.016?) and further investigation by multiple range testing 
indicated that there was statistically significant difference between -10 days and 0 days. 
The difference between -1 month and 0 days was close to statistically significant. There 
was also a statistically significant reduction in LDL cholesterol concentration when 
expressed as percentage change form the mean of the -1 month and -10 days results (p = 
0.0064) on general linear model analysis. Multiple range testing indicated that there were 
statistically significant differences between basal and all three CHF diet days (0 days, +2 
months and +4 months).
Graphically, the reductions in LDL cholesterol concentration are striking (Figures 101 
and 102).
HDL cholesterol
The plasma concentration of cholesterol associated with high density lipoprotein was 
measured after preparative ultracentrifugation and precipitation of LDL fi’om the 
infi-anatant. The reference range for this method was 2.34 ± 0.70 (mean ± SD, n=33) 
(Barrie et al, 1993b).
The results of HDL cholesterol estimations are given in Appendix 19 and displayed 
graphically in Figure 103. Figure 104 represents these results expressed a percentage 
change from the mean of the -1 month and -10 days results.
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General linear model analysis revealed no significant changes in HDL cholesterol 
concentration. Graphically it can be seen that there is a trend towards decreased HDL 
cholesterol at 0 days but that there is no change apparent at +2 months and +4 months.
Triglvcerides
The results of plasma triglyceride estimations are given in Appendix 19 and displayed 
graphically in Figure 105. Figure 106 represents these results expressed a percentage 
change fi'om the mean of the -1 month and -10 days results.
General linear model analysis revealed no statistically significant changes in plasma 
triglyceride concentrations and there are no trends apparent graphically.
Glvcerol
The results of plasma glycerol estimations are given in Appendix 19 and displayed 
graphically in Figure 10?. Figure 108 represents these results expressed a percentage 
change fi'om the mean of the -1 month and -10 days results.
Genera] linear model analysis revealed a statistically significant reduction in absolute fi'ee 
plasma glycerol concentrations (p= 0.0072). Multiple range testing indicated statistically 
significant differences between -1 month and +2 months and between -10 days and +2 
months. There was also a statistically significant reduction in fi'ee plasma glycerol when 
expressed as a percentage change from basal (p= 0.0397). Again, multiple range testing 
indicated statistically significant differences between basal and +2 months and between 0 
days and +2months. Differences between basal and +4 months and between 0 days and 
+4 months were close to statistically significant.
Non-esterified fattv acids
The results of plasma non-esterified fatty acids estimations are given in Appendix 19 and 
displayed graphically in Figure 109. Figure 110 represents these results expressed a 
percentage change from the mean of the -1 month and -10 days results.
General linear model analysis revealed a statistically significant reduction in plasma non- 
esterified fatty acid concentration (p= 0.0302). Multiple range testing indicated a 
statistically significant difference between -10 days and +2months. The difference 
between -1 month and + 2 months was close to statistically significant. There was no 
statistically significant change in plasma non-esterified fatty acid concentration when 
analysed on a percentage change basis although there was an apparent trend visible 
graphically (Figure 110).
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VLDL triglvceride/apolipoprotein B
Plasma concentrations of very low density lipoprotein associated triglyceride were 
measured in the same supernatant obtained from preparative ultracentrifugation and tube 
slicing originally intended for the direct measurement of VLDL cholesterol. Some 
difficulty was experienced in recovering all of the supernatant (VLDL fraction) and, 
therefore, the resulting triglyceride results may not have been very reliable. This was 
principally the result of an imperfect seal in the upper section of the tube splitting 
apparatus which caused loss of supernatant during the process of flushing with saline.
Very low density lipoprotein associated apolipoprotein B concentrations were measured 
in the VLDL fraction which resulted from preparative ultracentrifugation of EDTA 
plasma samples for quantitative lipoprotein cholesterol analysis. In some cases the 
concentration of apolipoprotein B was undetectable making the creation of a VLDL 
triglycerideiapoliprotein B ratio impossible.
VLDL triglyceride/apolipoprotein B ratios are given in Appendix 19 and displayed 
graphically in Figure 111. Figure 112 represents these results expressed a percentage 
change from the mean of the -1 month and -10 days results. General linear model 
analyses revealed no statistically significant changes in VLDL triglyceride: apoliporotein 
B ratios and graphically there were no apparent trends.
Post heparin hepatic triglyceride lipase
The measurement of plasma concentrations of lipoprotein lipase was abandoned because 
of technical difficulties. This was believed to be mainly due to sample handling and 
storage during which the very labile lipoprotein lipase was destroyed. However, post­
heparin hepatic triglyceride lipase is more stable and its measurement is a necessary part 
of lipoprotein lipase analysis. It was possible, therefore, to measure and record values for 
hepatic triglyceride lipase instead of lipoprotein lipase. The reference range for post 
heparin hepatic triglyceride lipase using this method is 6.92 ±1.44 (mean ± SD, n=6) (Dr 
J. Barrie - personal communication).
The results of post-heparin plasma hepatic triglyceride lipase activities are given in 
Appendix 19 and displayed graphically in Figure 113. Figure 114 represents these results 
expressed a percentage change from the mean of the -1 month and -10 days results.
There were no statistically significant changes in post heparin plasma hepatic triglyceride 
lipase activity when analysed as absolute results nor when analysed as percentage change 
from basal results.
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Figure 97. Absolute total plasma cholesterol concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 98. Percentage change in total plasma cholesterol concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Plasma VLDL-cholesterol concentration (mmol/l)
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Figure 99. Absolute plasma VLDL cholesterol concentrations in 11 dogs from one month before to 
4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 100. Percentage change in plasma VLDL cholesterol concentrations in 11 dogs from one
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Plasma LDL-cholesterol concentration (mmol/l)
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Figure 101. Absolute plasma LDL cholesterol concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 102. Percentage change in plasma LDL cholesterol concentrations in 11 dogs from one
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Plasma HDL-cholesterol concentration (mmol/l)
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Figure 103. Absolute plasma HDL cholesterol concentrations in 11 dogs from one month before to 
4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 104. Percentage change in plasma HDL cholesterol concentrations in 11 dogs from one
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 105. Absolute plasma triglyceride concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 106. Percentage change in plasma triglyceride concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Plasma concentration of glycerol (umol/l)
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Figure 107. Absolute plasma free glycerol concentrations in 11 dogs from one month before to 4 
months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 108. Percentage change in plasma free glycerol concentrations in 11 dogs from one month
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Absolute plasma concentration of non-esterified fatty acids (mmol/l)
5
□q3/q1 — median * mean • data
4
3
2
1
0
4 5-2 1 2 31 0
Months
Figure 109. Absolute plasma non-esterified fatty acids concentrations in 11 dogs from one month 
before to 4 months after changing to CHF diet (median, mean and interquartile ranges).
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Figure 110. Percentage change in plasma non-esterified fatty acids concentrations in 11 dogs from
one month before to 4 months after changing to CHF diet (median, mean and interquartile
ranges).
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VLDL triglyceride : VLDL apolipoprotein B ratio (mmol/ug)
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Figure 111. Absolute VLDL triglyceride/apolipoprotein B ratios in 11 dogs from one month before 
to 4 months after changing to CHF diet (median, mean and interquartile ranges) - values greater 
than 200mmol/ug have been omitted.
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Figure 112. Percentage change in VLDL triglyceride/apolipoprotein B ratios in 11 dogs from one 
month before to 4 months after changing to CHF diet (median, mean and interquartile ranges) - 
value greater than 500% have been omitted.
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Figure 113. Absolute post heparin plasma hepatic triglyceride lipase activities (p.molFA/ml/hr) in 
11 dogs from one month before to 4 months after changing to CHF diet (median, mean and 
interquartile ranges).
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Figure 114. Percentage change in post heparin plasam hepatic triglyceride lipase activities in 11
dogs from one month before to 4 months after changing to CHF diet (median, mean and
interquartile ranges).
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Long-term follow-up (> 4 months)
All dogs which were still being fed CHF diet by the end of the 4 month study period 
continued to be fed CHF diet for variable periods of time thereafter. This section 
contains brief clinical descriptions of the effects of the long term (> 4 months) feeding of 
CHF diet to 10 dogs with naturally occurring diabetes mellitus.
Dog 1
Dog 1 required to be treated with antibiotics (metronidazole and oxytetracycline) for the 
last month of the 4 month study period to control small intestinal bacterial overgrowth 
(SIBO). Neither of these prolonged courses of antibiotic treatment nor a further one of 
tylosin successfully controlled the weight loss and intermittent diarrhoea associated with 
the SIBO and body and coat condition became very poor. By March 1993 (8 months of 
feeding CHF diet) the possibility of an underlying intestinal disease was considered as the 
cause of the refractory SIBO and small intestinal biopsies were taken at exploratory 
celiotomy. Histopathological examination of these biopsies yeilded a diagnosis of 
eosinophilic enteritis and as a result, treatment with a reducing course of corticosteroids 
and dietary management with Pedigree Canine Selected Protein (Pedigree Petfoods) was 
instituted. Following a little improvement the diet was changed to Eukanuba Lamb and 
Rice (Leander International) and a successful and uneventful recovery was achieved 
within 8 weeks. Lost weight was regained and body and coat condition became excellent.
D o g l
Dog 3 continued to be fed CHF diet until October 1993 (15 months of CHF feeding) 
when body condition became unacceptably poor. At that time the dog weighed 6.86kg 
and had lost 12.5% of its pre-CHF bodyweight. This dog was in good bodily condition at 
the beginning of the study and weight loss had not been considered to be a necessary part 
of its management. No diarrhoea or signs of diabetic instability had been observed over 
the period that this dog was fed CHF diet. The dog was returned to its original diet of 
Chappie (Pedigree Petfoods), regained lost weight and continued to do very well.
Dog 4
Dog 4 continued uneventfully on CHF diet until April 1993 (8 months of feeding CHF 
diet) when it began to suffer occasional diarrhoea. By September 1993 (13 months) this 
had become a regular problem and was accompanied by signs of colitis. A course of 
sulphasalazine was instituted and B12 and folate estimations performed. A high plasma 
folate consistent with SIBO was discovered and treatment with metronidazole and 
dietary management with Prescription Diet i/d (Hills) was begun. Exploratory celiotomy 
was performed and intestinal biopsies obtained in an attempt to rule out underlying
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intestinal disease. Histopathological examination of the biopsies revealed evidence of a 
mild non-specific enteropathy and this was thought to be a consequence of the SIBO 
rather than a contributor. Recovery was uneventful and the dog was returned to its 
original diet of Chappie and bread.
Po&i
Dog 5 continued to be fed CHF diet along with small quantities of Pedigree Chum 
(Pedigree Petfoods) without any clinically obvious problems until the end of an agreed 
subsidised period of 12 months after the end of the 4 month study. Thereafter the dog 
was fed the original diet of Pedigree Chum (Pedigree Petfoods) and biscuit.
Dog6
Dog 6 continued to be fed CHF diet until the end of a subsidised period of 12 months 
after the end of the 4 month study without any clinically obvious problems. The owners 
were pleased with the CHF diet and continued to obtained it fi'om their own veterinary 
surgeon until changing the dog back to Chappie (Pedigree Petfoods) after 21 months of 
feeding CHF.
Dog 8
Dog 8 continued to be fed CHF diet without any problems until May 1993 (7 months of 
feeding CHF diet) when it was hospitalised for treatment of watery diarrhoea and signs 
of colitis. Therapy with sulphasalazine and metronidazole was begun and B12 and folate 
estimations revealed a low plasma B12 concentration consistent with SIBO. Weight loss 
and intermittent diarrhoea continued despite treatment and in August 1993 (10 months) 
an exploratory celiotomy was performed and intestinal biopsies obtained to investigate 
the refi'actory SIBO. After histopathological examination of the biopsies a diagnosis of 
immune-mediated lymphocytic/plasmacytic enteritis was made and as a result the feeding 
of CHF was discontinued and therapy with corticosteroids and metronidazole was begun 
in conjunction with dietary management with Pedigree Canine Selected Protein (Pedigree 
Petfoods). Within 6 weeks, recovery was complete and the dog was returned to the 
original diet of Chum (Pedigree Petfoods) and bread.
Dog 9
Dog 9 continued on CHF diet with only occasional bouts of sulphasalazine responsive 
colitis until July 1993 (9 months of feeding CHF diet) when intermittent diarrhoea 
became apparent. In November 1993 (15 months), body condition was unacceptably 
poor, with a loss of 9% of the pre-CHF bodyweight. Weight loss had not been a priority 
in this dog's management. The feeding of CHF diet was discontinued and the dog
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returned to being fed Chappie. Weight loss continued and by January 1994 the dog had 
lost 12.7% of its pre-CHF weight and plasma folate concentration was low consistent 
with proximal small intestinal disease or dietary sensitivity. An exploratory celiotomy 
was performed and intestinal biopsies were obtained. Histopathological examination of 
the intestinal biopsies revealed evidence of an non-specific inflammatory enteropathy in 
which there was prominent intestinal infiltration with lymphocytes and eosinophils. 
Corticosteroid therapy was begun and dietary management with Pedigree Canine 
Selected Protein (Pedigree Petfoods) instituted. The dog made an impressive recovery 
and within 2 months had regained lost weight (to 98% of pre-CHF weight) and the diet 
was changed back to Chappie (Pedigree Petfoods).
Dog 10
Dog 10 was fed CHF diet until October 1994 (19 months) when his original diet was 
reinstituted without any significant problems. There has been a gradual loss of weight 
over this period but with acceptable body condition throughout. There was one brief 
bout of diarrhoea in September 1993 (6 months) which required no treatment in addition 
to the clavulanate potentiated amoxycillin which was being administered to control a 
bout of bacterial cystitis. Estimation of plasma B12 and folate concentration was 
performed at that time and found to be consistent with bacterial overgrowth (high 
folate). No additional treatment was administered and there was no further recurrence of 
diarrhoea.
Dog 11
Within a week of finishing the 4 month study period, dog 11 experienced a bout of 
vomiting and diarrhoea which was treated non-specifically. In September 1993 (6 months 
of feeding CHF diet), diarrhoea again became a problem. Plasma B12 was low, 
consistent with SIBO, and a 3 week course of metronidazole was begun. The diarrhoea 
was controlled by this treatment and this dog continued to be fed CHF until the end of a 
12 months subsidised period. The dog remained in good body condition.
Dog 13
Dog 13 encountered no more problems after suffering diarrhoea during the 4 month 
study. However, by December 1993 (7 months of feeding CHF diet), this dog's body 
condition was unacceptably poor and 21% of its pre-CHF weight had been lost. The 
feeding of CHF diet was discontinued and the dog returned to its original diet. Over the 
months preceding the discontinuation of CHF feeding, polydipsia had been observed by 
the owners and so it is likely that some degree of diabetic instability contributed to this 
dog’s dramatic weight loss.
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In summary, 10 dogs continued to be fed CHF diet after the end of a 4 month study 
period. Of these, 4 remained on the diet until the end of a 12 month subsidised period 
and of these two continued on the diet thereafter. In six dogs, the feeding of CHF diet 
was discontinued after between 7 and 15 months. The reasons for discontinuation of 
CHF were unacceptable weight loss (three dogs) or recurrent or persistent diarrhoea (4 
dogs). There was plasma biochemical evidence of SIBO in 5 dogs (one of which was 
unassociated with diarrhoea) and treatment with antibiotics was required in 4 of these 
dogs. Four dogs underwent exploratory celiotomy as part of the investigation of their 
weight loss or diarrhoea and in all of these dogs there was histopathological evidence of 
an enteropathy and in three dogs, this included the presence of an inflammatory cellular 
infiltrate. These three dogs required further treatment with corticosteroids and a change 
to an *hypoallergenic diet’ and made good recoveries. Table 57 summarises the duration 
of feeding CHF diet, the reasons for its discontinuation and any requirements for 
treatment in 10 dogs fed CHF diet for longer than 4 months.
Dog
No.
Duration 
of feeding 
CHF 
(months)
Poor body 
condition
Diarrhoea SIBO Treatment 
for SIBO
Intestinal
biopsy
Histopath. 
evidence of 
enteropathy
Further
specific
treatment
1 8 + + 4- + + + +
3 15 +
4 13 + + + + +
5 16
6 21
8 10 + + + + + +
9 15 + + + +
10 19 +
11 16 + + +
13 7 +
Table 44. Further Observations: effects of very long term feeding (> 4 months) of CHF diet
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Discussion 
Post-prandial glycaemia
The parameters ABSMEAN, ABSSD, INCMEAN, and INCAUC were measured in an 
attempt to describe the 24 hour plasma glucose curves as fully as possible. Standard 
deviations (ABSSD) were calculated for the plasma glucose concentrations as indicators 
of the degree of fluctuation in glucose concentrations over the sample period and areas 
under the glucose versus time curve (INCAUC) are indicators of the mean deviation 
from baseline adjusted for uneven sampling frequency. The incremental values were 
generated to try to compensate for any variation in the quality of glycaemic control 
among the dogs.
The reduction in absolute mean plasma glucose concentration (ABSMEAN) may not 
have been the result of the change of diet alone. It has to be remembered that these dogs 
were hospitalised between the generation of the two plasma glucose curves and their 
insulin doses were being adjusted. If the nadir plasma glucose concentrations for all the 
dogs on both original and CHF diets had been in the range 3.5-7.5mmol/l then the effects 
of hospitalisation and adjusted insulin dose could have been ruled out completely. 
However, nadir plasma glucose concentration for dogs nos. 2, 4, 6, and 8 were above 
this range on the original diet and well below this range in dogs nos. 4, 5, 8 and 9 on 
CHF diet. This complicates the interpretation of both the 24 hour and afternoon post­
prandial glucose concentrations. However, of these 6 dogs, two (dog nos. 5 and 8) had 
had their insulin doses decreased between the original and CHF diet days; one dog (dog 
no. 4) had its insulin dose increased only very slightly and one dog (dog no. 9) whose 
insulin dose had been increased between diets was only below the 3.5-7.5mmol/l range 
for one sample point on the CHF diet day, leaving only two dogs (dog nos. 2 and 6) 
which had had an appreciable increase in insulin dose between the two diets. Taking 
these considerations into account along with the fact that the median nadir plasma 
glucose concentrations for the original and CHF diets fell into the acceptable range 3.5- 
7.5 mmol/1 should have meant that valid conclusions could be drawn from the post­
prandial glycaemia data.
There was no apparent or statistically significant absolute increase in insulin dose (lU/kg) 
over the hospitalisation period (Figures 115 and 116) and these dogs were clinically 
stable before hospitalisation. There may have been an effective increase in insulin dose if 
the CHF diet reduced insulin requirement and insulin doses were not decreased 
sufficiently to match this decreased requirement.
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Despite the uncertainty over the main source of the reduced ABSMEAN, be it diet alone 
or absolute or effective insulin dose increase, there was a reduction in INCMEAN and 
apparent (but not statistically significant) decreases in ABSSD and INCAUC and Figures 
51 and 52 highlight these reductions. The CHF plasma glucose curve is smoother and 
less erratic than the original diet curve and there is a striking reduction in afternoon post­
prandial hyperglycaemia in the CHF curve.
The afternoon post-prandial period was chosen for further study because the potentially 
dramatic effects of exogenous insulin on plasma glucose concentrations were likely to be 
more stable at this time than after the morning meal. Plasma glucose concentrations were 
standardised by subtracting the 6 hour plasma glucose concentration in an attempt to 
compensate for variations in the degree of glycaemic control among the dogs. This 
should mean that unless dogs were hopelessly underdosed with insulin when on the 
original diet, or significantly overdosed when on the CHF diet, any changes due to 
hospitalisation or altered insulin dose were largely corrected for so that changes due to 
diet could be more readily identified.
Figures 53 and 54 show that in the immediate post-prandial period there is a greater 
decrease in plasma glucose concentration when on original diet than when on CHF. This 
was probably because it was the second meal in the day which was being studied. On the 
CHF diet, it is possible that substrate fi*om the morning meal (6 hours earlier) was 
maintaining plasma glucose concentrations. Whereas, on the original diet, all the 
substrate fi*om the morning meal may have already been absorbed by 6 hours allowing 
plasma glucose to fall. It was to reduce the bias created by the smaller sampling interval 
in this immediate post-prandial period that the adjusted values ADJMEAN, ADJAUC 
and ADJSD were created.
The standard deviations of the afternoon plasma glucose concentrations (APPGSD and 
ADJSD) were lower on the CHF diet than on the original diet, although this difference 
could not be tested by statistical analyses. This can be interpreted as a smoother, less 
erratic post-prandial plasma glucose curve. The mean concentrations of plasma glucose 
(APPGMEAN and ADJMEAN) and areas under the plasma glucose versus time curve 
(APPGAUC and ADJAUC) were reduced but not statistically different between the diets 
(Table 42).
In the longer term study of 5 dogs, there were no statistically significant differences 
between original diet, one week on CHF and 4 months on CHF for any of the derived 
values. Examination of the results Table 43 and the Figures 55 to 60 reveals striking
CHAPTER 7 203
trends suggesting that the lack of statistical significance may have been a function of the 
small sample size.
Nelson et al (1991) successfully reduced mean 24 hour plasma glucose concentration 
and 24 hour plasma glucose fluctuation (SD) in 6 experimentally induced diabetic dogs 
using canned diets  ^which were high in soluble and insoluble fibre when compared to a 
low fibre canned diet. Similarly, Blaxter et al (1990) demonstrated a reduction in area 
under the plasma glucose versus time curve in normal dogs over a six hour morning 
post-prandial period following acute changes to home-made diets containing 20g of 
wheat bran and 20g of guar. In 4 dogs with naturally occurring diabetes mellitus there 
were similar trends but no statistically significant differences. Simpson et al (1981) 
studied the effects on 24 hour plasma glucose profiles of a high carbohydrate diet high in 
leguminous fibre versus a low carbohydrate diet in 9 insulin dependent diabetic humans. 
This high carbohydrate diet lowered and smoothed the mean plasma glucose curve and 
allowed the insulin dose to be reduced in 4 of the patients. Insulin dose was unchanged in 
the remaining 5 patients.
The present study is important and unique because there are no previous reports of the 
effects of canned high fibre diets on post-prandial glycaemia in dogs with naturally- 
occurring diabetes mellitus, none in which such a large group of dogs with naturally- 
occurring diabetes mellitus has been studied nor any in which a period of stable insulin 
dynamics has been chosen for further study.
The results of this study concur with previous findings of the effects of high-fibre diets 
on post-prandial glycaemia (Blaxter et al, 1990; Nelson et al, 1991) and confirm that a 
canned high fibre diet can reduce mean 24 hour glucose concentrations and may reduce 
post-prandial fluctuations in plasma glucose concentrations in dogs with naturally- 
occurring diabetes mellitus and that these effects may remain for at least 4 months.
* Diets used by Nelson, et al (1991)
Fibre content
(g/lOOOkcal ME) High insoluble fibre High soluble fibre Low fibre
Total fibre 70 55 24
Insoluble fibre 60 21 17
Soluble fibre 10 34 7
Furda enzymatic digestion
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Figure 115. Insulin doses (lU/kg) in 11 dogs before and after one week on CHF diet.
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Figure 116. Insulin doses (lU/kg) in 5 dogs before, one week after and 4 months after changing to
CHF diet
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Insulin dose and general health
Changing the diet of 11 dogs with naturally occurring diabetes mellitus to CHF diet 
resulted in statistically significant reductions in bodyweight and body condition score and 
increases in activity, demeanour and faecal volume scores. There were no statistically 
significant changes in insulin dose, coat condition score, vision score, faecal consistency 
score nor any apparent trends in routine haematological and biochemical parameters. 
There were no adverse changes in routine haematological or plasma biochemical 
parameters.
The change in bodyweight seen over the 4 month study period was generally a decrease 
with the exception of the absolute bodyweight for +2 months, the mean of which was 
higher than any of the other sample days. The reason for the weight loss is not instantly 
apparent since the quantity of CHF fed was isocaloric with each dog*s previous weight 
maintaining diet. This may suggest that incorrect assumptions were made about the 
caloric density of the CHF diet or of the original diets. However, the volumes of food fed 
seemed, subjectively, to be about correct. Another possibility is that nutrient availability 
fi’om the CHF diet was poorer than fi’om the original diets and this may be reflected in 
the diarrhoea experienced by a number of the dogs (Appendix 15). In some of the dogs, 
a loss of bodyweight would have been beneficial because a number were overweight at 
the beginning of the study. This can be seen in the absolute body condition scores in 
which the majority of dogs have scores greater than 50 near the beginning of the study 
(Appendix 17). A score of around 50 was likely to be allocated to dogs in ideal’ 
condition. If it were only the overweight dogs which had lost weight then a strong 
negative correlation between the mean body condition scores for the original diet days 
and the percentage of bodyweight lost at each of the CHF diet days would be expected. 
This was not the case. However, there was a statistically significant correlation between 
the percentage weight lost at 0 days and at both +3 months and +4 months (Pearson’s 
correlation; r > 0.60, p<0.05) suggesting that, the dogs which started to lose weight 
within the first week of CHF were the ones which lost the most weight in the longer 
term.
Examination of the absolute body condition score results (Figure 65) revealed a trend 
towards the ‘ideal’ score of 50 but by the last month of the follow-up period it was 
apparent that a number of dogs had scores which suggested that body condition had in 
fact become poor. The reasons underlying this trend are, like those for the changes in 
bodyweight, unclear.
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The increases in activity and veterinary observed demeanour scores most likely represent 
an improvement in glycaemic control and to some extent, in the late stages of the study, 
reduced bodyweight. The most likely explanation for the lack of statistically significant 
improvement in the owner observed demeanour scores in comparison with that in the vet 
observed scores is the owners’ adaptation to any changes in demeanour because of 
continual exposure to their pets.
Increased faecal volume may be expected because of the inclusion of indigestible 
components in the CHF diet but also because of a contribution fi*om the growth of 
colonic microflora (Cummings, 1983). Although there was no statistically significant 
trend in faecal consistency, clinically significant episodes of both constipation and 
diarrhoea were recorded in some dogs (Appendix 15).
There was no statistically significant change in insulin dose (lU/kg) over the period of the 
study, however, there was a trend towards a slight increase at +4 months. This is 
probably a reflection of the decrease in bodyweight seen especially at the end of the 
study rather than an active increase in insulin dose (lU) administered.
One previously published study of high fibre diets in experimentally induced diabetic 
dogs reported loose faeces and poor coat condition after feeding a high soluble fibre diet. 
In that study insulin dose was unchanged, as in the present study, and bodyweight was 
maintained by adjusting the volume of diet fed (the volume of high insoluble fibre diet fed 
was reduced compared to high soluble fibre and low fibre diets) (Nelson et cd 1991). One 
other previously published study of home made high fibre diets in dogs with naturally 
occurring diabetes mellitus (Blaxter et al 1990) reported only the biochemical effects of 
an acute change in diet.
In human medicine, insulin doses have sometimes been decreased following a change to a 
high fibre diet (Simpson et al, 1981). Weight loss normally only occurs in human 
diabetics fed high fibre diets which are calorie restricted, however, concerns over the 
possibility of micro and macronutrient malabsorption associated with chronic feeding of 
high fibre diets have been voiced (Vinik and Jenkins, 1988). High levels of soluble (guar) 
and insoluble dietary fibre have been associated with gastrointestinal upset including 
increased faecal bulk and decreased faecal consistency (Fuessl et al, 1987; Vinik and 
Jenkins, 1988).
When fed to dogs with naturally occurring diabetes mellitus, CHF diet appeared to be 
safe and was capable of improving demeanour and activity without a change in insulin
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dose over a 4 month study period but was associated with weight loss and increased 
faecal volume. It has no adverse effects on routine haematological or plasma biochemical 
parameters.
Indicators of glycaemic control
Changing the diets of 11 dogs to CHF diet during a period of hospitalisation resulted in 
statistically significant improvements in the concentrations of the indicators of glycaemic 
control; plasma fitictosamine, glycated haemoglobin, plasma alkaline phosphatase and 
afternoon plasma glucose. There were trends towards improvement, which were not 
statistically significant, in the plasma concentrations of plasma alanine aminotransferase, 
aspartate aminotransferase and fasting glucose.
The reductions in finctosamine, glycated haemoglobin, alkaline phosphatase and 
afternoon glucose indicate that an improvement in glycaemic control was achieved. This 
improvement appeared to wane towards the end of the study in the cases of fiuctosamine 
and afternoon glucose but was consistently present in the case of glycated haemoglobin. 
This discrepancy can be explained by a lag-phase in the reflection of changes in 
glycaemic control due to the long half-life of haemoglobin compared to that of the 
plasma proteins.
The lack of statistically significant improvements in the concentrations of plasma alanine 
aminotransferase and plasma aspartate aminotransferase concurs with the finding in 
Chapter 5 that these are not sensitive tests for glycaemic control or may suggest that 
there was little room for improvements in these parameters, which is wholly feasible 
since these dogs were ‘stable’ diabetics at the beginning of the study.
Fasting plasma glucose concentrations are mostly dependent on the duration of the 
exogenous insulin preparation administered, so no particular improvement in this 
parameter was expected.
The improvements seen in glycaemic control (the reductions in fiiictosamine, glycated 
haemoglobin, alkaline phosphatase and afternoon glucose) may not have been the result 
of the CHF diet alone. The effects of the hospitalisation period and the changes in insulin 
dose have to be considered. As discussed under ‘Insulin Dose and General Health’, the 
insulin doses of this group did not change significantly over the period of the study and in 
some cases insulin dose decreased by 20 to 40%. There may have been an effective 
increase in insulin dose if the CHF diet reduced insulin requirement and this was not
CHAPTER 7 208
followed by a decreased insulin dose. If this was the case, however, it could still only be 
described as a benefit of the diet.
The inclusion of previously stable diabetic dogs and the lack of an upward trend in 
insulin dose meant that any effect seen in the 4 month follow-up period was more likely 
to result fiom the CHF diet than the hospitalisation period.
With the exception of glycated haemoglobin, improvements in glycaemic control seemed 
to be more apparent in the first 2 months of the follow-up period and seem to wane 
towards the end of the study period. This may mean that the duration of the effects of the 
CHF diet are limited and that somehow there is gastrointestinal or metabolic adaptation 
to the diet. On the other hand, if any improvements in glycaemic control were the result 
of closer supervision in the hospitalisation period then these would be expected to 
diminish with time. One explanation for waning glycaemic control which could fit both a 
continuous effect of diet (unlimited duration) and the reduced level of supervision, is 
that, for endogenous reasons, these dogs may have had a steadily increasing requirement 
for insulin over the period of the study and that this increased requirement was not being 
followed. Yki-Jarvinen and Koivisto (1986) recorded a phenomenon of changing insulin 
requirement in treated Type I diabetic humans but whether this occurs in diabetic dogs is 
not yet known. Also, 7 of the dogs were receiving insulin of bovine origin. This is known 
to be antigenic in dogs and it is not inconceivable that its prolonged use leads to 
decreased potency and consequent increased requirement. Again, this has not yet been 
documented in dogs.
Previously published studies of the effects of dietary fibre in diabetic dogs have been 
limited to Blaxter et al (1990) and Nelson et al (1991). Blaxter et al (1990) studied the 
acute effects of two high fibre diets but did not monitor glycaemic control in a long term 
study. Nelson et al (1991) documented reduced glycated haemoglobin in a group of 
alloxan-induced diabetic dogs using a diet high in insoluble fibre over a 2 month study 
period. They, in concordance with the present CHF diet study, did not observe any 
statistical difference in fasting plasma glucose between low fibre and high soluble and 
insoluble fibre diets. They did not report the results of alkaline phosphatase, alanine 
aminotransferase or aspartate aminotransferase analyses and did not perform 
fiiictosamine measurements and so no direct comparison with their study can be made 
for these parameters.
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In human diabetic medicine, Fuessl et al (1987) reduced fasting plasma glucose and 
glycated haemoglobin concentrations in 18 non-insulin dependent diabetic patients over a 
4 week period using guar granules sprinkled onto food.
The protocol followed in this study improved glycaemic control during a 4 month 
follow-up period and, although the effects of hospitalisation on glycaemic control cannot 
be ruled out completely, this improvement was most likely to be the result of feeding 
CHF diet. These findings concur with previously published studies on ‘high-fibre’ diets in 
experimental diabetic dogs and non-insulin dependent diabetic humans, provide 
additional information by measurement of fiiictosamine and confirm that feeding a 
canned ‘high-fibre’ diet can improve long term glycaemic control in dogs with naturally- 
occurring diabetes mellitus.
Lipid metabolism
Feeding a high fibre diet to 11 dogs with naturally occurring diabetes mellitus over a 
period of 4 months following 10 days hospitalisation resulted in statistically significant 
reductions in the plasma concentrations of total cholesterol, low density lipoprotein 
associated cholesterol, fi*ee glycerol and non-esterified fatty acids. There were no 
statistically significant changes in plasma concentrations of triglyceride, VLDL 
cholesterol, HDL cholesterol or post-heparin hepatic lipase activity, although, there were 
trends towards reductions in VLDL and HDL cholesterol concentrations.
With the exception of percentage change in LDL cholesterol concentration fi*om basal 
the effects of any change seemed to wane by the end of the study (+4 months). This may 
be a reflection of the importance of the effects of the hospitalisation period on lipid 
metabolism and suggests that the changes seen are not the result of the change of diet 
alone. However, insulin dose over the period of the study did not change (Insulin Dose 
and General Health; Indicators of Glycaemic Control) which suggests that any 
improvements in glycaemic control (which will contribute to any changes in lipid 
profiles) did not result from increased insulin dose. The CHF diet could also have 
directly affected lipid profiles without affecting glycaemic control.
Blaxter et al (1990) studied the acute effects of home-made high fibre diets on post 
prandial serum concentrations of total cholesterol and triglycerides in naturally occurring 
diabetic dogs and found none and Nelson e/ a/ (1991) found no effects on plasma total 
cholesterol or triglyceride after feeding diets high in soluble and insoluble fibre to dogs 
with experimentally induced diabetes mellitus for periods of two months. There are no 
previous reports of the effects of high fibre diets on the cholesterol content of the
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lipoprotein classes in dogs with naturally occurring diabetes mellitus. High fibre diets 
have been shown to have effects on plasma concentrations of total (Vinik and Jenkins, 
1988; Simpson et al, 1981; Riccardi et al, 1984), LDL (Riccardi et al, 1984; Vinik and 
Jenkins, 1988) and HDL cholesterol (Simpson et al, 1981; Riccardi et al, 1984) when 
fed to insulin dependent diabetic humans. VLDL cholesterol concentrations are seldom 
changed by high fibre diets (Miettinen, 1987; Simpson et al, 1981). A ratio calculated in 
human medicine to assess the atherogenic potential of a lipoprotein profile (VLDL 
cholesterol + LDL cholesterol/HDL cholesterol) has been reduced by high fibre diets in 
insulin dependent diabetic humans (Riccardi et al, 1984). This ratio was also reduced in 
the current study (p=0.0426) but the relevance of this to the health of diabetic dogs is 
unclear since it is known that the atherogenic lipid profile in dogs is different fi'om that in 
humans (the most likely major canine atherogenic lipoprotein classes are an HDL and p- 
VLDL).
There was no statistically significant change in the plasma concentration of triglycerides 
in the present study and this is in agreement with the findings of previous reports 
studying the effects of high fibre diets in diabetic dogs (Nelson et al, 1991) and humans 
(Miettinen, 1987; Vinik and Jenkins, 1988; Riccardi, 1984; Simpson et al, 1981). High 
fibre diets have been associated with reduced total plasma triglyceride by others (Vinik 
and Jenkins, 1988) and with reduced VLDL triglyceride (Riccardi et al, 1984).
Plasma concentration of free glycerol and non-esterified fatty acids (NEFA) are 
qualitative markers of adipose tissue lipolysis but are generally not considered 
quantitative because the kinetics of adipose lipolysis and NEFA and glycerol re- 
esterification are complex and best studied by tracer isotope technology. Adipose tissue 
lipolysis is very sensitive to inhibition by insulin (via LPL and hormone sensitive lipase) 
and improved diabetic control has been associated with decreased lipolysis and plasma 
concentrations of NEFA and glycerol in diabetic humans (Coppack et al, 1994). A 
decrease in plasma concentrations of NEFA and glycerol in the present study is difficult 
to explain. The possibility that weight loss and reduced adipose depot has a role cannot 
be discounted but statistical analysis by multiple range testing did not identify differences 
in NEFA or glycerol concentrations at the times when weight loss was greatest. Since 
there was no increase in insulin dose this may mean that there is a mechanism by which a 
high fibre diet could contribute to the inhibition of lipolysis. Perhaps absorbed 
fermentation products can modulate insulin’s inhibitory effect on lipolysis. Hjollund et al 
(1983) have demonstrated improved insulin sensitvity in non-insulin dependent diabetic 
humans fed diets high in complex carbohydrates including fibre.
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Post heparin hepatic triglyceride lipase (H-TGL) activities in this study were generally 
much higher than the reference range and this is in agreement with Muller et al (1985) 
who found elevated activities of H-TGL in pancreatectomised diabetic dogs. In that 
study reductions in H-TGL activity towards normal were seen following improved 
glycaemic control by increased insulin dosage. Although feeding CHF diet to diabetic 
dogs in the present study does improve glycaemic control (see under Indicators of 
Glycaemic Control), this did not result from an increased insulin dose which probably 
explains why there was no change seen in H-TGL.
Feeding Pedigree Canine High Fibre Diet after a period of hospitalisation did appear to 
have beneficial effects on lipid metabolism in dogs with naturally occurring diabetes 
mellitus and these effects are similar to those produced by high fibre diets in diabetic 
humans.
Long-term foUow-up (> 4 months)
The significance of these findings is difficult to ascertain. There was no comparative data 
available on the occurrence of diarrhoea or chronic weight loss when these dogs were 
fed their original diets because a double crossover study was not performed. 
Subjectively, the prevalence of weight loss, recurrent diarrhoea and small intestinal 
bacterial overgrowth (70% in total) in this group of dogs seems high even when 
considering that they are all diabetic. The incidence or prevalence of SIBO in dogs with 
naturally occurring diabetes mellitus has not been reported and is not currently known.
Those dogs in which the feeding of CHF diet was discontinued because of very poor 
body condition, had not been expected to lose weight because an amount of CHF was 
fed which was isocaloric with their previous weight maintaining diets (if the assumed 
caloric density of CHF was correct - see under Materials and Methods). The occurrence 
of unexpected weight loss, recurrent diarrhoea and SIBO in this group of dogs is difficult 
to explain but the possibility that the CHF diet could be a direct contributor to their 
occurrence has to be considered. It is likely that the induction of intestinal malabsorption 
is an underlying phenomenon common to unexpected weight loss, recurrent diarrhoea 
and SIBO. Mechanisms by which a high fibre diet could induce malabsorption, may 
include alteration of intestinal morphology (Wahlqvist, 1987), or the promotion of SIBO. 
Pre-existent SIBO might be exacerbated by a high fibre diet because of retention of 
nutrients within the intestinal lumen and promotion of bacterial growth (Cummings, 
1983) but high fibre diets are unlikely to be able to initiate SIBO other than indirectly by 
inducing an intestinal malabsorption.
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Very long term (>4 months) feeding of Pedigree Canine High Fibre diet to dogs with 
naturally occurring diabetes mellitus may be associated with unexpected weight loss, 
recurrent diarrhoea or SIBO. It may be prudent to recommend that CHF diet might be 
unsuitable for feeding to diabetic dogs which have a history of intestinal malabsorption or 
small intestinal bacterial overgrowth.
Conclusions
Pedigree Canine lEgh Fibre Diet (CHF) was fed to 11 dogs with naturally occurring 
diabetes mellitus and its effects on post-prandial glycaemia, general health, biochemical 
indicators of glycaemic control and lipid metabolism were studied both in the short term 
(7 days) and in the longer term (4 months). In the short term, feeding CHF diet led to a 
statistically significant reduction in mean 24 hour plasma glucose concentration, and an 
apparent reduction in the fluctuation in afternoon post-prandial glycaemia. In the longer 
term, feeding CHF diet improved demeanour scores, activity scores, plasma 
concentrations of fiiictosamine, concentrations of glycated haemoglobin, plasma 
concentrations of alkaline phosphatase and afternoon plasma glucose concentrations. 
Reductions were also observed in the plasma concentrations of total cholesterol, low 
density lipoprotein cholesterol, free glycerol and non-esterified fatty acids. Thus, the 
effects of feeding CHF improved many aspects of diabetic control and this improvement 
was achieved without any statistically significant increase in insulin dose over the 4 
month study period. There was no haematological or plasma biochemical evidence of any 
adverse effects of feeding CHF. However, there was an association between feeding 
CHF and weight loss, reduced body condition score and increased faecal volume score.
The change from each dog's original diet to CHF diet was made during a 7-10 day period 
of hospitalisation. The contribution of hospitalisation to the improvements in diabetic 
control seen is difficult to judge. Certainly, dogs were clinically stable when they entered 
the study and no apparent increase in insulin dose was observed over the 4 months of the 
study. This should mean that the effects seen were mostly due to the CHF diet. The only 
way to separate the effects of hospitalisation from those of diet would have been to 
perform a double crossover study. This was not possible because of the proposed study 
duration and cost.
The duration of effect of CHF diet on diabetic control is not clear from this study. The 
greatest improvements in diabetic control appear, in general, to be after feeding CHF diet 
for two months. However, the improvements in a number of parameters seem to wane 
after this time. Again the potential influence of changes in insulin dose within individual
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animals and the effects of hospitalisation make it very difficult to be sure whether the 
beneficial effects of CHF diet did last for the 4 months of the study.
The opportunity was taken to follow the effects of feeding CHF diet to 10 dogs after the 
end of the 4 month study. The very long term (>4 months) feeding of CHF diet was 
associated with a subjectively high prevalence of unexpected weight loss, recurrent 
diarrhoea and small intestinal bacterial overgrowth.
The results of this study imply (assuming minimal effects of hospitalisation) that CHF 
diet has properties which enable it to significantly improve many aspects of diabetic 
control in dogs with naturally occurring diabetes mellitus when used in conjunction with 
an appropriate insulin replacement regimen. However, based on the observations made 
after the very long term feeding of CHF diet, this diet would be contraindicated in 
diabetic dogs with histories of intestinal malabsorption or small intestinal bacterial 
overgrowth.
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Chapter 8:
Longevity In canine diabetes mellitus
introduction
In the management of any chronic illness it is helpful to be able to predict longevity. One 
of the most common questions asked by owners of diabetic dogs at an initial consultation 
is: How long is my pet likely to survive on insulin treatment? In addition to the intrinsic 
value of such knowledge, a more accurate estimate of longevity would be helpful in 
calculating the size of the financial and psychological undertaking before owners commit 
themselves to have their dog treated. Moreover, comparative measures of longevity can 
be used to identify the most useful treatment strategies.
Two methods of survival analyses are commonly used by epidemiologists in order to 
ascertain likely survival following specific diseases in people and animals and to compare 
the relative benefit of different therapies. Of these, the product-limit (PL) method of 
estimating survivorship function described by Kaplan and Meier (1958) is the more 
fi’equently used. This method facilitates the generation of step-shaped survivorship 
function curves, the calculation of median survival times and comparisons of subgroups 
or treatments.
Canine diabetes mellitus is an age-related disease and many diabetic dogs are aged when 
first diagnosed; consequently they can only be expected to have a relatively short life 
remaining, regardless of their diabetic state. The other common method of survival data 
analysis is the life table method for large sample estimates of survivorship function, 
which can assist in ‘age-correcting’ survival data. In the life table method, survival times 
are grouped into intervals (the PL method uses individual survival times) and because of 
the necessity for a reasonable number of observations in each interval, it is best suited to 
large sample sizes. Two types of life table can be created: a general life table which 
applies to the general population, in which the time intervals are age groups, and a 
clinical life table in which the intervals are months or years survived after diagnosis or 
start of therapy. By relating the survival of diseased patients to that expected fi'om 
individuals of the same age, gender and ideally breed or race in the general life table a 
relative survival rate can be generated. For many years, general life tables have been
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generated for humans by governmental agencies to monitor the health status of their 
populations and to make comparisons between nations, states and regions.
There are two techniques for creating general life tables: one is the cohort method in 
which a large group of people or animals are followed from birth to death and a table 
constructed of the number of deaths at each age. The other is the current life table, 
constructed from census data concerning the numbers of individuals in the population for 
each age interval combined with data from a register of deaths providing the number of 
deaths in each age interval, thereby creating age-specific death rates. Because of the very 
long follow-up period required by the cohort method, the current life table method is 
more commonly used.
In the UK there is neither a national dog census nor a register of canine deaths so a 
classical current life table for the study of canine survival cannot be generated. A 
modified current life table for dogs could be generated from a large random sample of 
dogs, followed for one year, so that age-specific death rates could be calculated. Such 
information is probably held by pet insurance companies because of the annual renewal 
of policies. However, during the period of this study, requests for data from a British pet 
insurance agency were refused. A modified cohort-based life table which forms the basis 
of the only previously published canine life table was reported by Hayashidani et al 
(1988). In this method, records of the age at death for 4915 dogs presented to a Tokyo 
pet cemetery between June 1981 and May 1982 were used to generate age-specific death 
rates.
The aims of the present study were: to generate values for longevity in diabetic dogs 
treated with single daily injections of an intermediate acting insulin preparation and to 
make comparisons of survival between males versus females, isophane-treated versus 
lente-treated and the presence of concurrent endocrinopathy versus no other identifiable 
endocrinopathy.
Materials and methods
Eighty six diabetic dogs seen at the University of Glasgow between 1989 and 1994 were 
used as the study population. Dogs in which only temporary insulin therapy was required 
(metoestrus-associated diabetes) were excluded. All but one dog received isophane or 
lente insulin by single daily injection. In two other dogs the nature of the intermediate 
insulin preparation used was not recorded. All three dogs were excluded from the insulin 
comparison.
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Because dogs entered this study at different times; some were lost to follow-up and 
many were still alive at the end of the study, precise survival times were not known for 
all dogs. This is a common problem in survival data analysis and a technique known as 
censoring is employed (in this case Type m , random or progressive censoring). 
Censored survival times were calculated from the date at the end of the study or the date 
of last contact with the patient and denoted as censored by an asterisk or plus sign. All 
the statistical methods used were able to incorporate censored data.
Many of the following statistical methods are those recommended in Statistical Methods 
fo r Survival Data Analysis (Lee, 1992), Principles o f Biostatistics (Pagano and 
Gauvreau, 1992) and Stata Reference Manual: Release 3.1 6th ed (Stata Corporation, 
1993) but the originators of the methods are cited where appropriate.
Product-limit estimates
The method of Kaplan and Meier (1958) cited by Lee (1992) was used to estimate 
survivorship function. The following notation was used; /i, the number of animals studied
(in this case 86); t\, t2,.... t„, the survival times ranked in ascending order, the
survivorship function or the proportion of sample alive at time t (the circumflex denotes 
an estimate of the function) and r, the ranked position of each observation. The 
survivorship function at time zero,  ^ because all dogs are alive at the beginning of
the study. For each uncensored survival time the proportion of dogs surviving up to and 
through that time is given by (« - /*)/(« - r  + 1). S^ >^^ is then calculated as the product of all 
preceding (w - r)!{n - r  + 1) since cumulative probability follows the multiplicative rule. 
Table 45 gives an example based on 18 dogs with concurrent hyperadrenocorticism and 
diabetes mellitus.
Separate survivorship plots were created to allow comparison between male and female, 
between those treated with isophane insulin and those treated with lente insulin and 
among those which had concurrent hypothyroidism (HypoT4), hyperadrenocorticism 
(HAC) or no other identifiable endocrinopathy (Norm). The log-rank test was performed 
to compare survival distributions using Stata Statistical Software (Stata Corporation) 
based on the methods described by Peto et al (1977). Probability values of < 0.05 were 
taken to indicate statistical significance.
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t (years) r (n-r)/(n-r+l)
*^(0
0.00 1 0.944 0.944
0.02 2 0.941 0.941 X 0.944 = 0.889
0.10 3 0.938 0.938 X 0.941 X 0.944 = 0.833
0.24 4 0.933 0.933 X 0.938 x 0.941 x 0.944 = 0.778
0.30 5 0.929 0.722
0.31 +
0.31 7 0.917 0.662
0.36 8 0.909 0.602
0.39 9 0.900 0.542
0.84 +
1.00 +
1.60 +
1.66 13 0.833 0.451
1.89 14 0.800 0.361
2.77 15 0.750 0.271
3.17 16 0.667 0.181
3.67 +
3.86 18 0.000 0.000
Table 45. Calculation of survivorship function for 18 dogs with concurrent diabetes mellitus and 
hyperadrenocorticism using the product-limit method.
General life table
In the absence of survey data to generate a current life table, the method described by 
Hayashidani et al (1988) was used to create a modified cohort life table based on a 
sample of dead dogs. The sample of dead dogs used was generated fi'om the hospital 
necropsy database at the University of Glasgow Veterinary School. An age at death was 
calculated for each canine necropsy between 1988 and 1994 fi'om date received for post­
mortem examination and date of birth. Following removal of those records where date of 
birth was incorrectly recorded or not recorded and where gender was not defined, a total 
of 926 necropsy records were used to generate two gender-specific (male and female) 
cohort life tables.
The general life tables were made up of the following columns:
Column 1. Age interval (years) 0 -1 , 1 -2 , 2 -3 , etc, denoted as (x, x  +/), where / is the 
length of the age interval. In this case f = 1 year.
Column 2. Number alive at time x, denoted as /%. At X(o), I = n (the number of 
observations in the sample). is thereafter equal to n minus the sum of observed deaths 
preceding time x.
Column 3. Number dying in the age interval (x, x +1), denoted as
CHAPTERS 218
Column 4. Conditional probability of dying in the age interval (x, x +1), denoted by 
= djly,
Column 5. Conditional probability of surviving the age interval (x, x +1), denoted by Px.
Px = 1 - x^.
Column 6. Total number of years lived in age interval (x, x +1), denoted by Deaths 
within the age interval are assumed to be evenly distributed through the interval and are 
therefore each considered to contribute half an age interval. ~ tiJxH + id jl)) .
Column 7. Total number of dog-years lived beyond age x by dogs alive at age x, denoted 
by Tx. Tx = the sum of Z* and all subsequent Vs.
Column 8. Average number of years of life remaining at beginning of age interval (or age 
specific life expectancy), denoted by x^ = TJlx.
Columns 5b and 5c were created to provide age specific probabilities of surviving 1 and 
6 month intervals used in the age correction of clinical life table data. These contained 
the average probability of surviving 1 month = (1 - and of surviving 6 months =
(1 - for each 1 year age interval.
Clinical life table
For 86 diabetic dogs, survival time (including censored observations) was grouped into 
intervals of 6 months. The first 6 month period was fiirther subdivided into individual 
months.
A life table for all diabetics was constructed according to the following method (Lee, 
1992):
Column 1. Time interval (fj, fj+i). In this case, 0 -1 , 1 - 2, 2 - 3, 3 - 4, 4 - 5, 5 - 6, 6 - 12 
months, 1-1.5 years, 1.5-2 years etc. The final interval was >5 years.
Column 2. Midpoint of the time interval in years (/mi). In this case, 0.041, 0.125, 0.208, 
0.291, etc. The midpoint is used for plots of hazard and probability density below.
Column 3. Width of the time interval (A, /j+i) in years (6J.
Column 4. Number of cases lost to follow up (/J
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Column 5. Number of cases withdrawn alive (wi). Dogs still alive at the end of the study 
period.
Column 6. Number of cases dying {d\).
Column 7. Number of cases entering the time interval («'O- For the first interval n \ = the 
total sample size. Thereafter n\ -  the number entering the previous interval minus those 
lost to follow-up, withdrawn alive or dead in the previous interval i.e. n\ = /iVi - t i  - 
- d\.\.
Column 8. Number of cases exposed to risk (wj. Cases which are lost to follow-up or 
withdrawn alive are assumed to have been exposed to risk for half the interval. 
Consequently, = n\ - 0.5% + wj.
Column 9. Conditional proportion dying {q^). g, = djrii.
Column 10. Conditional proportion surviving {p^). = 1 - g,.
Colunm 11. Cumulative proportion surviving (,5%)). This is an estimate of survivorship 
fimction with time, i.e., the proportion of cases alive at time /. It is calculated fi'om the 
probability of surviving to the beginning of, and then through, the previous interval, i.e. 
Sit^) = PtS(ti_i). At time zero % )  = 1.
Column 12. Estimated probability density fimction, / ( / ^ ) .  This is the probability of 
dying in the /th interval per unit width (i.e., per year). It is estimated at the midpoint of
the interval. /( /^ . ) = .
4
Column 13. Hazard fimction, h{t^). This is the number of deaths per unit time (year) 
divided by the average number of survivors at the midpoint of the /th interval (or deaths 
per animal per year), i.e., 7 ( L ) /^ ( L ) .  ^ ( L )  = 0 .5 [ % J + % ) ]  since % )  is the 
probability of surviving at the beginning and not the midpoint of the interval. This 
reduces to .
Column 14. Estimated median remaining lifetime at time /i, denoted as If ,5(/J is 
the proportion of cases surviving at time t\, then the proportion of these cases which will
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still be alive at the median survival time for interval / will be S (1^ )12. If, for each interval 
i, the interval containing S{t) = S{t^)!2 is denoted %, /j+i), then:
Columns 15-18. These are square roots of the variances of the estimated functions 
f i lm  )» ) &nd which give approximate confidence intervals. The variances are
calculated using the following formulae (Lee, 1992):
Var[5(/, )] = [5(/< )p (/ refers to preceding intervals)
V ar[/(/„  )] = (/ refers to preceding intervals)
b,
Var[Â(/^ )] s
Var[/^ ] s  — —-  (J refers to the start of the interval containing S{t) =
Following the generation of a clinical life table for all diabetic dogs separate tables were 
created for male and female dogs, isophane treated and lente treated dogs, and for all 
diabetic dogs minus those suffering fiom concurrent hyperadrenocorticism. It was not 
possible to make separate tables for concurrent hypothyroidism, concurrent 
hyperadrenocorticism and ‘normal’ diabetic dogs because the numbers of dogs in these 
individual groups were insufficient for the clinical life table method.
Relative survival rates
For each dog alive at the beginning of each interval an expected rate of survival for that 
dog for that interval, /?*, was obtained according to its age and gender from the general 
life table created above. For each additional year that a dog survived, its expected 
survival rate had to be taken from successive age groups within the general life table. 
The expected survival rate for each interval was calculated as the mean of all the 
individual expected survival rates of j  dogs alive at the beginning of the interval, i.e.
■
"  i
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A relative survival rate was then calculated from a ratio of the observed survival rate to 
the expected survival rate, i.e. / p*. Relative survival rate curves were generated
for each of the subgroups for which a clinical life table had been created.
Results
Product-limit estimates 
Gender
The Kaplan-Meier survivorship function versus time plots for male (n=35) and female (n 
= 51) diabetics are given in Figure 117. Median survival time for males was 2.13 years 
and for females was 2.75 years. There was no statistically significant difference between 
the survival of these two groups. The overall median survival time was 2.71 years.
Insulin treatment
The Kaplan-Meier survivorship function versus time plots for isophane-treated (n=50) 
and lente-treated (n = 33) diabetics are given in Figure 118. Median suvival time for 
isophane-treated was 2.53 years and for lente-treated was 2.80 years. There was no 
statistically significant difference between the survival of these two groups.
Type
Survival plots for ‘normal’ diabetics (n = 61) and those with concurrent hypothyroidism 
(n = 7) or hyperadrenocorticism (n = 18) are represented in Figure 119. Median survival 
times were 2.93 years for the ‘normal’ group and 3.68 and 0.96 years for the 
hypothyroid and hyperadrenocorticism groups, respectively. There was a statistically 
significant difference among the survivals of these three groups (p = 0.02). Following 
exclusion of the hypothyroid group (because of the small number of cases), the dogs with 
hyperadrenocorticism had a significantly shorter survival than the ‘normal’ dogs (p = 
0.03).
General life table
The general life tables generated for female and male dogs which underwent post­
mortem examination at the University of Glasgow Veterinary School are given in Tables 
46 and 47. Life expectancy at age zero was approximately 6.9 years for the two genders. 
There was no apparent difference between the male and female life tables. Figure 120 
represents the age group specific death rates for male and females and also for the first 
17 year intervals reported by Hayashidani et al (1988).
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Proportion surviving
1
— Female Male + Censored
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Figure 117. Survivorship function by product-limit method versus time for all 86 diabetic dogs 
according to gender (males n = 35, females n = 51).
Proportion surviving
1
— Isophane Lente + Censored
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Figure 118. Survivorship function hy product-limit method versus time according to type of 
intermediate acing insulin preparation (isophane n = 50, lente n = 33).
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Proportion surviving
1
HAC -*-HypoT4 — Norm : Censored
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Figure 119. Survivorship function by product-limit method versus time according to type of 
diabetes mellitus. HAC (n = 18), HypoT4 (n * 7) and Norm (n * 61).
1 2 3 4 5a 5b 5c 6 7 8
(x, X +/) /x 4 Px(/yr) /?x (/mth) Px (/6mth) Z.X 7’x
0, -1 430 45 0.105 0.895 0.991 0.948 407.5 2941.0 6.84
1.-2 385 26 0.068 0.932 0.994 0.966 372.0 2533.5 6.58
2. -3 359 23 0.064 0.936 0.995 0.968 347.5 2161.5 6.02
3.-4 336 23 0.068 0.932 0.994 0.966 324.5 1814.0 5.40
4, -5 313 20 0.064 0.936 0.995 0.968 303.0 1489.5 4.76
5,-6 293 33 0.113 0.887 0.991 0.944 276.5 1186.5 4.05
6, -7 260 40 0.154 0.846 0.987 0.923 240.0 910.0 3.50
7,-8 220 34 0.155 0.845 0.987 0.923 203.0 670.0 3.05
8, -9 186 48 0.258 0.742 0.978 0.871 162.0 467.0 2.51
9, -10 138 35 0.254 0.746 0.979 0.873 120.5 305.0 2.21
10, -11 103 31 0.301 0.699 0.975 0.850 87.5 184.5 1.79
11,-12 72 35 0.486 0.514 0.959 0.757 54.5 97.0 1.35
12.-13 37 21 0.568 0.432 0.953 0.716 26.5 42.5 1.15
13,-14 16 9 0.563 0.438 0.953 0.719 11.5 16.0 1.00
14,-15 7 6 0.857 0.143 0.929 0.571 4.0 4.5 0.64
15,-16 1 1 1.000 0.000 0.917 0.500 0.5 0.5 0.50
Table 46. General life table for female dogs (n = 430) generated from the University of Glasgow 
Veterinary School necropsy database.
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1 2 3 4 5a 5b 5c 6 7 8
(X, X +t) /x 4 9x Px(/yr) Px (/mth) Px (/6mth) Z,x Tx «X
0, -1 496 39 0.079 0.921 0.993 0.961 476.5 3458.0 6.97
1,-2 457 29 0.063 0.937 0.995 0.968 442.5 2981.5 6.52
2, -3 428 22 0.051 0.949 0.996 0.974 417.0 2539.0 5.93
3.-4 406 24 0.059 0.941 0.995 0.970 394.0 2122.0 5.23
4, -5 382 35 0.092 0.908 0.992 0.954 364.5 1728.0 4.52
5.-6 347 44 0.127 0.873 0.989 0.937 325.0 1363.5 3.93
6. -7 303 47 0.155 0.845 0.987 0.922 279.5 1038.5 3.43
7.-8 256 39 0.152 0.848 0.987 0.924 236.5 759.0 2.96
8.-9 217 57 0.263 0.737 0.978 0.869 188.5 522.5 2.41
9, -10 160 54 0.338 0.663 0.972 0.831 133.0 334.0 2.09
10, -11 106 33 0.311 0.689 0.974 0.844 89.5 201.0 1.90
11,-12 73 30 0.411 0.589 0.966 0.795 58.0 111.5 1.53
12,-13 43 21 0.488 0.512 0.959 0.756 32.5 53.5 1.24
13,-14 22 16 0.727 0.273 0.939 0.636 14.0 21.0 0.95
14, -15 6 3 0.500 0.500 0.958 0.750 4.5 7.0 1.17
15,-16 3 1 0.333 0.667 0.972 0.833 2.5 2.5 0.83
16,-17 2 2 1.000 0.000 0.917 0.500 1.0 0.0 0.00
Table 47. General life table for male dogs (n = 496) generated from the University of Glasgow 
Veterinary School necropsy database.
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Figure 120. Probability of death versus age curve for male and female dogs from 926 canine post 
mortem records at the University of Glasgow Veterinary School (female n=430, male n=496) and 
for the first 17 years of data reported by Hayashidani et al (1988) from 4915 pet cemetery records.
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Clinical life table
The life table for all 86 diabetic dogs is given in Table 48. Survivorship function, 
probability density and hazard function versus time are represented in Figures 121 - 123. 
Median survival time from the survivorship function graph was 2.82 years. Included in 
the survivorship function versus time graph there is another curve generated from a case 
series by Foster (1975) in which sufficient raw data on the survival times of 98 diabetic 
dogs was reported to create a clinical life table (median survival time 1.00 years). 
Unfortunately, these data were not presented in a form from which product-limit 
estimates or statistical comparisons could be made. In the present study, the hazard 
function was greatest during the first month of treatment, remains relatively low from 6 
months to 2.5 years and then begins to increase again. The reasons for failure (death) in 
the uncensored observations during this initial ‘hazardous’ 6 month period (n= 17) were: 
owners unwilling to continue therapy (6), no response to initial treatment (3), unknown 
(2), hypoglycaemia (1), renal failure (1), cirrhosis (1), failure to recover following 
ovariohysterectomy (1), septicaemia (1) and aggression (1).
Because of the difference between survival of ‘normal* diabetics and those with 
concurrent hyperadrenocorticism within the first 6 months of treatment, highlighted in 
Figure 119, an expanded plot of hazard function for all diabetics and those without HAC 
was generated to compare these two groups within the early part of treatment (Figure 
124). There is an apparent difference in hazard between all dogs and those without HAC 
especially between 2 and 5 months after start of therapy.
Median remaining lifetime is represented in histogram form in Figure 125 and increases 
from 2.82 years at the start of treatment to 3.11 years for those dogs which have 
survived the first 5 months of therapy. Median remaining lifetime could not be calculated 
for dogs surviving longer than 2.50 years because of an insufficient follow-up period. 
Median remaining lifetimes based on data from Foster (1975) are also represented in 
Figure 125, where they increase from 1.00 year at diagnosis to a maximum of 2.84 years 
for dogs which survived the first 5 months.
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Proportion surviving
1
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Figure 121. Survivorship function of 86 diabetic dogs seen at the University of Glasgow Veterinary 
School and also for data derived from 98 diabetic dogs reported by Foster (1975).
Probability density
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Figure 122. Probability density function for death in 86 diabetic dogs seen at the University of 
Glasgow Veterinary School
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Hazard function
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Figure 123. Hazard function for 86 diabetic dogs seen at the University of Glasgow Veterinary 
School
Hazard function
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Figure 124. Hazard function for all diabetic dogs (n = 86) and for all diabetic dogs without 
hyperadrenocorticism (all - HAC, n = 68).
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Time after diagnosis
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Figure 125. Median remaining lifetime for 86 diabetic dogs seen at the University of Glasgow 
Veterinary School (shaded bars) and also for data derived from 98 diabetic dogs reported by 
Foster (1975) (vertical bars).
Relative survival rates
Relative survival rates for all 86 dogs were close to or greater than 100% for up to 4 to
4.5 years of treatment. After that time there were insufficient data to make a useful 
estimate of relative survival rate. This means that, for the first 4.5 years, treated diabetic 
dogs have a near equal or greater chance of survival than that expected from a general 
population (generated from canine post-mortem data).
The relative survival rate curves for the gender and insulin groups are presented in 
Figures 126 and 127. Relative survival rate appeared to be higher for males during the 
period 3 to 4.5 years after diagnosis and for lente-treated dogs during the preriod 3.5 to
4.5 years. The numbers of dogs involved in these survival intervals and the erratic nature 
of the curves made the significance of these ‘differences’ in estimates of relative survival 
rate difficult to interpret.
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Relative survival rate (%)
140
120
100
r male ♦ r  female
53.5 4 4.52 2.5 31.50.5 10
Years after d ia g n o sis
Figure 126. Relative survival rates by gender (female n = 51; male n = 35). NB y - axis extends 
from 40% to 140%.
Relative survival rate
140
120
100
-H-risophane -*-r lente
53.5 4 4.52.5 30 0.5 1 1.5 2
Years after d ia g n o sis
Figure 127. Relative survival rates by insulin type (isophane n = 50; lente n = 33). NB y - axis 
extends from 40% to 140%.
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Because of the difference in survival (product-limit estimates) and hazard between the 
‘normal’ diabetics and those with concurrent hyperadrenocorticism, a relative survival 
rate for those dogs without HAC was plotted alongside that for all diabetics (Figure 
128). It appears from the relative survival rate graph that following age-correction there 
is very little difference in survival related to the presence of concurrent HAC
Relative survival rate
120
110
100
All ^ A ll  - HAC
4.5 542 2.5 3.50 0.5 1.5 31
Years after diagnosis
Figure 128. Relative survival rates for all diabetic dogs (n = 86) and for those without 
hyperadrenocorticism (All - HAC, n = 68). NB y - axis extends from 80% to 120%.
Discussion
The duration of survival in diabetic dogs treated with single daily injections of 
intermediate acting insulin was not dependent on gender or the type of insulin 
preparation used. The product limit and clinical life table methods gave very similar 
overall median survival times of 2.71 and 2.80 years, respectively. The presence of 
concurrent hyperadrenocorticism significantly affected survival time and median survival 
time for these diabetic dogs was only 0.96 years. The hazard (of death) to diabetic dogs 
is greatest within the first 6 months of treatment especially for those with concurrent 
HAC and this is reflected in the median remaining lifetime which reaches a peak in dogs 
which have survived the first 5 months of treatment. The greatest single hazard to 
diabetic dogs within the first 6 months of treatment is their owner’s unwillingness to 
continue treatment. Following correction (principally for age) of survival data using a 
general population based on veterinary school necropsy data, it appears that treated
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diabetic dogs have a near equivalent or greater chance of survival than expected and that 
the increased ‘hazard’ experienced by dogs with concurrent HAC may be age related.
There are few previous reports of survival of treated canine diabetics and none in which 
statistical methods for survival data analysis have been employed. Some reports contain 
very vague estimates of survival such as 3 to 12 months and sometimes 1.5 to 2 years 
(Joshua, 1963) or 2-5 years (Feldman and Nelson, 1987).
Some previously published reports contain sufficient information for some inferences 
about survival to be derived. In 1960, Wilkinson reported the first large British case 
series of canine diabetes mellitus at which time insulin treatment in dogs was still 
relatively new. Of 58 cases from a veterinary hospital based population in London, 30 
had died very early in the course of treatment and so a median survival time would 
probably have only been one or two months at the most. Unwillingness by owners to 
continue treatment was responsible for about 14% of deaths (7% in the present study) 
and renal and hepatic failure were believed to be responsible for many of the other 
treatment failures. In 1972, Lauder reported a review of 97 veterinary hospital based 
cases at the University of Glasgow which provided some survival data. At the end of the 
first month of treatment only 60% remained alive (94% in the present study), after 6 
months 40% were alive (79% in the present study) and only 15% were alive after one 
year (72% in the present study). No explanation was given as to the causes of treatment 
failure. Ling et al (1977) reported on a veterinary hospital based series of 59 diabetic 
dogs from the United States. In that study, at least 33 were dead within two months of 
starting treatment, i.e., only 44% survived longer than two months (90% in the present 
study). Again the unwillingness of owners to continue treatment was a major cause of 
death (11%) followed by ketoacidosis, necrotising pancreatitis and renal failure. Doxey 
et al (1985) reported a veterinary hospital based group of 43 diabetic dogs from 
Edinburgh in which 29 survived the initial stabilisation period. Of these 29 dogs, 64% 
survived to one year, i.e. an overall one year survivorship function of 43% (72% in the 
present study).
Foster (1975) reported a large veterinary practice survey-based case series of 98 dogs in 
such a way that the survival data could be manipulated and incorporated into the present 
study for comparison (Figures 121 and 125). In that series there was a much higher death 
rate in the first few months of treatment than in the present study, resulting in a median 
survival time of only one year. However, after the first three months, median remaining 
life was reasonably comparable with that in the present study. Possible reasons for the 
very large difference between the studies in survival during the first month are that 
Foster’s survey was practice based (first opinion) and not hospital based (second
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opinion) and that early management of canine diabetes mellitus has improved 
considerably over the last 20 years. It is reassuring that the median remaining lifetimes 
are generally greater in a group of referred diabetic dogs than in those derived from a 
practice based population nearly 20 years previously. However, the difference between 
the two groups is not large after the first three months, suggesting that there has only 
been a small improvement in the long-term management of canine diabetes mellitus in 20 
years. This may be a reflection of the age at which many dogs become diabetic and the 
limits that the natural canine life-span places on improvements in survival time.
Based on the above reports, it seems that in the present study dramatic improvements in 
the longevity of dogs with diabetes mellitus have been achieved and that the principal 
improvements are in early management and during the first year after diagnosis.
None of the previous reports indicated whether the dogs they studied were diabetic only 
or whether they were complicated by the presence of other endocrinopathies. Peterson et 
al (1981) reported on 30 dogs presented with concurrent diabetes mellitus and 
hyperadrenocorticism from the United States. Approximate survivorship functions 
derived from survival data in that report are (present study in brackets): 1 month 76% 
(84%), 6 months 63% (53%) and at one year 53% (50%). Peterson et al (1981) reported 
that ketoacidosis, renal failure and pancreatitis were responsible for most deaths in this 
group and that owner unwillingness to continue was responsible for around 13% of 
deaths. In the United Kingdom, Blaxter and Gruffydd-Jones (1990) reported on a much 
smaller series of concurrent diabetes mellitus and hyperadrenocorticism in 8 dogs from 
Bristol in which median survival time was approximately 0.66 years (0.96 years in the 
present study). The results of the present study concur with those of Peterson et al 
(1981) and Blaxter and Gruffydd-Jones (1990) and suggest that survival time in dogs 
with concurrent diabetes mellitus and hyperadrenocorticism is short compared with 
diabetic dogs which do not have hyperadrenocorticism.
There are no previous reports of relative survival rates for canine diabetes mellitus but it 
is very encouraging that, based on the general population used for comparison in the 
present study, it appears that ‘normal’ life expectancy can be restored or even exceeded 
in diabetic dogs treated with once daily insulin therapy. The possibilty of a relative 
survival rate greater than 100% may be explained by the unusually high degree of 
committed care and attention that owners will provide for diabetic dogs, manifested by 
their decision to opt for treatment of their pet’s diabetes in the first place and also the 
amount of disciplined contact necessitated by the insulin injection and dietary regimen.
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The use of a general life table generated from veterinary hospital necropsy data may be 
considered inappropriate by some but there are a number of points in its favour. It may 
be suggested that hospital necropsies are performed on animals which are both terminally 
ill (including those which are indirectly terminal, i.e., the presence of an illness causes 
owners to elect euthanasia for their pet) and referred to a specialist centre. However, if 
these dogs had not been referred, their survival times would have been equivalent or 
shorter and they consequently represent a cross-section of survival experience by the 
general canine population. Such a cross-section may be biased by factors which affect the 
decision to refer to the hospital such as age, gender, breed and nature of disease but the 
hospital canine diabetic population is similarly biased because the effects of these factors 
will also apply to their selection for referral. A comparison between the two groups on 
this basis is therefore valid.
Further observations suggest that the general life table created in the present study is 
likely to be a reasonable reflection of the general UK canine population. The similarity in 
shape between the age specific probability of death curves created in the present study 
and those of Hayashidani et al (1988) is striking (Figure 120). However, the probability 
of death curve of Hayashidani et al (1988) is generally lower than that generated in the 
present study. This is not surprising after consideration of the following information. 
Hayashidani et al (1988) reported on a group of Tokyo dogs which were putatively up to 
26 years of age at death and of which 42% lived longer than 10 years. This seems 
unlikely to be the case in the British canine population and this is confirmed in two 
publications on the demography of British dogs. Thrusfield (1989) reported that only 
15% of British dogs were greater than 10 years of age based on a very large owner 
survey, which supported results of a veterinary practice survey which showed that 18% 
were greater than or equal to 10 years old (Edney and Smith, 1986).
The percentages of a population dying and the percentage alive at a certain age are not 
directly interchangeable, but of the necropsy data in the present study 22% of dogs were 
alive at equal to or greater than 10 years old and only 2.4% were alive after 14 years of 
age (2.45% of British dogs were greater than 14 years old in 1986 (Thrusfield, 1989)). 
This suggests that, at least in terms of aged dogs, the necropsy data used in the present 
study reflects the general UK canine population reasonably well and that a higher 
probability of death curve generated from this data than from Hayashidani et al (1988) is 
to be expected given the considerably greater longevity of dogs in Tokyo than in the UK.
In conclusion, the median survival time for diabetic dogs treated with single daily 
injections of an intermediate acting insulin was 2.71 years. Survival is not affected by 
gender or choice of insulin type. Median remaining lifetime was 3.11 years for those
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diabetic dogs which survived the first 5 months of treatment. Dogs with concurrent 
hyperadrenocorticism had a much poorer prognosis but this may have been a reflection 
of their age at diagnosis. Survival times for diabetic dogs have improved considerably in 
the last 20-30  years but improvements in long-term survival may be limited by a natural 
canine lifespan. Survival of treated diabetic dogs is near equivalent to or greater than that 
of an age and gender matched general canine population using a necropsy based modified 
cohort general life table.
During the conduct of this study areas for further research have been highlighted. More 
vigorous attempts to create a current life table for UK dogs need to be made, preferably 
with a large enough data set to allow breed specific tables to be created. This would 
allow validation of the relative survival rate results presented in this study. Furthermore, 
in order to increase the usefulness of the results of this study, logistic and linear 
regression modelling could help identify prognostic or risk factors associated with 
longevity such as; preliminary concentrations of certain plasma biochemical analytes, 
including basal insulin, initial response to treatment, mean or integrated values for plasma 
biochemical analyses during treatment, in addition to age at diagnosis and the presence of 
concurrent illness.
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Chapter 9: 
Conclusions and future study
The results of each section of this study have been discussed in detail at the end of each 
chapter. The aim of this chapter is to summarise the findings of the work and to highlight 
potential areas for future study.
Epidemiological investigation of a large group of diabetic dogs concluded that age, 
gender and breed were all important factors associated with the presence of diabetes 
mellitus. Similar breed predispositions to those in previous reports (Wilkinson, 1960; 
Krook et al, 1960; Foster, 1975; Ling et al, 1977; Marmor et al, 1982; Doxey et al, 
1985) were found. In particular, the over-representation of Poodles and Cairn terriers 
and the under-representation of German shepherd dogs have once again been confirmed. 
The findings of this study also served to emphasise the large proportion of diabetic dogs 
which were young (20% were < 7 years) and the complex relationship between age and 
gender associated with the condition.
No previous reports have compared the epidemiological characteristics of the condition 
in dogs from high and low or normal-risk breeds. The work presented in this thesis 
suggests that the disease in these breed groups may be different and highlights another 
area for future study. Candidate approaches for such an investigation include genetic and 
immunological techniques to attempt the identification of markers for disease sub-groups 
and to confirm or reject the hypothesis that an autoimmune process (similar to human 
Type I disease) may be involved in the ‘high risk’ breeds. In humans and experimental 
mouse models, genetic markers based in the major histocompatability complex (MHC) 
have been identified for susceptibility to diabetes mellitus (Vadheim and Rotter, 1992). 
Considerable work on MHC typing in the dog has been undertaken and it would now be 
possible to investigate MHC based genetic markers in spontaneous canine diabetes 
mellitus.
In Chapter 4, an attempt was made to identify characteristics of the clinically 
recognisable different forms of canine diabetes mellitus. This work showed that diabetic 
dogs with hypothyroidism were generally younger and those with hyperadrenocorticism 
were generally older than ‘normal’ diabetic dogs. In addition half of the dogs with
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concurrent hypothyroidism and diabetes mellitus were of only two (uncommon) breeds. 
The pathophysiology of diabetes mellitus in these dogs may be different from ‘normal’ 
diabetic dogs and warrants further investigation again by genetic and immunological 
techniques to discover if this condition is a canine manifestation of an autoimmune based 
polyendocrine failure similar to those found in man.
Based on a small number of observations, basal plasma insulin analysis prior to 
ovariohysterectomy was a useful prognostic tool in metoestrus associated diabetes 
mellitus. However, more examples of the use of this technique need to be gathered in 
order for a more definite conclusion of its value to be reached.
Two tests new to the veterinary clinical laboratory, fructosamine and glycated 
haemoglobin, were validated for use with canine samples. Both tests performed well in 
the laboratory and were useful for diabetic monitoring. This was in contrast to alkaline 
phosphatase, alanine aminotransferase and aspartate aminotransferase which were not 
useful for this purpose. The assessment of these tests was performed using relative 
operating characteristic curve analysis, a powerful technique for the comparison of 
laboratory tests which is likely to become increasingly popular in the realm of veterinary 
laboratory medicine.
Future work on the use of fructosamine and glycated haemoglobin in diabetic dogs must 
include an attempt to define algorithms which can relate fructosamine or glycated 
haemoglobin concentrations to mean plasma glucose concentrations. Such work would 
involve repeated plasma glucose measurements on a daily basis for a number of weeks or 
months and, therefore, would be better suited to an experimental environment than a 
clinical setting.
The pharmacokinetic analysis of a highly purified porcine mixed insulin zinc suspension 
(IZS-P) revealed that it is well absorbed following subcutaneous injection and that it has 
two reasonably predictable times of peak activity at around 4 and 11 hours and an overall 
duration of activity of between 14 and 24 hours. This is the first report of the 
pharmacokinetics of a lente insulin preparation in dogs. Opportunities for further study in 
this area include: a comparison of the pharmacokinetics of lente preparations of bovine 
and porcine origin and an investigation of the pharmacokinetics of protamine zinc insulin 
preparations which have not been reported so far, despite the availability of a veterinary 
licensed formulation (Insuvet PZI; Schering-Plough).
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An efficacy study of IZS-P showed it to be effective in both the short and long term 
management of canine diabetes mellitus when used on a single daily basis in combination 
with a twice daily feeding schedule. Rates of bacterial infections and blindness resulting 
from diabetic cataracts were calculated during its long term use and were found to be 1 
per 1.11 and 1 per 2.23 diabetic-dog-years respectively. Unfortunately, no comparison 
with other insulin preparations could be made at this stage but future work on the long 
term complications of canine diabetes mellitus (including cataracts, bacterial infections 
and small intestinal bacterial overgrowth) will be performed and will consider risk factors 
such as: age at diagnosis, gender, insulin type and dietary management using statistical 
methods for survival data analysis, including logistic regression modelling.
The use of a commercially produced canned ‘high fibre’ diet as an adjunct to the 
management of canine diabetes mellitus was studied. Feeding this diet reduced mean 24 
hour plasma glucose concentration and the fluctuation in afternoon post-prandial 
glycaemia. Demeanour and activity scores and plasma concentrations of afternoon 
glucose, fructosamine and alkaline phosphatase were also improved. In addition, 
reductions were observed in plasma concentrations of total cholesterol, LDL cholesterol, 
free glycerol and non-esterified fatty acids. There was an association between feeding 
this diet and weight loss, reduced body condition scores and increased faecal volume 
score and in the very long term (> 4 months) there was a subjectively high prevalence of 
unexpected weight loss, recurrent diarrhoea and SIBO.
Two broad areas of future work were highlighted by the ‘high fibre’ diet study. The first 
is the need to characterise the absorbable fermentation products produced by this kind of 
diet and to investigate the association with decreased lipolysis evidenced by the 
reductions in plasma free glycerol and non-esterified fatty acid concentrations, perhaps 
utilising stable isotope tracer technology. Secondly, the association between this diet and 
colitis, unexpected weight loss, recurrent diarrhoea and SIBO needs to be investigated 
further. Relatively non-invasive technology such as proctoscopy and breath hydrogen 
analysis could be of use in such an investigation. Recently, encouraging work supported 
by Leander International Pet Foods Ltd., has highlighted the effects of short chain fatty 
acids resulting from intestinal bacterial fermentation of different fibre sources on colonic 
structure and the presence of colonic cryptitis (Reinhart, 1994).
Median survival time for diabetic dogs treated at the University of Glasgow Veterinary 
School by single daily injection of intermediate duration insulin was 2.71 years by 
product limit analysis. Survival was not affected by gender or the choice of insulin 
preparation but the presence of concurrent hyperadrenocorticism was important and
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these dogs had a much poorer prognosis. A clinical life table method was also used to 
analyse the survival data and this method gave a very similar median survival time of 
2.82 years confirming its validity in this situation. The clinical life table method also 
facilitated the generation of other survival indices such as hazard function and median 
remaining life time. Median remaining lifetime increased to a maximum of 3.11 for those 
dogs which survived the first 5 months of therapy and hazard function was greatest 
during the first 6 months. Comparisons with previously published series of dogs with 
diabetes mellitus confirmed that improvements in survival times have been achieved in 
the last 20-30  years but that improvements in very long term survival have been limited, 
perhaps by the combination of mean age at diagnosis and the natural life span of dogs.
The use of the clinical life table method in combination with necropsy based modified 
cohort general life tables created for dogs, facilitated the creation of relative survival 
rates. This proved to be a useful technique for the study of longevity in canine diabetes 
mellitus because of the wide age range of dogs affected. Survival rates for diabetic dogs 
were shown by this method to be close to or greater than that expected from an age and 
gender matched general canine population.
Both the longevity and epidemiology studies have highlighted the need for a national 
canine census and disease survey as the ultimate method of validation for their findings. 
The first and most readily achievable future study in this area would be the creation of 
gender and breed specific general life tables for dogs based, perhaps, on pet insurance 
company data. In this way, the survival data of many chronic, and particularly neoplastic, 
canine diseases can be more accurately studied and compared.
During this study, a number of aspects of the presentation and management of canine 
diabetes mellitus were investigated and many original observations were made such that 
significant progress in our understanding of the condition and its management was 
achieved. The practical application of this new information in the veterinary clinic has the 
potential to substantially improve the health, well-being and life-expectancy of many 
diabetic dogs.
As might be expected in a study of this kind, almost as many new questions arose as 
were answered, thus confirming the existence of further scope for the continued 
investigation of canine diabetes mellitus.
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Appendix 1: 
List of manufacturers
Laboratory reagents and equipment
Amersham International pic Amersham Place, Little Chalfont, Bucks. HP7 9BR
Ames see Bayer
Bayer Diagnostics Manufacturing, B-7501 Orcq-Toumai, 
Belgium
Beckman Progress Road, Sands Industrial Estate, High Wycombe, 
Buckinghamshire. HP 12 4JL
Bio-Stat Ltd 40 Osborne St, Bredbuiy, Stockport. SK6 2BT
Boehringer Maimheim (Diagnostics and 
Biochemicals) UK Ltd
Bell Lane, Lewes, East Sussex. BN7 ILG
Canberra Packard Brook House, 14 Station Road, Pangboume, Berkshire. 
RG87DT
Ciba-Coming Colchester Road, Halstead, Essex. C09 2DX
Diagnostic Products Corporation 5700 West 96th Street, Los Angeles, CA 90045 USA
Dynatech Laboratories Ltd Daux Road, Billingshurst, West Sussex. RH14 9SJ
Greiner Labortechnik Ltd Station Road, Cam, Dursley, Gloucestershire. GLll 5NS
Helena Laboratories UK Team Valley Trading Estate, Gateshead, Tyne and Wear. 
NEllOLH
IDDEX Laboratories Ltd Milton Court, Churchfield Road, Chalfont St Peter, 
Buckinghamshire SL9 9EW
Instrumentation Laboratories Ltd Kelvin Close, Warrington, Cheshire. WA3 7BP
Randox Laboratories Ardmore, Diamond Road, Crumlin, Co Antrim, 
Northern Ireland. BT29 4QY
Roche Products Ltd PO Box 8, Welwyn Garden City, Hertfordshire. 
AL7 3AY
Sigma Chemical Company Ltd Fancy Road, Poole, Dorset. BH17 7NH
Sarstedt Ltd 66 Boston Road, Beaumont Leys, Leicester. LE 14 lAW
Terumo Europe BV 3001 Leuven, Belgium
Wako Chemical GmBH Nissanstr. 2, W-4040 Neuss 1, Germany.
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Pharmaceuticals and foodstulTs
The following products were used in the management of the dogs included in this study:
Pharmaceuticals
Isopto-plain artificial tears Alcon Laboratories Ltd, Imperial 
Way, Watford, Herts. WD2 4YR
Lacrilube liquid paraffin Allergan Ltd, Crown Centre, 
Coronation Road, Cressex 
Industrial Estate, High Wycome, 
Bucks, HP12 3SH
Metronidazole Tablets 
Co-trimoxazole Tablets
metronidazole
co-trimoxazole
Approved Prescription Service 
(APS) Ltd, Water Street, 
Towngate, Bradford, West Yorks. 
BD12 9AF
Synacthen tetracosactrin Ciba Laboratories, Wimblehurst 
Road, Horsham, West Sussex. 
RH12 4AB
Evan’s Isophane isophane insulin (bovine) lOOiu/ml Evans Medical Ltd, Langhurst, 
Horsham, Sussex. RH12 4QD
Hypurin Isophane isophane insulin (bovine) lOOiu/ml Fisons, Pharmaceutical Division, 
12 Derby Road, Loughborough, 
Leicestershire. LE 11 OBB
Eltroxin 1-thyroxine Goldshield Pharmaceuticals, 
Bensham House, 324 Bensham 
Lane, Thornton Heath, Surrey. 
CR7 7EQ
Caninsulin
Covinan
mixed insulin zinc suspension 
(porcine) 40iu/ml
proligestone
Intervet UK Ltd, Science Park, 
Milton Road, Cambridge.
CB4 4FP
Salazopyrin Tablets 
Intralipid
sulphasalazine
soya bean oil and glycerol emulsion
Kabi Pharmacia Ltd, Davy Ave, 
Knowlhill, Milton Keynes.
MK5 8PH
Lysodren mitotane (o,p’-DDD) Kingston Animal Health Ltd, 
Canbury 2000 Business Centre, 
Elm Crescent, Kingston-upon- 
Thames, Surrey, KT2 6HJ
Heparin (Mucous) 
Injection BP
Leo Laboratories Ltd, Longwick 
Road, Princes Risborough, 
Aylesbury, Bucks. HP 17 9RR
Oxytetracycline Tablets 
Phenylbutazone Tablets
oxytetracycline
phenylbutazone
Millpledge Pharmaceuticals Ltd, 
Whinleys Estate, Church Lane, 
Clarborough, Retford, Notts. 
DN22 9NA
Amfipen Capsules 
Delvosterone
ampicillin
proligestone
Mycofarm UK Ltd, Science Park, 
Milton Road, Cambridge.
CB4 4FP
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Pharmaceuticals (cont.)
Lentard MC mixed insulin zinc suspension (30% 
porcine, 70% bovine) lOOiu/ml
Novo-Nordisk Pharmaceutical Ltd, 
Novo-Nordisk House, Broadfîeld 
Park, Brighton Road, Pease 
Pottage, Crawley, West Sussex. 
RHll 9RT
Chloromycetin 
Ophthalmic Ointment
chloramphenicol 1% Parke-Davis Veterinaiy, Usk 
Road, Pontypool, Gwent. 
NP4 0YH
Zaquilan 12% baquiloprim and sulphadimethoxine Pitman-Moore Ltd, Crewe Hall, 
Crewe, Cheshire. CWl lYR
Insuvet Lente 
Insuvet Neutral
mixed insulin zinc suspension 
(bovine) lOOiu/ml
soluble insulin (bovine) lOOiu/ml
Schering-Plough Animal Health, 
Schering-Plough House, Shire 
Park, Welwyn Garden City, 
Hertfordshire. AL7 ITW
Bovine TSH Sigma Chemical Company Ltd, 
Fancy Road, Poole, Dorset. 
BH17 7NH
Synulox Tablets 
Emequell Tablets
clavulanic acid and amoxycillin 
metoclopramide
SmithKline Beecham Animal 
Health Ltd, Hunter’s Chase, 
Walton Oaks, Dorking Road, 
Tadworth,Surrey. KT20 7NT
Kaobiotic kaolin and neomycin Upjohn Ltd, Animal Health 
Division, Fleming Way, Crawley, 
West Sussex. RHIO 2NJ
Soloxine 1-thyroxine Vet-2-Vet Marketing, PO Box 98, 
Buiy St Edmunds, Suffolk.
IP33 2QN
Feedstuffs
Prescription Diets r/d, i/d Hill’s Pet Products Ltd, 1 The Beacons, Beaconsfield 
Road, Hatfield, Herts. ALIO 8EQ
Eukanuba Lamb and Rice Leander International Petfoods Ltd, Arden Grange, 
London Road, Alboume, Hassocks, Wets Sussex. 
BN6 9BJ
Pedigree Canine High Fibre Diet
Pedigree Canine Selected Protein Diet
Pedigree Chum
Chappie
Whiskas
Pedigree Petfoods, Waltham-on-the-Wolds, 
Melton Mowbray, Leicestershire.
LE14 4RS
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Appendix 2: 
Details of 89 referred diabetic dogs used for epidemiological 
investigation
Case
Number
Breed Date of 
Birth
Date First 
Seen
Age
(years)
Gender
109826 West Highland White terrier 10/01/76 08/01/89 13.00 F
109899 German shepherd dog 17/01/81 17/01/89 8.00 F
110113 Whippet 08/02/79 08/02/89 10.00 F
101600 Rottweiler 06/11/81 08/05/89 7.50 FN
111353 Labrador retriever 08/06/78 08/06/89 11.00 F
111513 Labrador retriever 03/07/81 03/07/89 8.00 F
111876 Cross breed 20/08/80 21/08/89 9.00 FN
109126 West Highland White terrier 04/10/78 20/09/89 10.96 MN
112324 Labrador retriever 04/10/78 04/10/89 11.00 F
112527 West Highland White terrier 23/10/80 24/10/89 9.00 M
112598 Samoyed 31/10/80 31/10/89 9.00 F
112714 Tibetan terrier 08/11/85 08/11/89 4.00 FN
113105 Cross breed 04/01/78 04/01/90 12.00 M
113430 Cross breed 07/02/82 07/02/90 8.00 M
113498 Cross breed 13/02/80 13/02/90 10.00 FN
113648 Scottish terrier 04/03/85 05/03/90 5.00 M
113936 Cairn terrier 08/04/76 09/04/90 14.00 FN
114460 Dobermann 05/12/82 06/06/90 7.50 F
114511 Miniature smooth-haired dachshund 12/06/81 13/06/90 9.00 M
114653 Cross breed 02/07/79 02/07/90 11.00 F
114695 Terrier cross 05/07/81 06/07/90 9.00 FN
114895 Bull terrier 07/08/83 07/08/90 7.00 M
115009 Miniature smooth-haired dachshund 15/08/80 16/08/90 10.00 FN
115088 Labrador retriever 29/08/80 30/08/90 10.00 MN
115131 Jack Russell terrier 05/09/82 05/09/90 8.00 F
115164 Cairn terrier 11/09/86 11/09/90 4.00 FN
115258 Cocker spaniel 24/09/80 25/09/90 10.00 FN
115678 Rottweiler 05/11/85 06/11/90 5.00 M
107674 Beagle 22/11/83 22/11/90 7.00 F
115980 Labrador retriever 07/12/82 07/12/90 8.00 FN
116146 English setter 11/01/84 11/01/91 7.00 M
116315 West Highland White terrier 30/07/76 30/01/91 14.50 FN
116318 Labrador retriever 29/01/85 30/01/91 6.00 M
116334 - Cross breed 04/02/80 04/02/91 11.00 M
116594 Cairn terrier 05/09/85 07/03/91 5.50 M
116724 German shepherd dog 23/09/84 26/03/91 6.50 M
116744 Miniature poodle 01/04/82 02/04/91 9.00 M
116825 Australian terrier 23/06/83 11/04/91 7.80 M
117056 Jack Russell terrier 06/05/80 07/05/91 11.00 F
117162 Border terrier 16/05/78 17/05/91 13.00 M
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Case
Number
Breed Date of 
Birth
Date First 
Seen
Age
(years)
Gender
117164 Cross breed 19/05/80 20/05/91 11.00 M
117222 Whippet 22/05/81 25/05/91 10.01 F
117369 Cross breed 05/06/82 06/06/91 9.00 M
117705 Cross breed 10/07/77 11/07/91 14.00 FN
117783 Rottweiler 28/07/84 29/07/91 7.00 F
117898 Cairn terrier 12/03/91 12/08/91 0.42 F
103348 Border collie 26/08/81 27/08/91 10.00 F
118388 Labrador retriever 14/10/81 15/10/91 10.00 M
118568 Greyhound 03/11/82 04/11/91 9.00 F
118601 King Charles spaniel 05/11/88 06/11/91 3.00 M
118626 Jack Russell terrier 10/11/80 11/11/91 11.00 M
118680 Cocker spaniel 18/11/83 18/11/91 8.00 F
118839 Border terrier 04/12/84 05/12/91 7.00 FN
118939 Cross breed 23/12/83 23/12/91 8.00 F
119136 English setter 02/09/86 27/01/92 5.40 M
119147 Retriever cross 20/12/84 27/01/92 7.10 F
119173 Labrador retriever 28/01/83 29/01/92 9.00 M
119446 Cairn terrier 03/03/87 03/03/92 5.00 FN
119447 Wire haired fox terrier 03/03/84 03/03/92 8.00 M
97218 Labrador retriever 10/03/84 10/03/92 8.00 F
119821 Miniature poodle 05/05/80 05/05/92 12.00 F
120173 Collie cross 17/12/78 17/06/92 13.50 FN
120177 Collie cross 18/06/82 18/06/92 10.00 M
120811 Tibetan terrier 07/10/85 07/10/92 7.00 FN
120827 Rottweiler 07/03/87 12/10/92 5.60 M
120899 Yorkshire terrier 19/04/84 19/10/92 8.50 FN
120931 Cairn terrier 16/03/88 22/10/92 4.60 MN
121031 Cocker spaniel 02/11/83 02/11/92 9.00 FN
121062 Cairn terrier 09/11/85 09/11/92 7.00 FN
121143 Border collie 17/11/82 17/11/92 10.00 F
121192 Cairn terrier 24/11/83 24/11/92 9.00 MN
121228 Collie cross 01/12/83 01/12/92 9.00 MN
121252 Rottweiler 03/12/89 03/12/92 3.00 F
121320 Toy poodle 05/12/83 15/12/92 9.03 F
109434 Miniature poodle 07/11/80 09/02/93 12.26 FN
121626 Jack Russell terrier 16/02/81 16/02/93 12.00 FN
122026 Bearded collie 26/04/82 26/04/93 11.00 FN
122125 Border collie 11/05/86 11/05/93 7.00 M
122131 German shepherd dog 11/05/81 11/05/93 12.00 M
122150 Yorkshire terrier 17/05/81 17/05/93 12.00 FN
122200 Collie cross 18/06/81 24/05/93 11.93 F
122551 Labrador retriever 13/07/86 13/07/93 7.00 F
122686 Labrador retriever 13/08/87 13/08/93 6.00 M
122739 Shetland sheepdog 22/08/88 23/08/93 5.00 M
122768 Jack Russell terrier 30/08/87 30/08/93 6.00 M
122970 Jack Russell terrier 23/02/82 30/09/93 11.60 M
122973 Labrador retriever 01/10/83 01/10/93 10.00 FN
123086 Labrador retriever 18/10/86 18/10/93 7.00 M
124186 King Charles spaniel 24/03/83 24/03/94 11.00 FN
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Appendix 3: 
Numbers of dogs in the hospital control population categorised 
by age, gender and referral group
Referral group
Age
(years)
Gender General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
0 F 20 7 4 3 23 0 57
FN 0 0 0 0 1 0 1
M 13 16 6 5 41 0 81
0 Total 33 23 10 8 65 0 139
1 F 6 7 2 8 16 1 40
FN 3 5 0 1 1 0 10
M 15 6 3 4 14 1 43
MN 0 1 0 0 3 0 4
1 Total 24 19 5 13 34 2 97
2 F 5 6 2 0 7 1 21
FN 2 1 2 0 1 1 7
M 8 6 3 1 8 0 26
MN 3 0 1 0 1 0 5
2 Total 18 13 8 1 17 2 59
3 F 5 8 0 1 6 3 23
FN 3 3 3 0 1 1 11
M 6 4 3 2 4 0 19
MN 1 0 0 1 0 0 2
3 Total 15 15 6 4 11 4 55
4 F 7 11 2 2 5 2 29
FN 6 5 0 0 6 0 17
M 5 8 6 1 7 0 27
MN 1 0 0 0 1 0 2
4 Total 19 24 8 3 19 2 75
5 F 8 6 3 0 4 0 21
FN 3 4 0 0 4 0 11
M 10 7 4 4 9 0 34
MN 0 1 1 0 0 0 2
5 Total 21 18 8 4 17 0 68
6 F 6 3 0 2 5 0 16
FN 3 7 1 6 2 0 19
M 12 15 3 0 4 0 34
MN 0 1 0 0 0 0 1
6 Total 21 26 4 8 11 0 70
7 F 2 5 2 1 4 0 14
FN 7 6 2 4 5 0 24
M 12 7 6 4 5 0 34
MN 0 2 0 0 0 0 2
7 Total 21 20 10 9 14 0 74
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Referral group
Age
(years)
Gender General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
8 F 3 8 0 0 0 0 11
FN 8 7 3 1 1 0 20
M 10 17 1 4 7 0 39
MN 0 1 2 0 0 0 3
8 Total 21 33 6 5 8 0 73
9 F 5 4 1 0 0 0 10
FN 6 5 2 5 4 0 22
M 9 9 6 1 4 0 29
MN 1 1 1 0 0 0 3
9 Total 21 19 10 6 8 0 64
10 F 2 0 1 2 3 0 8
FN 2 1 2 0 0 0 5
M 9 11 2 0 2 1 25
MN 0 1 2 0 0 0 3
10 Total 13 13 7 2 5 1 41
11 F 5 0 0 0 0 0 5
FN 3 3 1 1 1 0 9
M 9 7 0 1 2 0 19
MN 0 2 0 0 1 0 3
11 Total 17 12 1 2 4 0 36
12 F 0 3 0 1 0 0 4
FN 2 3 0 0 0 0 5
M 2 3 0 4 1 0 10
12 Total 4 9 0 5 1 0 19
13 F 1 1 0 0 0 0 2
FN 1 1 0 2 1 0 5
M 2 2 0 1 0 0 5
13 Total 4 4 0 3 1 0 12
14 F 0 0 0 1 0 0 1
FN 0 1 0 0 0 0 1
M 0 2 0 0 0 0 2
14 Total 0 3 0 1 0 0 4
15 F 1 0 0 0 0 0 1
FN 1 1 0 0 0 0 2
M 0 1 0 0 0 0 1
15 Total 2 2 0 0 0 0 4
Grand total 254 253 83 74 215 11 890
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Appendix 4: 
Numbers of dogs In a time matched hospital control population 
categorised by breed, gender and referral group
Referral group
Age
(years)
Gender General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Akita
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Beagle
F 0 0 0 0 0 1 1
M 0 1 0 1 0 0 2
Total 0 1 0 1 0 1 3
Belgian shepherd dog 
M 0 2 1 0 0 0 3
Total 0 2 1 0 0 0 3
Bernese mountain dog 
F 1 1 1 0 2 0 5
M 0 0 0 0 2 0 2
Total 1 1 1 0 4 0 7
Bichon frise
F 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Bloodhound
M 0 0 0 0 2 0 2
Total 0 0 0 0 2 0 2
Bouvier de Flandres 
M 0 2 0 0 0 0 2
Total 0 2 0 0 0 0 2
Boxer
F 3 1 1 1 2 0 8
FN 0 1 0 1 0 0 2
M 4 6 2 1 1 0 14
MN 0 1 0 0 0 0 1
Total 7 9 3 3 3 0 25
Briard
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Bulldog
FN 0 1 0 0 0 0 1
M 1 1 0 0 0 0 2
Total 1 2 0 0 0 0 3
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Referral group
Age Gender General General Neurology Ophthalm- Ortho­ Repro­ Total
(years) Medicine Surgery ology paedics duction
Bullmastiff
F 0 0 0 0 1 0 1
FN 1 0 0 0 0 0 1
M 0 2 2 0 2 0 6
Total 1 2 2 0 3 0 8
Chihuahua
F 0 0 1 1 0 0 2
Total 0 0 1 1 0 0 2
Chow Chow
M 0 0 0 1 0 0 1
Total 0 0 0 1 0 0 1
Bearded collie
F 0 0 0 0 3 1 4
FN 0 1 0 0 0 0 1
M 3 1 0 0 2 0 6
MN 1 0 0 0 0 0 1
Total 4 2 0 0 5 1 12
Border collie
F 5 4 0 0 3 0 12
FN 1 3 0 0 0 1 5
M 3 6 0 1 5 0 15
MN 1 0 1 0 1 0 3
Total 10 13 1 1 9 1 35
Rough collie
F 0 1 0 0 0 0 1
M 2 2 0 0 0 0 4
Total 2 3 0 0 0 0 5
Smooth collie
F 0 0 0 . 0 1 0 1
Total 0 0 0 0 1 0 1
Huntaway collie
F 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Collie cross
FN 2 2 0 0 0 0 4
M 2 7 2 0 2 0 13
Total 4 9 2 0 2 0 17
Corgi
F 0 0 0 0 1 0 1
- FN 0 0 0 1 0 0 1
Total 0 0 0 1 1 0 2
Dachshund
FN 0 1 0 0 1 0 2
M 0 1 0 0 0 0 1
Total 0 2 0 0 1 0 3
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Long haired dachshund
M 0 0 0 0 0 1 1
Total 0 0 0 0 0 1 1
Miniature long-haired dachshund
F 1 0 0 0 0 0 1
M 1 0 0 0 0 0 1
Total 2 0 0 0 0 0 2
Miniature smooth-haired dachshund
F 1 1 0 0 0 0 2
M 0 0 0 1 0 0 1
Total 1 1 0 1 0 0 3
Miniature wire-haired dachshund
F 0 0 1 0 0 0 1
Total 0 0 1 0 0 0 1
Smooth-haired dachshund
F 0 0 1 0 0 0 1
M 0 0 1 0 0 0 1
Total 0 0 2 0 0 0 2
Dalmatian
F 1 0 0 0 0 0 1
FN 1 0 0 0 0 0 1
M 1 1 0 0 1 0 3
Total 3 1 0 0 1 0 5
Deerhound
M 1 0 0 0 1 1 3
Total 1 0 0 0 1 1 3
Dobermann
F 0 4 1 0 1 0 6
FN 1 2 1 1 1 0 6
M 4 0 0 1 2 0 8
Total 5 6 3 2 4 0 20
Elkhound
M 0 1 0 0 0 0 1
Total 0 1 0 0 0 0 1
Foxhound
F 1 0 0 0 0 0 1
M 1 0 0 0 0 0 1
Total 2 0 0 0 0 0 2
German shepherd dog
F 10 11 1 1 9 1 33
FN 5 3 1 1 3 0 13
M 7 25 9 0 16 0 57
MN 0 1 0 0 1 0 2
Total 22 40 11 2 29 1 105
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Referral group
Age Gender General General Neurology Ophthalm- Ortho­ Repro­ Total
(years) Medicine Surgery ology paedics duction
German shepherd dog cross
FN 0 1 0 0 1 0 2
M 3 0 0 0 0 0 3
MN 0 0 0 0 1 0 1
Total 3 1 0 0 2 0 6
Great Dane
F 0 0 0 0 0 2 2
FN 0 1 0 0 1 0 2
M 4 1 0 0 3 0 8
Total 4 2 0 0 4 2 12
Greyhound
F 2 0 1 0 2 0 5
FN 0 0 0 0 1 0 1
M 0 1 0 0 2 0 3
Total 2 1 1 0 5 0 9
Afghan hound
M 0 0 1 0 0 0 1
Total 0 0 1 0 0 0 1
Basset hound
F 0 1 0 0 0 0 1
M 1 0 0 0 1 0 2
Total 1 1 0 0 1 0 3
Irish wolfhound
F 2 0 0 0 0 0 2
M 0 0 1 0 0 0 1
Total 2 0 1 0 0 0 3
Husky
M 1 0 0 0 0 0 1
MN 0 1 0 0 0 0 1
Total 1 1 0 0 0 0 2
Japenese chin
FN 0 1 0 0 0 0 1
Total 0 1 0 0 0 0 1
Keeshond
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Lhasa apso
FN 1 0 1 0 0 0 2
Total 1 0 1 0 0 0 2
Lurcher
F 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Alaskan malamute
F 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Maltese
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Tibetan mastiff
F 0 0 0 0 0 1 1
Total 0 0 0 0 0 1 1
Newfoundland
F 0 1 0 0 1 0 2
FN 0 1 0 0 1 0 2
Total 0 2 0 0 2 0 4
Old English sheepdog
FN 1 1 0 1 0 0 3
M 3 2 1 1 1 0 8
MN 0 0 1 0 1 0 2
Total 4 3 2 2 2 0 13
Papillon
F 0 0 1 0 0 0 1
FN 1 0 0 0 0 0 1
Total 1 0 1 0 0 0 2
Pekingese
F 0 0 1 1 0 0 2
Total 0 0 1 1 0 0 2
Pinscher
F 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Miniature pinscher
M 0 1 0 0 0 0 1
Total 0 1 0 0 0 0 1
Standard pinscher
F 0 0 1 0 0 0 1
Total 0 0 1 0 0 0 1
English pointer
F 0 0 0 0 1 0 1
FN 0 0 1 0 0 0 1
MN 0 0 1 0 0 0 1
Total 0 0 2 0 1 0
German short-haired pointer 
F 0 0 0 1 0 0 1
FN 0 0 0 1 0 0 1
' M 1 1 0 0 0 0
Total 1 1 0 2 0 0
Pomeranian
M 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Miniature poodle 
F 0 1 0 0 0 0 1
FN 1 0 0 3 0 0 4
Total 1 1 0 3 0 0 5
Standard poodle 
F 0 2 0 0 0 0 2
FN 0 1 1 0 0 1 3
M 1 0 0 0 0 0 1
Total 1 3 1 0 0 1
Toy poodle
FN 0 1 0 0 0 0
M 0 1 0 0 0 0 1
MN 0 0 1 0 0 0 1
Total 0 2 1 0 0 0
Pug
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Curly coated retriever 
M 0 0 1 0 0 0 1
Total 0 0 1 0 0 0 1
Flat coated retriever
F 1 0 0 1 0 0
FN 1 0 0 0 0 0 1
M 1 0 1 0 0 0
MN 0 1 0 0 0 0 1
Total 3 1 1 1 0 0 6
Golden retriever
F 7 1 1 0 4 0 13
FN 5 2 2 0 0 0 9
M 11 3 0 2 6 0 22
MN 1 0 1 1 0 0 3
Total 24 6 4 3 10 0 47
Labrador retriever
F 4 8 0 3 9 1 25
FN 4 6 2 4 3 0 19
M 11 14 3 0 24 0 52
MN 2 0 1 0 0 0 3
Total 21 28 6 7 36 1 99
Retriever cross
F 1 0 0 0 0 0 1
FN 0 2 0 0 1 0 3
M 1 1 0 0 1 0 3
MN 1 0 0 0 0 0 1
Total 3 3 0 0 2 0 8
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Referral group
Age Gender General General Neurology Ophthalm- Ortho­ Repro­ Total
(years) Medicine Surgery ology paedics duction
Rhodesian ridgeback
F 0 0 0 0 2 0 2
M 1 0 0 0 0 0 1
Total 1 0 0 0 2 0 3
Rottweiler
F 2 1 1 0 8 0 12
FN 0 0 1 0 1 0 2
M 1 2 1 1 5 0 10
MN 0 0 0 0 1 0 1
Total 3 3 3 1 15 0 25
Saint Bernard
F 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Samoyed
FN 0 3 0 0 0 0 3
Total 0 3 0 0 0 0 3
Giant schnauzer
FN 1 0 0 0 0 0 1
M 1 0 0 0 0 0 1
Total 2 0 0 0 0 0 2
Miniature schnauzer
F 0 0 0 0 1 0 1
M 0 1 0 0 1 0 2
Total 0 1 0 0 2 0 3
Standard schnauzer
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
English setter
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Gordon setter
F 1 0 0 0 1 0 2
FN 1 1 0 0 0 0 2
M 1 2 1 0 1 0 5
Total 3 3 1 0 2 0 9
Irish setter
F 2 1 1 0 1 0 5
M 3 0 0 0 1 0 4
MN 0 1 0 0 0 0 1
Total 5 2 1 0 2 0 10
Setter cross
M 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Shetland sheepdog
F 1 1 0 0 1 0 3
FN 1 0 0 0 1 0 2
M 2 2 0 0 1 0 5
Total 4 3 0 0 3 0 10
Shih tzu
FN 0 0 1 1 0 0 2
M 0 1 0 0 0 0 1
Total 0 1 1 1 0 0 3
Cavalier King Charles spaniel 
F 1 4 0 0 2 0 7
FN 3 1 0 0 2 0 6
M 0 1 1 2 1 0 5
MN 0 1 0 0 0 0 1
Total 4 7 1 2 5 0 19
Cocker spaniel
F 3 1 1 2 2 0 9
FN 1 0 0 0 0 0 1
M 6 4 0 3 1 0 14
Total 10 5 1 5 3 0 24
English Springer spaniel
F 4 5 0 2 1 0 12
FN 1 2 1 1 0 0 5
M 3 4 3 2 6 0 18
Total 8 11 4 5 7 0 35
King Charles spaniel
F 1 0 0 0 2 0 3
FN 0 1 0 0 0 0 1
MN 0 1 0 0 0 0 1
Total 1 2 0 0 2 0 5
Tibetan spaniel
F 0 0 0 2 0 0 2
M 0 1 0 0 0 0 1
Total 0 1 0 2 0 0 3
Welsh Springer spaniel
F 0 1 0 1 0 0 2
Total 0 1 0 1 0 0 2
Blue roan spaniel
FN 0 0 0 1 0 0 1
Total 0 0 0 1 0 0 1
Spaniel cross
FN 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Spinone
M 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Australian terrier
FN 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Bedlington terrier 
F 0 2 0 0 0 0 2
M 1 0 0 0 0 0 1
Total 1 2 0 0 0 0 3
Border terrier
F 0 1 0 0 0 0 1
M 0 0 1 0 1 0 2
Total 0 1 1 0 1 0 3
Bull terrier
F 3 0 0 1 0 0 4
M 6 0 0 0 0 0 6
Total 9 0 0 1 0 0 10
Cairn terrier
F 1 3 0 0 0 0 4
FN 0 2 0 0 0 0 2
M 0 1 0 1 0 0 2
Total 1 6 0 1 0 0 8
Dandie Dinmont terrier
M 0 1 0 0 0 0 1
Total 0 1 0 0 0 0 1
Wire-haired fox terrier
F 0 0 0 1 1 0 2
FN 1 0 1 0 0 0 2
MN 0 1 0 0 0 0 1
Total 1 1 1 1 1 0 5
Jack Russell terrier
F 2 2 0 2 0 0 6
FN 0 2 0 1 0 0 3
M 0 2 3 1 2 0 8
Total 2 6 3 4 2 0 17
Lakeland terrier
FN 0 0 0 0 1 0 1
Total 0 0 0 0 1 0 1
Scottish terrier
F 1 0 0 0 0 0 1
FN 1 0 0 0 0 0 1
- M 0 2 0 0 0 0 2
Total 2 2 0 0 0 0 4
Skye terrier
FN 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
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Referral group
Age Gender 
(years)
General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Soft Coated Wheaten terrier
F 6 0 0 0 0 0 6
M 4 0 0 0 0 0 4
Total 10 0 0 0 0 0 10
Staffordshire bull terrier
F 1 0 0 0 0 0 1
FN 1 0 0 0 1 0 2
M 0 0 1 0 2 0 3
Total 2 0 1 0 3 0 6
Tibetan terrier
M 1 0 0 0 0 0 1
Total 1 0 0 0 0 0 1
Welsh terrier
M 0 0 0 1 0 0 1
Total 0 0 0 1 0 0 1
West Highland White terrier
F 2 3 0 0 0 0 5
FN 1 3 1 1 1 0 7
M 3 2 0 2 1 0 8
MN 0 1 0 0 0 0 1
Total 6 9 1 3 2 0 21
Yorkshire terrier
F 2 1 2 0 4 0 9
FN 0 1 0 0 0 0 1
M 4 3 3 0 2 0 12
Total 6 5 5 0 6 0 22
Terrier cross
FN 0 1 0 0 1 0 2
M 0 0 1 0 0 0 1
Total 0 1 1 0 1 0 3
Hungarian yizsla
F 0 1 0 0 0 0 1
FN 0 0 0 0 1 0 1
M 0 0 1 0 0 0 1
Total 0 1 1 0 1 0 3
Weimaraner
F 0 1 0 1 0 0 2
M 1 0 0 2 0 0 3
MN 0 1 0 0 0 0 1
Total 1 2 0 3 0 0 6
Whippet
F 0 1 0 0 0 0 1
M 1 0 0 1 0 0 2
Total 1 1 0 1 0 0 3
Sharpei
M 0 1 0 0 0 0 1
Total 0 1 0 0 0 0 1
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Referral group
Age
(years)
Gender General
Medicine
General
Surgery
Neurology Ophthalm­
ology
Ortho­
paedics
Repro­
duction
Total
Cross bred
F 1 3 0 0 3 0 7
FN 11 5 2 2 5 0 25
M 8 8 1 7 6 0 30
MN 0 0 1 0 1 0 2
Total 20 16 4 9 15 0 64
Grand total 254 253 83 74 215 11 890
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Appendix 5: 
Synacthen stimulation test results In 7 dogs with concurrent 
hypothyroidism and diabetes mellltus
Hospital
number
Date Basal
cortisol
(nmol/1)
Post-ACTH Post-ACTH 
cortisol at cortisol at 
45 or 60 90 minutes 
minutes
107303 18/02/88 57 240 *
112714 08/02/90 38 556 *
113648 18/02/91 57 373 575
116146 11/01/91 35 178 250
120811 07/10/92 33 201 239
120931 22/10/92 228 287 *
124684 07/06/94 56 306 *
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Appendix 6: 
initial biochemistry, body condition score and basal insulin 
concentrations in dogs with straightforward diabetes mellltus 
and dogs with associated syndromes
Hospital
number
Gender Age
years
Days Glucose
mmol/1
Choies
mmol/1
ALKP
U/1
ALT
U/1
AST
U/1
Insulin
|aIU/ml
Condition
score
Hvoeradrenocorticism 
109434 FN 12.3 0 27.2 12.3 668 66 25 9.2 0
109826 F 13.0 7 8.9 10.0 861 218 51 * 4
113105 M 12.0 0 30.1 9.7 3114 397 77 * 5
113936 FN 14.0 0 31.0 5.8 * 161 72 * 4
116315 FN 14.5 0 24.8 4.7 1602 79 43 * 4
116318 M 6.0 0 19.3 10.0 117 81 14 * 4
116744 M 9.0 0 26.0 6.0 627 317 330 4.1 4
117369 M 9.8 0 19.6 7.6 495 179 54 5.8 3
117705 FN 13.8 77 * * * * * 27.0 *
118388 M 10.0 3 27.3 6.0 1431 100 66 3.6 4
118626 M 11.0 0 71.5 12.2 15873 114 74 17.2 4
122970 M 11.6 0 23.0 16.1 1948 255 49 41.0 3
122973 FN 10.0 0 16.2 8.2 3850 182 21 41.0 4
Hvix)throidism 
112714 FN 4.0 0 24.6 7.8 1202 180 163 * 4
113648 M 5.0 0 19.9 14.0 8259 78 43 5.0 4
119136 M 5.4 0 25.0 20.2 100 162 64 4.8 3
124684 FN 8.0 0 29.7 8.1 891 86 82 11.5 5
Metoestrus
103348 F 10.0 0 19.6 7.1 237 173 47 3.2 3
109899 F 8.0 0 32.4 9.8 119 29 18 « 4
110113 F 10.0 0 30.4 11.9 164 138 55 * 3
111353 F 11.0 0 24.5 8.4 822 67 27 * 2
114460 F 7.5 0 21.5 12.2 1465 85 53 6.0 3
114653 F 11.0 0 20.5 8.3 1479 51 23 * 4
117056 F 11.0 0 16.4 12.8 929 113 23 93.0 3
118568 F 9.0 0 20.1 7.8 145 82 35 189.0 4
119821 F 12.0 6 28.2 9.5 288 67 20 16.2 4
120899 F 8.5 0 13.1 6.4 168 80 38 6.2 2
121143 F 9.9* 36 * * * * * 10.7 4
122200 F 11.9 4 24.6 8.1 1129 254 60 6.5 3
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Hospital
number
Gender Age
years
Days Glucose
mmol/1
Choies
mmol/1
ALKP
U/1
ALT
U/1
AST
U/1
Insulin
|iIU/ml
Conditic
score
Progestagen associated 
112598 F 8.0 2 21.0 9.3 571 76 28 * 4
115131 F 8.0 0 22.7 7.0 97 135 99 * 3
Islet cell hvDolasia 
117898 F 0.4 0 23.6 3.7 748 55 56 3.0 3
‘Normal’
97218 FN 8.0 6 27.3 4.1 2984 133 82 8.0 6
101600 FN 7.5 0 32.5 7.7 245 62 25 * 4
105869 F 8.6 0 27.9 * 2046 31 18 * 1
107674 F 7.0 0 25.4 8.9 152 199 43 * 4
109126 M 11.0 0 21.7 7.8 211 84 26 * 4
111513 F 8.0 0 31.8 6.4 925 44 43 * 2
111876 FN 9.0 0 23.6 5.7 3372 399 274 * 4
114511 M 9.0 0 21.8 11.1 1596 269 53 * 4
114695 FN 8.7 141 * * * * * 13.0 *
115009 FN 10.0 16 18.1 13.2 1164 444 85 7.0 3
115164 FN 4.0 0 21.8 8.4 1085 61 38 * 4
115678 M 5.0 0 22.8 8.7 472 185 144 * 3
115980 FN 8.0 1 27.5 10.0 3858 61 34 * 5
116334 M 11.0 0 31.1 6.2 372 97 24 * 4
116594 M 5.5 0 22.4 6.9 224 50 14 9.0 4
116724 M 6.7 0 20.3 9.2 89 134 119 * 0
116825 M 7.8 0 26.6 5.0 140 172 36 * 4
117164 M 11.0 0 25.7 13.5 1835 965 143 * 3
117222 F 10.0 1 19.5 14.6 274 146 25 6.2 4
117783 F 7.0 3 14.2 10.9 3102 97 270 * 4
118601 M 3.0 1 13.1 8.3 6930 64 43 5.7 4
118680 F 8.0 0 18.5 10.6 320 41 35 9.6 5
118839 FN 7.0 1 19.0 6.1 505 37 43 3.0 4
119147 FN 7.1 0 20.0 6.7 322 252 92 4.3 4
119173 M 11.0 4 35.1 13.5 3746 468 204 9.6 4
119447 M 8.0 0 17.0 7.1 1774 61 35 * 3
120173 FN 13.5 0 27.3 12.2 125 94 74 * 4
120177 M 10.0 0 16.9 20.4 1267 172 75 « 0
120827 M 5.5 31 * * * * * 10.8 *
121062 FN 7.0 2 16.9 6.2 7568 192 56 9.0 3
121192 M 9.1 0 19.0 7.9 5786 307 109 14.9 4
121228 M 9.0 0 21.1 6.0 492 178 109 7.1 5
121626 FN 12.0 0 24.7 6.1 526 105 92 * 4
122125 M 7.0 0 25.7 8.8 2585 151 86 5.9 3
122131 M 12.0 0 16.9 7.9 535 115 44 8.7 4
122686 M 6.0 0 16.8 7.7 1039 84 21 9.3 5
122768 M 5.7 0 18.4 5.6 368 94 38 10.1 4
123086 M 7.0 0 18.3 6.3 192 57 27 12.0 5
124186 FN 11.0 0 35.7 12.7 4128 229 58 10.5 4
124748 FN 10.0 0 22.2 6.2 522 17 20 * 4
124785 FN 9.0 0 19.8 5.2 398 62 17 15.6 2
125113 FN 7.6 0 20.4 6.8 1338 267 222 * 4
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Appendix 7:
Endocrine tests in dogs with straightforward diabetes mellitus
Hospital
number
Date Cortisol
pre-ACTH
Cortisol at 
45 or 60 
min
Cortisol at 
90 min
Thyroxin
pre-TSH
Thyroxii 
6 hrs po 
TSH
97218 17/06/92 * * * 18.1 64.3
101600 23/02/93 * * * 20.7 53.7
107674 21/01/91 * * * 19.4 *
109126 29/10/90 122 320 * * *
114695 14/08/91 * * * 16.3 40.8
115009 21/08/90 27 524 527 * *
115678 20/08/93 * * * 28.0 63.0
116594 21/03/91 78 289 325 * *
116825 11/04/91 53 194 222 * *
117164 25/07/91 112 301 380 * *
118601 29/09/93 * * * 32.0 75.0
118680 06/12/91 * * * 15.3 *
118839 08/08/94 66 308 * * *
119173 11/02/92 29 245 378 * *
119446 03/03/92 40 301 * * *
119447 03/03/92 69 524 * * *
121062 28/09/93 89 475 520 24.0 87.0
121192 22/09/93 151 435 551 38.0 88.0
121228 01/12/92 68 340 354 * *
122686 13/08/93 * * * 37.0 54.0
122739 23/08/93 149 285 * 52.9 *
122768 09/09/93 * * * 24.0 94.0
123086 18/10/93 * * * 16.3 47.0
124186 24/03/94 44 302 * * *
124748 14/06/94 129 296 * * *
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Appendix 8:
Post-stabiiisation insulin doses for dogs with straightforward 
diabetes mellitus and those with associated syndromes
Hospital
number
Mean insulin 
dose lU/kg
Minimum 
insulin dose
Maximum 
insulin dose
Number of 
visits
Hvoeradrenocorticism 
109434 2.08 1.73 2.40 4
109826 2.70 1.25 3.56 7
113105 1.21 1.21 1.21 1
113498 2.34 2.34 2.34 2
113936 2.33 2.33 2.33 1
114895 1.25 1.25 1.25 1
116315 1.32 1.15 2.08 6
116318 2.42 2.42 2.42 1
116744 2.34 2.00 2.67 9
117705 2.51 2.02 3.00 2
118388 1.78 1.72 1.83 2
119010 4.33 4.33 4.33 1
122026 2.24 2.24 2.24 1
122150 5.24 5.21 5.26 2
122970 3.79 3.79 3.79 2
Hypothyroidism 
107303 1.72 1.72 1.72 1
112714 2.51 1.60 3.09 5
113648 2.32 1.45 2.80 9
116146 0.76 0.40 0.76 1
120811 2.73 2.73 2.73 1
120931 3.24 3.24 3.24 1
Metoestrus 
103348 0.82 0.47 1.20 4
109899 0.53 0.00 1.06 2
110113 0.18 0.00 0.31 6
110364 1.19 0.68 1.52 3
111353 1.07 0.44 1.51 10
112324 0.92 0.92 0.92 1
114460 1.02 0.53 1.66 17
114653 1.14 1.14 1.14 1
120899 1.26 0.83 1.94 10
121143 0.60 0.54 0.66 2
122200 0.75 0.00 1.46 8
Islet cell hvDoolasia 
117898 1.42 0.89 2.08 18
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Hospital Mean insulin 
number dose lU/kg
Minimum 
insulin dose
Maximum 
insulin dose
Number of 
visits
Progestagen
112598
associated
0.78 0.70 0.83 3
115131 1.20 0.93 1.49 26
122551 2.67 1.58 3.45 6
‘Normal’
97218 1.29 1.02 1.72 18
101600 1.07 0.00 1.78 12
107674 0.92 0.51 1.16 8
109126 1.83 1.57 2.20 9
111513 3.00 3.00 3.00 1
111876 1.01 0.95 1.10 6
114695 1.50 1.33 1.90 14
115009 2.31 1.79 2.64 5
115164 2.18 1.70 2.35 5
115258 1.80 1.60 2.00 2
115678 1.24 0.79 2.31 23
115980 1.03 0.78 1.68 29
116334 1.31 1.08 1.47 6
116594 2.09 1.67 2.73 17
116825 1.31 0.92 1.56 26
117162 1.77 0.92 2.62 2
117164 0.60 0.38 0.93 13
117222 1.45 0.52 8.85 18
117783 1.62 1.00 1.88 5
118601 0.66 0.00 1.15 16
118680 0.55 0.55 0.55 2
118839 1.13 0.35 1.52 6
118939 1.59 1.59 1.59 1
119147 1.28 0.72 1.93 18
119173 1.25 0.93 1.70 10
119446 3.42 3.30 3.60 5
119447 1.74 1.46 2.15 4
120173 1.00 0.53 1.39 18
120827 1.27 1.02 1.50 15
121031 1.90 1.90 1.90 1
121062 2.97 1.95 3.89 4
121192 1.81 1.42 2.60 8
121228 1.93 1.55 2.47 23
121252 1.20 1.00 1.45 11
121320 3.17 3.17 3.17 1
121626 1.66 1.47 1.82 4
122131 1.10 1.00 1.22 4
122686 1.55 1.32 1.88 5
122739 0.59 0.36 0.83 8
122768 1.64 1.58 1.74 8
123086 1.49 1.25 1.64 5
124186 1.13 0.95 1.29 4
124748 3.14 2.13 3.93 5
124785 1.43 1.19 1.82 3
125113 1.02 0.77 1.28 4
N.B. excludes insulin doses for dogs on Lysodren or thyroxin therapy
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Appendix 9:
Caiculation of the area under a relative operating characteristic
curve
The calculation of area under the ROC curve was calculated according to the method of 
Jensen and Poulsen (1992) based on that of Hanley and McNeil (1982). The following 
example presents data from 10 cut-off values for plasma fructosamine concentration used 
to differentiate between samples form dogs under poor or very poor glycaemic control 
(glycaemic control score 2 and 3) and those from dogs with fair to excellent diabetic 
control (glycaemic control groups 4, 5 and 6).
fructosamine cut-off value jimol/1
430 431 432 434 435 439 440 442 443 444
Nx 3 2 2 1 0 0 2 1 2 1
Nbx 174 177 179 181 182 182 182 184 185 187
Ax 0 0 0 0 2 1 1 1 1 0
Aax 66 66 66 66 64 63 62 61 60 60
Wpartial 198 132 132 66 0 0 125 62 121 60
Ql Partial 13068 8712 8712 4356 0 0 7813 3782 7321 3600
Q2Partial 0 0 0 0 66248 33124 33489 34040 34596 0
Nx The number of results from dogs with glycaemic control score 4, 5 or 6 at the cut-off value
Nbx The number of results from dogs with glycaemic control score 4, 5 or 6 below the cut-off value
Ax The number of results from dogs with glycaemic control score 2 or 3 at the cut-off value
Aax The number of results from dogs with glycaemic control score 2 or 3 above the cut-off value
At each cut-off value the partial terms of the are under the ROC curve (Wpartial) and of 
the intermediate probabilities Qi Partial and Q2 Partial are calculated using the formulae:
W Partial = (Nx * Aax) +(0.5 * Nx * Ax)
Ql Partial = Nx ♦ [(Aax ♦ Aax) + (Aax ♦ Ax) + (0.33 ♦ (Ax * Ax))]
Q2 Partial = Ax * [(Nbx * Nbx) + (Nbx ♦ Nx) + (0.33 * (Nx * Nx))]
When W Partial, Ql Partial and Q2 Partial have been calculated for each cut-off value, 
the final value of the area under the ROC curve (W) and of the intermediate probabilities 
Ql and Q2 are calculated using the following formulae in which Nd represents the 
number of results from dogs in glycaemic control groups 2 and 3 and Nn represents the 
number from dogs in glycaemic control groups 4, 5 and 6.
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W = (S W Partial)/(Nd ♦ Nn)
Ql = ( I  Ql PartialV(Nd * Nd ♦ Nn) 
Q2 = (Z Q2 Partial)/(Nn * Nn ♦ Nd)
The Standard error of the area under the ROC curve (SEw) is then calculated as:
_ l(W*[\-W])  + i[Nd -1] * [fl -W^]) + ([Nn - 1] * [Q, -  ])
V Nd*Nn
To statistically test whether the area under the ROC curve was different from 0.5, a 
z-score was calculated as:
z = (W-0.5)/SEw
and the resulting score was compared to z-scores from the normal distribution to obtain a 
probability (p) value.
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Appendix 10:
24 hour profiles of plasma concentrations of alkaline 
phosphatase, alanine aminotransferase, fructosamine and 
glucose in three diabetic dogs
Case No. Hours post - Alkaline Alanine amino­ Fructosamine Glucose
injection phosphatase IU/1 transferase IU/1 pmol/1 mmol/1
117222 0.00 209 53 356 6.2
2.00 221 51 322 3.6
4.00 242 50 316 4.6
6.00 239 51 329 6.0
6.16 232 49 * 6.2
6.32 248 48 * 6.5
6.50 200 50 * 5.6
7.00 219 46 * 6.6
7.50 216 44 * 7.6
8.00 241 43 316 8.0
9.00 227 44 * 7.1
10.00 219 50 320 6.4
12.00 205 44 302 10.9
14.00 213 45 310 7.7
16.00 216 43 313 7.8
20.00 199 44 301 5.3
24.00 216 48 317 5.4
113648 0.00 4109 109 526 11.1
2.00 4179 109 520 14.7
4.00 4630 111 533 16.6
6.00 3934 103 517 15.4
6.16 4019 114 * 18.9
6.32 4266 112 * 20.2
6.50 3985 114 * 18.7
7.00 4195 109 * 21.1
7.50 4395 106 * 23.1
8.00 3669 103 538 21.8
9.00 4306 107 * 24.1
10.00 4389 102 521 25.1
12.00 4130 100 529 25.5
- 14.00 3737 93 520 23.1
16.00 3656 92 521 20.6
20.00 3727 96 525 16.4
24.00 3537 93 518 14.8
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Case No. Hours post - 
injection
Alkaline 
phosphatase IU/1
Alanine amino­
transferase IU/1
Fructosamine
pmol/1
Glucose
mmol/1
115980 0.00 1194 194 634 27.1
2.00 1170 187 647 29.8
4.00 1187 180 610 20.9
6.00 1138 168 605 25.6
6.16 1166 182 * 24.7
6.32 1171 183 * 26.1
6.50 1121 183 * 26.4
7.00 1125 178 * 27.1
7.50 * * * *
8.00 1140 191 630 26.5
9.00 1073 183 * 26.7
10.00 1176 183 663 24.2
12.00 1215 170 612 29.5
14.00 * * * «
16.00 * * 613 19.9
20.00 1275 170 593 21.4
24.00 1300 115 644 22.7
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Appendix 11:
Case reports of 19 dogs treated with mixed insulin zinc
suspension
The following abbreviations and acronyms have been used throughout this appendix 
(units of measurement indicated where appropriate):
WBCC Total white cell count xl09/l
NEUTROPHILS Circulating neutrophils xl09/l
LYMPHOCYTES Circulating lymphocytes xl09/l
MONOCYTES Circulating monocytes xl09/l
EOSINOPHILS Circulating eosinophils xl09/l
RBCC Total red cell count xlOl2/l
HAEMOGLOBIN (HB) Haemoglobin concentration g/dl
HAEMATOCRIT m
MEAN CELL VOLUME Mean red cell volume ft
MEAN CELL HB Mean cell haemoglobin Pg
MEAN CELL HB CONC. Mean cell haemoglobin concentration g/dl
PLATELETS xl09/l
UREA Plasma urea concentration mmol/1
SODIUM Plasma sodium concentration mmol/1
POTASSIUM Plasma potassium concentration mmol/1
CHLORIDE Plasma chloride concentration mmol/1
CALCIUM Plasma calcium concentration mmol/1
PHOSPHATE Plasma phosphate concentration mmol/1
GLUCOSE Plasma glucose concentration mmol/1
CHOLESTEROL Plasma cholesterol concentration mmol/1
CREATININE Plasma creatinine concentration umol/1
TOTAL BILIRUBIN Plasma bilirubin concentration umol/1
ALKALINE PHOS Plasma alkaline phosphatase concentration U/1
ALT Plasma alanine aminotransferase concentration U/1
AST Plasma aspartate aminotransaminase 
concentration
U/1
TOTAL PROTEIN Plasma total protein concentration g/1
ALBUMIN Plasma albumin concentration g/1
GLOBULIN Plasma globulin concentration gd
GAMMA GT Gamma-glutamyl transferase U/1
CORTISOL Plasma cortisol concentration nmol/1
POST ACTH STIM Plasma cortisol concentration after injection of 
ACTH analogue
nmol/1
CRT Capillary refill time seconds
NEG Negative test result
TRACE Slightly positive test result
MOD or SMALL Positive test result
LARGE or (L) Strongly positive test result
NM Not measured
NS No sample
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CASE REPORT DOG 03
BREED: Scottish terrier
AGE: 5 years 
SEX: Male 
HISTORY:
This animal was referred for diabetic stabilisation with the following history. Two 
months earlier the dog had begun to lose weight and had become polydipsic, weaker and 
exercise intolerant. The dog had also been affected by ocular, nasal and pedal infections 
over this two month period. Initially polyphagia had been marked but a few days before 
admission to the University of Glasgow Veterinary School (G.U.V.S.) appetite had 
become severely depressed. There was no history of previous major medical or surgical 
illness, prolonged steroid therapy nor any history consistent with pancreatitis.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was noticeably dull and smelt strongly of ketones. The coat was sparse for a 
dog of this type. Mucous membranes were pink, CRT was less than 2 seconds and pulse 
volume was good. Heart rate was 112/minute. On auscultation, there were no cardiac 
murmurs nor adventitous lung sounds. Abdominal palpation revealed a ‘full’ feeling 
abdomen and hepatic enlargement. There was bilateral thick, tacky, mucopurulent ocular 
discharge but no evidence of cataract formation.
Schirmer tear test gave results of 7mm/min. and 12mm/min. (normal > 10  mm/min) in 
the left and right eyes respectively, confirming keratoconjuntivitis sicca of the left eye.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 1.3 WBCC 38.9
SODIUM 143 NEUTROPHILS 35.70
POTASSIUM 3.7 LYMPHOCYTES 0.58
CHLORIDE 104 MONOCYTES 1.56
CALCIUM 2.41 EOSINOPHILS 0
PHOSPHATE 0.80 RBCC 5.47
GLUCOSE 19.9 HAEMOGLOBIN 11.9
CHOLESTEROL 13.96 HAEMATOCRIT 33.7
CREATININE 50 MEAN CELL VOLUME 62
TOTAL BILIRUBIN 3 PLATELETS 661
ALKALINE PHOS 8,259
ALT 78
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BIOCHEMISTRY 
(CONT):
AST 43
TOTAL PROTEIN 64
ALBUMIN 28
GLOBULIN 36
CORTISOL 34
POST SYN 45MIN 38
GAMMA GT 12
Bacteriological examination of urine failed to demonstrate the presence of any significant 
urinaiy infection.
In view of the thin hair coat and elevated plasma alkaline phosphatase concentration, the 
presence of concurrent Cushing's disease was suspected. Plasma cortisol concentrations 
before and after stimulation with ACTH analogue (Synacthen) indicated that this was not 
the case.
Radiography of thorax and abdomen revealed only hepatomegaly and prostatomegaly. 
The day following admission, stabilisation with Caninsulin was begun. The starting dose 
was 5IU. Diet consisted of 285g of canned dog food (Chum: Pedigree Petfoods) and 70g 
of bread fed twice daily (75kcal/kg/day).
HOSPITALISATION:
For the first 3 days of hospitalisation this dog remained moderately dull, after which he 
was bright, alert and playful. The ocular discharge resolved following treatment with 
artificial tears (Isopto-plain: Allergan Ltd), ocular lubricant (Lacri Lube: Alcon Labs. 
UK, Ltd) and Chloromycetin Ophthalamic Ointment (Parke-Davis). A course of 
clavulanate potentiated amoxycillin (Synulox: SK Beecham) was instituted in view of the 
elevated total white blood cell count.
Rectal temperature during the hospitalisation period did not exceed 100.6°F and water 
intake reduced from a maximum of 900ml/day to 350ml/day. Heart rate remained below 
120/minute at all examination times. Bodyweight remained constant.
The dog was discharged on day 12. The owners were instructed to increase insulin dose 
only if polydipsia returned.
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HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)________________________________ (mis)
DAY NO. 1
9.30am 5 LARGE 2.0 17.1 700 11
5pm 22.8
9.30pm MOD./L 1.5 25.5
DAY NO. 2
9.30am 7 LARGE 2.0 22.3 800
5pm 20.5
9.30pm MOD. 2.0 17.7
DAY NO. 3
9.30am 12 MOD 2.0 17.6 475
5pm 17.3
9.30pm SMALL 1.5 26.7
DAY NO. 4
9.30am 16 SMALL 1.5 17.8 250
5pm 12.5
9.30pm NEG 2.0 19.1
DAY NO. 5
9.30am 20 TRACE 2.0 23.5 500
5pm 13.9
9.30pm NEG 1.5 17.4
DAY NO. 6
9.30am 20 NEG 2.0 17.3 400
5pm 11.6
9.30pm NEG 2.0 11.7
DAY NO. 7
9.30am 24 NEG 2.0 25.4 900
5pm 11.7
9.30pm NEG 1.5 29.4
DAY NO. 8
9.30am 26 NEG 1.5 16.8 550
5pm 8.5
9.30pm NEG 2.0 12.8
DAY NO. 9
9.30am 26 NEG 1.0 12.6 150
5pm 5.1
9.30pm NEG 1.5 17.3
DAY NO. 10
9.30am 26 NEG 1.5 22.1 550
5pm 7.8
9.30pm NEG 2.0 20.3
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Insulin
dose
(lU)
Urine
ketones
Urine
glucose
Plasma
glucose
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 11 
9.30am 
5pm 
9.30pm
26 NEC
NEC
1.5
0.5
17.8
4.3
10.7
NM 11
DAY NO. 12 
9.30am 26 NEC 1.5 15.6
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CASE REPORT DOG 04
BREED: West Highland White terrier
AGE: 11 years 
SEX: Castrated male 
HISTORY:
This animal was first seen for diabetic stabilisation 9 months previously, when he was 
stabilised on 26IU Isophane insulin (Evans). Previous illnesses included cystitis and 
bladder haemangioma.
Prior to re-admission this dog had been stable and polydipsia had been well controlled. 
He was transferred to Caninsulin therapy whilst boarding for a period of 2 weeks.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was bright and alert. Mucous membranes were pink and CRT was less than 2 
seconds. Heart rate was 120/minute. Respiratory rate was 30/minute. On auscultation 
there were no cardiac murmurs or pulmonary adventitious sounds. Rectal temperature 
was 101 °F. There was marked cataract formation in the left eye and to a lesser degree in 
the right. Vision was limited but the dog was not blind.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 4.8 WBCC 7.5
SODIUM 147 NEUTROPHILS 5.96
POTASSIUM 4.7 LYMPHOCYTES 1.20
CHLORIDE 108 MONOCYTES 0.26
CALCIUM 2.70 EOSINOPHILS 0.04
PHOSPHATE 1.05 RBCC 7.65
GLUCOSE 8.8 HAEMOGLOBIN 17.4
CHOLESTEROL 6.92 HAEMATOCRIT 49.0
CREATININE 61 MEAN CELL VOLUME 64
TOTAL BILIRUBIN 0 MEAN CELL HB 22.7
ALKALINE PHOS 209 MEAN CELL HB CONC. 35.5
ALT 29 PLATELETS 438
AST - 20
TOTAL PROTEIN 70
ALBUMIN 34
GLOBULIN 36
Radiography was not performed
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This dog was included in the Caninsulin trial from the day following admission for 
boarding. Starting dose of insulin was 26IU and diet comprised 250g canned dog food 
(Chum; Pedigree Petfoods) and lOOg bread fed twice daily.
HOSPITALISATION:
The dog remained bright and alert throughout the 2 weeks. Insulin dose was decreased 
by decrements of 2IU from the initial 26IU to a final dose of I8IU. Water intake over 
this period varied between 200 and 1500ml/day. There was a 0.3kg loss of bodyweight.
The dog was discharged on 18IU Caninsulin and owners were advised on the use of 
urine test strips for glucose.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
Plasma
glucose
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 26 NEC 0.0 9.8 NM 11.8
5pm 4.5
9.30pm NEC 0.0 9.7
DAY NO. 2
9.30am 26 NEC 0.0 8.5 NM
5pm 2.6
9.30pm NEC 0.0 12.7
DAY NO. 3
9.30am 26 NEC 0.0 5.7 750
5pm 3.0
9.30pm NEC 0.0 9.7
DAY NO. 4
9.30am 26 NEC 0.0 7.5 NM 11.5
5pm 3.0
9.30pm NEC 0.0 5.7
DAY NO. 5
9.30am 26 NEC 0.0 9.3 500
5pm 2.6
9.30pm NEC 2.0 14.1
DAY NO. 6
9.30am 26 NEG 0.25 6.5 NM
5pm 3.0
9.30pm NEG 0.0 3.6
DAY NO. 7
9.30am 26 NEG 0.0 4.4 NM
5pm 1.7
9.30pm NEG 0.0 4.0
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Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)________________________________ (mis)
DAY NO. 8
9.30am 24 NEG 0.0 2.2 NM
5pm
9.30pm NEG 0.0
1.9
5.1
DAY NO. 9
9.30am 22 NEG 0.0 7.0 NM
5pm
9.30pm NEG 0.0
3.1
5.0
DAY NO. 10
9.30am 22 NEG 0.25 10.1 NM
5pm
9.30pm NEG 0.0
2.3
9.0
DAY NO. 11
9.30am 20 NEG 0.0 4.6 1500 11.5
5pm
9.30pm NEG 0.25
3.3
12.3
DAY NO. 12
9.30am 18 NEG 0.0 8.1 1500
5pm
9.30pm NEG 0.0
2.5
7.8
DAY NO. 13
9.30am 18 NEG 0.0 15.4 1500
5pm
9.30pm NEG 0.25
7.7
15.1
DAY NO. 14
9.30am 18 NEG 0.25 11.0 1500
5pm
9.30pm NEG 1.0
6.8
17.3
DAY NO. 15
9.30am 18 NEG 0.0 8.2
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CASE REPORT DOG 05
BREED: Labrador-X
AGE: 12 years 
SEX: Speyed female 
HISTORY:
This dog was first seen 10 months prior to entry to Caninsulin trial with a history of 
polyuria, polydipsia and weight loss. Clinical examination at that time revealed bilateral 
cataracts and a grade III, holosystolic cardiac murmur. Faeces were also noted to be 
pale, suggesting an exocrine pancreatic component to this dog's condition. The dog was 
initially stabilised on lOIU of Isophane insulin (Evans). Four months later 
ovariohysterectomy was performed following increasing diabetic instability.
The dog was converted from Isophane (Evans) to Caninsulin when re-admitted to 
G.U.V.S. for boarding for a three week period.
CLINICAL EXAMINATION AND INVESTIGATION:
On clinical examination this dog was thin, bright and alert, but was obviously blind. 
There were bilateral mature cataracts. Mucous membranes were pink and CRT was less 
than 3 seconds. Heart rate was 112/minute. Auscultation revealed a grade III 
holosystolic murmur but no pulmonary adventitious sounds. Abdominal palpation 
revealed hepatomegaly.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 2.7 WBCC 7.0
SODIUM 142 NEUTROPHILS 4.69
POTASSIUM 5.2 LYMPHOCYTES 1.47
CHLORIDE 107 MONOCYTES 0.63
CALCIUM 2.40 EOSINOPHILS 0.21
PHOSPHATE 0.69 RBCC 6.39
GLUCOSE 21.8 HAEMOGLOBIN 15.1
CHOLESTEROL 4.42 HAEMATOCRIT 43.4
CREATININE 69 MEAN CELL VOLUME 68
TOTAL BILIRUBIN 2 MEAN CELL HB 23.6
ALKALINE PHOS 2,686 MEAN CELL HB CONC. 34.7
ALT 120 PLATELETS 509
AST 28
TOTAL PROTEIN 61
ALBUMIN 30
GLOBULIN 31
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Radiography was not performed.
Diet was maintained as before at 500g canned dog food (Chum: Pedigree Petfoods) and 
lOOg of bread twice daily. Starting dose of Caninsulin was 17 lU.
HOSPITALISATION:
During the 3 week hospitalisation period the rectal temperature did not exceed 101.8°F. 
Daily water intake varied between 600ml and 2900ml. On day 6, two-hourly blood 
samples and four-hourly urine samples were collected for pharmacokinetic study. On day 
12 a purulent ocular discharge was noted. This responded to a five day course of 
Chloromycetin Ophthalamic Ointment (Parke-Davis).
From day 5 to day 14, 5.00pm plasma glucose concentrations were consistently 
subnormal despite decreasing insulin dosages. On day 12, an episode of clinical 
hypoglycaemia occurred which required treatment with 1 lU of glucagon intramuscularly 
(im), 100ml of 40% dextrose saline per os and 1500ml of 4% dextrose saline 
intravenously (iv). Faeces from this dog were pale and steatorrhoeic between days 5 and 
16. However, during this period the presence of exocrine pancreatic insufficiency was 
not demonstated by faecal trypsin activity analyses. Between admission and discharge the 
dog lost 2 kg bodyweight (14 kg to 12 kg) and became observably thin.
The dog was discharged on 15 lU of Caninsulin daily and the owner was instructed to 
increase the dose only if the dog remained polydipsic.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 17 NEG 2.0 23.2 NM 14
5pm 8.4
9.30pm NEG 2.0 24.5
DAY NO. 2
9.30am 17 NS NS 36.1 NM
5pm 6.3
9.30pm TRACE 2.0 24.6
DAY NO. 3
9.30am 17 TRACE 2.0 19.0 1000
5pm 31.4
9.30pm NS NS 37.4
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Insulin
dose
(lU)
Urine
ketones
Urine
glucose
Plasma
glucose
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 4
9.30am 17 MOD 2.0 29.0 1250 14
5pm 16.5
9.30pm TRACE 1.0 18.6
DAY NO. 5
9.30am 17 NS NS 7.4 1200
5pm 2.2
9.30pm NEG 0.0 3.2
DAY NO. 6
9.30am 19 NS NS 17.5 1200
5pm 2.0
9.30pm NEG 0.0 1.5
DAY NO. 7
9.30am 17 NEG 0.0 18.9 1100
5pm 1.0
9.30pm NEG 0.0 2.0
DAY NO. 8
9.30am 15 NEG 0.0 22.1 1250
5pm 3.9
9.30pm NS NS NS
DAY NO. 9
9.30am 15 NS NS NS 1200
5pm 1.8
9.30pm NS NS NS
DAY NO. 10
9.30am 15 NS NS 21.2 850
5pm 1.7
9.30pm NS NS NS
DAY NO. 11
9.30am 15 NEG 0.0 16.8 1050 13.5
5pm 2.1
9.30pm NEG 0.0 3.1
DAY NO. 12
9.30am 11 NEG 0.0 4.3 1200
5pm 1.1
9.30pm NS NS 3.5
DAY NO. 13
9.30am 8 NS NS 6.9 900
5pm 1.8
9.30pm NEG 0.0 6.4
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Insulin Urine
dose ketones
(lU)___________
Urine Plasma Water Body-
glucose glucose intake weight
________________(mis) (kg)
DAY NO. 14 
9.30am 
5pm 
9.30pm
DAY NO. 15 
9.30am 
5pm 
9.30pm
DAY NO. 16 
9.30am 
5pm 
9.30pm
DAY NO. 17 
9.30am 
5pm 
9.30pm
DAY NO. 18 
9.30am 
5pm 
9.30pm
DAY NO. 19 
9.30am 
5pm 
9.30pm
DAY NO. 20 
9.30am 
5pm 
9.30pm
10
13
15
NEG
NEG
TRACE
NEG
NEG
NEG
TRACE
NS
12 SMALL 
NEG
SMALL
NEG
NEG
0.75
0.75
2.0
2.0
0.0
1.5
1.5 
NS
1.5 
2.0
1.0
2.0
2.0
11.7
12.7 
20.4
27.4
15.7
21.0
20.7
21.2
31.0
30.5 
20.1
38.5
29.3 
10.8
33.3
28.8
18.2
18.9
32.2
600
750
1500
2900
2000
1900
12
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CASE REPORT DOG 06
BREED: Dobermann
AGE: 7 years 
SEX: Female 
HISTORY:
This dog was referred for investigation of polydipsia of 2 months duration (water intake 
was > 8 litres/day). There was no history consistent with pancreatitis nor prolonged 
steroid therapy but she had been in season 2.5 months previously.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was alert and bright. The coat was dry, dull and scurfy. Ketotic breath was 
obvious and enlarged prescapular lymph nodes were palpated. Heart rate was 
120/minute. Mucous membranes were pink and CRT was less than 2 seconds. Rectal 
temperature was 101°F. Moderate hind limb ataxia was noticed at walk. The bitch's 
mammary glands were developed and milk could be expressed from them. There were no 
vulval discharges. There were no cardiac murmurs or pulmonary adventitious sounds on 
auscultation. Abdominal palpation revealed no abnormalities.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 5.9 WBCC 11.8
SODIUM 138 NEUTROPHILS 9.20
POTASSIUM 4.2 LYMPHOCYTES 1.77
CHLORIDE 99 MONOCYTES 0.53
CALCIUM 2.65 EOSINOPHILS 0.30
PHOSPHATE 1.80 RBCC 4.96
GLUCOSE 21.5 HAEMOGLOBIN 11.9
CHOLESTEROL 12.16 HAEMATOCRIT 33.0
CREATININE 61 MEAN CELL VOLUME 67
TOTAL BILIRUBIN 0 MEAN CELL HB 23.9
ALKALINE PHOS 1,465 MEAN CELL HB CONC. 35.8
ALT 85 PLATELETS 216
AST 53
TOTAL PROTEIN 63
ALBUMIN 32
GLOBULIN 31
CORTISOL 60
CORTISOL POST 497
SYNACTHEN
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Examination of lateral thoracic and abdominal radiographs revealed hepatomegaly but no 
evidence of uterine enlargement.
A lymph node aspirate was taken from a prescapular node which showed that the 
lymphadenopathy was non-neoplastic.
This dog was entered into the Caninsulin study 5 days after admission. The starting dose 
of insulin was 18IU and diet comprised 495g canned dog food (Chappie; Pedigree 
Petfoods) an 1 lOg bread fed twice daily (40kcal/kg/day).
HOSPITALISATION:
The dog was hospitalised for a further 23 days for stabilisation. During this period daily 
dose was increased steadily until day 22. Much weight (8.7kg) was lost during the 
hospitalisation period (body weight 27.3kg at discharge). Water intake reduced from 
approximately 2000ml/day to 200-800ml/day. Ketotic breath could not be detected after 
day 4. After day 10, milk could no longer be expressed from mammary glands and all 
evidence of lymphadenopathy had disappeared.
The dog remained bright and lively throughout.
The dog was discharged at a dose of 46IU and the owners were advised that the bitch 
was probably suffering from progesterone related insulin resistance, that she would 
require less insulin in time and that ovariohysterectomy was stongly recommended. Urine 
glucose testing strips were supplied and the owners were instructed in adjusting insulin 
dose according to morning urine glucose concentrations.
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body­
dose ketones glucose glucose intake weight
(lU) (g/dl) (mmol/1) (mis) (kg)
DAY NO. 1
9.30am 18 SMALL 2.0 26.5 2000 34
5pm 25.3
9.30pm SMALL 2.0 29.3
DAY NO. 2
9.30am 20 LARGE 1.0 22.9 NM
5pm 21.9
9.30pm MOD 2.0 27.2
DAY NO. 3
9.30am 22 SMALL 1.0 25.1 1900
5pm 23.5
9.30pm NEG 2.0 37.7
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Insulin Urine
dose ketones
Urine Plasma Water Body-
glucose glucose intake weight
(mmol/1) (mis)
DAY NO. 4
9.30am 24 MOD 1.0 29.3 2400
5pm 27.0
9.30pm NEG 2.0 28.5
DAY NO. 5
9.30am 26 SMALL 2.0 28.8 6500
5pm 21.0
9.30pm NEG 2.0 38.5
DAY NO. 6
9.30am 28 SMALL 2.0 30.1 2500
5pm 21.9
9.30pm NEG 2.0 35.6
DAY NO. 7
9.30am 28 SMALL 1.0 34.6 1500
5pm 27.3
9.30pm TRACE 2.0 38.0
DAY NO. 8
9.30am 30 NEG 2.0 29.0 3750
5pm 22.5
9.30pm NEG 2.0 33.0
DAY NO. 9
9.30am 36 NEG 2.0 26.3 NM 32
5pm 21.0
9.30pm NEG 2.0 33.7
DAY NO. 10
9.30am 40 TRACE 2.0 29.9 4000
5pm 17.4
9.30pm NEG 2.0 28.0
DAY NO. 11
9.30am 40 SMALL 2.0 29.6 3000
5pm 16.8
9.30pm NEG 2.0 28.0
DAY NO. 12
9.30am 40 NEG 1.0 32.0 4500
5pm 15.1
9.30pm NEG 2.0 27.0
DAY NO. 13
9.30am 42 NEG 1.0 30.1 3000
5pm 14.0
9.30pm NEG 2.0 28.8
IDIX 11
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 14
9.30am 42 NEG 2.0 32.0 1000
5pm 17.5
9.30pm NEG 2.0 32.0
DAY NO. 15
9.30am 42 NEG 2.0 26.2 550 29.5
5pm 12.9
9.30pm NEG 2.0 23.7
DAY NO. 16
9.30am 44 NEG 2.0 30.1 1500
5pm 12.1
9.30pm NEG 2.0 25.2
DAY NO. 17
9.30am 46 NEG 2.0 30.2 800
5pm 10.2
9.30pm NEG 1.0 18.2
DAY NO. 18
9.30am 48 NEG 2.0 21.5 200
5pm 7.5
9.30pm NEG 1.5 21.1
DAY NO. 19
9.30am 48 NEG 1.0 25.2 250
5pm 7.5
9.30pm NEG 0.75 17.1
DAY NO. 20
9.30am 48 NEG 0.75 18.4 800
5pm 6.1
9.30pm NEG 1.0 7.8
DAY NO. 21
9.30am 48 NEG 0.25 13.7 200
5pm 8.5
9.30pm NEG 1.0 15.8
DAY NO. 22
9.30am 48 NEG 0.25 15.9 NM
5pm 4.0
9.30pm NEG 0.5 7.8
DAY NO. 23
9.30am 46 NEG 0.25 14.3 27.3
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CASE REPORT DOG 07
BREED; Spaniel X
AGE; 11 years 
SEX: Female 
HISTORY:
This dog had been polydipsic, to some extent, for 1 year before being referred for 
diabetic stabilisation. There had been a further increase in thirst two weeks prior to 
referral and this had reduced, in part, following oral hypoglycaemic therapy instituted by 
the referring veterinary surgeon. This bitch had been in season 3 weeks prior to referral 
and had commonly suffered from pseudopregnancy. There was no history of prolonged 
steroid or reproductive hormone therapy.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was bright and alert. Mucous membranes were pink and CRT was less than 2 
seconds. Heart rate was 108/minute. Rectal temperature was 100°F. On auscultation 
there was a left sided, systolic cardiac murmur but no adventitious pulmonary sounds. 
The left submandibular lymph node was enlarged. There was marked periodontal disease.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 5.5 WBCC 12.7
SODIUM 139 NEUTROPHILS 10.92
POTASSIUM 3.8 LYMPHOCYTES 1.40
CHLORIDE 96 EOSINOPHILS 0.39
CALCIUM 2.83 RBCC 5.89
PHOSPHATE 1.47 HAEMOGLOBIN (HB) 13.3
GLUCOSE 20.5 HAEMATOCRIT 38.1
CHOLESTEROL 8.32 MEAN CELL VOLUME 65
CREATININE 62 MEAN CELL HB 22.5
TOTAL BILIRUBIN 1 MEAN CELL HB CONC. 34.9
ALKALINE PHOS 1,479 PLATELETS 567
ALT 51
AST 23
TOTAL PROTEIN 66
ALBUMIN 32
GLOBULIN 34
Radiography of thorax and abdomen did not demonstrate any abnormalities.
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The day following admission this dog was included in the Caninsulin study. Starting dose 
of insulin was 28IU and diet comprised 300g canned dog food (Chum; Pedigree 
Petfoods) and 60g bread fed twice daily (60kcal/kg/day).
HOSPITALISATION:
Whilst hospitalised the insulin dose was increased in 2-4IU increments until reaching 
62IU on day 10. This dose was continued until day 16 when the dose was reduced by 
increments of 4IU until day 24 when the dog was obviously no longer diabetic and 
insulin therapy was stopped. During the hospitalisation period water intake was reduced 
from a maximum of 4950 to less than 400ml/day and the dog lost 2kg bodyweight. 
Rectal temperature never exceeded 101.6°F. Clinical condition and bright demeanour did 
not vary whilst hospitalised. This dog was considered to have been suffering from a 
progesterone induced diabetes mellitus.
The dog was boarded after discontinuing insulin therapy until ovariohysterectomy and 
mammary tumour removal was performed on day 28.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1 
9.30am 
5pm 
9.30pm
28 NEG 2.0 20.5
18.5 
26.8
3000 24.5
DAY NO. 2 
9.30am 
5pm 
9.30pm
32 NEG
NEG
2.0
2.0
22.9
19.9 
29.3
3000
DAY NO. 3 
9.30am 
5pm 
9.30pm
34 NEG
NEG
2.0
2.0
23.7 
20.3
26.8
4500
DAY NO. 4 
9.30am 
5pm 
9.30pm
38 NEG
NEG
2.0
2.0
22.0
NS
25.5
NM
DAY NO. 5 
9.30am 
5pm 
9.30pm
42 NEG
NEG
2.0
2.0
24.8
26.3
28.0
NM
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Insulin Urine
dose ketones
(lU)___________
Urine Plasma Water Body-
glucose glucose intake weight
(g/dl) (mmol/1) (mis) (kg)
DAY NO. 6 
9.30am 
5pm 
9.30pm
DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm 
9.30pm
DAY NO. 11 
9.30am 
5pm 
9.30pm
DAY NO. 12 
9.30am 
5pm 
9.30pm
DAY NO. 13 
9.30am 
5pm 
9.30pm
DAY NO. 14 
9.30am 
5pm 
9.30pm
DAY NO. 15 
9.30am 
5pm 
9.30pm
46 TRACE
NEG
50 SMALL
NEG
54
58
62
62
62
62
62
62
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
2.0
2.0
2.0
2.0
2.0
1.0
2.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
22.3
23.6
25.0
NS
15.3
26.6
23.5
2.0
24.4
20.3
15.2
17.5
16.8
5.0
13.8
4.2 
5.0
8.2
10.8
4.7
14.2
6.0
4.1
4.5
5.0
3.5
4.4
NS
2.3
4.4
NM
3000
4950
2750
2200
2100 23.5
NM
NM
NM
300
APPENDIX 11 289
DAY NO. 16 
9.30am 
5pm 
9.30pm
DAY NO. 17 
9.30am 
5pm 
9.30pm
DAY NO. 18 
9.30am 
5pm 
9.30pm
DAY NO. 19 
9.30am 
5pm 
9.30pm
DAY NO. 20 
9.30am 
5pm 
9.30pm
DAY NO. 21 
9.30am 
5pm 
9.30pm
DAY NO. 22 
9.30am 
5pm 
9.30pm
DAY NO. 23 
9.30am 
5pm 
9.30pm
DAY NO. 24 
9.30am 
5pm 
9.30pm
DAY NO. 25 
9.30am 
5pm_______
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)________________(g/dl) (mmol/1) (mis) (kg)
58
54
50
46
40
38
36
32
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
5.0 
2.3
5.1
4.2
2.0
3.9
4.0
2.4
3.7
5.1
2.4
5.3
4.8
2.2
5.2
5.3
4.4 
4.7
5.0
3.0 
3.3
4.0 
1.8
4.1
4.6
5.5
5.3
5.5
5.4
200
300 22.75
NM
NM
400
650
100
200
350
100
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CASE REPORT DOG 08
BREED; Terrier X
AGE: 9 years 
SEX: Speyed female 
HISTORY:
This dog had been in the owners’ possession for 6 years and had been neutered prior to 
their ownership. A diagnosis of diabetes mellitus had been made by the referring 
veterinary surgeon 5 months prior to admission to G.U.V.S., after a one-week-period of 
polydipsia and nocturia. There had been no history of prolonged therapy with steroid 
hormones or consistent with pancreatitis. The dog was initially stabilised at home by the 
owners using isophane insulin of bovine origin and urine glucose testing strips. The dose 
had been increased from 10 to 20IU. No blood samples were taken from this dog prior 
to her admission to G.U.V.S. Weight loss was noted around the time of original 
diagnosis but latterly the dog had maintained weight well. The eyes were dry and mattery 
initially but this had improved after a few weeks of insulin therapy. She was admitted to 
G.U.V.S. for thorough assessment and conversion to Caninsulin.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was bright and alert and appeared moderately overweight. Heart rate was 
110/min. Respiratory rate was 30/min. Mucous membranes were pink and capillary refill 
time was less than 2 seconds. There were no pulmonary adventitious sounds or cardiac 
murmurs detected on thoracic auscultation. Abdominal palpation revealed no 
abnormalities.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 6.9 WBCC 9.9
SODIUM 142 NEUTROPHILS 7.62
POTASSIUM 4.2 LYMPHOCYTES 1.88
CHLORIDE 108 MONOCYTES 0.30
CALCIUM 2.54 EOSINOPHILS 0.10
PHOSPHATE 0.82 RBCC 6.33
GLUCOSE 5.0 HAEMOGLOBIN (HB) 14.9
CHOLESTEROL 17.87 HAEMATOCRIT 41.1
CREATININE 42 MEAN CELL VOLUME 65
TOTAL BILIRUBIN 2 MEAN CELL HB 23.5
ALKALINE PHOS 909 MEAN CELL HB CONC. 36.2
ALT 53 PLATELETS 443
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BIOCHEMISTRY (cont):
TOTAL PROTEIN
ALBUMIN
GLOBULIN
72
40
32
Lateral thoracic and abdominal radiographs demonstrated enlargement of the hepatic 
shadow.
In view of the plasma glucose concentration of 5mmol/1 at the time of blood sampling 
insulin therapy was withheld for one day. The fasting plasma glucose concentration the 
following day was 22mmol/l. Therapy with Caninsulin was then started at a dose of 
15IU. Diet comprised 9oz canned dog food (Pedigree Chum; Pedigree Petfoods) and 
2oz of bread fed twice daily (75kcal/kg/day).
HOSPITALISATION:
This dog was hospitalised for a further 12 days, during which time it remained very 
bright, active and ate well. Rectal temperature never exceeded 101.8°F. Insulin dose was 
initially increased to 19IU but reduced to a final dose of 14IU. Water intake remained 
below 250ml/day. Bodyweight remained constant.
The dog was discharged on day 13 and the owners were advised to continue monitoring 
morning urine glucose concentrations but to contact G.U.V.S. before adjusting the 
insulin dose.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 15 TRACE 2.0 25.4 NM 10.5
5pm 15.4
9.30pm TRACE 2.0 19.9
DAY NO. 2
9.30am 19 NEG 2.0 19.7 50
5pm 4.6
9.30pm TRACE 2.0 8.1
DAY NO. 3
9.30am 18 TRACE 0.25 11.2 100
5pm 3.3
9.30pm TRACE 0.25 9.8
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Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 4
9.30am 17 TRACE 0.25 NS NM
5pm 4.3
9.30pm TRACE 0.25 NS
DAY NO. 5
9.30am 17 NEG 0.0 NS 200
5pm 4.9
9.30pm NEG 0.0 15.3
DAY NO. 6
9.30am 17 NEG 2.0 12.0 250 10.5
5pm 4.6
9.30pm NEG 0.0 4.9
DAY NO. 7
9.30am 17 NEG 0.0 7.1 NM
5pm 4.9
9.30pm NEG 0.0 7.6
DAY NO. 8
9.30am 17 NEG 0.0 NS NM
5pm 5.4
9.30pm NEG 0.0 5.5
DAY NO. 9
9.30am 17 NEG 0.0 4.9 NM
5pm 7.3
9.30pm NEG 0.0 7.0
DAY NO. 10
9.30am 17 NEG 0.0 7.4 150
5pm 3.9
9.30pm NEG 0.0 3.1
DAY NO. 11
9.30am 15 NEG 0.0 9.9 150
5pm 4.0
9.30pm NEG 0.0 3.9
DAY NO. 12
9.30am 15 NEG 0.0 6.5 150
5pm 3.4
9.30pm NEG 0.0 3.9
DAY NO. 13
9.30am 14 NEG 0.0 8.6 NM 10.5
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CASE REPORT DOG 09
BREED: Miniature Smooth-haired Dachshund
AGE: 10 years 
SEX: Speyed female 
HISTORY:
This dog was referred to G.U.V.S. for thorough investigation and re-stabilisation. A 
progressively increasing thirst had been noted for three months prior to referral. Weight 
loss and exercise intolerance became obvious in the 4 weeks before admission. The 
referring veterinary surgeon diagnosed diabetes mellitus and ketoacidosis when weight 
loss became apparent and attempted stabilisation using single daily evening injections of 
Lentard MC (Novo, Nordisk). Doses of insulin were high (20-28IU for a 6kg dog), 
hence referral for further investigation.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was bright and alert. Rectal temperature was 100.5®F. There was obvious 
cataract opacification of the left lens. There were no ocular discharges. Lymph nodes 
were normal. Heart rate was 120/min. Colour, CRT and pulse volume were good. On 
auscultation, there was a grade III/V left sided systolic cardiac murmur but no 
adventitious pulmonary sounds. On abdominal palpation, hepatomegaly was obvious. 
There was also erythema and tacky purulent discharge around the vulva. The skin of the 
axillae, abdominal folds and ear pinnae was also erythematous.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 6.0 WBCC 8.5
SODIUM 146 NEUTROPHILS 6.72
POTASSIUM 4.6 LYMPHOCYTES 111
CHLORIDE 107 MONOCYTES 0.43
CALCIUM 2.33 EOSINOPHILS 0.26
PHOSPHATE 1.15 RBCC 6.67
GLUCOSE 18.1 HAEMOGLOBIN 14.6
CHOLESTEROL 13.24 HAEMATOCRIT 42.4
CREATININE 64 PLATELETS 321
TOTAL BILIRUBIN 1
ALKALINE PHOS 1,164
ALT 444
AST 85
TOTAL PROTEIN 65
ALBUMIN 33
GLOBULIN 32
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Radiography of thorax and abdomen revealed only hepatomegaly.
This dog was included in Caninsulin trial on the day of admission. Starting dose of 
Canisulin was I5IU because of the recent history of high insulin requirement. Diet 
comprised 125g canned dog food (Chum; Pedigree Petfoods) and 25g of bread fed twice 
daily (80kcal/kg)
HOSPITALISATION:
Over the first 5 days of hospitalisation the clinical condition varied very little. Insulin 
dose was increased to 20IU and then decreased to lOIU. Water intake varied between 
150 and 300ml/day. The dog remained bright and alert throughout this initial period. On 
the sixth day, however, she dog passed soft faeces and a course of kaolin and neomycin 
(Kaobiotic; Upjohn) was instituted. The next day (day 7), watery diarrhoea was passed 
but she remained bright. On days 8 and 9, the dog became dull, anorexic and passed 
fresh blood with diarrhoea. Insulin dose for these and subsequent 2 days was halved and 
a light, easily digested diet was offered. Bacterial culture of faeces subsequently yielded 
significant growth of P-haemolytic E. coli. Diet and appetite returned to normal and 
insulin dose returned to lOIU on day 12. The dog was discharged on day 14 on an insulin 
dose of 12 rU .
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis)
DAY NO. 1
9.30am 15 NEG 2.0 24.4 150 6
5pm
9.30pm NEG 2.0
18.1
15.9
DAY NO. 2
9.30am 20 NEG 1.0 18.7 200
5pm
9.30pm NEG 1.0
4.7
12.5
DAY NO. 3
9.30am 20 NEG 0.0 10.5 NM
5pm
9.30pm NEG 0.0
3.6
13.9
DAY NO. 4
9.30am 18 NEG 0.0 3.5 NM
5pm
9.30pm NEG 0.0
3.3
3.2
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Insulin Urine
dose ketones
(lU) _____
Urine Plasma Water Body-
glucose glucose intake weight
(g/dl) (mmol/1) (mis) (kg)
DAY NO. 5 
9.30am 
5pm 
9.30pm
DAY NO. 6 
9.30am 
5pm 
9.30pm
DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm 
9.30pm
DAY NO. 11 
9.30am 
5pm 
9.30pm
DAY NO. 12 
9.30am 
5pm 
9.30pm
DAY NO. 13 
9.30am 
5pm 
9.30pm
DAY NO. 14 
9.30am 
5pm_______
14 NEG
NEG
10 NEG
NEG
10 NEG
NEG
8 NEG
NEG
6 NEG
NEG
5 NEG
TRACE
5 NEG
NEG
10 TRACE
NEG
14
12
NEG
TRACE
NEG
0.0
1.5
1.5
1.5
2.0
2.0
0.25
0.0
0.75
0.75
0.75
1.0
0.75
1.0
1.0
1.0
1.0
0.5
0.5
13.4
3.2
21.9
16.7
7.2
26.0
20.8
3.4
3.2
15.1
4.0
6.4
18.0
3.0
14.4
18.8
5.8
22.2
22.7
17.9
29.1
27.5
10.6 
27.3
22.4
3.5
21.0
18.9
4.7
250 5.8
300
200 5.5
NM
400 5.25
400
400
450 5.5
175
300 5.75
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CASE REPORT DOG 010
BREED; Samoyed
AGE: 8 years 
SEX: Entire female
HISTORY:
This dog was first referred for diabetic stabilisation 5 months prior to admission to the 
Caninsulin study. This was achieved using an isophane insulin (Isophane; Evans) and the 
dog had been ‘stable’ on 20IU since that time. The owners were advised to have the dog 
speyed but refused. Conversion to Caninsulin was carried out whilst the dog was 
boarding.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was bright and lively. Heart rate was 108/minute. Mucous membrane colour, 
CRT and pulse volume were all good. Rectal temperature was 101.8°F. Vision was good 
but there mild increases in density of the ventral parts of both lenses. No abnormalities 
were detected on thoracic auscultation nor on abdominal palpation. Lymph nodes were 
normal.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 6.3 WBCC 8.6
SODIUM 141 NEUTROPHILS 6.19
POTASSIUM 4.6 LYMPHOCYTES 1.98
CHLORIDE 107 MONOCYTES 0.34
CALCIUM 2.46 EOSINOPHILS 0.04
PHOSPHATE 1.07 RBCC 7.14
GLUCOSE 24.3 HAEMAGLOBIN (HB) 17.0
CHOLESTEROL 9.12 HAEMATOCRIT 45.0
CREATININE 19 MEAN CELL VOLUME 63
TOTAL BILIRUBIN 2 MEAN CELL HB 23.8
ALKALINE PHOS 380 MEAN CELL HB CONC. 37.7
ALT 30 PLATELETS 224
AST 13
TOTAL PROTEIN 66
ALBUMIN 32
GLOBULIN 34
Radiography was not performed.
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This dog was included in the Caninsulin study from the day of re-admission. Starting 
dose of Caninsulin was 24IU and diet was as before at 500g canned dog food (Pedigree 
Chum; Pedigree Petfoods) and lOOg bread fed twice daily (45kcal/kg/day).
HOSPITALISATION:
This dog was hospitalised for 6 days for conversion to Caninsulin, during which time, 
there was no change in clinical condition. The dog remained bright and lively. Rectal 
temperature remained below 102.0°F at all examination times. Insulin dose was increased 
to 26IU but then lowered again to 24IU. Water intake varied between 750 and 
1400ml/day. Bodyweight remained constant at 29kg.
The dog was discharged on 24IU and the owners were advised to monitor morning urine 
glucose concentrations using test strips but not to alter the insulin dose unless directed 
by G.U.V.S. hospital staff.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine Urine Plasma Water Body-
ketones glucose glucose intake weight
DAY NO. 1
9.30am 24 NEG 2.0 24.3 NM 29
5pm 8.1
9.30pm NEG 2.0 9.2
DAY NO. 2
9.30am 25 NEG 2.0 23.4 900
5pm 9.7
9.30pm NEG 1.0 20.4
DAY NO. 3
9.30am 26 NEG 0.25 14.3 750
5pm 3.8
9.30pm NEG 0.0 6.5
DAY NO. 4
9.30am 26 NS NS 19.4 1400
5pm 7.4
9.30pm NEG 0.0 3.8
DAY NO. 5
9.30am 24 NEG 0.0 13.0 NM
5pm 3.7
9.30pm NEG 0.0 9.9
DAY NO. 6
9.30am 24 NEG 0.0 18.0
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CASE REPORT DOG 011
BREED; Jack Russell terrier
AGE: 8 years 
SEX: Entire female
HISTORY:
This dog was referred to G.U.V.S. for diabetic stabilisation, having been polydipsic 
(water intake approximately 1 litre/day), polyphagic and losing weight for the preceeding 
two months. These signs become more marked in the fortnight prior to referral.
The referring veterinary surgeon prescribed a low calorie/high fibre diet (r/d: Hill's), 6 
weeks prior to referral, and this seemed to reduce the polydipsia. There was no history of 
prolonged steroid therapy or consistent with pancreatitis. An injection to suppress 
oestrus had been administered one month before admission to G.U.V.S.. The preceeding 
oestrus had been 7 months earlier.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was noticeably thin but bright and alert. Mucous membranes were dry but pink 
and capillary refill time was less than 2 seconds. Heart rate was 84/minute. There were 
no cardiac murmurs or adventitious pulmonary sounds to be heard on auscultation. 
Abdominal palpation revealed a ‘full’ feeling abdomen, especially cranially, suggesting 
hepatic enlargement. There was no vaginal discharge and no signs of cataract formation 
but bilateral nuclear sclerosis of both lenses was present.
Lateral radiographs of thorax and abdomen revealed only hepatomegaly. There was no 
obvious uterine shadow.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 5.9 WBCC 6.5
SODIUM 142 NEUTROPHILS 3.90
POTASSIUM 4.2 LYMPHOCYTES 1.98
CHLORIDE 107 MONOCYTES 0.49
CALCIUM 2.25 EOSINOPHILS 0.13
PHOSPHATE 0.64 RBCC 6.78
GLUCOSE 22.7 HAEMOGLOBIN (HB) 14.9
CHOLESTEROL 6.95 HAEMATOCRIT 44.1
CREATININE 62 MEAN CELL VOLUME 65
TOTAL BILIRUBIN 2 MEAN CELL HB 21.9
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BIOCHEMISTRY (CONT): HAEMATOLOGY (CONT):
ALKALINE PROS 97 MEAN CELL HB CONC. 33.7
ALT 135 PLATELETS 432
AST 99
TOTAL PROTEIN 57
ALBUMIN 32
GLOBULIN 25
The day following admission this dog was included in the Caninsulin trial. Starting dose 
of Caninsulin was 7IU and diet comprised 172g of canned dog food (Chappie;Pedigree 
Petfoods) and 42g of bread fed twice daily (65kcal/kg/day).
HOSPITALISATION:
The dog was hospitalised for a total of 16 further days, during which time the insulin 
dose rose to lOIU but settled down at 8IU. After a series of very low afternoon plasma 
glucose concentrations, it was decided to reduce the insulin dose drastically and no 
insulin was given on day 7. Water intake, whilst hospitalised, varied between 150ml and 
600ml. Body weight increased from 5.8kg on admission to 6.5 kg at discharge. The 
clinical condition of this dog did not vary throughout the hospitalisation period. The dog 
remained bright, alert and playful. Rectal temperature varied between 100.4°F and 
101.6°F. Heart rate remained below 120/minute.
This dog was discharged on day 16 and instructions were given to the owner to monitor 
morning urine glucose concentrations using Keto-diastix (Ames). The owners were 
advised to increase Caninsulin dose by IIU if morning urine glucose concentrations were 
2% or greater for more than two consecutive days.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 1
9.30am 7 NS NS 21.7 200 5.8
5pm 8.8
9.30pm NS NS 15.3
DAY NO. 2
9.30am 9 NEG 1.5 18.7 400
5pm 10.6
9.30pm NS NS NS
DAY NO. 3
9.30am 11 NEG 0.0 4.5 600
5pm 20.5
9.30pm NS NS NS
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Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 4
9.30am 9 NS NS 7.7 200
5pm 4.1
9.30pm TRACE 0.0 3.8
DAY NO. 5
9.30am 8 NEG 0.0 11.1 400 6.5
5pm 2.9
9.30pm NEG 2.0 24.5
DAY NO. 6
9.30am 6 NS NS 17.0 600
5pm 2.6
9.30pm NEG 0.0 8.0
DAY NO. 7
9.30am 0 NEG 0.0 17.9 500
5pm 18.0
9.30pm NEG 2.0 21.5
DAY NO. 8
9.30am 4 NEG 2.0 28.5 500
5pm 7.9
9.30pm NEG 2.0 19.6
DAY NO. 9
9.30am 4 NEG 2.0 17.3 650 6.0
5pm 20.6
9.30pm NEG 2.0 22.1
DAY NO. 10
9.30am 6 NEG 2.0 26.3 500
5pm 111
9.30pm NEG 2.0 18.5
DAY NO. 11
9.30am 8 NEG 2.0 17.2 275
5pm 7.3
9.30pm NEG 2.0 13.4
DAY NO. 12
9.30am 10 NEG 0.25 18.9 350
5pm 4.0
9.30pm NEG 0.25 9.4
DAY NO. 13
9.30am 10 NEG 2.0 19.7 150
5pm 3.2
9.30pm NEG 2.0 4.5
DAY NO. 14
9.30am 9 NEG 0.5 20.5 200
5pm 3.8
9.30pm NEG 0.25 6.4
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Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU) (g/dl) (mmol/1) (mis) (kg)
DAY NO. 15
9.30am 8 MEG 0.0 7.3 400
5pm 4.0
9.30pm NEG 0.0 20.1
DAY NO. 16
9.30am 8 NEG 0.0 14.2 NM 6.5
5pm 4.1
9.30pm
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CASE REPORT DOG 012
BREED: Caim terrier
AGE: 4 years 
SEX: Speyed female
HISTORY:
This bitch had been speyed prior to her first oestrus and had no history of previous major 
medical or surgical illness. Over a 6 week period, prior to admission to G.U.V.S., she 
became noticeably polydipsic, polyuric, polyphagic and was presented to the referring 
veterinary surgeon 4 days prior to admission. Ampicillin was prescribed pending referral. 
There was no history of previous therapy with corticosteroids or reproductive hormones 
nor of any pancreatic disease.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was bright and alert. Mucous membranes were pink and moist and capillary 
refill time was less than 2 seconds. Heart rate was 120/minute. There were no cardiac 
murmurs or adventitious pulmonary sounds on auscultation and pulses were good. The 
dog's eyes were clear and bright with no obvious discharges or cataract formation. 
Abdominal palpation revealed a ‘fullness’ and possible hepatomegaly. Lymph nodes were 
not enlarged.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 6.4 WBCC 9.3
SODIUM 144 NEUTROPHILS 7.30
POTASSIUM 3.9 LYMPHOCYTES 1.81
CHLORIDE 105 MONOCYTES 0.09
CALCIUM 2.46 EOSINOPHILS 0.09
PHOSPHATE 1.00 RBCC 6.93
GLUCOSE 21.8 HAEMOGLOBIN (HB) 16.4
CHOLESTEROL 8.38 HAEMATOCRIT 47.1
CREATININE 55 MEAN CELL VOLUME 68
TOTAL BILIRUBIN 2 MEAN CELL HB 23.6
ALKALINE PHOS 1,085 MEAN CELL HB CONC. 34.8
ALT 61 PLATELETS 529
AST - 38
TOTAL PROTEIN 66
ALBUMIN 40
GLOBULIN 26
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Examination of lateral abdominal and thoracic radiographs confirmed only the presence 
of hepatomegaly.
The dog was included in the Caninsulin trial from the day of admission. The starting dose 
of Caninsulin was 11 lU and diet comprised 195g canned commercial dog food 
(Chappie:Pedigree Petfoods) and 45g bread fed twice daily (70kcal/kg/day).
HOSPITALISATION:
The dog was hospitalised for a further 10 days, during which time the dose of Caninsulin 
rose to 16IU but was reduced to 15IU. At this point the dog was discharged. Whilst 
hospitalised water intake dropped from 600-800ml/day to 150ml/day. The dog's general 
condition improved marginally although she was bright and lively throughout. Rectal 
temperature remained normal whilst hospitalised.
On discharge (day 10), the owners were instructed in the use of urine glucose test strips 
and were advised to adjust insulin dose according to morning urine glucose 
concentrations.
Two days following discharge the dog was re-admitted as she had become dull and the 
owner was unhappy with her condition. Morning urine glucose concentrations had been 
2% or greater. On examination no abnormalities were detected. Re-stabilisation was 
undertaken over the following 10 days. A rectal temperature of 103°F was recorded the 
day after the second admission and a course of ampicillin was instituted. Water intake 
again fell to 150ml/day. Doses varied up to 22IU during this second period but the dog 
was discharged again on a dose of 18IU.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(K/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 1
9.30am 11 LARGE 1.0 22.3 600 8.5
5pm 7.5
9.30pm LARGE 2.0 16.9
DAY NO. 2
9.30am 12 SMALL 1.0 20.3 NM
5pm 13.2
9.30pm NEG 2.0 15.0
DAY NO. 3
9.30am 14 NEG 2.0 27.4 800
5pm 16.5
9.30pm NEG 2.0 14.6
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DAY NO. 4 
9.30am 
5pm 
9.30pm
DAY NO. 5 
9.30am 
5pm 
9.30pm
DAY NO. 6 
9.30am 
5pm 
9.30pm
DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm______
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis) (kg)
16
16
16
16
16
15
15
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
2.0
2.0
2.0
2.0
1.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
27.3 
6.4
16.4
24.0
5.8
17.8
9.6
4.5
20.0
19.3
5.5
17.9
15.1
3.9
12.6
15.0
4.4
14.8
10.9
7.1
750 8.5
600
250
150
150
400
8.8
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CASE REPORT DOG 013
BREED: Beagle.
AGE: 7 years 
SEX: Entire female
HISTORY;
This dog was referred for diabetic stabilisation with a history of weight loss, lethargy and 
polydipsia of 2 months duration. She had been in season 3 to 4 months earlier. There was 
no history of reproductive hormone therapy, prolonged corticosteroid therapy nor of 
generalised pancreatic disease. Two years prior to referral thyroxin (Eltroxin) therapy 
had been prescribed.
CLINICAL EXAMINATION AND INVESTIGATION;
The dog was bright but quiet. Mucous membranes were pink and moist. Heart rate was 
92/minute. CRT and pulse volume were both good. There were no ocular discharges nor 
evidence of cataract formation. On auscultation, there were no cardiac murmurs or 
pulmonary adventitous sounds detected. Abdominal palpation revealed a ‘full’ feeling 
abdomen and possible hepatomegaly. Hypothyroidism was not suspected.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 3.5 WBCC 11.2
SODIUM 140 NEUTROPHILS 9.52
POTASSIUM 4.7 LYMPHOCYTES 0.90
CHLORIDE 97 MONOCYTES 0.67
CALCIUM 2.48 EOSINOPHILS O il
PHOSPHATE 1.12 RBCC 6.85
GLUCOSE 25.4 HAEMOGLOBIN HB 16.7
CHOLESTEROL 8.89 HAEMATOCRIT 47.8
CREATININE 79 MEAN CELL VOLUME 70
TOTAL BILIRUBIN 0 MEAN CELL HB 24.3
ALKALINE PHOS 152 MEAN CELL HB CONC. 34.9
ALT 199 PLATELETS 277
AST 43
TOTAL PROTEIN 66
ALBUMIN 35
GLOBULIN 31
Radiography revealed no abnormalities.
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Bacteriological culture of urine yielded p-haemolytic Streptococcus and non-haemolytic 
E. coli. Ampicillin therapy was instituted.
The day following admission this dog was included in the Caninsulin trial. The starting 
dose of Caninsulin was 13IU. Diet comprised 370g of canned dog food (Chum:Pedigree 
Petfoods) and 50g bread fed twice daily.
HOSPITALISATION:
The dog remained bright until day 10 when she began to pass bloody diarrhoea, which 
continued until day 13. During this three day period her appetite was considerably 
reduced. The diarrhoea was treated with clavulanate potentiated amoxycillin (Synulox: 
SK Beecham). Bacterial culture of faeces yielded P-haemolytic E. coli and 
Campylobacter spp.. Rectal temperature never exceeded 101.8°F at all examination 
times. Whilst hospitalised bodyweight initially increased and then fell again to 12kg. 
Water intake remained below 450mls. Insulin dose was increased to 18IU then lowered 
again to a final dose of 13IU.
The dog was boarded after this stabilisation period until ovariohysterectomy, which was 
performed on day 18. Recovery was uneventful.
The dog was discharged on 13 lU of Caninsulin and owners were advised to adjust 
insulin dose according to morning urine glucose concentrations i.e., to increase the 
insulin dose by one unit if morning glucose concentrations were 2% or greater for more 
than two consecutive days and to lower it if urine glucose concentrations were negative 
for more than two days.
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body­
dose ketones glucose glucose intake weight
(lU) (g/dl) (mmol/1) (mis) (kg)
DAY NO. 1
9.30am 13 NEG 2.0 20.7 50 11.5
5pm 23.1
9.30pm NEG 2.0 23.2 50
DAY NO. 2
9.30am 15 NS NS 22.3 50
5pm 21.7
9.30pm NEG 2.0 20.7
DAY NO. 3
9.30am 15 NEG 0.0 11.2 200
5pm 14.0
9.30pm NEG 0.0 14.7
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DAY NO. 4 
9.30am 
5pm 
9.30pm
DAY NO. 5 
9.30am 
5pm 
9.30pm
DAY NO. 6 
9.30am 
5pm 
9.30pm
DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm 
9.30pm
DAY NO. 11 
9.30am 
5pm 
9.30pm
DAY NO. 12 
9.30am 
5pm 
9.30pm
DAY NO. 13 
9.30am 
5pm_______
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis) (kg)
15
17
18
17
17
17
13
13
13
13
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
0.0
2.0
2.0
2.0
0.0
0.25
0.25
0.25
0.0
2.0
0.0
0.75
0.0
0.0
0.0
0.0
0.0
0.0
0.0
12.1
10.5
10.1
8.0
7.7
15.3
6.1
4.5
10.4
5.1
5.6
8.9
5.4
6.2
13.7
4.1 
2.8
8.1
8.6
8.2
8.8
7.4
5.1
9.8
111
11.6
16.5
14.6
8.1
200
450 12.75
150
100
100 12.5
150
200 12.5
25
100
100
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CASE REPORT DOG 014
BREED; Rottweiler
AGE; 5 years 
SEX: Male
HISTORY:
This dog was referred for diabetic stabilisation with a history of weight loss, polyphagia, 
polydipsia and polyuria of 4 weeks duration. Diarrhoea, vomiting, dullness and exercise 
intolerance had been noted over the latter 2 weeks. There was no history of chronic 
steroid therapy or pancreatitis.
CLINICAL EXAMINATION AND INVESTIGATION:
This dog was alert but dull in demeanour. His breath smelt strongly of ketones. Heart 
rate was 80/min. Rectal temperature was 101°F. Thoracic auscultation and abdominal 
palpation revealed no abnormalities. Hair coat was in poor condition. There was 
bilateral, tacky, mucopurulent ocular discharge.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 4.7 WBCC 12.9
SODIUM 137 NEUTROPHILS 10.06
POTASSIUM 3.4 LYMPHOCYTES 2.06
CHLORIDE 102 MONOCYTES 0.36
PHOSPHATE 1.19 EOSINOPHILS 0.32
GLUCOSE 22.8 RBCC 7.33
CHOLESTEROL 8.71 HAEMOGLOBIN (HB) 16.7
CREATININE 68 HAEMATOCRIT 47.8
TOTAL BILIRUBIN 4 MEAN CELL VOLUME 65
ALKALINE PHOS 472 MEAN CELL HB 22.7
ALT 185 MEAN CELL HB CONC. 34.9
AST 144 PLATELETS 239
TOTAL PROTEIN 68
ALBUMIN 27
GLOBULIN 49
Lateral thoracic and abdominal radiographs revealed moderate hepatomegaly.
Schirmer tear test on both eyes showed tear production to be normal and trypsin-like- 
immunoreactivity test showed exocrine pancreatic function to be normal.
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The day following admission this dog was entered into the Caninsulin study. Starting 
dose was 40IU and diet comprised 750g canned dog food (Chappie; Pedigree Petfoods) 
and 175g bread fed twice daily (60kcal/kg/day).
HOSPITALISATION:
This dog was hospitalised for a period of 14 days. During this time rectal temperature 
never exceeded 102°F. Therapy with Chloromycetin Ophthalmic ointment (Parke Davis) 
was begun on day 1. Water intake fell from 3000 - 3500ml/day to 1600 - 1900ml/day. 
Insulin dose increased to 49IU by day 8 and remained at that level until discharge. 
Bodyweight increased by 1kg whilst hospitalised. The dog became noticeably bright by 
day 7 and coat condition had improved markedly by this time. The ocular discharge 
resolved by day 4.
The dog was discharged on day 14 and the owners were advised to monitor morning 
urine glucose concentrations.
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________(g/dl) (mmol/1) (mis)
DAY NO. 1
9.30am 40 LARGE 2.0 21.4 NM 40
5pm 17.4
9.30pm MOD. 1.0 33.1
DAY NO. 2
9.30am 44 NEG 0.0 22.1 NM
5pm 3.8
9.30pm NEG 0.0 3.5
DAY NO. 3
9.30am 42 NS NS 30.1 3000
5pm 12.4
9.30pm NEG 2.0 19.6
DAY NO. 4
9.30am 44 NEG 2.0 22.2 3500
5pm 16.2
9.30pm NEG 2.0 19.8
DAY NO. 5
9.30am 46 NEG 2.0 21.3 3000
5pm 11.7
9.30pm NEG 0.0 9.9
DAY NO. 6
9.30am 46 NEG 2.0 25.2 3500
5pm 10.7
9.30pm NEG 2.0 19.6
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DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm 
9.30pm
DAY NO. 11 
9.30am 
5pm 
9.30pm
DAY NO. 12 
9.30am 
5pm 
9.30pm
DAY NO. 13 
9.30am 
5pm 
9.30pm
DAY NO. 14 
9.30am 
5pm______
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)________________(g/dl) (mmol/1) (mis) (kg)
47
49
49
49
49
49
49
49
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
2.0
2.0
2.0
2.0
0.25
0.0
0.25
0.25
0.0
0.0
0.0
0.0
0.25
0.0
0.75
23.9
19.6
27.1
15.1
5.5
17.9
9.3
5.2
4.5
24.5
8.1
16.7
17.5
5.2
9.6
16.0
8.1
8.6
22.3
10.5
6.9
17.5
7.4
2000
1800
1600 41
1800
NM
1900
1600
41
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CASE REPORT DOG 015
BREED: Labrador
AGE 8 years
SEX: Speyed female
HISTORY:
One year before referral the dog developed a painful neck and was placed on continuing 
corticosteroid therapy (5mg eod). Three months later an ovariohysterectomy was 
performed as treatment for pyometritis. Extreme polydipsia and marked weight loss 
developed during the 3 weeks prior to referral. The dog had formerly been obese. The 
dog's condition progressively deteriorated until she was referred to G.U.V.S. in a 
collapsed state.
CLINICAL EXAMINATION AND INVESTIGATION:
On admission this dog was collapsed. Heart rate was 124/minute. Mucous membranes 
were tacky but pink. Abdominal palpation revealed no abnormalities and was not 
resented. No cardiac murmurs or adventitious pulmonary sounds were detected on 
auscultation.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 18.2 WBCC 18.3
SODIUM 141 NEUTROPHILS 17.39
POTASSIUM 2.7 LYMPHOCYTES 0.73
CHLORIDE 111 MONOCYTES 0.18
CALCIUM 2.35 RBCC 6.29
PHOSPHATE 1.62 HAEMOGLOBIN (HB) 14.4
GLUCOSE 27.5 HAEMATOCRIT 43.1
CHOLESTEROL 9.95 MEAN CELL VOLUME 69
CREATININE 112 MEAN CELL HB 22.8
TOTAL BILIRUBIN 2 MEAN CELL HB CONC. 33.4
ALKALINE PHOS 3,858 PLATELETS 584
ALT 61
AST 34
TOTAL PROTEIN 64
ALBUMIN 30
GLOBULIN 34
AMYLASE 16,120
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Radiographs of thorax and abdomen revealed an area of localised peritonitis consistent 
with pancreatitis.
Urine was very dark and red/brown in colour and on bacteriological culture was found to 
contain p-haemolytic E. coli.
Diagnoses of diabetes mellitus, ketoacidosis, pancreatitis, hypokalaemia and bacterial 
cystitis were made. The dog was denied access to oral food or fluids for 8 days and 
treated with intravenous fluids, intravenous potassium supplementation, neutral insulin 
(Hypurin Neutral, Fisons), Caninsulin and clavulanate potentiated amoxycillin (Synulox: 
SK Beecham).
At the end of this initial 8 day period this dog was included in the Caninsulin trial. 
Starting dose of Caninsulin was 25IU and diet comprised 560g of canned dog food 
(Chappie: Pedigree Petfoods) and 135g of bread twice daily.
HOSPITALISATION:
The dog was hospitalised for a further 11 days for stabilisation with Caninsulin. During 
this period insulin dose increased to 48IU. Unfortunately because of owner pressure this 
dog was discharged before reaching ‘ideal’ glycaemic stability. During stabilisation the 
dog’s clinical condition varied very little, remaining bright and lively throughout. Rectal 
temperature never exceeded 101.8°F at any examination time. By day 4, urine was clear 
and culture negative for bacteria. Polydipsia reduced as a result of treatment with 
Caninsulin but this was impossible to record because the dog regularly tipped its water 
bowl.
The dog was discharged before good glycaemic control was achieved and the owners 
were instructed to continue to adjust insulin dosage according to morning urine glucose 
concentrations.
APPENDIX 11 313
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 25 NEG 0.0 3.5 NM 30
5pm 5.3
9.30pm NEG 0.0 6.3
DAY NO. 2
9.30am 21 NEG 0.0 12.7 NM
5pm 3.7
9.30pm NEG 0.0 7.7
DAY NO. 3
9.30am 21 NEG 1.0 31.1 NM
5pm 17.5
9.30pm NEG 2.0 17.1
DAY NO. 4
9.30am 23 NEG 1.0 21.0 NM
5pm 20.2
9.30pm NEG 2.0 24.8
DAY NO. 5
9.30am 27 NEG 2.0 22.9 NM
5pm 24.8
9.30pm NEG 2.0 31.1
DAY NO. 6
9.30am 30 NEG 2.0 18.7 NM
5pm 22.7
9.30pm NEG 2.0 25.3
DAY NO. 7
9.30am 32 NEG 2.0 20.7 NM
5pm 21.0
9.30pm NS NS 23.6
DAY NO. 8
9.30am 36 NEG 2.0 23.4 NM 33
5pm 22.8
9.30pm NEG 2.0 24.2
DAY NO. 9
9.30am 40 NEG 0.0 NS NM
5pm 22.0
9.30pm NEG 2.0 NS
DAY NO. 10
9.30am 44 NEG 2.0 NS NM
5pm 24.0
9.30pm NEG 2.0 NS
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Insulin Urine Urine Plasma Water Body­
dose ketones glucose glucose intake weight
(lU) (g/dl) (mmol/1) (mis) (kg)
DAY NO. 11
9.30am 48 NEG 1.0 7.5 NM
5pm 15.4
9.30pm NS NS NS
DAY NO. 12
_ 9.30am 48 NEG 1.0 NS NM
5pm 7.2
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CASE REPORT DOG 016
BREED: West Highland White terrier
AGE: 14.5 years 
SEX: Speyed female 
HISTORY;
This dog was referred to G.U.V.S. for diabetic stabilisation following sudden onset 
blindness. There was no history of previous major medical or surgical illness. Polydipsia 
and polyuria had been apparent for approximately 14 days. There was no history of 
pancreatic disease or therapy with reproductive or corticosteroid hormones. 
Ovariohysterectomy had been performed when the dog was less than one year of age.
CLINICAL EXAMINATION AND INVESTIGATION;
The dog was dull and disinterested. There was a tacky mucopurulent discharge from the 
right eye. Much dental calculus and gingivitis were present. Heart rate was 130/minute 
and colour, CRT and pulse volume were good. There were no cardiac murmurs. Rectal 
temperature was 103.4°F. Peripheral lymph nodes, i.e., submandibular, prescapular and 
popliteal were all significantly enlarged. The dog smelt stongly of ketones. There were 
bilateral, diffuse, mature cataracts. The hair coat was thin for this breed of dog. 
Abdominal palpation revealed a pendulous abdomen and hepatomegaly.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 4.7 WBCC 16.0
SODIUM 142 NEUTROPHILS 11.12
POTASSIUM 5.7 LYMPHOCYTES 3.68
CHLORIDE 96 MONOCYTES 1.12
CALCIUM 2.85 EOSINOPHILS 0.08
PHOSPHATE 0.94 RBCC 6.96
GLUCOSE 24.8 HAEMOGLOBIN (HB) 15.6
CHOLESTEROL 4.74 HAEMATOCRIT 44.7
CREATININE 74 MEAN CELL VOLUME 64
TOTAL BILIRUBIN 0 MEAN CELL HB 22.4
ALKALINE PHOS 1,602 MEAN CELL HB CONC. 34.8
ALT 79 PLATELETS 507
AST 43
TOTAL PROTEIN 68
ALBUMIN 39
GLOBULIN 29
AMYLASE 1891
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A Schirmer tear test was performed and tear production was normal. Aspirates of 
enlarged lymph nodes were examined and found to contain a mixed population of cells 
consistent with reactive hyperplasia. Radiographic examination of the thorax and 
abdomen revealed hepatomegaly, osteoporosis, bronchial calcification and a pendulous, 
fat-filled abdomen.
This dog was entered into the Caninsulin trial on the day after admission to G.U.V.S.. 
The starting dose of Caninsulin for this dog was 12IU. Diet comprised 325g canned dog 
food (Chum; Pedigree Petfoods) and 65g bread fed twice daily. Therapy with potentiated 
sulphonamide (co-trimoxazole) was instituted on day 1 because of the lymphadenopathy.
HOSPITALISATION:
The dog was hospitalised for 14 days and for the first 3 days she remained dull, although 
her appetite remained good. After day 3, her rectal temperature was below 102.6°F at all 
examination times, she became bright and alert and the ocular discharge improved. 
Insulin dose was increased to 25IU over the first week but this was then reduced to a 
final dose of 14IU. On day 4 the previous day's insulin results were not available when 
the decision to increase insulin dose to 24IU was made. This was an incorrect decision, 
as Somogyi overswing phenomen would appear to have occurred on day 3 and perhaps 
also on day 4. During the 14 day period of hospitalisation water intake reduced from 
1500ml/day to 600ml/day.
On day 15 the dog was discharged on 14IU. Lymphadenopathy was still present and co- 
trimoxazole therapy was continued for another 7 days. The owners were not provided 
with urine testing equipment.
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HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 12 NS NS 20.7 1500 12
5pm 22.5
9.30pm SMALL 2.0 20.7
DAY NO. 2
9.30am 16 NEG 2.0 23.7 1500
5pm 19.7
9.30pm SMALL 2.0 21.2
DAY NO. 3
9.30am 20 TRACE 2.0 22.0 1450
5pm 2.0
9.30pm NEG 2.0 32.4
DAY NO. 4
9.30am 24 TRACE 2.0 28.7 1350
5pm 5.5
9.30pm NEG 2.0 31.7
DAY NO. 5
9.30am 24 TRACE 2.0 22.8 NM
5pm 3.8
9.30pm SMALL 2.0 23.0
DAY NO. 6
9.30am 25 MOD 2.0 25.7 650
5pm 2.8
9.30pm NEG 0.0 7.1
DAY NO. 7
9.30am 22 NEG 1.0 13.5 850 12.25
5pm 2.8
9.30pm NEG 2.0 23.4
DAY NO. 8
9.30am 18 NEG 0.0 16.8 650
5pm 2.4
9.30pm NEG 0.5 15.8
DAY NO. 9
9.30am 14 NEG 1.0 17.3 NM
5pm 3.1
9.30pm NEG 0.25 12.3
DAY NO. 10
9.30am 14 NEG 0.25 9.3 1000
5pm 3.1
9.30pm NEG 0.0 12.8
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Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(itg)
DAY NO. 11
9.30am
5pm 14 NEG 1.0 21.1 950
9.30pm 3.4
NEG 2.0 23.8
DAY NO. 12
9.30am 14 TRACE 2.0 20.7 900
5pm 5.2
9.30pm NEG 2.0 13.2
DAY NO. 13
9.30am 14 TRACE 2.0 22.2 600
5pm 5.9
9.30pm NEG 0.0 6.2
DAY NO. 14
9.30am 14 NEG 0.25 20.5
5pm 6.3
9.30pm NEG 0.0 11.8
DAY NO. 15
9.30am 14 NEG 1.0 20.4 12
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CASE REPORT DOG 017
BREED; Collie-X
AGE: 11 years 
SEX: Male 
HISTORY:
This dog was referred for diabetic stabilisation following polydipsia and polyuria over the 
preceeding 2 weeks. Weight loss and exercise intolerance had become apparent during 
the previous week. There was no history of prolonged steroid therapy nor of generalised 
pancreatic disease.
CLINICAL EXAMINATION AND INVESTIGATION:
On examination this dog was bright and alert. Colour, CRT and pulse volume were all 
good. Heart rate was 108/minute. There were no ocular discharges. Auscultation 
revealed no cardiac murmurs and no pulmonary adventitious sounds. Lymph nodes were 
normal in size. Abdominal palpation revealed no significant abnormalities.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 6.1 WBCC 14.6
SODIUM 141 NEUTROPHILS 12.56
POTASSIUM 4.0 LYMPHOCYTES 1.31
CHLORIDE 102 MONOCYTES 0.37
PHOSPHATE 0.94 EOSINOPHILS 0.79
GLUCOSE 31.1 RBCC 6.62
CHOLESTEROL 6.16 HAEMOGLOBIN (HB) 15.2
CREATININE 91 HAEMATOCRIT 42.9
TOTAL BILIRUBIN 0 MEAN CELL VOLUME 65
ALKALINE PHOS 372 MEAN CELL HB 22.9
ALT 97 MEAN CELL HB CONC. 35.4
AST 24 PLATELETS 274
TOTAL PROTEIN 73
ALBUMIN 37
GLOBULIN 36
Radiography of thorax and abdomen revealed only slight hepatomegaly.
Bacteriological culture of urine yielded significant growth of a P-haemolytic 
Streptococcus sensitive to ampicillin. A 7 day course of ampicillin was commenced.
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On the day of admission this dog was included in the Caninsulin trial. Starting dose of 
Caninsulin was 19IU and diet comprised 450g of canned dog food (Chum; Pedigree 
Petfoods) and lOOg of bread fed twice daily (65kcal/kg/day).
HOSPITALISATION:
During the subsequent 11 days of hospitalisation the dog remained bright and active. 
Rectal temperature remained below 101.6°F at all examination times. Water intake 
varied between 300 and 1400ml/day. Insulin dose was increased to 28IU by day 4 and 
maintained at that level until the dog was discharged. Body weight remained constant.
Upon discharge the owners were advised to maintain the diet and insulin dose at the 
hospitalisation levels unless instructed to change them at at follow up check. They were 
not supplied with urine glucose testing equipment.
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis)
DAY NO. 1
9.30am 19 NEG 2.0 31.1 NM 19
5pm
9.30pm NEG 2.0
19.5
21.7
DAY NO. 2
9.30am 20 NEG 2.0 28.5 800
5pm
9.30pm NEG 2.0
16.1
19.6
DAY NO. 3
9.30am 24 NS NS 16.6 300
5pm
9.30pm NEG 1.0
12.2
20.6
DAY NO. 4
9.30am 28 NEG 0.5 14.3 550
5pm
9.30pm NEG 1.0
5.2
14.7
DAY NO. 5
9.30am 28 NEG 0.0 5.0 NM
5pm
9.30pm NEG 0.0
4.5
12.1
DAY NO. 6
9.30am 28 NEG 0.0 10.1 450
5pm
9.30pm NEG 0.0
3.5
14.0
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DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm 
9.30pm
DAY NO. 
9.30am 
5pm
11
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis) (kg)
28
28
28
28
28
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
0.0
0.0
1.5 
2.0
0.0
1.0
1.5 
0.0
0.0
7.9
4.2
11.9
16.6
4.7
5.5
15.1 
4.2
17.1
7.2
3.3
6.3
9.1
3.5
NM
1400
NM
450
NM 19
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CASE REPORT DOG 018
BREED: Caim terrier
AGE: 5.5 years 
SEX: Male 
HISTORY:
This dog was referred for diabetic stabilisation having had a mature diffuse cataract of 
the right eye for 5 months and polyuria, polydipsia and weight loss during the few weeks 
prior to referral. The polydipsia was noted to be greatest in the evenings following meals. 
Exercise intolerance became apparent one week before referral. There was no history of 
prolonged steroid or reproductive hormone therapy nor of generalised pancreatic 
disease.
CLINICAL EXAMINATION AND INVESTIGATION:
On clinical examination this dog was bright and alert and apparently in good bodily 
condition. There was a dense cataract obvious in the right eye. The dog smelt strongly of 
ketones. Mucous membrane colour, CRT and pulses were good. Heart rate was 108/min. 
There were no cardiac murmurs nor adventitious lung sounds detected on thoracic 
auscultation. Rectal temperature was 102.4°F. Abdominal palpation revealed a tense fat 
abdomen and possible hepatomegaly.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 4.5 WBCC 10.1
SODIUM 137 NEUTROPHILS 7.58
POTASSIUM 4.0 LYMPHOCYTES 1.11
CHLORIDE 99 MONOCYTES 0.86
CALCIUM 2.58 EOSINOPHILS 0.56
PHOSPHATE 0.73 RBCC 6.56
GLUCOSE 22.4 HAEMOGLOBIN (HB) 15.1
CHOLESTEROL 6.89 HAEMATOCRIT 44.1
CREATININE 68 MEAN CELL VOLUME 67
TOTAL BILIRUBIN 1 MEAN CELL HB 23.0
ALKALINE PHOS 224 MEAN CELL HB CONC. 34.2
ALT 50 PLATELETS 475
AST 14
TOTAL PROTEIN 74
ALBUMIN 40
GLOBULIN 34
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Radiography of thorax and abdomen demonstrated only hepatomegaly.
The day following admission, the dog was entered to the Caninsulin trial. Starting dose 
of Caninsulin was 12IU and diet comprised 260g canned dog food (Chappie: Pedigree 
Petfoods) and 60g bread fed twice daily (60kcal/kg/day).
HOSPITALISATION:
This dog was hospitalised for 14 days during which time the dose of insulin was 
increased to 2IIU over the first 5 days and then reduced to 19IU. The dog remained 
bright and alert throughout the hospitalisation period. Rectal temperature remained 
below 101.4°F at all examination times. Water intake varied between 200 and 
1500ml/day. On day 14, the dog was discharged and the owners were advised to 
continue the new diet and 19IU of insulin unless directed otherwise at follow up 
examinations.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body­
weight
(kg)
DAY NO. 1
9.30am 12 LARGE 2.0 19.2 1500 12.0
5pm 21.7
9.30pm TRACE 1.0 22.4
DAY NO. 2
9.30am 16 SMALL 1.0 28.4 NM
5pm 7.5
9.30pm NEG 0.25 28.5
DAY NO. 3
9.30am 17 NEG 0.25 9.4 100
5pm 6.4
9.30pm NEG 0.0 5.9
DAY NO. 4
9.30am 17 NEG 0.0 5.3 950
5pm 4.2
9.30pm NEG 0.0 4.6
DAY NO. 5
9.30am 21 NEG 0.75 12.0 900
5pm 3.7
9.30pm NEG 0.0 6.9
DAY NO. 6
9.30am 20 NEG 0.0 3.5 NM 12.5
5pm 3.4
9.30pm NEG 0.0 5.0
APPENDIX 11 324
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 7
9.30am 19 NEC 0.0 11.9 NM
5pm 4.3
9.30pm NEC 0.0 8.7
DAY NO. 8
9.30am 19 NEC 0.25 11.7 200
5pm 4.9
9.30pm NEC 0.0 6.6
DAY NO. 9
9.30am 19 NEC 0.5 12.6 450
5pm 4.6
9.30pm NEC 0.0 5.1
DAY NO. 10
9.30am 20 NEC 0.0 13.0 NM
5pm 3.6
9.30pm NEC 0.0 6.6
DAY NO. 11
9.30am 19 NEC 0.0 8.0 NM 12.0
5pm 4.3
9.30pm NEC 0.0 7.1
DAY NO. 12
9.30am 19 NEC 0.0 8.4 345
5pm 4.2
9.30pm NEC 0.0 10.1
DAY NO. 13
9.30am 19 NEC 0.5 14.6 400 12.0
5pm 3.6
9.30pm NEC 0.0 2.5
DAY NO. 14
9.30am 19 NEC 0.0 11.8
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CASE REPORT DOG 019
BREED: Miniature Poodle
AGE: 9 years 
SEX: Male 
HISTORY:
For one month prior to referral for diabetic stabilisation, this dog had become 
significantly polydipsic and polyphagic and had lost weight in the two weeks before 
referral. There was no history of prolonged steroid therapy or pancreatitis. There was no 
history of any previous major medical or sugical illness.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was bright and alert. Hair coat appeared thin over caudal dorsum but the dog 
had recently been clipped. The dog also smelt strongly of ketones. Rectal temperature 
was 101°F. Colour and CRT were good. Auscultation revealed no cardiac murmurs nor 
adventitious pulmonary sounds. There was bilateral purulent ocular discharge and 
bilateral enlargement of submandibular and prescapular lymph nodes. Abdominal 
palpation revealed hepatomegaly.
LABORATORY FINDINGS:
BIOCHEMISTRY; HAEMATOLOGY:
UREA 7.4 WBCC 14.1
SODIUM 137 NEUTROPHILS 9.73
POTASSIUM 4.6 LYMPHOCYTES 2.68
CHLORIDE 97 MONOCYTES 1.62
CALCIUM 2.24 RBCC 6.93
PHOSPHATE 1.35 HAEMATOCRIT 44.4
GLUCOSE 26.0
CHOLESTEROL 5.95
CREATININE 44
ALKALINE PHOS 627
ALT 317
AST 330
TOTAL PROTEIN 70
ALBUMIN 33
GLOBULIN 37
CORTISOL 40
POST SYN 45MIN 195
POST SYN 90MIN 231
BASAL INSULIN 4.1
APPENDIX 11 326
Radiography of thorax and abdomen revealed changes consistent with hypovolaemia in 
addition to hepatomegaly and obesity.
This dog was included in the Caninsulin study from the day after admission on a starting 
dose of 6 IU and a diet comprising 190g canned dog food (Chum;Pedigree Petfoods) and 
40g bread fed twice daily.
HOSPITALISATION:
Diabetic stabilisation of this dog was undertaken during 11 days of hospitalisation. 
Ampicillin therapy was prescribed on admission because of the enlarged lymph nodes. 
Clinical condition did not vary much over this period and the dog remained bright, alert 
and appetite improved after 3 days of hospitalisation. Submandibular and prescapular 
lymph nodes decreased in size only slightly. The purulent ocular discharge resolved after 
7 days. Rectal temperature remained below 101°F. Water intake reduced from 1300 to 
150-200ml/day. Insulin dose was increased up to 18IU but was reduced to a final dose of 
16IU.
The dog was discharged on 16IU on day 10 and the owners were advised to increase the 
insulin dose if polydipsia became marked.
HOSPITAL SUMMARY:
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU) __________(g/dl) (mmol/1) (mis)
DAY NO. 1
9.30am 6 MOD 2.0 21.5 1300 6
5pm
9.30pm MOD 2.0
9.4
30.6
DAY NO. 2
9.30am 6 SMALL 2.0 31.6 850
5pm
9.30pm NEC 2.0
27.2
30.6
DAY NO. 3
9.30am 10 MOD 2.0 25.6 720
5pm
9.30pm NEC 2.0
25.1
22.1
DAY NO. 4
9.30am 14 TRACE 2.0 27.0 800
5pm
9.30pm NEC 2.0
21.0
20.1
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DAY NO. 5 
9.30am 
5pm 
9.30pm
DAY NO. 6 
9.30am 
5pm 
9.30pm
DAY NO. 7 
9.30am 
5pm 
9.30pm
DAY NO. 8 
9.30am 
5pm 
9.30pm
DAY NO. 9 
9.30am 
5pm 
9.30pm
DAY NO. 10 
9.30am 
5pm
Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)________________(g/dl) (mmol/1) (mis) (kg)
16
18
18
18
18
16
NEC
NEC
NEC
NEC
NEC
NEG
NEG
NEG
NEG
NEG
NEG
2.0
2.0
2.0
2.0
2.0
1.5
0.25
0.5
1.0
0.0
0.25
24.9
19.4
19.1
30.7 
6.7
18.7
4.6
7.7 
17.0
5.9
4.8
5.1
3.5
2.5 
5.9
3.4
4.8
650
150
250
150
200
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CASE REPORT DOG 020
BREED: Australian terrier
AGE: 8  years 
SEX: Male 
HISTORY:
This dog was referred to G.U.V.S. for diabetic stabilisation after being polydipsic for 2 
months. In the 2 weeks prior to referral, polyphagia, weight loss and exercise intolerance 
had also become apparent. There was no history of prolonged corticosteroid therapy nor 
of generalised pancreatic disease.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was quiet and dull but interested in its surroundings. His coat was sparse and he 
smelt strongly of ketones. On auscultation there were no cardiac murmurs or pulmonary 
adventitious sounds. Heart rate was 130/minute. Pulse volume, colour and CRT were all 
good. There was no cataract formation nor lymphadenopathy.
LABORATORY FINDINGS:
BIOCHEMISTRY; HAEMATOLOGY;
UREA 6.6 WBCC 16.6
SODIUM 142 NEUTROPHILS 12.62
POTASSIUM 4.2 LYMPHOCYTES 1.91
CHLORIDE 103 MONOCYTES 1.25
CALCIUM 2.22 EOSINOPHILS 0.83
PHOSPHATE 0.71 RBCC 7.34
GLUCOSE 26.6 HAEMOGLOBIN (HB) 17.2
CHOLESTEROL 5.02 HAEMATOCRIT 46.8
CREATININE 131 MEAN CELL VOLUME 64
TOTAL BILIRUBIN 0 MEAN CELL HB 23.4
ALKALINE PHOS 14 MEAN CELL HB CONC. 36.7
ALT 172 PLATELETS 192
AST 36
TOTAL PROTEIN 69
ALBUMIN 38
GLOBULIN 31
Because of the thin hair coat and a tendency to bruise on blood sampling, an ACTH 
stimulation test was performed but Cushing's disease was not present (plasma cortisol; 
pre-ACTH 53, post-ACTH 45min 94, post-ACTH 90min 222nmol/l).
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Radiography of thorax and abdomen revealed hepatomegaly, prostatomegaly, right sided 
cardiomegaly and a pendulous abdomen containing much fat.
The day following admission this dog was included in the Caninsulin study. The starting 
dose of insulin was lOIU and diet comprised 150g canned dog food (Chappie; Pedigree 
Petfoods) and 50g of bread fed twice daily (75kcal/kg/day).
HOSPITALISATION:
In the first 3 days of hospitalisation the dog’s clinical condition improved significantly 
and he became brighter and more active. Rectal temperature never exceeded 101.6°F at 
all examination times. Water intake reduced from 1000-1050 to 200-3OOml/day. Insulin 
dose was increased initially to 13IU but was reduced to 8 IU. Body weight remained 
constant.
The dog was discharged on day 12 with instructions to the owners to maintain the dog 
on this dose and diet until instructed to do otherwise. They were not supplied with urine 
testing equipment.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 1
9.30am 10 TRACE 1.75 26.5 800 8.7
5pm 15.3
9.30pm NEG 2.0 18.7
DAY NO. 2
9.30am 12 NEG 2.0 19.8 600
5pm 6.2
9.30pm NEG 2.0 18.2
DAY NO. 3
9.30am 13 NEG 2.0 16.5 1000
5pm 5.2
9.30pm NEG 2.0 23.5
DAY NO. 4
9.30am 13 NEG 1.0 14.7 750 8.7
5pm 2.9
9.30pm NEG 0.0 3.8
DAY NO. 5
9.30am 11 NEG 0.25 8.8 750
5pm 3.4
9.30pm NEG 0.0 5.1
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Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU)_______________ (g/dl) (mmol/1) (mis)
DAY NO. 6
9.30am 10 NEG 0.1 11.8 1050
5pm 4.1
9.30pm NEG 0.0 6.0
DAY NO. 7
9.30am 10 NEG 2.0 4.0 800
5pm 3.9
9.30pm NEG 2.0 20.1
DAY NO. 8
9.30am 8 NEG 1.5 14.0 NM
5pm 4.8
9.30pm NEG 2.0 28.7
DAY NO. 9
9.30am 8 NEG 1.5 13.9 450
5pm 6.3
9.30pm NEG 1.5 25.4
DAY NO. 10
9.30am 8 NEG 1.0 19.7 200
5pm 14.9
9.30pm NEG 2.0 21.4
DAY NO. 11
9.30am 8 NEG 1.0 14.7 300 8.7
5pm 5.3
9.30pm NEG 0.25 7.0
DAY NO. 12
9.30am 8 NS NS NS
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CASE REPORT DOG 021
BREED: Jack Russell terrier
AGE: II years 
SEX: Female 
HISTORY:
This dog was referred for diabetic stabilisation with a two week history of polydipsia and 
progressive exercise intolerance. She had suffered a similiar condition for a few weeks 7 
months previously. There was no history of previous therapy with long acting 
corticosteroids nor progestagens and she had been in oestrus 4-6 weeks prior to referral.
CLINICAL EXAMINATION AND INVESTIGATION:
The dog was bright and alert. Mucous membranes were congested in colour and there 
was much dental calculus. Heart rate was 130/minute. Capillary refill time and pulse 
volume were good. Auscultation of the thorax revealed no cardiac murmurs nor 
adventitious pulmonary sounds. There were small cataracts in the ventral borders of both 
lenses and, in addition, a number of mammary tumours were present.
LABORATORY FINDINGS:
BIOCHEMISTRY: HAEMATOLOGY:
UREA 4.7 WBCC 25.3
SODIUM 145 NEUTROPHILS 20.24
POTASSIUM 3.6 LYMPHOCYTES 3.29
CHLORIDE 97 MONOCYTES 1.01
CALCIUM 2.94 EOSINOPHILS 0.13
PHOSPHATE 1.08 RBCC 5.04
GLUCOSE 16.4. HAEMOGLOBIN (HB) 11.0
CHOLESTEROL 12.75 HAEMATOCRIT 33.9
CREATININE 65 MEAN CELL VOLUME 67
TOTAL BILIRUBIN 0 MEAN CELL HB 21.8
ALKALINE PHOS 929 MEAN CELL HB CONC. 32.4
ALT 113 PLATELETS 396
AST 23
TOTAL PROTEIN 71
ALBUMIN 37
GLOBULIN 34
Lateral radiographs of thorax and abdomen revealed no significant abnormalities.
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The day following admission to G.U.V.S. this dog was entered into the Caninsulin trial. 
The starting dose of insulin was 6 IU and diet comprised 170g canned dog food 
(Chappie; Pedigree Petfoods) and 40g of bread fed twice daily (70kcal/kg).
HOSPITALISATION:
The clinical condition of this dog remained unchanged during hospitalisation. Rectal 
temperature remained normal. Because of the initial neutrophilia, ampicillin therapy was 
instituted on day 1. Insulin dose increased up to a maximum of 20IU by day 6 . Water 
intake varied between 50 and 650ml/day. Collection of urine samples was seldom 
possible. By day 9, it was apparent that plasma glucose concentrations were never 
significantly greater than normal values, suggesting that the insulin requirement had 
become minimal. Insulin dosages from this time were, therefore, reduced dramatically 
until only very low doses of insulin were required to control plasma glucose 
concentrations. Ovariohysterectomy was performed on day 13 as it was felt that the dog 
had diabetes mellitus secondary to raised circulating levels of progesterone following the 
recent oestrus. She made an uneventful recovery during which insulin replacement 
therapy was discontinued.
When discharged on day 17 the owner was instructed to treat the dog normally. A follow 
up check was arranged for one week post discharge with the intention of re-instituting 
insulin therapy if the plasma glucose concentration was markedly elevated at that time 
but this was not necessary.
HOSPITAL SUMMARY:
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 1
9.30am 6 NS NS 17.2 300 6.3
5pm 31.1
9.30pm NS NS 32.2
DAY NO. 2
9.30am 10 NS NS 20.9 600
5pm 25.7
9.30pm NS NS 35.8
DAY NO. 3
9.30am 14 NS NS 19.5 400 6.5
5pm 19.5
9.30pm NS NS 30.9
DAY NO. 4
9.30am 16 NS NS 20.6 300
5pm 21.6
9.30pm NS NS 30.1
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Insulin Urine Urine Plasma Water Body-
dose ketones glucose glucose intake weight
(lU) (g/dl) (mmol/1) (mis)
DAY NO. 5
9.30am 18 NS NS 18.9 600
5pm 22.6
9.30pm NS NS 20.2
DAY NO. 6
9.30am 20 NS NS 18.4 400 6.6
5pm 6.6
9.30pm NS NS 8.8
DAY NO. 7
9.30am 20 NS NS 15.2 200
5pm 5.4
9.30pm 7.2
DAY NO. 8
9.30am 20 NS NS 10.1 200
5pm 3.1
9.30pm NS NS 11.6
DAY NO. 9
9.30am 18 NS NS 8.2 400
5pm 3.0
9.30pm NS NS 6.8
DAY NO. 10
9.30am 14 NS NS 8.1 100
5pm 3.1
9.30pm NS NS 5.3
DAY NO. 11
9.30am 10 NS NS 6.8 650
5pm 3.0
9.30pm NEG 0.0 6.7
DAY NO. 12
9.30am 10 NEG 0.0 7.2 650
5pm 2.9
9.30pm NEG 0.0 6.3
DAY NO. 13
9.30am 0 NS NS 7.3 NM
5pm 9.1
9.30pm NS NS 9.6
DAY NO. 14
9.30am 4 NS NS 8.1 50
5pm 7.9
9.30pm NS NS 9.1
APPENDIX 11 334
Insulin
dose
(lU)
Urine
ketones
Urine
glucose
(g/dl)
Plasma
glucose
(mmol/1)
Water
intake
(mis)
Body-
weight
(kg)
DAY NO. 15
9.30am 4 NS NS 6.9 NM
5pm 5.4
9.30pm NS NS 7.1
DAY NO. 16
9.30am 3 NS NS 6.4 50
5pm 6.1
9.30pm NS NS 6.8
DAY NO. 17
9.30am 3 NS NS 6.3 6.6
5pm 6.1
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Appendix 12: 
Quantitative analysis of canine plasma lipoproteins
The concentration of cholesterol in each lipoprotein fraction (very low density 
lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL)) 
were measured following separation by a combined ultracentrifugation/precipitation 
technique (Lipids Research Clinics, 1982; Barrie et al, 1993b).
In this method, 4ml of plasma was placed in a thermoplastic ultracentifuge tube 
(Ultraclear, 13x64mm; Beckman) and overlayered with 2.5ml normal saline (density 
1.006g/ml). The tubes were capped and centrifuged at 164,000g at 4°C for 18 hours in a 
fixed angle rotor (type 50.4 Ti, Optima L-70 preparative ultracentrifuge; Beckman). The 
lipoproteins with density less than 1.006g/ml (VLDL) were removed in the top fraction 
by tube slicing and made up to a total volume of 3 ml with normal saline. The cholesterol 
concentration of the plasma and infranatant were measured using a Cobas Mira clinical 
chemistry analyser and enzymatic colorimetric method (Chapter 2). The VLDL 
cholesterol was calculated as the difference between the cholesterol concentration of the 
plasma and that of the infranatant.
The apolipoprotein B containing lipoproteins (LDL) were precipitated from 1ml of the 
infranatant by the addition of 50pl of 92nM heparin-manganese chloride followed by 
incubation at 4°C for 30 minutes and separated by centrifugation at 10,800g at 4°C for 
30 minutes. The cholesterol concentration of the resulting supernatant (HDL cholesterol) 
was measured and the LDL cholesterol concentration was calculated as the difference in 
cholesterol concentration between the infranatant and HDL.
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Appendix 13: 
Method for the analyses of LPL and H-TGL
Post-heparin plasma lipase activities were measured in heparinsed plasma from fasted 
dogs according to a method validated in horses (Watson et al, 1992) under the 
supervision of Dr TDG Watson in The Department of Pathological Biochemistry, 
Glasgow Royal Infirmary. Blood was collected 10 minutes after the intravenous 
adminstration of sodium heparin (70IU/kg) (Heparin (Mucous) Injection BP; Leo 
Laboratories Ltd) into lithium heparin containers and placed on ice before separation by 
centrifugation at 4°C for 15 minutes. Plasma was divided into 1 ml aliquots and stored at 
-20°C until analysis.
Radioactive triolein was formed by the addition of 50pCi glycerol (1-14C) oleate (CFA 
258; Amersham International pic) to 24.5 toluene, and then divided into 3.5ml aliquots 
and placed in round bottom flasks. To each flask was then added 3.5ml cold triolein 
(500mg triolein (T7140; Sigma) in 25ml toluene). The substrate was dried down under 
nitrogen in a water bath at 55°C, washed three times with 3ml heptane and stored under 
nitrogen at -20°C. The substrate emulsion was prepared 30 minutes prior to use by the 
addition of 5.5ml 5% gum arabic in 0.2M Tris-HCl pH8.4, followed by sonication at 18 
microns for 4 minutes. Then 5.5ml 10 % bovine serum albumin (Fraction V (A-4503); 
Sigma) in 0.2M Tris HCl, pH8.4 was added.
For the measurement of total post-heparin plasma (PHP) lipase activity, lOpl of post­
heparin plasma was diluted in 30pl 0.15M NaCl and incubated in duplicate with 200pl 
substrate, 250pl low salt buffer (0.2M Tris, 0.2M NaCl, pH 8.4) and 50pl pooled, heat- 
inactivated serum at 28°C for 60 minutes. Heparin triglyceride lipase (H-TGL) activity 
was assayed by the dilution of lOpl post-heparin plasma in 30pl 0.I5M NaCl and 
incubated in duplicate with 200pl substrate, 250pl high salt buffer (0.2M Tris, 2.0M 
NaCl, pH 8:4) under the same conditions. Fatty acids were extracted by adding 3.25ml 
methanol : chloroform: heptane (1.41:1.25:1 parts) and 0.75ml 0.14M K2 CO3 , 0.14M 
H3 BO3 , pH 10.5. The tubes were vortexed and centrifuged at 3 000 rpm at 4°C for 30 
minutes. One ml of the upper fraction was removed and counted in 10ml scintillation 
fluid (Ultima Gold; Canberra Packard) and 200pl acetic acid, the radioactivity in 1 ml of 
the upper fraction of blank incubations (containing lOpl 0.15M sodium chloride instead
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of post-heparin plasma) was subtracted from the sample counts and the total 
radioactivity taken as the counts in 1 ml of the lower fraction of the blank incubations. 
The lipolytic activity was then calculated according to the following equation:
Activity (pmolFA/ml/hr) = ((Sample cpm - Blank cpm) * 755.1)/
(Total cpm - Background cpm)
Lipoprotein lipase was calculated as the difference between total post-heparin lipolytic 
activity and hepatic triglyceride lipase activity
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Appendix 14: 
Method for the analysis of VLDL apolipoprotein B concentration
A colorimetric microplate protein method was designed using bicinchonic acid/copper 
sulphate microprotein reagent (B9643; Sigma) read against bovine serum albumin (BSA) 
standards (Sigma procedure No. TPRO-562). Apolipoprotein B concentrations were 
calculated from the differences between the total protein concentrations of the 
supernatants before and after precipitation of apolipoprotein B by isopropanol (Egusa, et 
al 1983).
To 2ml of VLDL containing top fraction resulting from quantitative analysis of plasma 
lipoproteins (Appendix 12) was added 2ml of 100% isopropanol. The mixture was 
vortexed for 1 minute, incubated overnight at room temperature in sealed conical plastic 
centrifuge tubes and then centrifuged (lOOOg for 30 minutes). If the precipitate was 
incompletely sedimented an aliquot was passed through a syringe filter (0.22pm pore).
Protein estimations were performed using a microplate modification of Sigma procedure 
number TPRO-562. 5pi of sample was added to 200pl of bicinchonic acid/copper 
sulphate solution containing 1% sodium dodecyl sulphate (to reduce light dispersal by 
the lipid content of the samples) in quadruplicate in a 96 well flat bottomed microplate 
(Cat no. 655101; Greiner Labortechnik Ltd). Bovine serum albumin standards were also 
included in quadruplicate in each plate at concentrations of 12.5, 25, 50, 100, 150, 200 
and 400 pg/1. Each plate was read in a microplate reader (MR 5000, Dynatech 
Laboratories Ltd) at 560 nm. Integral curve fitting software calculated the protein 
concentration of each sample from a linear standard curve based on the the BSA 
standards.
Apolipoprotein B concentration was calculated from the difference in protein 
concentration between the original VLDL fraction and the post-precipitation supernatant 
(x2).
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Appendix 15:
Case reports of 11 diabetic dogs from one month before to 4 
months after changing to a canine high fibre diet
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Dog 1
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths 
Treatment
Weeks since last visit
115678
Schultz Mulligan 
Rottweiler 
6yrs 6 mths 
Male
8/6/92
Diabetes mellitus 
November 1990 
Insulin - Caninsulin 
Diet - Chappie
Chappie 1238g twice daily 
(Zaninsulin dose varied (38 60IU) once daily
Diet as above (approx. 2030kcal/day)
Insulin dose varied (38 - 56IU) because of 4 
hypoglycaemic episodes.
6/7/92
Insulin dose 46IU at the moment 
I I43g Pedigree CHF twice daily 
4 weeks
14/7/92
46IU Caninsulin. No hypoglycaemic crises 
Soft faeces and mild diarrhoea on days 1,2 
and 5 
1 week
10/8/92
Dose constant at 44IU. No hypoglycaemic 
episodes. One bout of bacterial cystitis - 
treated with Zaquilan 12% injection- 
Faeces soft 
4 weeks
7/9/92
38IU Caninsulin
Faeces diarrhoeic. Some weight loss. Body 
condition good.
4 weeks
20/10/92
40IU Caninsulin. Metronidazole 400mg BID 
for suspected SIBO. Faeces diarrhoeic.
6 weeks
3/12/92
40IU Caninsulin. SIBO confirmed by plasma 
BI2 and folate analyses (2/11/92) 
Oxytetracycline 500mg BID
5 weeks
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Dog 2
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
119147
Mitzi Macaldowie 
Large cross-bred 
7yrs
Female neutered
8/6/92
Diabetes mellitus 
January 1992
Insulin - Hypurin Isophane 
Diet - Chappie
Chappie 825g and 2 slices of bread twice daily 
Isophane insulin 38-46IU once daily
Diet as above (approx. 1785kcal/day)
Insulin dose constant 46IU
6/7/92
Insulin dose still 46IU. No other treatment. 
950g Pedigree CHF twice daily 
4 weeks
14/7/92
50IU Isophane insulin. No other treatment.
Soft faeces and mild diarrhoea on days 1 and 2. 
1 week
10/8/92
Insulin dose down to 44IU. One hypoglycaemic 
episode in first week home.
4 diarrhoeic ‘accidents’ in house.
4 weeks
7/9/92
Dog withdrawn from trial at owners’ request. 
Seen at hospital 4 times for vomiting, colitis 
and diarrhoea. Treated with sulphasalazine, 
ampicillin and metaclopramide to little effect. 
Occasionally defecating in the house. 
Investigated for haematemesis - NAD. SIBO 
diagnosed (high plasma folate).
4 weeks
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Dog 3
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
Date at 3 mths 
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
115131
Shira Robertson 
Jack Russell terrier 
8.9yrs
Female neutered
8/6/92
Diabetes mellitus 
September 1990 
Insulin - Caninsulin 
Diet - Chappie and bread
176g Chappie and 40g bread twice daily 
Caninsulin 8-9IU once daily
Diet as above (approx. 450kcal/day) 
Caninsulin 8IU
6/7/92
8IU Caninsulin. No other treatment.
250g Pedigree CHF twice daily 
4 weeks
14/7/92
lOIU Caninsulin. No other treatment.
No diarrhoea 
1 week
11/8/92
lOIU Caninsulin
Doing very well. Owners believe dog is much 
livelier 
4 weeks
7/9/92
lOIU Caninsulin.
Very bright and lively.
4 weeks
20/10/92 
lOIU Caninsulin.
Still doing very well.
6 weeks
3/12/92
lOIU Caninsulin
Still very bright and active. Some weight loss
5 weeks
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Dog 4
Case No.
Dog Reference No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
Date at 3 mths 
Treatment
Weeks since last visit
Date at 4 mths 
Treatment
Weeks since last visit
115980
4
Wendy Rowan 
Labrador retriever 
9yrs
Female neutered
8/7/92
Diabetes mellitus, cervical disc disease. 
December 1990 
Insulin - Caninsulin 
Diet - Chappie and bread
324g Chappie and 108g bread twice daily 
38-42IU (Zaninsulin
Diet as above (approx. 963kcal/day)
40IU Caninsulin
10/8/92
40IU Caninsulin
500g Pedigree CHF twice daily
4 weeks
20/8/92
421U Caninsulin 
No diarrhoea 
1 week
19/9/92
42IU Caninsulin 
Brighter and livelier.
4 weeks
20/10/92
42IU Caninsulin
Still very bright and happy.
4 weeks
24/11/92 
42IU Caninsulin
One bout vomiting and diarrhoea but 
generally very much more active.
4 weeks
6/1/93
44IU Caninsulin 
Still doing well.
6 weeks
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Dog 5
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
117222 
Lina Tannoch 
Whippet 
ll.lyrs
Female neutered
13/7/92
Diabetes mellitus, anal sacculitis/sinus. 
May 1991
Insulin - Hypurin Isophane 
Diet - Pedigree Chum and biscuit.
400g Chum and 80g biscuit twice daily 
20IU isophane once daily
Diet as above (approx. 936kcal/day) 
Insulin dose constant at 20IU
10/8/92 
20IU isophane
500g Pedigree CHF twice daily 
4 weeks
20/8/92 
14IU isophane.
Appetite poor. No diarrhoea.
10 days
24/9/92 
lOIU isophane
Appetite poor. Constipation complicated by 
anal surgery (24/8). Vegetable oil fed with 
CHF 
4 weeks
20/10/92
lOlU isophane. Very bright and happy. 
Appetite returned.
24/11/92
lOIU isophane. Appetite variable.
Still getting some vegetable oil in food. 
Faeces firm.
4 weeks
4/2/93
14IU isophane
Thin; otherwise doing well.
8 weeks
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Dog 6
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
Date at 3 mths 
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
113648 
Bertie Elliot 
Scottish terrier 
7.3yrs 
Male
13/7/92
Diabetes mellitus and pyoderma.
March 1990
Insulin - (Caninsulin
Diet - Pedigree Chum and biscuit
284g Chum and 60g biscuit twice daily 
28IU Caninsulin once daily
Diet as above (approx. 680 kcal/day) 
Insulin dose constant at 28IU 
Co-trimoxazole Vi x 480 twice daily for 
pyoderma.
11/8/92
28IU Caninsulin. Skin still poor. TSH 
stimulation test suggests hypothyroidism. 
Thyroxin replacement therapy begun. 
370g Pedigree CHF twice daily 
4 weeks
20/8/92
38IU Caninsulin
Appetite good. Bright and lively. No 
diarrhoea.
9 days
18/9/93
38IU Caninsulin
Bright and alert. Skin improved and 
antibiotics stopped.
4 weeks
26/10/92
36IU Caninsulin
Still very bright and active.
5 weeks
7/12/92
36IU Caninsulin 
Still doing well.
5 weeks
6/1/93
36IU Caninsulin
Doing well. Some weight gain.
4 weeks
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Dog 8
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose 
Treatment
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
97218
Mandy Leitch 
Labrador 
8yrs 6mths 
Female neutered
15/9/92
Diabetes mellitus, osteoarthritis. 
March 1992
Insulin - Hypurin Isophane 
Diet - Pedigree Chum and bread
405g Chum and 95g bread twice daily 
56IU isophane once daily 
Phenylbutazone 200mg twice daily
Diet as above (approx. lOOOkcal/day) 
56IU isophane
20/10/92 
56IU isophane
500g pedigree CHF twice daily 
4weeks
28/10/92 
52IÜ isophane
Uneventful changeover. No diarrhoea.
8 days
1/12/92 
52IU isophane
Bright and lively. 1 bout hypoglycaemia. 
4 weeks
5/1/93
521U isophane
Bright and active at home but vision 
worsening 
4 weeks
9/2/93
46IU isophane
Still doing well but vision deteriorating 
further 
4 weeks
16/3/93
46IU isophane 
Still doing well.
4 weeks
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Dog 9
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero
Treatment
Weeks since last visit
Date at 1 mth 
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths 
Treatment
Weeks since last visit
117898 
Jodie Downs 
Cairn terrier 
lyr 6mths 
Female neutered
17/9/92
Islet cell hypoplasia 
August 1991
Insulin - Hypurin Isophane 
Diet - WhislŒS and bread
200g Whiskas and 14g bread twice daily 
Isophane 4-6IU once daily
Diet as above (approx. 360kcal/day) 
6-91U isophane
20/10/92
9IU isophane. No other treatment.
200g CHF twice daily 
4 weeks
28/10/92
lOIU isophane. No other treatment. 
Colitis days 1 and 2.
8 days
1/12/92
lOIU isophane. No other treatment.
4 weeks 
7/1/93
9IU isophane
Lively and active. Slimmer appearance. 
4 weeks
11/2/93
8IU isophane. No other treatment.
4 weeks 
10/3/93
9IU isophane. No other treatment.
Still doing well.
4 weeks
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Dog 10
Case No.
Dog Reference No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin history 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths 
Treatment
Weeks since last visit
121228
10
Flip Bissett 
Labrador X 
9.2yrs
Male neutered
17/2/93
Diabetes mellitus
December 1992
Insulin - Hypurin Isophane
Diet - Pedigree Chum and biscuit
500g Chum and lOOg biscuit twice daily 
46-50IU isophane
Diet as above (approx. 1200kcal/day) 
50IU isophane
15/3/93
50IU isophane. No other treatment 
600g Pedigree CHF twice daily 
4 weeks
24/3/93
46IU isophane. No other treatment 
No diarrhoea 
9 days
20/4/93 
46IU isophane
More lively and playful. Some weight loss. 
Owner very pleased.
4 weeks
18/5/93
44IU isophane
Still very bright and lively. Further weight 
loss.
4 weeks
15/6/93
44IU isophane 
Vision deteriorated.
4 weeks
22/7/93 
44IU isophane
Doing well but very little vision.
4 weeks
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Dog 11
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin historv 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth
Treatment
Weeks since last visit
Date at 2 mths 
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
121252
Roxanne McNally
Rottweiler
3.2yrs
Female neutered
25/2/93
Diabetes mellitus
December 1992
Insulin - Hypurin Isophane
Diet - Pedigree Chum and biscuit
600g Chum and 225g biscuit twice daily 
54-58IU isophane once daily
Diet as before (approx. 1870kcal/day) 
58IU isophane
16/3/93
58IU isophane
1200g Pedigree CHF twice daily
3 weeks
24/3/93 
46IU isophane 
No diarrhoea.
8 days
4/5/93
58IU isophane for last two weeks.
Doing well. Insulin dose reduced to 50IU 
based on blood glucose concentration.
5 weeks
1/6/93
50IU isophane.
Still doing very well
4 weeks
29/6/93
50IU isophane
Healthy, bright and active.
4 weeks
21/7/93 
541U isophane
Polydipsic and blood glucose high; insulin 
dose increased to 60IU 
4 weeks
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Dog 13
Case No.
Dog name (+ owner surname)
Breed
Age (at initial visit)
Sex
Diagnosis, visit dates and treatment 
Date at -1 mth
Diagnosis
Time since diagnosis 
Treatment
Dietarv and insulin historv 
Previous diet 
Insulin type and dose
Details of diet and 
insulin dose during 
month pre-trial
Date at -10 days 
Treatment 
New diet
Weeks since last visit
Date at time zero 
Treatment
Weeks since last visit
Date at 1 mth 
Treatment
Weeks since last visit
Date at 2 mths
Treatment
Weeks since last visit
Date at 3 mths
Treatment
Weeks since last visit
Date at 4 mths
Treatment
Weeks since last visit
120899 
Jenna Michie 
Yorkshire terrier 
8.8yrs
Female neutered
16/3/93
Diabetes mellitus 
November 1992 
Insulin - Hypurin Isophane 
Diet - Pedigree Chum and bread
125g Chum and 30g bread twice daily 
7IU isophane once daily
Diet as before (approx. 312kcal/day) 
7IU isophane
27/4/93 
7IU isophane
200g Pedigree CHF twice daily 
4 weeks
5/5/93
5IU isophane
Appetite very poor over week. No diarrhoea 
8 days
4/6/93
5IU isophane
Normal faeces when first went home. Very 
watery diarrhoea for the last few days. 
Diarrhoea continued (7-8/6/93). Started 
lOOmg metronidazole bid. Plasma B12 and 
folate concentrations normal.
4 weeks
Unable to contact owners
Unable to contact owners
13/9/93 
4IU isophane
No more diarrhoea since last visit 
13 weeks
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Appendix 16:
24 hour plasma glucose concentrations and derived values in 11 
dogs before and 10 days after changing to a canine high fibre 
diet and in 5 dogs after 4 months.
ABSMEAN
ABSSD
INCMEAN
INCAUC
APPGMEAN
APPGSD
APPGAUC
ADJMEAN
ADJAUC
ADJSD
Mean of plasma glucose concentrations at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20 and 24 
hours after insulin injection
Standard deviation of plasma glucose concentrations at 0, 2, 4, 6, 8, 10, 12, 14, 
16, 20 and 24 hours after insulin injection
Mean of plasma glucose concentrations at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20 and 24 
hours after insulin injection following subtractionof the nadir concentration 
Area under the plasma glucose versus time curve generated from plasma glucose 
concentrations at 0, 2, 4, 6, 8, 10, 12, 14, 16, 20 and 24 hours after insulin 
injection
Mean of plasma glucose concentrations at 6, 6.16, 6.32, 6.5, 7, 7.5, 8, 9, 10, 12 
and 14 hours post insulin injection following subtraction of the plasma glucose 
concentration at 6 hours
Standard deviation of plasma glucose concentrations at 6, 6.16, 6.32, 6.5, 7, 7.5, 
8, 9, 10,12 and 14 hours post insulin injection following subtraction of the plasma 
glucose concentration at 6 hours
Area under the plasma glucose versus time curve generated from plasma glucose 
concentrations at 6, 6.16, 6.32, 6.5, 7, 7.5, 8, 9, 10, 12 and 14 hours post insulin 
injection following subtraction of the plasma glucose concentration at 6 hours 
Mean of plasma glucose concentrations at 6, 7, 8, 9, 10, 12 and 14 hours post 
insulin injection following subtraction of the plasma glucose concentration at 6 
hours
Standard deviation of plasma glucose concentrations at 6, 7, 8, 9, 10, 12 and 14 
hours post insulin injection following subtraction of the plasma glucose 
concentration at 6 hours
Area under the plasma glucose versus time curve generated from plasma glucose 
concentrations at 6, 7, 8,9, 10, 12 and 14 hours post insulin injection following 
subtraction of the plasma glucose concentration at 6 hours
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Appendix 17:
Insulin dose and indicators of general health in 11 dogs from 
one month before to 4 months after changing to canine high
fibre diet
Shaded area represents hospitalisation period
No
DOG
REFERENCE
M O N T H S
-1 1-10 days iiiiiiii 1 2 3 4
1 115678 1.41 :W0m2$ 1.06 1.00 1.00 1.29
2 119147 1.18 U S 1.31 1.05 1.20 * *
3 115131 1.06 1.00 1.25 1.28 1.29 1.28 1.31
4 115980 1.02 1.00 1.06 1.00 1.07 1.10 1.14
5 117222 1.60 L60 i 116 0.90 0.88 1.28 1.33
6 113648 2.24 %t4 \iiiw i 3.04 2.76 2.72 2.71
8 97218 1.40 1.42 1.32 1.40 1.40 1.31 1.27
9 117898 1.09 1.60 1.80 1.81 167 1.45 1.63
10 121228 1.60 1>60 1.63 1.57 1.60 1.63
11 121252 1.20 t,l« iiiiiioii 1.23 1.04 1.10 1.30
13 120899 1.22 1.27 i.00 1.00 * * 0.83
Absolute insulin dose (lU/kg).
No
DOG
REFERENCE
M O N T H S
-1 -10 davs 0 1 2 3 4
1 115678 42.5 . 42.0 4L0 41.5 40.0 40.0 38.5
2 119147 39.0 iiiililiii 38.0 38.0 36.5 * *
3 115131 8.00 8.00 8.00 7.80 7.75 7.80 7.62
4 115980 41.0 40.0 Iiiiiiii 39.5 39.0 38.3 38.6
5 117222 12.5 12.5 12.0 11.0 11.5 10.9 10.5
6 113648 12.5 Î I5 m m zm 12.5 13.0 13.2 13.2
8 97218 40.0 39.5 39 2 37.0 37.0 35.0 36.0
9 117898 5.50 5.50 5.50 5.50 5.38 5.50 5.55
10 121228 30.0 30.0 iiiiiiii 28.2 28.0 27.5 26.9
11 121252 45.0 iiiiiiii 45.8 47.0 47.7 45.3 44.6
13 120899 5.7 5.5 iiiiiiii 5.3 * * 4.8
Absolute bodyweight (kg).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 41 50 45 40 16 21
2 119147 82 iiiiiiii 80 72 73 * *
3 115131 52 60 iiiiiiii 49 48 46 30
4 115980 92 96 lllllill 90 80 83 66
5 117222 64 iiiiiiji iiiiiiiil 60 60 60 45
6 113648 43 iiiiiioi 50 48 46 59 60
8 97218 95 iiiiliw iiiiwoi 80 64 62 60
9 117898 60 iiiiiii;: 50 46 44 42
10 121228 90 iiiiiidii iiiiiiii 90 87 80 70
11 121252 65 m m m m iiiiiiii 67 70 60 55
13 120899 57 58 50 56 * * 42
Absolute body condition score.
No
DOG
REFERENCE
M O N T H S
-1 -Î0 days 0 1 2 3 4
1 115678 66 Iiiiiiii: :#|g:iïl:l#:8l::::l 75 45 42 36
2 119147 80 iliiilili 80 76 77 * *
3 115131 72 iiiiiiiii Iiiiiiiii 80 82 80 80
4 115980 75 75 77 86 78 88 83
5 117222 71 I^iiiiiiiIiiiiiii 74 75 85 84
6 113648 35 iiliilOi 54 64 71 75
8 97218 95 iiiiiiiii 95 87 86 87
9 117898 48 iiiiiiisiii 50 50 46 57 50
10 121228 62 iiiiiiii iiiiiiii 63 64 68 61
11 121252 75 75 iiiiiisii; 71 78 68 66
13 120899 64 iiiiiiiii Iiiiiiiii 62 * * 62
Absolute coat condition score.
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No
DOG
REFERENCE
M O N T H S
-1 -IQ days 0 1 2 3 4
1 115678 76 iiiiilisi «111811 90 72 74 80
2 119147 91 iiiiiiii::iiiiiiii 89 89 * *
3 115131 82 90 « 1 1 8 # 95 95 97 97
4 115980 32 iiiiisl iiiiiiii 80 90 96 98
5 117222 70 Iiiiiiii iiiiiii» 79 90 90 92
6 113648 36 iiiiiiii iiiiiiii 90 92 94 95
8 97218 90 87 iiiiiiii 90 93 96 97
9 117898 80 Iiiiiiii 93 96 95 92 98
10 121228 72 iiiiiisi 80 95 94 97 100
11 121252 87 iiiiiii 92 87 90 90
13 120899 82 iiiiissii 90 86 * * 92
Absolute activity score.
No
DOG
REFERENCE
M O N T H S
-1 -10 days iiiiiiii 1 2 3 4
1 115678 90 iiiiiiii iiiiiiiii 92 76 86 80
2 119147 95 iiiiiiiii iiiiiiis#; 85 89 * *
3 115131 100 iiiiiiii 90 96 96 96 96
4 115980 91 # # # # iliiiioi 84 92 92 96
5 117222 89 : 89 iiiiiiii 66 77 90 94
6 113648 36 Iiiiiiii 85 92 91 95 96
8 97218 90 86 iiiiiiii; 90 95 96 100
9 117898 82 iiiiiiii iiiiiiii 96 99 96 98
10 121228 80 ÈIÉi#iiiiw i 95 98 99 100
11 121252 90 90 iiiiiiiii 92 87 90 90
13 120899 85 iiiiiiSQiil 91 87 * * 92
Absolute owner observed demeanour score.
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 n 3 4
1 115678 90 95 n 95 76 85 82
2 119147 70 76 90 90 90 * *
3 115131 78 78 80 84 95 90 91
4 115980 95 92 65 86 92 90 95
5 117222 50 50 43 49 73 86 87
6 113648 48 iiiii» 90 90 90 95
8 97218 95 90 90 92 95 97
9 117898 76 79 90 94 94 96 97
10 121228 90 iiiiisgi:iiiiiiiii 96 98 98 100
11 121252 86 90 93 90 90
13 120899 82 85 84 * * 90
Absolute vet observed demeanour score.
No
DOG
REFERENCE
M O N T H S
-1 : -todays iiiiiiiii 1 2 3 4
1 115678 100 100 iiiiioii 97 95 90 91
2 119147 100 100 100 100 100 * *
3 115131 46 iiiiiiioi iiiiiiii 55 50 50 48
4 115980 20 iiiiiiiii 36 32 25 27 15
5 117222 0 0 0 0 0 0
6 113648 11 iiiiiiiii i l 12 15 12 14
8 97218 100 liiiiiiJl 'liiiimi 94 35 18 15
9 117898 100 iiiiiooiiiiiiloil 100 100 100 100
10 121228 100 100 iiiiliOOi 100 100 100 76
11 121252 100 100 : 100 100 100 100 100
13 120899 100 100 100 100 * * 80
Absolute owner observ ed vision score.
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 100 iiiiiiiii iliiioii 95 92 90 90
2 119147 100 100 100 100 100 * *
3 115131 70 66 Iiiiiiiii 82 82 80 82
4 115980 34 iiiiiiii iiiiiii 22 32 30 24
5 117222 0 iiiiiiii Iiiiiiii 0 0 0 0
6 113648 11 Iiiiiii i^iiiiiii 12 16 11 15
8 97218 95 87 11111841 80 37 33 20
9 117898 100 100 100 98 100 100 100
10 121228 100 iiiiiiii too 100 100 100 72
11 121252 98 100 iiiiiiii 100 100 100 100
13 120899 100 100 100 100 * « 100
Absolute vet observed vision score.
No
DOG
REFERENCE
M O N T H S
-1 -to days # # 0 : « 1 2 3 4
1 115678 45 ili### 74 77 74 73
2 119147 50 IIIIIIIIiiiiiiiii 75 80 * *
3 115131 46 50 iiiiiiii 52 46 50 50
4 115980 46 i l i l i i iiiiiii 64 74 80 79
5 117222 61 . 56 iiiiiii 57 61 84 58
6 113648 45 50 iiiiiiiii^ 62 75 65 61
8 97218 46 iiiillilii 45 48 47 50
9 117898 50 iiiiiiiii Iiiiiii 48 52 52 50
10 121228 45 45 iiiiiii 55 55 52 51
11 121252 50 48 57 50 54 50 49
13 120899 48 50 54 65 * * 46
Absolute faecal volume score.
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 46 i i i i i i s i 21 10 20 23
2 119147 50 i i i i i i i i i i i i i i i i i i 14 16 * *
3 115131 49 5Î I I I I I I I I 52 47 50 50
4 115980 70 i i i i i i i i i i i i i i i i 65 76 85 49
5 117222 51 i i i i i i i i i l i i i i s 85 85 90 46
6 113648 45 50 46 46 45 50 50
8 97218 50 i i l i i i io i i 51 75 50 56 51
9 117898 50 '::ii::i:::!ii48::!:i i i i i i i i 40 47 48 35
10 121228 50 52 : 53 50 50 53 51
11 121252 50 50 56 50 55 51 49
13 120899 46 50 : 53 15 * * 46
Absolute faecal consistency score.
No
DOG
REFERENCE
M O N T H S
-1 -to days iiiiiiii 1 2 3 4
1 115678 4.5 M rnmmm iiiiiiii 8.1 5.3 7.9 4.4
2 119147 2.4 2.5 iiiiiiii 5.7 2.1 * *
3 115131 2.3 Iiiiiiii iiiiiii 6.3 2.1 4.5 4.1
4 115980 2.7 2.9 3.8 5.4 3.2 3.8 3.3
5 117222 2.7 6.0 2.8 6.7 5.5 6.5 4.3
6 113648 3.6 5.6 2.8 5.0 2.1 5.2 2.8
8 97218 5.0 8.5 2.3 6.3 4.9 4.0 5.4
9 117898 5.6 iiiiiiiii 4.1 8.0 3.8 6.9 3.4
10 121228 4.6 5.0 iiiiiiii 4.8 2.9 3.8 3.3
11 121252 3.5 4.0 4.6 3.9 3.3 5.9 3.9
13 120899 3.7 3.2 2.8 4.2 « * 5.2
Plasma urea concentrations (mmol/1).
APPENDIX 17 361
No
DOG
REFERENCE
M O N T H S
-1 -10 days iiiiiiii 1 2 3 4
1 115678 99 iiiiiïli 84 90 94 92
2 119147 79 86 iiiiiiii 61 70 * *
3 115131 66 iiiiiii* Iiiiiii# 70 64 64 76
4 115980 74 88 69 67 92 69 79
5 117222 57 66 54 : 60 72 64 71
6 113648 71 Iiiiiii 56 64 60 57 59
8 97218 64 ililii» 73 76 83 73 94
9 117898 75 iiiiiiiSi 76 66 63 59 66
10 121228 86 iiiiiiii Iiiiiii 73 84 70 82
11 121252 97 iiiiiliiii 87; 79 91 81 105
13 120899 75 iiiiiiiii 67 74 * * 81
Plasma creatinine concentrations (fimoI/1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days : 6 1 2 3 4
1 115678 1.44 1.32 1.62 1.69 1.57 1.36 1.23
2 119147 1.13 1.11 1.02 2.20 1.18 * *
3 115131 0.85 iiiiiii t o i 1.60 0.81 1.22 0.98
4 115980 0.83 0,79 l.Ol 1.79 0.83 1.00 0.81
5 117222 1.28 I.Î6 1.37 1.19 1.08 0.54 1.06
6 113648 1.23 1.34 iiiliiilili 1.14 1.02 1.41 0.96
8 97218 1.44 iiiilBi •U l 0.77 0.41 0.73 0.72
9 117898 1.57 1.50 iiiiiiii 2.05 1.28 1.92 1.19
10 121228 1.04 0.88 0.92 0.87 0.81 0.56 0.83
11 121252 1.43 1.15 132 1.62 1.59 1.96 1.42
13 120899 1.19 0,98 U 4 0.79 * * 1.17
Plasma phosphate concentrations (mmol/1).
APPENDIX 17 362
No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 150 147 145 150 149 150
2 119147 146 147 147 146 * *
3 115131 145 lilllllil Î38 147 142 148 142
4 115980 142 Iiiiiiii 145 146 146 148 151
5 117222 142 i l i l i i 145 * 144 146 140
6 113648 140 iiiiiioii iiiiiiii 144 1448 149 150
8 97218 138 140 iiiiiiiii 148 145 150 144
9 117898 137 142 143 145 148 144 141
10 121228 138 iiiiïiii iiiiiiiii 146 146 148 140
11 121252 140 148 140 147 142 138 136
13 120899 146 148 151 146 * * 141
Plasma sodium concentrations (mmol/1).
No
DOG
REFERENCE
M O N T H S
-1 -todays 0 1 2 3 4
1 115678 3.9 4.4 4J 4.7 3.8 4.0 3.9
2 119147 4.1 3.9 ÊÊmmm 3.5 4.2 * *
3 115131 3.7 3.9 3,9 3.8 4.0 3.9 4.3
4 115980 4.8 4.9 4J 4.6 4.6 4.3 4.1
5 117222 4.1 4,6 43 * 4.5 5.0 3.8
6 113648 4.3 4.6 3.8 4.5 4.2 4.3
8 97218 4.8 4.9 4.8 4.0 3.6 3.9 4.8
9 117898 4.3 41 4.3 4.1 4.4 4.1
10 121228 5.0 iiiiiii 3.7 4.3 3.6 4.6
11 121252 4.6 3,9 4.6 4.2 4.5 4.0 4.6
13 120899 4.6 4.0 4.0 4.0 « * 4.5
Plasma potassium concentrations (mmol/1).
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No
DOG
REFERENCE
M O N T H S
-1 i -todays iiiiiiiii 1 2 3 4
1 115678 116 wm m m tl7 113 119 115 117
2 119147 111 iiiiiiiii 117 113 115 « *
3 115131 113 108 Iiiiiiii 115 109 114 106
4 115980 113 iiiiieii 110 114 107 113 112
5 117222 115 iiiiiiiii: in 109 105 101 108
6 113648 111 iiiiioii iiiiiOii 110 115 110 109
8 97218 106 iiiiioii 116 115 109 114 109
9 117898 104 iliilMi 110 111 108 113 104
10 121228 96 99 tl9 116 103 110 103
11 121252 101 10$ in 107 106 105 96
13 120899 100 110 108 110 * * 101
Plasma chloride concentrations (mmol/1).
No
DOG
REFERENCE
M O N T H S
-1 -todays 0 1 2 3 4
1 115678 2.55 196 2.62 2.92 2.32 2.3
2 119147 2.66 iiiiiiii 2,94 2.78 2.81 * *
3 115131 2.56 iiiiiiïi iiiiiii 2.53 2.72 2.37 2.47
4 115980 2.53 ï l i i i l iiiiisii 2.66 2.66 2.64 2.63
5 117222 2.96 172 3iiiiiiiii 1.88 2.62 * 2.5
6 113648 3.20 2.69 2.94 2.86 2.72 2.77 2.66
8 97218 2.79 2.54 2.70 2.73 2.81 2.69 2.54
9 117898 2.77 • ZM 190 2.85 2.83 2.68 2.70
10 121228 2.80 2,56 2.80 2.84 2.72 2.90 2.75
11 121252 2.70 2.71 2,69 2.70 2.60 2.79 2.63
13 120899 2.73 2.92 2.54 2.32 * * 2.52
Plasma calcium concentrations (mmol/1).
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No
DOG
REFERENCE
M O N T H S
-1 i -todays ; 0 1 2 3 4
1 115678 0 iiiiiiii 0 0 0 0 1
2 119147 1 iiiiiiiii iiiiiiii * 0 * *
3 115131 2 iiiiiiiii;; 0 1 0 0 1
4 115980 0 iiiiiiii iiiiiiii * 0 0 0
5 117222 0 iiiiiiii iiiiiii * 1 * 2
6 113648 0 iiiiiiiii iiiiiii 1 0 0 1
8 97218 1 1 iiiiiiiii 0 0 0 0
9 117898 0 i ;iiiiiiii 0 0 0 0
10 121228 4 * ;iiiiiiiii * 0 $ *
11 121252 1 im m m i 1 0 1 1
13 120899 1 iiiiiiiii I 1 * * 1
Plasma bilirubin concentrations (pmol/1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days 1 2 3 4
1 115678 8 Iiiiiiii; 6 17 18 6
2 119147 4 Iiiiiiiii iiiliiilii 12 19 * *
3 115131 9 Iiiiiiii: iiiiiii 12 10 22 6
4 115980 8 iiiiiii 5 2 30 * 26
5 117222 8 9 iiiiiii;; 1 31 * 26
6 113648 13 iiiiiiii ; |||||||i| 5 24 23 18
8 97218 5 iiiiiii iiiiiii 14 45 5 1
9 117898 19 iiiiiiii illlllll;;*;;;; 15 2 11 21
10 121228 * iiiiiiii iiiiiiii 4> 43 4 *
11 121252 10 iiiiiii 14 27 28 * 10
13 120899 19 iiiiiiii Iiiiiii * * * 37
Plasma gamma glutamyl transferase concentrations (IU/1).
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No
DOG
REFERENCE
M O N T H S
-1 i -10 days 0 1 2 3 4
1 115678 2710 iiiiWi;iiiiissiii 2095 2771 2606 2771
2 119147 1833 i i l l W I 1770 1250 1100 $ *
3 115131 1675 iiiisssi iiilWi 1398 1270 1180 1116
4 115980 2888 2667 11119941 2766 2950 2617 2786
5 117222 1237 iiliiWiiiiMii; 900 863 891 654
6 113648 1560 953 1000 950 1043 1611 1262
8 97218 1511 iiiiliiiii 1379 1469 * 1344
9 117898 694 m 2 : 1057 995 1137 1195 1069
10 121228 1946 m i \ 2352 * 1774 1879 1701
11 121252 3164 5054 : 2878 2583 2551 * 1701
13 120899 1010 1340 : 1860 2240 * * 1317
Plasma amylase concentrations (IU/1).
No
DOG
REFERENCE
M O N T H S
-1 i -10 days i i i i i i i i 1 2 3 4
1 115678 72 65 68 69 65 59 63
2 119147 73 67 i i i l i l6 6 i 71 66 * *
3 115131 70 i i i i S i 62 72 64 61 63
4 115980 64 69 ; 66 70 65 68 65
5 117222 69 73 i i i i i i i i 69 62 71 63
6 113648 74 i i i i i 6 8 i 63 66 64 63
8 97218 66 i i i i i i i s i i i i i i i i i i 70 63 64 57
9 117898 67 65 l i i i i » 66 64 61 62
10 121228 71 84 iiiiiii; 76 68 72 68
11 121252 66 69 iIiiiiii 70 62 67 63
13 120899 70 74 64 * * 68
Plasma total protein concentrations (g/1).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 27 29 30 28 27 23 25
2 119147 31 32 33 35 29 * *
3 115131 30 32 iiiiiiii 31 29 27 27
4 115980 32 iiiiiiiii iiiiiiii 35 29 33 32
5 117222 31 iiiiiiii 40 28 34 31
6 113648 36 33 i##3# 34 28 32 31
8 97218 35 iiiiiiiii iiiiiiii 31 30 32 26
9 117898 38 iiiiiiii: 30 33 32 34 32
10 121228 33 iiiiiiiii 30 34 36 37 35
11 121252 30 iiiiiiiii 29 33 30 32 30
13 120899 37 39 36 34 * * 32
Plasma albumin concentrations (g/1).
No
DOG
REFERENCE
M O N T H S
-1 : -to days 0 1 2 3 4
1 115678 10.6 10.9 14J 11.6 10.9 12.0 8.9
2 119147 12.0 16.6 » 13.4 10.4 * *
3 115131 6.9 iiiiiii 6.6 7.9 6.1 6.4 6.6
4 115980 12.1 9,6 : 11.0 * 10.5 8.4
5 117222 6.6 iiiiiiii0 8.4 15.5 7.2 7.6 6.6
6 113648 9.8 8.0 8.9 8.5 16.8 10.4
8 97218 6.7 9.2 iiiiiiiii 6.4 6.7 7.6 5.1
9 117898 6.9 62 6.5 5.6 7.7 5.9
10 121228 12.1 9.6 Iiiiiii; 11.0 9.6 12.3 11.6
11 121252 8.3 9.7 8.8 9.6 10.0 13.8 8.8
13 120899 9.7 4.1 0iiiil;iiii 6.0 * « 9.6
Total white blood cell counts (10 /^1).
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No
DOG
REFERENCE
M O N T H S
-1 1 -todays 6 1 2 3 4
1 115678 6.70 620 9,5$ 6.14 7.14 8.70 5.11
2 119147 7.70 10.30 * 8.10 6.34 * *
3 115131 4.70 407 iiiiiii 5.92 5.00 4.86 4.55
4 115980 8.30 6.00 6.94 7.04 * 5.56 6.76
5 117222 4.02 9,87 SJ9 12.80 5.18 5.20 5.10
6 113648 6.37 5.72 5.76 6.00 5.57 14.11 7.64
8 97218 4.99 7.90 6.83 3.58 4.79 5.16 3.13
9 117898 6.90 4.46 6.50 5.60 7.70 5.90
10 121228 7.74 liiiMl 9.10 7.37 6.24 7.81 7.94
11 121252 3.81 4.90 4.80 3.84 5.20 8.10 3.96
13 120899 7.76 2.00 8.70 4.17 * * 4.56
Absolute neutrophil counts (10 /^1).
No
DOG
REFERENCE
M O N T H S
-1 ; -todays mmmm 1 2 3 4
1 115678 2.80 2,90 2.89 3.53 1.96 2.16 2.14
2 119147 2.90 300 * 3.01 2.55 * *
3 115131 1.60 1.20 iiiiiïii 1.50 0.52 1.12 1.12
4 115980 2.84 Iiiiiiii 3.12 3.08 * 4.41 1.10
5 117222 2.17 0.77 2.05 2.24 1.87 2.09 1.22
6 113648 2.94 1.84 1.53 2.44 2.34 1.01 2.13
8 97218 1.17 0.64 2.18 2.49 1.67 1.98 1.71
9 117898 1.41 iiiisli 1.40 1.34 1.69 1.06
10 121228 2.66 1.92 2.43 1.98 2.59 2.89 2.14
11 121252 3.36 2.57 2.72 3.93 3.05 4.20 3.16
13 120899 1.45 1.43 L4l 1.17 * * 3.55
Absolute lymphocyte counts (10 /^1).
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No
DOG
REFERENCE
M O N T H S
-1 i -IQ days 0 1 2 3 4
1 115678 0.90 iiiiiii: 0.14 0.58 0.76 0.54 0.80
2 119147 0.84 * • 1.00 2.55 * *
3 115131 0.31 0,22 0.00 0.19 0.12 0.16 0.23
4 115980 0.61 0.62 0.21 0.38 * 0.16 0.25
5 117222 0.10 0,00 0,04 0.16 0.04 0.00 0.01
6 113648 0.10 0.32 0.29 0.31 0.21 0.34 0.36
8 97218 0.03 0.05 0,00 0.06 0.00 0.23 0.13
9 117898 0.10 0.09 0.07 0.17 0.23 0.09
10 121228 0.97 0.45 0.64 0.88 0.38 1.17 1.22
11 121252 0.78 0.82 i 0,70 0.91 1.40 1.30 1.40
13 120899 0.05 0.23 0.17 0.30 * * 130
Absolute eosinophil counts (10 /^1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 7.10 7,56 6.43 7.38 6.58 6.64 6.49
2 119147 6.64 8.87 Iiiiiii# 7.07 6.55 * *
3 115131 7.10 6.95 iiiiiiii 7.38 6.95 7.29 6.96
4 115980 6.77 IIIIHl 5.77 6.49 * 6.99 6.55
5 117222 7.44 8 . 2 7 7 , 2 0 7.87 7.81 8.11 7.67
6 113648 6.49 6.28 5.62 6.28 7.27 7.49 6.99
8 97218 6.86 6.77 5.91 7.70 7.45 7.98 7.32
9 117898 7.13 7,04 * 6.96 7.05 6.86 5.69
10 121228 6.99 7,01 6.14 7.05 6.93 6.93 6.96
11 121252 6.71 7 . 2 6 6.02 7.45 6.12 6.88 6.27
13 120899 8.49 8.93 7.64 8.20 * * 7.48
Total red blood cell counts (10l2/|).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days Ô 1 2 3 4
I 115678 45.5 iiiiiii iiiiiiii 49.5 43.2 42.9 42.2
2 119147 44.5 60,3 1111111111*1 50.4 43.8 * *
3 115131 48.8 48.8 44,3 51.1 48.1 49.5 47.8
4 115980 45.2 46,2 45.2 * 46.5 47.8
5 117222 51.8 49.6 59.7 54.6 57.4 53.4
6 113648 44.0 40.5 iiiiiii 44.2 46.3 50.1 45.8
8 97218 44.0 44,3 m m om 49.8 48.1 50.8 48.1
9 117898 48.1 liliisili 46.8 46.8 48.1 38.2
10 121228 46.5 47 8 |!:ii::4i2:!!:: 46.5 46.2 45.7 44.8
11 121252 43.8 48,1 40.5 48.8 39.6 46.8 40.9
13 120899 54.7 64.1 49,5 52.1 * * 49.8
Packed cell volumes (%).
No
DOG
REFERENCE
M O N T H S
-1 : -10 days 0 1 2 3 4
1 115678 64 65 65 67 66 65 65
2 119147 67 68 * 71 67 * *
3 115131 69 70 70 69 69 68 69
4 115980 67 66 66 70 * 67 67
5 117222 70 69 69 76 70 71 70
6 113648 68 64 0iiiiil: 70 64 67 66
8 97218 64 65 Iiiiiiii 65 65 64 66
9 117898 67 iiiiiiii iiiiiiiii 67 66 70 67
10 121228 67 iiiiim#:iiiiiiii 66 67 66 67
11 121252 65 66 65 68 65
13 120899 64 ;iiiiiiii: iiiiiiii 64 * * 67
Mean corpuscular volumes (fl).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 352 264 iilsWI 252 295 353 363
2 119147 168 114 * 228 * *
3 115131 249 iiiliiilii 330 216 254 324
4 115980 304 342 1111951 427 * 300 308
5 117222 195 248 iiiiiioi 207 273 258 285
6 113648 242 252 mmmAm 179 195 163 189
8 97218 416 440 398 358 428 372 375
9 117898 518 i l i i i i ||||||||||* |: 492 392 427 502
10 121228 310 412 343 319 307 327 338
11 121252 375 308 iiiiisii 345 310 199 333
13 120899 289 321 iiiiililiili 318 * * 234
Absolute platelet counts (10 /^1).
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Appendix 18:
Concentrations of indicators of glycaemic control in 11 dogs 
from one month before to 4 months after changing to a canine
high fibre diet
Shaded area represents hospitalisation period
No
DOG
REFERENCE
M O N T H S
-1 : -10 days 0 1 2 3 4
1 115678 349 .i#:!#240:x 301 351 247 347 294
2 119147 407 334 393 497 290 * *
3 115131 464 Iiiliiilii iiiiiiii 419 323 388 382
4 115980 553 iiiiiWi 468 457 494 367 366
5 117222 379 iiiiiiii %73 435 377 406 417
6 113648 572 iiiiWi * 295 328 261
8 97218 561 626 iiiiiisi 378 318 358 339
9 117898 449 iliiil376i: 357 329 407 413
10 121228 456 iiiiWi 361 355 391 432
11 121252 414 440 Iiiiiiii 377 404 508 583
13 120899 326 iiiiiiiii iiiiiiii 263 * * 386
Absolute plasma fructosamine concentrations (p.mol/1).
No
DOG
REFERENCE
M O N T H S
-1 -lOdavs 0 1 2 3 4
1 115678 5.00 Iiiiiii i2 8 4.72 4.34 5.72 3.72
2 119147 4.30 ll::|:::i:90:! 3,50 5.01 4.90 * *
3 115131 4.60 4.70 4.40 4.50 4.60 4.56 4.03
4 115980 8.60 9.36 : 8.20 6.40 6.36 5.13 4.58
5 117222 6.74 8,08 liiisiil 6.76 6.79 7.26 6.00
6 113648 7.65 9J9 8.30 4.59 3.45 2.90 2.48
8 97218 7.90 6.87 5,52 3.96 4.39 3.84 4.93
9 117898 6.64 6.50 6.16 3.42 * 4.25 5.06
10 121228 7.70 8,39 7.23 5.38 6.63 5.55 6.41
11 121252 4.36 5.09 5,38 4.33 5.58 6.14 8.08
13 120899 4.63 iiiiiiiii * 4.36 * * 4.90
Absolute glycated haemoglobin concentrations (% of total haemoglobin).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 475 750 547 269 219 338 350
2 119147 227 204 iiiiiiii 248 183 * *
3 115131 639 737 477 516 439 514 509
4 115980 1016 .. .1400 iiiiiiiii 467 783 1406 760
5 117222 263 iiiiiiii iiiiiiii 276 315 419 286
6 113648 3134 iiiiwi mm5om 2416 1936 1619 2050
8 97218 2642 2645 iiiiislii 1227 865 725 451
9 117898 219 270 Iiiiiiii 212 255 225 308
10 121228 565 iiliiMliiiiiiii 358 590 282 226
11 121252 582 :m::||::|87::::: 532 617 647 550
13 120899 42 iiiiiiiii iiliiiiimi 57 * * 132
Absolute plasma alkaline phosphatase concentrations (IU/1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days :::!iiimili: 1 2 3 4
1 115678 52 rn m m m 36 51 58 57
2 119147 50 iiiiiiii iiiiiiii 42 27 * *
3 115131 72 . 65 24 28 54 51
4 115980 204 iiiiWi 148 146 280 582 226
5 117222 28 32 23 36 19 28
6 113648 113 iiiiiiii iiiiisioli 294 247 185 296
8 97218 86 iiiiiiii l l i l l i p i l 30 25 40 25
9 117898 19 iiiiiiiii 37 28 27 23
10 121228 197 117 iiiiiiiii: 177 182 194 101
11 121252 51 81 47 73 52 48
13 120899 34 iiliiliiii 41 * * 43
Absolute plasma alanine aminotransferase concentrations (IU/1).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days i i i O i i i l 1 2 3 4
1 115678 28 43 i i i i i i i ; : 24 30 25 23
2 119147 14 23 * 15 * *
3 115131 40 i i i i i i i i ; i i i i i i i i : 26 25 41 25
4 115980 54 i i i i i i i i 38 35 54 53 45
5 117222 17 i i i i i i i i i i i l l i i 53 19 23 19
6 113648 26 I i i i i i i i i 41 32 27 32
8 97218 77 i i i i i S i iiiliiiSi:;:; 12 20 17 24
9 117898 23 15 21 16 15 16 15
10 121228 53 55 : 40 46 52 56 39
11 121252 16 36 13 14 14 17 18
13 120899 10 17 ! 25 22 * * 21
Absolute aspartate aminotransferase concentrations (IU/1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 5.8 20.7 . 16,4 * 8.2 * 3.9
2 119147 8.8 7,7 4.7 * 7.7 * *
3 115131 5.2 19,4 * 14.3 * 18.1
4 115980 15.8 Iiiiiiii Iiiiiiii * 14.3 * 3.4
5 117222 11.7 i i i i w i 4.2 * 19.4 * 18.6
6 113648 14.5 22.2 Iiiiiiii * 5.5 * 4.8
8 97218 28.6 27,3 iiiiiiii:: * 7.8 * 20.3
9 117898 23.1 24.4 14 7 * 6.9 * 18.2
10 121228 26.3 34.3 iiiiiiii * 9.4 * 19.9
11 121252 22.4 8,4 2L3 * 20.9 * 30.1
13 120899 15.4 iiiiiii 72 * * * 22.7
Absolute fasting plasma glucose concentrations (mmol/1).
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No
DOG
REFERENCE
M O N T H S
-1 -10 davs 0 1 2 3 4
1 115678 3.7 9,7 4.4 7.9 2.5 3.9 1.1
2 119147 16.7 i i i i i i i i i 4,2 14.2 5.1 * *
3 115131 4.5 156 4.0 4.0 5.5 5.6
4 115980 5.7 i i i i i i i 2,7 111 8.4 3.2 4.6
5 117222 9.9 8.2 2.1 10 4.3 18.1 7.6
6 113648 18.3 19,2 3.2 2.6 2.3 2.0 23.4
8 97218 17.3 n s 14 3.7 2.7 5.4 4.7
9 117898 16.2 6.0 2.7 7.2 4.0 9.2 4.2
10 121228 9.2 12,6 5.0 3.8 4.4 4.1 9.1
11 121252 17.4 6.4 3,2 3.7 9.1 18.2 20.3
13 120899 3.8 4.9 3.5 8.3 * « 3.5
Absolute afternoon (nadir) plasma glucose concentrations (mmol/1).
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Appendix 19:
Plasma concentrations of indicators of lipid metabolism in 11 
dogs from one month before to 4 months after changing to a
canine high fibre diet
Shaded area represents hospitalisation period
No
DOG
REFERENCE
M O N T H S
-1 -10 days iiiiiiiii 1 2 3 4
1 115678 8.17 8.09 * 6.25 * 7.96
2 119147 4.79 4.14 4.03 * 3.91 * *
3 115131 6.92 6.00 4.82 * 5.50 * 5.34
4 115980 5.95 6.09 3.81 * 5.45 « 5.56
5 117222 11.84 iiiiiili 6.66 * 9.80 * 12.63
6 113648 22.46 16.81 10.41 * 11.21 * 12.88
8 97218 6.29 6.60 iiiW i * 7.39 * 7.44
9 117898 6.52 6.10 4.37 * 4.34 * 4.39
10 121228 16.71 14.86 iiiiiiil * 9.95 * 9.67
11 121252 5.44 13.63 9.37 * 10.15 * 9.66
13 120899 8.95 8.67 5.39 * * * 6.03
Absolute total plasma cholesterol concentrations (mmol/1).
No
DOG
REFERENCE
M O N T H S
-1 -10 days i i i i i i i l 1 2 3 4
1 115678 1.50 l i i i i i i i 1.43 * 0.92 * 0.54
2 119147 0.43 iiiiO lS ii i i i o i l i i * 0.64 * *
3 115131 1.70 064 0.66 * 0.77 * 0.67
4 115980 1.56 1.34 i i l i i s S i i * 0.50 * 0.82
5 117222 1.42 3.05 • 3.32 * 0.78 * 0.00
6 113648 * l i i l i i o i 3>ia * 0.70 * 1.89
8 97218 0.63 0.90 0.64 * 1.02 * 1.42
9 117898 0.06 2.55 0.62 * 0.50 * 0.72
10 121228 3.94 2.99 1.07 * 2.53 * 2.10
11 121252 1.20 l i i i i i i i » 1.10 * 2.15
13 120899 0.95 0.93 0.79 * * * 1.67
Absolute plasma VLDL cholesterol concentrations (mmol/1)).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days iiiiiii 1 2 3 4
1 115678 2.74 * 2.20 * 2.58
2 119147 0.90 0.59 0.70 * 0.13 * *
3 115131 1.88 1.34 1.45 * 1.02 * 0.72
4 115980 1.37 : 1.60 0.78 * 1.20 * 1.09
5 117222 5.80 iiiiiiil iiiiiiil * 3.77 * 7.40
6 113648 10.24 10.19 1.70 * 5.87 * 5.92
8 97218 1.73 2.60 1.22 * 2.16 * 2.63
9 117898 1.59 1.19 0.85 * 0.71 * 1.01
10 121228 7.81 iiiiiii 315 * 3.55 * 2.74
11 121252 0.46 l i i » l x n * 4.40 * 3.47
13 120899 2.23 2.52 1.24 * * * 1.00
Absolute plasma LDL cholesterol concentrations (mmol/1)).
No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 3.93 3.92 3.68 * 3.13 * 4.84
2 119147 3.46 2.80 2.60 * 3.15 * *
3 115131 3.34 4.02 l i i i i i i i * 3.71 * 3.95
4 115980 3.02 i i i i i i i l 2.47 * 3.75 * 3.65
5 117222 4.62 3.72 2.99 * 5.25 * 6.48
6 113648 5.45 5.32 5.59 * 4.65 * 5.07
8 97218 3.94 3.10 3.73 * 4.21 * 3.40
9 117898 4.87 l i i i i i i i 2,90 * 3.12 * 2.66
10 121228 4.96 6.02 4.21 * 3.87 * 3.64
11 121252 3.78 6.64 4.61 * 4.65 * 4.04
13 120899 5.78 5.22 3.33 * * * 3.36
Absolute plasma HDL cholesterol concentrations (mmol/1)).
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No
DOG
REFERENCE
M O N T H S
-1 -10davs i i i O i i i i 1 2 3 4
1 115678 1.14 2.41 2,06 * 1.26 * 1.04
2 119147 0.89 0.64 * 1.55 * *
3 115131 0.54 0,50 0.97 * 0.79 * 1.25
4 115980 1.69 2.02 0.80 * 0.46 * 0.70
5 117222 0.82 Î.Ô9 0.71 * 0.35 * 1.02
6 113648 0.93 1,30 0 49 * 0.52 * 1.46
8 97218 2.34 1.75 0.61 * 2.31 * 1.48
9 117898 2.09 0.64 0.91 * 0.95 * 0.88
10 121228 12.67 8.07 J.46 * 3.12 * 11.44
11 121252 2.48 3.08 2J6 * 2.06 * 1.57
13 120899 0.72 0.61 067 * * * 4.03
Absolute plasma triglyceride concentrations (mmol/1)).
No
DOG
REFERENCE
M O N T H S
-1 :-10 days iiiiiiiii 1 2 3 4
1 115678 107 iiiiiiiii: iliimi: * 81 * 93
2 119147 66 iiiiiiiii iiiiiiiii * 66 * *
3 115131 155 liiiiiisi iiiiiMi * 175 * 220
4 115980 124 iiliiiloliiiiiiisi * 161 * 101
5 117222 147 ^liiiiiii ♦ * 154 * 212
6 113648 223 iiiiiiiii 93 * 117 * 107
8 97218 395 * 150 * 201
9 117898 163 liiiiiii: iiiiiiil * 91 * 80
10 121228 244 iiiiiwi:iiiiiii * 96 * 73
11 121252 341 iiiilil • 231 * 81 * 110
13 120899 305 220 :iiiiissi * * * 254
Absolute plasma free glycerol concentrations (pmol/1) in 11 dogs from one month before to 4 
months after changing to CHF diet).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days i i i i s i i i l 1 2 3 4
1 115678 0.91 L20 1.51 * 0.96 * 0.87
2 119147 0.76 Ô31 i l i l i o i i i * 0.88 * *
3 115131 1.82 199 4.16 * 2.71 * 3.42
4 115980 1.36 1.22 Lis * 1.12 * 0.84
5 117222 1.68 3.09 * * 2.05 « 2.19
6 113648 3.02 l i i i i i i i i i i i i 9 i i * 1.34 * 1.44
8 97218 3.52 3.98 i l i i i i i i i * 1.33 * 1.85
9 117898 * 2.51 0.72 * 0.93 * 1.09
10 121228 3.64 3.34 1.52 * 1.78 * 1.32
11 121252 * L44 m ê m m * 1.57 * 2.63
13 120899 * 2.74 2.05 * * * 2.08
Absolute plasma non-esterified fatty acids concentrations (mmol/1)).
No
DOG
REFERENCE
M O N T H S
-1 -todays iliiiiii 1 2 3 4
1 115678 30 iiiiiii #im# « 14 * 9
2 119147 11 iiiiiii iiilisi « 14 * *
3 115131 10 • 5 iiiiiiil * 7 * 7
4 115980 12 Iiiiiii 15 * 2 * NR
5 117222 NR iiWIM# i^iiiiiiii * 3 * 28
6 113648 5 iiiiiii iiiiWi * 16 * NR
8 97218 43 19 17 * NR * 76
9 117898 49 Iiiiiii iiiiiiil * 35 * NR
10 121228 50 27 l i i i i i i i * 28 * 19
11 121252 33 31 393 * 25 * 143
13 120899 22 i i i i i i i liiiiiii * * * 418
NR denotes samples in which the concentration of apolipoprotein B was undetectable 
Absolute VLDL triglyceride/apolipoprotein B ratios (mmol/ug equiv. bovine serum albumin)).
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No
DOG
REFERENCE
M O N T H S
-1 -10 days 0 1 2 3 4
1 115678 2.48 5.45 3.25 * 5.34 * 9.49
2 119147 7.11 m m 6 m 9J6 * 9.63 * *
3 115131 9.35 11.64 n.44 * * * 11.66
4 115980 14.49 19.15 18.97 * 18.64 * 16.89
5 117222 17.17 14.44 20.37 * 23.65 * 19.32
6 113648 11.46 I i i i i i i * 17.27 * 11.49
8 97218 35.73 28.23 29,40 * 19.25 * 18.05
9 117898 18.44 18.54 i i i l i l s i i * 9.09 * 13.76
10 121228 10.63 11.10 * * 14.15 * 17.97
11 121252 16.60 13.6Î Î2J3 * 16.53 * 21.43
13 120899 27.01 22.74 19.63 * * * 18.36
Absolute post heparin hepatic lipase activities (pmolFA/ml/hr)).
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Glossary
p beta
a alpha
Ci Curie
cm centimetre
cpm counts per minute
CV coefficient of variation
EDTA ethylenediaminetetra-acetate
FA fatty acid
HDL high density lipoprotein
hr hour
lU international unit
kg kilogram
1 litre
LDL low density lipoprotein
M molar
m milli
mmol millimole
n number of observations
OR odds ratio
P probability
r correlation coefficient
rpm revolutions per minute
SD standard deviation of a sample
SE standard error
SEM standard error of the mean
p or u micro
VLDL very low density lipoprotein
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Laboratory reference ranges
Biochemistry
Alanine aminotransferase 0-65 U/1
Albumin 22-35 g/1
Alkaline phosphatase <230 U/1
Ammonia < 100 pmol/1
Amylase 400 - 3500 U/1
Aspartate aminotransferase 0-35 U/1
Bilirubin < 10 pmol/1
Calcium 2.34 - 3.03 mmol/1
Chloride 95-115 mmol/1
Cholesterol 1.80-6.96 mmol/1
Creatinine 44 - 132 pmol/1
Gamma-glutamyl transferase 0 -6 U/1
Globulin 22-45 g/i
Glucose 2.5-4.5 mmol/1
Inorganic phosphorus 1.29-2.90 mmol/1
Lipase < 1000 U/1
Potassium 34-5 .8 mmol/1
Sodium 136 - 160 mmol/1
Total protein 50-78 g/1
Urea 0 - 7.47 mmol/1
Haematology
Red blood cell count 4.25 - 8.50 xl0»2/l
Haemoglobin 10.5-21.0 g/dl
Haematocrit 0.34-0.58 1/1
Mean cell volume 6 0 -7 7 fl
Mean cell haemoglobin 19.5 - 24.5 Pg
Mean cell haemoglobin conc. 3 2 -3 6 g/dl
Reticulocytes 0 .0 - 1.5 %
White blood cell count 6.0 - 17.5 X109/1
Neutrophils 3.0-11.5 X109/1
Lymphocytes 1.0- 4.8 X109/1
Monocytes 0.15-1.35 X109/1
Eosinophils 0 .1 -1 .2 X109/1
Platelets 200 - 500 X109/1
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